WO2022232142A1 - G-alpha-s inhibitors and uses thereof - Google Patents

G-alpha-s inhibitors and uses thereof Download PDF

Info

Publication number
WO2022232142A1
WO2022232142A1 PCT/US2022/026345 US2022026345W WO2022232142A1 WO 2022232142 A1 WO2022232142 A1 WO 2022232142A1 US 2022026345 W US2022026345 W US 2022026345W WO 2022232142 A1 WO2022232142 A1 WO 2022232142A1
Authority
WO
WIPO (PCT)
Prior art keywords
substituted
unsubstituted
alkyl
membered
compound
Prior art date
Application number
PCT/US2022/026345
Other languages
French (fr)
Inventor
Kevan M. Shokat
Qi Hu
Shizhong DAI
Original Assignee
The Regents Of The University Of California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Regents Of The University Of California filed Critical The Regents Of The University Of California
Priority to EP22796551.4A priority Critical patent/EP4330228A1/en
Publication of WO2022232142A1 publication Critical patent/WO2022232142A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/23—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
    • C07C323/39—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton at least one of the nitrogen atoms being part of any of the groups, X being a hetero atom, Y being any atom
    • C07C323/43—Y being a hetero atom
    • C07C323/44—X or Y being nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/23—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
    • C07C323/39—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton at least one of the nitrogen atoms being part of any of the groups, X being a hetero atom, Y being any atom
    • C07C323/40—Y being a hydrogen or a carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/84—Nitriles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
    • C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
    • C07D251/12—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D251/26—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hetero atoms directly attached to ring carbon atoms
    • C07D251/40—Nitrogen atoms
    • C07D251/42—One nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
    • C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D257/04—Five-membered rings
    • C07D257/06—Five-membered rings with nitrogen atoms directly attached to the ring carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
    • C07D261/10—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D261/14—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/01—Five-membered rings
    • C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
    • C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
    • C07D285/12—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles
    • C07D285/125—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles with oxygen, sulfur or nitrogen atoms, directly attached to ring carbon atoms, the nitrogen atoms not forming part of a nitro radical
    • C07D285/135—Nitrogen atoms

Definitions

  • GNAS Guanine nucleotide-binding protein G, alpha (a) subunit
  • GPCR G- protein-coupled receptor
  • R 1 is OCH 2 X 1 , -OCHX ⁇ , -CN, -SO existenceiR 1D , -SO vi NR 1A R 1B , -NR 1C NR 1A R 1B , -ONR 1A R 1b , -NHC(0)NR 1C NR 1A R 1B , -NHC(0)NR 1A R 1b , -N(0) mi , -NR 1A R 1B , -C(0)R 1c , -C(0)-0R 1c , -C (0)NR 1A R 1b , -OR 1d , -NR 1A S0 2 R 1d , -NR 1A C(0)R 1c , -NR 1A C(0)0R 1c , -NR 1A OR 1c , -N 3 , substituted or unsubstituted alkyl, substituted or unsubstituted heteroal
  • zl is an integer from 0 to 6.
  • Ring A is aryl or heteroaryl.
  • L 1 is a bond, -NH-, -0-, -S-, -C(O)-, -C(0)NH-, -NHC(O)-, -NHC(0)NH-, -C(0)0-, -OC(O)-, substituted or unsubstituted alkylene, substituted or unsubstituted heteroalkylene, substituted or unsubstituted cycloalkylene, substituted or unsubstituted heterocycloalkylene, substituted or unsubstituted arylene, or substituted or unsubstituted heteroarylene.
  • L 2 is a bond, -NH-, -0-, -S-, -C(O)-, -C(0)NH-, -NHC(O)-, -NHC(0)NH-, -C(0)0-, -OC(O)-, substituted or unsubstituted alkylene, substituted or unsubstituted heteroalkylene, substituted or unsubstituted cycloalkylene, substituted or unsubstituted heterocycloalkylene, substituted or unsubstituted arylene, or substituted or unsubstituted heteroarylene.
  • R 2 is an electrophilic moiety.
  • R 1A , R 1b , R 1C , and R 1D are independently hydrogen, -CX 3 , -CHX 2 , -CH 2 X, -CN, -OH, -COOH, -CONH 2 , substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl; R 1A and R 1B substituents bonded to the same nitrogen atom may optionally be joined to form a substituted or unsubstituted heterocycloalkyl or substituted or unsubstituted heteroaryl.
  • X and X 1 are independently -F, -Cl, -Br, or -I.
  • nl is independently an integer from 0 to 4.
  • ml and vl are independently 1 or 2.
  • zl is an integer from 1 to 3. In embodiments, zl is 0.
  • Ring A is phenyl or 5 to 6-membered heteroaryl.
  • the compound has the formula:
  • Each R u , R 1 2 , R 1 3 , R 1 4 , and R 1 5 is independently hydrogen, halogen, -CX ⁇ , - CHX -CH2X 1 , -OCX 1 : ! , -OCH2X 1 , -OCHX’i, -CN, -SO ProceedingsiR 1D , -SO vi NR 1A R 1B , -NR 1C NR 1A R 1B , -ONR 1A R 1b ,
  • R 1A , R 1b , R 1C , and R 1D are independently hydrogen, -CX 3 , -CHX2, -CH2X, -CN, -OH, -COOH, -CONH2, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl; R 1A and R 1B substituents bonded to the same nitrogen atom may optionally be joined to form a substituted or unsubstituted heterocycloalkyl or substituted or unsubstituted heteroaryl.
  • X and X 1 are independently -F, -Cl, -Br, or -I.
  • nl is independently an integer from 0 to 4.
  • ml and vl are independently 1 or 2.
  • L 1 is a bond, -NH-, -O-, -S-, -C(O)-, -C(0)NH-, -NHC(O)-, -NHC(0)NH-, -C(0)0-, -OC(O)-, substituted or unsubstituted alkylene, or substituted or unsubstituted heteroalkylene.
  • L 2 is a bond, -NH-, -O-, -S-, -C(O)-, -C(0)NH-, -NHC(O)-, -NHC(0)NH-, -C(0)0-, -OC(O)-, substituted or unsubstituted alkylene, or substituted or unsubstituted heteroalkylene.
  • R 16 is hydrogen, halogen, -CX 16 3 , -CHX 16 2 , -CH 2 X 16 , -CN, -SO ni6 R 16D , -SO VI6 NR 16A R 16B , -NHNR 16A R 16B , -ONR 16A R 16B , -NHC(0)NHNR 16A R 16B ,
  • R 17 is hydrogen, halogen, -CX 17 3 , -CHX 17 2 , -CH 2 X 17 , -CN, -SO Proceedings 17 R 17D , -SO vi 7NR 17A R 17B , -NHNR 17A R 17B , -ONR 17A R 17B , -NHC(0)NHNR 17A R 17B ,
  • R 18 is hydrogen, halogen, -CX 18 3 , -CHX 18 2 , -CH 2 X 18 , -CN, -SOêtI 8 R 18D , -SO V I 8 NR 18A R 18B , -NHNR 18A R 18B , -ONR 18A R 18B , -NHC(0)NHNR 18A R 18B ,
  • R 19 is hydrogen, halogen, -CX 19 3 , -CHX 19 2 , -CH 2 X 19 , -CN, -SOêtI 9 R 19D , -SO V I 9 NR 19A R 19B , -NHNR 19A R 19B , -0NR 19A R 19B , -NHC(0)NHNR 19A R 19B ,
  • R 19C , and R 19D are independently hydrogen, -CX 3 , -CHX 2 , -CH 2 X, -CN, -OH, -COOH, -CONH 2 , substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl.
  • R 16A and R 16B substituents bonded to the same nitrogen atom may optionally be joined to form a substituted or unsubstituted heterocycloalkyl or substituted or unsubstituted heteroaryl;
  • R 17A and R 17B substituents bonded to the same nitrogen atom may optionally be joined to form a substituted or unsubstituted heterocycloalkyl or substituted or unsubstituted heteroaryl;
  • R 18A and R 18B substituents bonded to the same nitrogen atom may optionally be joined to form a substituted or unsubstituted heterocycloalkyl or substituted or unsubstituted heteroaryl;
  • R 19A and R 19B substituents bonded to the same nitrogen atom may optionally be joined to form a substituted or unsubstituted heterocycloalkyl or substituted or unsubstituted heteroaryl.
  • X 16 , X 17 , X 18 , and X 19 are independently -F, -Cl, -Br, or -I.
  • nl 6, nl 7, nl 8, and nl 9 are independently an integer from 0 to 4.
  • ml 6, ml 7, ml 8, ml 9, vl6, vl7, vl8, and vl9 are independently 1 or 2.
  • composition comprising the compound as decribed herein and a pharmaceutically acceptable excipient.
  • a method of inhibiting Gas protein activity comprising: contacting the Gas protein with a compound as described herein.
  • a method of treating cancer including administering to a subject in need thereof an effective amount of a compound as described herein.
  • the cancer is pancreatic cancer, a pituitary tumor, or a bone tumor.
  • the cancer is sensitive to Gas inhibition.
  • a method of treating a bone condition comprising administering to a subject in need thereof an effective amount of a compound as described herein.
  • the bone condition is fibrous dysplasia.
  • the fibrous dysplasia is monostotic fibrous dysplasia or polystotic fibrous dysplasia.
  • a method of treating McCune-Albright Syndrome said method including administering to a subject in need thereof an effective amount of a compound described herein.
  • Gas protein covalently bonded to a compound as described herein.
  • Gas is in the GTP state.
  • Gas is in the GDP state.
  • the compound is bonded to a cysteine residue of the protein.
  • the Gas protein has the structure:
  • L 3 is substituted or unsubstituted alkylene or substituted or unsubstituted heteroalkylene.
  • the compound is bonded to cysteine 201. In embodiments, the compound is bonded to cysteine 237.
  • a Gas protein covalently bonded to a Gas small molecule inhibitor at R201C.
  • the Gas protein is a GTP-bound Gas protein.
  • the Gas protein is a GDP-bound Gas protein.
  • the Gas protein is a GTP-bound Gas protein.
  • the Gas protein is a GDP-bound Gas protein.
  • a method of treating cancer including administering a Gas cysteine 201 covalent inhibitor.
  • the Gas cysteine 201 covalent inhibitor is a compound as described herein.
  • a method of treating cancer including administering a Gas cysteine 237 covalent inhibitor.
  • the Gas cysteine 237 covalent inhibitor is a compound as described herein.
  • FIG. 1A shows that crystal structure of GNAS(R201C) GDP shows Cys 201, switch-I, switch-II, and switch-III (PDB: 6AU6).
  • FIGS. 1B-1D show alignment of crystal structure of Gaq-GDP-YM254890 (PDB code 3AH8) with that of Gas-GTPyS (PDB code 1AZT).
  • FIG. IB shows YM254890 bound into a pocket surrounded by switch I and the a-helix and b-sheet linked by switch I.
  • FIG. 1C shows that crystal structure of Gas-GTPyS complex has a very similar domain-arrangement to that of Gaq-GDP-YM254890 complex.
  • FIG. ID shows comparison with the local structure of YM254890-binding pocket in Gaq reveals a similar binding pocket in Gas.
  • FIGS. 1E-1G show structural information for design of a linker to connect YM254890 or its analogues with the cysteine mutation.
  • FIG. IE shows that the electrostatic surface of Gaq reveals a grove between the helical domain and Ras-like domain (PDB code 3AH8).
  • FIG. IF shows that local structure of YM254890-binding pocket of Gaq and the distance between R183 and YM254890.
  • FIG. 1G shows that YM254890 is aligned at where the potential inhibitor-binding pocket in Gas. The hydrophilic residues in the grove between the helical domain and Ras-like domain are showed as sticks.
  • FIG. 2 shows evaluation of the GTP occupancy of the R201C mutant in the presence of excess GTP.
  • FIGS. 3A-3C show motidification of C201 by acrylamide.
  • FIG. 3A shows that the reaction between the cysteine side chain and acrylamidine (Acr).
  • FIG. 3B shows that modification of C201 by Acr decreased the adenylyl cyclase-activating activity of the GDP- bound R201C/C237S mutant in the presence Gpi/y2(C68S).
  • the data represents the mean ⁇ SE of three independent measurements.
  • FIG. 3C shows that modification of C201 by Acr increased the single turnover GTPase activity of the R201C/C237S mutant to a level close to that of the C237S mutant.
  • the data represents the mean ⁇ SD of at least three independent measurements.
  • FIG. 4A shows a class of compounds with a urea moiety were identified in a tethering screen, in which 2 mM GDP-bound Gas(R201C/C237S) was incubated with 200 mM tethering compound and 200 pM b-mercaptoethanol (BME) at room temperature for 2 hours.
  • FIG. 4B shows evaluation of the reactivity of compound 1H11 against Gas using a competition assay.
  • 2 pM Wild-type or the R201C/C237S mutant Gas in the GDP or GNP (5'-Guanylyl imidodiphosphate)-bound state was incubated with 50 pM compound 1H11 and various concentration of BME at room temperature for 2 hours.
  • FIGS. 5A-5B show preliminary structure-activity relationship (SAR) analysis of 1H11. Covalent molecules from the tethering library (FIG. 5 A) were tested for their ability to label different Gas mutants (FIG. 5B).
  • FIGS. 6A-6B show preliminary structure-activity relationship (SAR) analysis of 1H11. Covalent molecules containing an aryl urea moiety (FIG. 6 A) were tested for their BME50 values (FIG. 6B). DETAILED DESCRIPTION
  • substituent groups are specified by their conventional chemical formulae, written from left to right, they equally encompass the chemically identical substituents that would result from writing the structure from right to left, e.g., -CH2O- is equivalent to - OCH2-.
  • alkyl by itself or as part of another substituent, means, unless otherwise stated, a straight (i.e., unbranched) or branched carbon chain (or carbon), or combination thereof, which may be fully saturated, mono- or polyunsaturated and can include mono-, di- and multivalent radicals.
  • the alkyl may include a designated number of carbons (e.g., C1-C10 means one to ten carbons).
  • the alkyl is fully saturated.
  • the alkyl is monounsaturated.
  • the alkyl is polyunsaturated.
  • Alkyl is an uncyclized chain.
  • saturated hydrocarbon radicals include, but are not limited to, groups such as methyl, ethyl, n-propyl, isopropyl, n-butyl, t-butyl, isobutyl, sec-butyl, methyl, homologs and isomers of, for example, n-pentyl, n-hexyl, n-heptyl, n-octyl, and the like.
  • An unsaturated alkyl group is one having one or more double bonds or triple bonds.
  • Examples of unsaturated alkyl groups include, but are not limited to, vinyl, 2-propenyl, crotyl, 2- isopentenyl, 2-(butadienyl), 2,4-pentadienyl, 3-(l,4-pentadienyl), ethynyl, 1- and 3-propynyl, 3-butynyl, and the higher homologs and isomers.
  • An alkoxy is an alkyl attached to the remainder of the molecule via an oxygen linker (-0-).
  • An alkyl moiety may be an alkenyl moiety.
  • An alkyl moiety may be an alkynyl moiety.
  • An alkenyl includes one or more double bonds.
  • An alkynyl includes one or more triple bonds.
  • alkylene by itself or as part of another substituent, means, unless otherwise stated, a divalent radical derived from an alkyl, as exemplified, but not limited by, - CH2CH2CH2CH2-.
  • an alkyl (or alkylene) group will have from 1 to 24 carbon atoms, with those groups having 10 or fewer carbon atoms being preferred herein.
  • a “lower alkyl” or “lower alkylene” is a shorter chain alkyl or alkylene group, generally having eight or fewer carbon atoms.
  • alkenylene by itself or as part of another substituent, means, unless otherwise stated, a divalent radical derived from an alkene.
  • alkynylene by itself or as part of another substituent, means, unless otherwise stated, a divalent radical derived from an alkyne.
  • the alkylene is fully saturated.
  • the alkylene is monounsaturated.
  • the alkylene is polyunsaturated.
  • An alkenylene includes one or more double bonds.
  • An alkynylene includes one or more triple bonds.
  • heteroalkyl by itself or in combination with another term, means, unless otherwise stated, a stable straight or branched chain, or combinations thereof, including at least one carbon atom and at least one heteroatom (e.g., O, N, P, Si, and S), and wherein the nitrogen and sulfur atoms may optionally be oxidized, and the nitrogen heteroatom may optionally be quatemized.
  • the heteroatom(s) e.g., O, N, S, Si, or P
  • Heteroalkyl is an uncyclized chain.
  • a heteroalkyl moiety may include one heteroatom (e.g., O, N, S, Si, or P).
  • a heteroalkyl moiety may include two optionally different heteroatoms (e.g., O, N, S, Si, or P).
  • a heteroalkyl moiety may include three optionally different heteroatoms (e.g., O, N, S,
  • a heteroalkyl moiety may include four optionally different heteroatoms (e.g., O, N, S, Si, or P).
  • a heteroalkyl moiety may include five optionally different heteroatoms (e.g., O, N, S, Si, or P).
  • a heteroalkyl moiety may include up to 8 optionally different heteroatoms (e.g., O, N, S, Si, or P).
  • the term “heteroalkenyl,” by itself or in combination with another term, means, unless otherwise stated, a heteroalkyl including at least one double bond.
  • a heteroalkenyl may optionally include more than one double bond and/or one or more triple bonds in additional to the one or more double bonds.
  • heteroalkynyl by itself or in combination with another term, means, unless otherwise stated, a heteroalkyl including at least one triple bond.
  • a heteroalkynyl may optionally include more than one triple bond and/or one or more double bonds in additional to the one or more triple bonds.
  • the heteroalkyl is fully saturated.
  • the heteroalkyl is monounsaturated.
  • the heteroalkyl is polyunsaturated.
  • heteroalkylene by itself or as part of another substituent, means, unless otherwise stated, a divalent radical derived from heteroalkyl, as exemplified, but not limited by, -CH2-CH2-S-CH2-CH2- and -CH2-S-CH2-CH2-NH-CH2-.
  • heteroatoms can also occupy either or both of the chain termini (e.g., alkyleneoxy, alkylenedioxy, alkyleneamino, alkylenediamino, and the like).
  • no orientation of the linking group is implied by the direction in which the formula of the linking group is written.
  • heteroalkyl groups include those groups that are attached to the remainder of the molecule through a heteroatom, such as -C(0)R', -C(0)NR', -NR'R", -OR', -SR', and/or -SO2R'.
  • heteroalkyl is recited, followed by recitations of specific heteroalkyl groups, such as - NR'R" or the like, it will be understood that the terms heteroalkyl and -NR'R" are not redundant or mutually exclusive.
  • heteroalkyl should not be interpreted herein as excluding specific heteroalkyl groups, such as -NR'R" or the like.
  • heteroalkenylene by itself or as part of another substituent, means, unless otherwise stated, a divalent radical derived from a heteroalkene.
  • heteroalkynylene by itself or as part of another substituent, means, unless otherwise stated, a divalent radical derived from a heteroalkyne.
  • the heteroalkylene is fully saturated.
  • the heteroalkylene is monounsaturated.
  • the heteroalkylene is polyunsaturated.
  • a heteroalkenylene includes one or more double bonds.
  • a heteroalkynylene includes one or more triple bonds.
  • cycloalkyl and heterocycloalkyl mean, unless otherwise stated, cyclic versions of “alkyl” and “heteroalkyl,” respectively. Cycloalkyl and heterocycloalkyl are not aromatic. Additionally, for heterocycloalkyl, a heteroatom can occupy the position at which the heterocycle is attached to the remainder of the molecule. Examples of cycloalkyl include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, 1 -cyclohexenyl, 3-cyclohexenyl, cycloheptyl, and the like.
  • heterocycloalkyl examples include, but are not limited to, 1- (1,2,5,6-tetrahydropyridyl), 1-piperidinyl, 2-piperidinyl, 3-piperidinyl, 4-morpholinyl, 3- morpholinyl, tetrahydrofuran-2-yl, tetrahydrofuran-3-yl, tetrahydrothien-2-yl, tetrahydrothien-3-yl, 1-piperazinyl, 2-piperazinyl, and the like.
  • a “cycloalkylene” and a “heterocycloalkylene,” alone or as part of another substituent, means a divalent radical derived from a cycloalkyl and heterocycloalkyl, respectively.
  • the cycloalkyl is frilly saturated.
  • the cycloalkyl is monounsaturated.
  • the cycloalkyl is polyunsaturated.
  • the heterocycloalkyl is fully saturated.
  • the heterocycloalkyl is monounsaturated.
  • the heterocycloalkyl is polyunsaturated.
  • cycloalkyl means a monocyclic, bicyclic, or a multicyclic cycloalkyl ring system.
  • monocyclic ring systems are cyclic hydrocarbon groups containing from 3 to 8 carbon atoms, where such groups can be saturated or unsaturated, but not aromatic.
  • cycloalkyl groups are fully saturated.
  • a bicyclic or multicyclic cycloalkyl ring system refers to multiple rings fused together wherein at least one of the fused rings is a cycloalkyl ring and wherein the multiple rings are attached to the parent molecular moiety through any carbon atom contained within a cycloalkyl ring of the multiple rings.
  • a cycloalkyl is a cycloalkenyl.
  • the term “cycloalkenyl” is used in accordance with its plain ordinary meaning.
  • a cycloalkenyl is a monocyclic, bicyclic, or a multicyclic cycloalkenyl ring system.
  • a bicyclic or multicyclic cycloalkenyl ring system refers to multiple rings fused together wherein at least one of the fused rings is a cycloalkenyl ring and wherein the multiple rings are attached to the parent molecular moiety through any carbon atom contained within a cycloalkenyl ring of the multiple rings.
  • heterocycloalkyl means a monocyclic, bicyclic, or a multicyclic heterocycloalkyl ring system.
  • heterocycloalkyl groups are fully saturated.
  • a bicyclic or multicyclic heterocycloalkyl ring system refers to multiple rings fused together wherein at least one of the fused rings is a heterocycloalkyl ring and wherein the multiple rings are attached to the parent molecular moiety through any atom contained within a heterocycloalkyl ring of the multiple rings.
  • halo or “halogen,” by themselves or as part of another substituent, mean, unless otherwise stated, a fluorine, chlorine, bromine, or iodine atom. Additionally, terms such as “haloalkyl” are meant to include monohaloalkyl and polyhaloalkyl.
  • halo(Ci-C4)alkyl includes, but is not limited to, fluoromethyl, difluoromethyl, trifluoromethyl, 2,2,2-trifluoroethyl, 4-chlorobutyl, 3-bromopropyl, and the like.
  • acyl means, unless otherwise stated, -C(0)R where R is a substituted or unsubstituted alkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl.
  • aryl means, unless otherwise stated, a polyunsaturated, aromatic, hydrocarbon substituent, which can be a single ring or multiple rings (preferably from 1 to 3 rings) that are fused together (i.e., a fused ring aryl) or linked covalently.
  • a fused ring aryl refers to multiple rings fused together wherein at least one of the fused rings is an aryl ring and wherein the multiple rings are attached to the parent molecular moiety through any carbon atom contained within an aryl ring of the multiple rings.
  • heteroaryl refers to aryl groups (or rings) that contain at least one heteroatom such as N, O, or S, wherein the nitrogen and sulfur atoms are optionally oxidized, and the nitrogen atom(s) are optionally quatemized.
  • heteroaryl includes fused ring heteroaryl groups (i.e., multiple rings fused together wherein at least one of the fused rings is a heteroaromatic ring and wherein the multiple rings are attached to the parent molecular moiety through any atom contained within a heteroaromatic ring of the multiple rings).
  • a 5,6-fused ring heteroarylene refers to two rings fused together, wherein one ring has 5 members and the other ring has 6 members, and wherein at least one ring is a heteroaryl ring.
  • a 6,6-fused ring heteroarylene refers to two rings fused together, wherein one ring has 6 members and the other ring has 6 members, and wherein at least one ring is a heteroaryl ring.
  • a 6,5 -fused ring heteroarylene refers to two rings fused together, wherein one ring has 6 members and the other ring has 5 members, and wherein at least one ring is a heteroaryl ring.
  • a heteroaryl group can be attached to the remainder of the molecule through a carbon or heteroatom.
  • Nonlimiting examples of aryl and heteroaryl groups include phenyl, naphthyl, pyrrolyl, pyrazolyl, pyridazinyl, triazinyl, pyrimidinyl, imidazolyl, pyrazinyl, purinyl, oxazolyl, isoxazolyl, thiazolyl, furyl, thienyl, pyridyl, pyrimidyl, benzothiazolyl, benzoxazoyl benzimidazolyl, benzofuran, isobenzofuranyl, indolyl, isoindolyl, benzothiophenyl, isoquinolyl, quinoxalinyl, quinolyl, 1 -naphthyl, 2-naphthyl, 4-biphenyl, 1 -pyrrolyl, 2-pyrrolyl, 3-pyrrolyl, 3-pyrazolyl, 2-imidazolyl, 4-
  • aryl and heteroaryl ring systems are selected from the group of acceptable substituents described below.
  • a heteroaryl group substituent may be -O- bonded to a ring heteroatom nitrogen.
  • a fused ring heterocyloalkyl-aryl is an aryl fused to a heterocycloalkyl.
  • a fused ring heterocycloalkyl-heteroaryl is a heteroaryl fused to a heterocycloalkyl.
  • a fused ring heterocycloalkyl-cycloalkyl is a heterocycloalkyl fused to a cycloalkyl.
  • a fused ring heterocycloalkyl-heterocycloalkyl is a heterocycloalkyl fused to another heterocycloalkyl.
  • Fused ring heterocycloalkyl-aryl, fused ring heterocycloalkyl-heteroaryl, fused ring heterocycloalkyl-cycloalkyl, or fused ring heterocycloalkyl-heterocycloalkyl may each independently be unsubstituted or substituted with one or more of the substituents described herein.
  • Spirocyclic rings are two or more rings wherein adjacent rings are attached through a single atom.
  • the individual rings within spirocyclic rings may be identical or different.
  • Individual rings in spirocyclic rings may be substituted or unsubstituted and may have different substituents from other individual rings within a set of spirocyclic rings.
  • Possible substituents for individual rings within spirocyclic rings are the possible substituents for the same ring when not part of spirocyclic rings (e.g. substituents for cycloalkyl or heterocycloalkyl rings).
  • Spirocylic rings may be substituted or unsubstituted cycloalkyl, substituted or unsubstituted cycloalkylene, substituted or unsubstituted heterocycloalkyl or substituted or unsubstituted heterocycloalkylene and individual rings within a spirocyclic ring group may be any of the immediately previous list, including having all rings of one type (e.g. all rings being substituted heterocycloalkylene wherein each ring may be the same or different substituted heterocycloalkylene).
  • heterocyclic spirocyclic rings means a spirocyclic rings wherein at least one ring is a heterocyclic ring and wherein each ring may be a different ring.
  • substituted spirocyclic rings means that at least one ring is substituted and each substituent may optionally be different.
  • alkylsulfonyl means a moiety having the formula -S(0 2 )-R', where R' is a substituted or unsubstituted alkyl group as defined above. R' may have a specified number of carbons (e.g., “C1-C4 alkylsulfonyl”).
  • alkylarylene as an arylene moiety covalently bonded to an alkylene moiety (also referred to herein as an alkylene linker).
  • alkylarylene group has the formula:
  • An alkylarylene moiety may be substituted (e.g. with a substituent group) on the alkylene moiety or the arylene linker (e.g. at carbons 2, 3, 4, or 6) with halogen, oxo, -N 3 , - CF 3 , -CCI 3 , -CBr 3 , -CI 3 , -CN, -CHO, -OH, -NH 2 , -COOH, -CONH 2 , -NO 2 , -SH, -S0 2 CH 3 - S0 3 H, , -OSOsH, -SO 2 NH 2 , -NHNH 2 , -ONH 2 , -NHC(0)NHNH 2 , substituted or unsubstituted C 1 -C 5 alkyl or substituted or unsubstituted 2 to 5 membered heteroalkyl).
  • the alkylarylene is unsubstituted.
  • R, R', R", R'", and R" each preferably independently refer to hydrogen, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl (e.g., aryl substituted with 1-3 halogens), substituted or unsubstituted heteroaryl, substituted or unsubstituted alkyl, alkoxy, or thioalkoxy groups, or arylalkyl groups.
  • aryl e.g., aryl substituted with 1-3 halogens
  • substituted or unsubstituted heteroaryl substituted or unsubstituted alkyl, alkoxy, or thioalkoxy groups, or arylalkyl groups.
  • each of the R groups is independently selected as are each R', R", R'", and R"" group when more than one of these groups is present.
  • R' and R" are attached to the same nitrogen atom, they can be combined with the nitrogen atom to form a 4-, 5-, 6-, or 7- membered ring.
  • -NR'R includes, but is not limited to, 1-pyrrolidinyl and 4- morpholinyl.
  • alkyl is meant to include groups including carbon atoms bound to groups other than hydrogen groups, such as haloalkyl (e.g., -CF3 and -CH2CF3) and acyl (e.g., - C(0)CH 3 , -C(0)CF 3 , -C(0)CH 2 0CH 3 , and the like).
  • haloalkyl e.g., -CF3 and -CH2CF3
  • acyl e.g., - C(0)CH 3 , -C(0)CF 3 , -C(0)CH 2 0CH 3 , and the like.
  • Substituents for rings may be depicted as substituents on the ring rather than on a specific atom of a ring (commonly referred to as a floating substituent).
  • the substituent may be attached to any of the ring atoms (obeying the rules of chemical valency) and in the case of fused rings or spirocyclic rings, a substituent depicted as associated with one member of the fused rings or spirocyclic rings (a floating substituent on a single ring), may be a substituent on any of the fused rings or spirocyclic rings (a floating substituent on multiple rings).
  • the multiple substituents may be on the same atom, same ring, different atoms, different fused rings, different spirocyclic rings, and each substituent may optionally be different.
  • a point of attachment of a ring to the remainder of a molecule is not limited to a single atom (a floating substituent)
  • the attachment point may be any atom of the ring and in the case of a fused ring or spirocyclic ring, any atom of any of the fused rings or spirocyclic rings while obeying the rules of chemical valency.
  • a ring, fused rings, or spirocyclic rings contain one or more ring heteroatoms and the ring, fused rings, or spirocyclic rings are shown with one more floating substituents (including, but not limited to, points of attachment to the remainder of the molecule), the floating substituents may be bonded to the heteroatoms.
  • the ring heteroatoms are shown bound to one or more hydrogens (e.g. a ring nitrogen with two bonds to ring atoms and a third bond to a hydrogen) in the structure or formula with the floating substituent, when the heteroatom is bonded to the floating substituent, the substituent will be understood to replace the hydrogen, while obeying the rules of chemical valency.
  • Two or more substituents may optionally be joined to form aryl, heteroaryl, cycloalkyl, or heterocycloalkyl groups.
  • Such so-called ring-forming substituents are typically, though not necessarily, found attached to a cyclic base structure.
  • the ring-forming substituents are attached to adjacent members of the base structure.
  • two ring-forming substituents attached to adjacent members of a cyclic base structure create a fused ring structure.
  • the ring-forming substituents are attached to a single member of the base structure.
  • two ring-forming substituents attached to a single member of a cyclic base structure create a spirocyclic structure.
  • the ring-forming substituents are attached to non- adjacent members of the base structure.
  • Two of the substituents on adjacent atoms of the aryl or heteroaryl ring may optionally form a ring of the formula -T-C(0)-(CRR') q -U-, wherein T and U are independently -NR-, -0-, -CRR'-, or a single bond, and q is an integer of from 0 to 3.
  • two of the substituents on adjacent atoms of the aryl or heteroaryl ring may optionally be replaced with a substituent of the formula -A-(CH2) r -B-, wherein A and B are independently -CRR'-, -0-, -NR-, -S-, -S(O) -, -S(0) 2 -, -S(0) 2 NR'-, or a single bond, and r is an integer of from 1 to 4.
  • One of the single bonds of the new ring so formed may optionally be replaced with a double bond.
  • two of the substituents on adjacent atoms of the aryl or heteroaryl ring may optionally be replaced with a substituent of the formula - (CRR')s-X'- (C"R"R"')d-, where s and d are independently integers of from 0 to 3, and X' is - 0-, -NR'-, -S-, -S(O)-, -S(0) 2 -, or -S(0) 2 NR'-.
  • R, R', R", and R' are preferably independently selected from hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, and substituted or unsubstituted heteroaryl.
  • heteroatom or “ring heteroatom” are meant to include oxygen (O), nitrogen (N), sulfur (S), phosphorus (P), selenium (Se), and silicon (Si).
  • heteroatom or “ring heteroatom” are meant to include oxygen (O), nitrogen (N), sulfur (S), phosphorus (P), and silicon (Si).
  • a “substituent group,” as used herein, means a group selected from the following moieties:
  • unsubstituted alkyl e.g., Ci-Cs alkyl, C 1 -C 6 alkyl, or C 1 -C 4 alkyl
  • unsubstituted heteroalkyl e.g., 2 to 8 membered heteroalkyl, 2 to 6 membered heteroalkyl, or 2 to 4 membered heteroalkyl
  • unsubstituted cycloalkyl e.g., C 3 -Cs cycloalkyl, C 3 -C 6 cycloalkyl, or C 5 - C 6 cycl
  • alkyl e.g., Ci-Cs alkyl, C 1 -C 6 alkyl, or C 1 -C 4 alkyl
  • heteroalkyl e.g., 2 to 8 membered heteroalkyl, 2 to 6 membered heteroalkyl, or 2 to 4 membered heteroalkyl
  • cycloalkyl e.g., C 3 -Cs cycloalkyl, C 3 -C 6 cycloalkyl, or C 5 -C 6 cycloalkyl
  • heterocycloalkyl e.g., 3 to 8 membered heterocycloalkyl, 3 to 6 membered heterocycloalkyl, or 5 to 6 membered heterocycloalkyl
  • aryl e.g., C6-C10 aryl, C10 aryl, or phenyl
  • heteroaryl e.g., 5 to 10 membered heteroaryl, 5 to 9 membered heteroaryl, or 5 to 6
  • unsubstituted alkyl e.g., Ci-Cs alkyl, C 1 -C 6 alkyl, or C 1 -C 4 alkyl
  • unsubstituted heteroalkyl e.g., 2 to 8 membered heteroalkyl, 2 to 6 membered heteroalkyl, or 2 to 4 membered heteroalkyl
  • unsubstituted cycloalkyl e.g., C 3 -C 8 cycloalkyl, C 3 -C 6 cycloalkyl, or C 5
  • alkyl e.g., Ci-Cs alkyl, C1-C6 alkyl, or C1-C4 alkyl
  • heteroalkyl e.g., 2 to 8 membered heteroalkyl, 2 to 6 membered heteroalkyl, or 2 to 4 membered heteroalkyl
  • cycloalkyl e.g., C3-C8 cycloalkyl, C3-C6 cycloalkyl, or C5-C6 cycloalkyl
  • heterocycloalkyl e.g., 3 to 8 membered heterocycloalkyl, 3 to 6 membered heterocycloalkyl, or 5 to 6 membered heterocycloalkyl
  • aryl e.g., C 6 - C10 aryl, C10 aryl, or phenyl
  • heteroaryl e.g., 5 to 10 membered heteroaryl, 5 to 9 membered heteroaryl, or 5 to 6 membered hetero
  • alkyl e.g., Ci-Cs alkyl, C 1 -C 6 alkyl, or C 1 -C 4 alkyl
  • heteroalkyl e.g., 2 to 8 membered heteroalkyl, 2 to 6 membered heteroalkyl, or 2 to 4 membered heteroalkyl
  • cycloalkyl e.g., C3-C8 cycloalkyl, C3-C6 cycloalkyl, or C5-C6 cycloalkyl
  • heterocycloalkyl e.g., 3 to 8 membered heterocycloalkyl, 3 to 6 membered heterocycloalkyl, or 5 to 6 membered heterocycloalkyl
  • aryl e.g., C 6 - C 10 aryl, C 10 aryl, or phenyl
  • heteroaryl e.g., 5 to 10 membered heteroaryl, 5 to 9 membered heteroaryl, or 5 to 6 membere
  • unsubstituted alkyl e.g., Ci-Cs alkyl, C 1 -C 6 alkyl, or C 1 -C 4 alkyl
  • unsubstituted heteroalkyl e.g., 2 to 8 membered heteroalkyl, 2 to 6 membered heteroalkyl, or 2 to 4 membered heteroalkyl
  • unsubstituted cycloalkyl e.g., C 3 -C 8 cycloalkyl, C 3 -C 6 cycloalkyl, or C 5 -C 6 cycloalkyl
  • unsubstituted heterocycloalkyl e.g., 3 to 8 membered heterocycloalkyl, 3 to 6 membered heterocycloalkyl, or 5 to 6 membered heterocycloalkyl
  • unsubstituted heterocycloalkyl e.g., 3 to 8 membered heterocycloalkyl, 3 to 6 membered heterocyclo
  • a “size-limited substituent” or “ size-limited substituent group,” as used herein, means a group selected from all of the substituents described above for a “substituent group,” wherein each substituted or unsubstituted alkyl is a substituted or unsubstituted C1-C20 alkyl, each substituted or unsubstituted heteroalkyl is a substituted or unsubstituted 2 to 20 membered heteroalkyl, each substituted or unsubstituted cycloalkyl is a substituted or unsubstituted C3-C8 cycloalkyl, each substituted or unsubstituted heterocycloalkyl is a substituted or unsubstituted 3 to 8 membered heterocycloalkyl, each substituted or unsubstituted aryl is a substituted or unsubstituted C6-C10 aryl, and each substituted or unsubstituted heteroaryl is a group selected
  • a “lower substituent” or “ lower substituent group,” as used herein, means a group selected from all of the substituents described above for a “substituent group,” wherein each substituted or unsubstituted alkyl is a substituted or unsubstituted Ci-Cs alkyl, each substituted or unsubstituted heteroalkyl is a substituted or unsubstituted 2 to 8 membered heteroalkyl, each substituted or unsubstituted cycloalkyl is a substituted or unsubstituted C3- C7 cycloalkyl, each substituted or unsubstituted heterocycloalkyl is a substituted or unsubstituted 3 to 7 membered heterocycloalkyl, each substituted or unsubstituted aryl is a substituted or unsubstituted phenyl, and each substituted or unsubstituted heteroaryl is a substituted or unsubstituted al
  • each substituted group described in the compounds herein is substituted with at least one substituent group. More specifically, in some embodiments, each substituted alkyl, substituted heteroalkyl, substituted cycloalkyl, substituted heterocycloalkyl, substituted aryl, substituted heteroaryl, substituted alkylene, substituted heteroalkylene, substituted cycloalkylene, substituted heterocycloalkylene, substituted arylene, and/or substituted heteroarylene described in the compounds herein are substituted with at least one substituent group. In other embodiments, at least one or all of these groups are substituted with at least one size-limited substituent group. In other embodiments, at least one or all of these groups are substituted with at least one lower substituent group.
  • each substituted or unsubstituted alkyl may be a substituted or unsubstituted C1-C20 alkyl
  • each substituted or unsubstituted heteroalkyl is a substituted or unsubstituted 2 to 20 membered heteroalkyl
  • each substituted or unsubstituted cycloalkyl is a substituted or unsubstituted C3-C8 cycloalkyl
  • each substituted or unsubstituted heterocycloalkyl is a substituted or unsubstituted 3 to 8 membered heterocycloalkyl
  • each substituted or unsubstituted aryl is a substituted or unsubstituted C 6 - Cio aryl
  • each substituted or unsubstituted heteroaryl is a substituted or unsubstituted 5 to 10 membered heteroaryl.
  • each substituted or unsubstituted alkylene is a substituted or unsubstituted C 1 -C 20 alkylene
  • each substituted or unsubstituted heteroalkylene is a substituted or unsubstituted 2 to 20 membered heteroalkylene
  • each substituted or unsubstituted cycloalkylene is a substituted or unsubstituted C 3 -C 8 cycloalkylene
  • each substituted or unsubstituted heterocycloalkylene is a substituted or unsubstituted 3 to 8 membered heterocycloalkylene
  • each substituted or unsubstituted arylene is a substituted or unsubstituted C 6 -C 10 arylene
  • each substituted or unsubstituted heteroarylene is a substituted or unsubstituted 5 to 10 membered heteroarylene.
  • each substituted or unsubstituted alkyl is a substituted or unsubstituted Ci-Cs alkyl
  • each substituted or unsubstituted heteroalkyl is a substituted or unsubstituted 2 to 8 membered heteroalkyl
  • each substituted or unsubstituted cycloalkyl is a substituted or unsubstituted C 3 -C 7 cycloalkyl
  • each substituted or unsubstituted heterocycloalkyl is a substituted or unsubstituted 3 to 7 membered heterocycloalkyl
  • each substituted or unsubstituted aryl is a substituted or unsubstituted C 6 -C 10 aryl
  • each substituted or unsubstituted heteroaryl is a substituted or unsubstituted 5 to 9 membered heteroaryl.
  • each substituted or unsubstituted alkylene is a substituted or unsubstituted Ci-Cs alkylene
  • each substituted or unsubstituted heteroalkylene is a substituted or unsubstituted 2 to 8 membered heteroalkylene
  • each substituted or unsubstituted cycloalkylene is a substituted or unsubstituted C 3 -C 7 cycloalkylene
  • each substituted or unsubstituted heterocycloalkylene is a substituted or unsubstituted 3 to 7 membered heterocycloalkylene
  • each substituted or unsubstituted arylene is a substituted or unsubstituted C 6 -C 10 arylene
  • each substituted or unsubstituted heteroarylene is a substituted or unsubstituted 5 to 9 membered heteroarylene.
  • the compound is a chemical species set forth in the Examples section, figures, or tables below.
  • a substituted or unsubstituted moiety e.g., substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted alkylene, substituted or unsubstituted heteroalkylene, substituted or unsubstituted cycloalkylene, substituted or unsubstituted heterocycloalkylene, substituted or unsubstituted arylene, and/or substituted or unsubstituted heteroarylene) is unsubstituted (e.g., is an unsubstituted alkyl, unsubstituted heteroalkyl, unsubstituted cycloalkyl, unsubstituted
  • a substituted or unsubstituted moiety e.g., substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted alkylene, substituted or unsubstituted heteroalkylene, substituted or unsubstituted cycloalkylene, substituted or unsubstituted heterocycloalkylene, substituted or unsubstituted arylene, and/or substituted or unsubstituted heteroarylene) is substituted (e.g., is a substituted alkyl, substituted heteroalkyl, substituted cycloalkyl, substituted heterocycloalkyl, substituted aryl, substituted heteroaryl, substituted alky
  • a substituted moiety e.g., substituted alkyl, substituted heteroalkyl, substituted cycloalkyl, substituted heterocycloalkyl, substituted aryl, substituted heteroaryl, substituted alkylene, substituted heteroalkylene, substituted cycloalkylene, substituted heterocycloalkylene, substituted arylene, and/or substituted heteroarylene
  • is substituted with at least one substituent group wherein if the substituted moiety is substituted with a plurality of substituent groups, each substituent group may optionally be different. In embodiments, if the substituted moiety is substituted with a plurality of substituent groups, each substituent group is different.
  • a substituted moiety e.g., substituted alkyl, substituted heteroalkyl, substituted cycloalkyl, substituted heterocycloalkyl, substituted aryl, substituted heteroaryl, substituted alkylene, substituted heteroalkylene, substituted cycloalkylene, substituted heterocycloalkylene, substituted arylene, and/or substituted heteroarylene
  • is substituted with at least one size-limited substituent group wherein if the substituted moiety is substituted with a plurality of size-limited substituent groups, each size-limited substituent group may optionally be different. In embodiments, if the substituted moiety is substituted with a plurality of size-limited substituent groups, each size-limited substituent group is different.
  • a substituted moiety e.g., substituted alkyl, substituted heteroalkyl, substituted cycloalkyl, substituted heterocycloalkyl, substituted aryl, substituted heteroaryl, substituted alkylene, substituted heteroalkylene, substituted cycloalkylene, substituted heterocycloalkylene, substituted arylene, and/or substituted heteroarylene
  • is substituted with at least one lower substituent group wherein if the substituted moiety is substituted with a plurality of lower substituent groups, each lower substituent group may optionally be different. In embodiments, if the substituted moiety is substituted with a plurality of lower substituent groups, each lower substituent group is different.
  • a substituted moiety e.g., substituted alkyl, substituted heteroalkyl, substituted cycloalkyl, substituted heterocycloalkyl, substituted aryl, substituted heteroaryl, substituted alkylene, substituted heteroalkylene, substituted cycloalkylene, substituted heterocycloalkylene, substituted arylene, and/or substituted heteroarylene
  • the substituted moiety is substituted with a plurality of groups selected from substituent groups, size-limited substituent groups, and lower substituent groups; each substituent group, size-limited substituent group, and/or lower substituent group
  • Certain compounds of the present disclosure possess asymmetric carbon atoms (optical or chiral centers) or double bonds; the enantiomers, racemates, diastereomers, tautomers, geometric isomers, stereoisometric forms that may be defined, in terms of absolute stereochemistry, as (i?)-or ( S )- or, as (D)- or (L)- for amino acids, and individual isomers are encompassed within the scope of the present disclosure.
  • the compounds of the present disclosure do not include those that are known in art to be too unstable to synthesize and/or isolate.
  • the present disclosure is meant to include compounds in racemic and optically pure forms.
  • Optically active (R)- and ( S )-, or (D)- and (L)-isomers may be prepared using chiral synthons or chiral reagents, or resolved using conventional techniques.
  • the compounds described herein contain olefinic bonds or other centers of geometric asymmetry, and unless specified otherwise, it is intended that the compounds include both E and Z geometric isomers.
  • isomers refers to compounds having the same number and kind of atoms, and hence the same molecular weight, but differing in respect to the structural arrangement or configuration of the atoms.
  • tautomer refers to one of two or more structural isomers which exist in equilibrium and which are readily converted from one isomeric form to another.
  • structures depicted herein are also meant to include all stereochemical forms of the structure; i.e., the R and S configurations for each asymmetric center. Therefore, single stereochemical isomers as well as enantiomeric and diastereomeric mixtures of the present compounds are within the scope of the disclosure.
  • structures depicted herein are also meant to include compounds which differ only in the presence of one or more isotopically enriched atoms.
  • compounds having the present structures except for the replacement of a hydrogen by a deuterium or tritium, or the replacement of a carbon by 13 C- or 14 C-enriched carbon are within the scope of this disclosure.
  • the compounds of the present disclosure may also contain unnatural proportions of atomic isotopes at one or more of the atoms that constitute such compounds.
  • the compounds may be radiolabeled with radioactive isotopes, such as for example tritium ( 3 H), iodine-125 ( 125 I), or carbon-14 ( 14 C). All isotopic variations of the compounds of the present disclosure, whether radioactive or not, are encompassed within the scope of the present disclosure.
  • bioconjugate and “bioconjugate reactive moiety” refers to the resulting association between atoms or molecules of bioconjugate reactive groups. The association can be direct or indirect.
  • a conjugate between a first bioconjugate reactive group e.g., -N3 ⁇ 4, -C(0)0H, -N-hydroxysuccinimide, or -maleimide
  • a second bioconjugate reactive group e.g., sulfhydryl, sulfur-containing amino acid, amine, amine sidechain containing amino acid, or carboxylate
  • covalent bond or linker e.g. a first linker of second linker
  • indirect e.g., by non-covalent bond (e.g. electrostatic interactions (e.g. ionic bond, hydrogen bond, halogen bond), van der Waals interactions (e.g.
  • bioconjugates or bioconjugate linkers are formed using bioconjugate chemistry (i.e. the association of two bioconjugate reactive groups) including, but are not limited to nucleophilic substitutions (e.g., reactions of amines and alcohols with acyl halides, active esters), electrophilic substitutions (e.g., enamine reactions) and additions to carbon-carbon and carbon-heteroatom multiple bonds (e.g., Michael reaction, Diels-Alder addition).
  • bioconjugate chemistry i.e. the association of two bioconjugate reactive groups
  • nucleophilic substitutions e.g., reactions of amines and alcohols with acyl halides, active esters
  • electrophilic substitutions e.g., enamine reactions
  • additions to carbon-carbon and carbon-heteroatom multiple bonds e.g., Michael reaction, Diels-Alder addition.
  • the first bioconjugate reactive group e.g., maleimide moiety
  • the second bioconjugate reactive group e.g. a sulfhydryl
  • the first bioconjugate reactive group (e.g., haloacetyl moiety) is covalently attached to the second bioconjugate reactive group (e.g. a sulfhydryl).
  • the first bioconjugate reactive group (e.g., pyridyl moiety) is covalently attached to the second bioconjugate reactive group (e.g. a sulfhydryl).
  • the first bioconjugate reactive group e.g., -N-hydroxysuccinimide moiety
  • is covalently attached to the second bioconjugate reactive group (e.g. an amine).
  • the first bioconjugate reactive group (e.g., maleimide moiety) is covalently attached to the second bioconjugate reactive group (e.g. a sulfhydryl).
  • the first bioconjugate reactive group (e.g., -sulfo-N- hydroxysuccinimide moiety) is covalently attached to the second bioconjugate reactive group (e.g. an amine).
  • Useful bioconjugate reactive moieties used for bioconjugate chemistries herein include, for example:
  • haloalkyl groups wherein the halide can be later displaced with a nucleophilic group such as, for example, an amine, a carboxylate anion, thiol anion, carbanion, or an alkoxide ion, thereby resulting in the covalent attachment of a new group at the site of the halogen atom;
  • a nucleophilic group such as, for example, an amine, a carboxylate anion, thiol anion, carbanion, or an alkoxide ion
  • dienophile groups which are capable of participating in Diels-Alder reactions such as, for example, maleimido or maleimide groups;
  • aldehyde or ketone groups such that subsequent derivatization is possible via formation of carbonyl derivatives such as, for example, imines, hydrazones, semicarbazones or oximes, or via such mechanisms as Grignard addition or alkyllithium addition;
  • amine or sulfhydryl groups (e.g., present in cysteine), which can be, for example, acylated, alkylated or oxidized;
  • alkenes which can undergo, for example, cycloadditions, acylation, Michael addition, etc;
  • metal silicon oxide bonding and (m) metal bonding to reactive phosphorus groups (e.g. phosphines) to form, for example, phosphate diester bonds.
  • reactive phosphorus groups e.g. phosphines
  • biotin conjugate can react with avidin or strepavidin to form an avidin- biotin complex or streptavidin-biotin complex.
  • bioconjugate reactive groups can be chosen such that they do not participate in, or interfere with, the chemical stability of the conjugate described herein.
  • a reactive functional group can be protected from participating in the crosslinking reaction by the presence of a protecting group.
  • the bioconjugate comprises a molecular entity derived from the reaction of an unsaturated bond, such as a maleimide, and a sulfhydryl group.
  • an analog is used in accordance with its plain ordinary meaning within Chemistry and Biology and refers to a chemical compound that is structurally similar to another compound (i.e., a so-called “reference” compound) but differs in composition, e.g., in the replacement of one atom by an atom of a different element, or in the presence of a particular functional group, or the replacement of one functional group by another functional group, or the absolute stereochemistry of one or more chiral centers of the reference compound. Accordingly, an analog is a compound that is similar or comparable in function and appearance but not in structure or origin to a reference compound.
  • a or “an,” as used in herein means one or more.
  • substituted with a[n] means the specified group may be substituted with one or more of any or all of the named substituents.
  • a group such as an alkyl or heteroaryl group
  • the group may contain one or more unsubstituted C1-C20 alkyls, and/or one or more unsubstituted 2 to 20 membered heteroalkyls.
  • R-substituted where a moiety is substituted with an R substituent, the group may be referred to as “R-substituted.” Where a moiety is R-substituted, the moiety is substituted with at least one R substituent and each R substituent is optionally different. Where a particular R group is present in the description of a chemical genus (such as Formula (I)), a Roman alphabetic symbol may be used to distinguish each appearance of that particular R group. For example, where multiple R 13 substituents are present, each R 13 substituent may be distinguished as R 13A , R 13B , R 13C , R 13D , etc., wherein each of R 13A , R 13B , R 13C , R 13D , etc. is defined within the scope of the definition of R 13 and optionally differently.
  • Oxidizing agent is used in accordance with its ordinary plain meaning within chemistry and biology and refers to a substance that has the ability to oxidize other substances (i.e. removes electrons from the substance).
  • the term “oxidizing agent” is a substance that, in the course of a chemical redox reaction, removes one or more electrons from a substance (e.g., the reactant), wherein the oxidizing agent gains one or more electrons from the substrate.
  • an oxidizing agent is a chemical species that transfers electronegative atoms to another substrate (e.g., a reactant).
  • the oxidizing agent is analogous to the term “electron acceptor” and may be used herein interchangeably.
  • Non-limiting examples of oxidizing agents include oxygen (O2), ozone (O3), hydrogen peroxide (H2O2), nitric acid (HNO3), sulfuric acid (H2SO4), hexavalent chromium, pyridinium chlorochromate (PCC), iV-methylmorpholine-iV-oxide (NMO), chromium trioxide (CrC> 3 , Jones reagent), potassium permanganate (K 2 Mhq 4 ), potassium nitrate (KNO3), Dess- Martin periodinane (DMP), 2-iodoxybenzoic acid (IBX), 2,2,6,6-tetramethylpiperidinyloxy (TEMPO), and Selectfluor ® (F-TEDA-BF4, chloromethyl-4-fluoro-l,4- diazoniabicyclo[2.2.2]octane bis(tetrafluoroborate), potassium perchlorate, or ammonium persulfate.
  • oxygen
  • halogenating agent is used in accordance with its ordinary plain meaning within chemistry and refers to a substance (e.g., compound or composition) that has the ability to incorporate one or more halogen atoms (e.g. bromination, dibromination tribromination, chlorination, dichlorination, trichlorination, iodination, diiodination, triiodination, fluorination, difluorination, trifluorination, etc.) into another substance (e.g., compound or composition).
  • halogen atoms e.g. bromination, dibromination tribromination, chlorination, dichlorination, trichlorination, iodination, diiodination, triiodination, fluorination, difluorination, trifluorination, etc.
  • Halogenating agents include chlorinating agents, brominating agents, iodinating agents and fluorinating agents, wherein a chlorinating agent incorporates a chlorine atom, a brominating agent incorporates a bromine atom, an iodinating agent incorporates an iodine atom, or a fluorinating agent incorporates a fluorine atom.
  • Brominating agents include, but are not limited to, iV-bromosuccinimide (NBS), dibromoisocyanuric acid (DBI), bromine, bromotrichloromethane, l,2-dibromo-l,l,2,2- tetrachloroethane, carbon tetrabromide, tetrabutylammonium tribromide, trimethylphenylammonium tribromide, benzyltrimethylammonium tribromide, pyridinium bromide perbromide, 4-dimethylaminopyridinium bromide perbromide, 1 -butyl-3 - methylimidazolium tribromide, l,8-diazabicyclo[5.4.0]-7-undecene, hydrogen tribromide, N- bromophthalimide, iV-bromosaccharin, iV-bromoacetamide, 2-bromo-2-cyano-iV r V
  • Chlorinating agents include, but are not limited to, iV-chlorosuccinimide (NCS), thionyl chloride, methanesulfonyl chloride, trichloromethanesulfonyl chloride, tert- butyl hypochlorite, chloromethyl methyl ether, dichloromethyl methyl ether, methoxyacetyl chloride, oxalyl chloride, cyanuric chloride, N- chlorophthalimide, sodium dichloroisocyanurate, trichloroisocyanuric acid, chloramine B hydrate, o-chloramine T dihydrate, chloramine T trihydrate, dichloramine B, dichloramine T, benzyhrimethylammonium, tetrachloroiodate.
  • NCS iV-chlorosuccinimide
  • thionyl chloride methanesulfonyl chloride
  • Iodinating agents include, but are not limited to, iV-iodosuccinimide (NIS), l,3-diodo-5,5'-dimethylhidantoin (DIH), iodine, hydriodic acid, diiodomethane, l-chloro-2-iodoethane, carbon tetraiodide, tetramethylammonium dichloroiodate, benzyltrimethylammonium dichloroiodate, pyridine iodine monochloride, iV,iV-dimethyl-iV-(methylsulfanylmethylene)-ammonium iodide, iV-iodosaccharin, trimethylsilyl iodide, bis(pyridine)iodonium tetrafluoroborate, bis(2,4,6-trimethylpyridine)- iodonium hexafluorophosphate.
  • the term “leaving group” is used in accordance with its ordinary meaning in chemistry and refers to a moiety (e.g., atom, functional group, molecule) that separates from the molecule following a chemical reaction (e.g., bond formation, reductive elimination, condensation, cross-coupling reaction) involving an atom or chemical moiety to which the leaving group is attached, also referred to herein as the “leaving group reactive moiety”, and a complementary reactive moiety (i.e. a chemical moiety that reacts with the leaving group reactive moiety) to form a new bond between the remnants of the leaving groups reactive moiety and the complementary reactive moiety.
  • a chemical reaction e.g., bond formation, reductive elimination, condensation, cross-coupling reaction
  • a complementary reactive moiety i.e. a chemical moiety that reacts with the leaving group reactive moiety
  • Non limiting examples of leaving groups include hydrogen, hydroxide, organotin moieties (e.g., organotin heteroalkyl), halogen (e.g., Br), perfluoroalkylsulfonates (e.g. triflate), tosylates, mesylates, water, alcohols, nitrate, phosphate, thioether, amines, ammonia, fluoride, carboxylate, phenoxides, boronic acid, boronate esters, and alkoxides.
  • organotin moieties e.g., organotin heteroalkyl
  • halogen e.g., Br
  • perfluoroalkylsulfonates e.g. triflate
  • tosylates mesylates, water, alcohols, nitrate, phosphate, thioether, amines, ammonia, fluoride, carboxylate, phenoxides, boronic
  • two molecules with leaving groups are allowed to contact, and upon a reaction and/or bond formation (e.g., acyloin condensation, aldol condensation, Claisen condensation, Stille reaction) the leaving groups separates from their respective molecule.
  • a leaving group is a bioconjugate reactive moiety.
  • at least two leaving groups e.g., R 1 and R 13 ) are allowed to contact such that the leaving groups are sufficiently proximal to react, interact or physically touch.
  • the leaving group is designed to facilitate the reaction.
  • protecting group is used in accordance with its ordinary meaning in organic chemistry and refers to a moiety covalently bound to a heteroatom to prevent reactivity of the heteroatom during one or more chemical reactions performed prior to removal of the protecting group.
  • the protecting group is covalently bound to a heteroatom that is part of a heteroalkyl, heterocycloalkyl or heteroaryl moiety.
  • a protecting group is bound to a heteroatom (e.g., O) during a part of a multistep synthesis wherein it is not desired to have the heteroatom react (e.g., a chemical reduction) with a reagent. Following protection the protecting group may be removed (e.g., by modulating the pH).
  • the protecting group is an alcohol protecting group.
  • Alcohol protecting groups include acetyl, benzoyl, benzyl, methoxymethyl ether (MOM), tetrahydropyranyl (THP), and silyl ether (e.g., trimethylsilyl (TMS), tert- butyl dimethylsilyl (TBS)).
  • the protecting group is an amine protecting group.
  • Non-limiting examples of amine protecting groups include carbobenzyloxy (Cbz), p- methoxybenzyl carbonyl (Moz or MeOZ), ter/-butyl oxycarbonyl (BOC), 9- fluorenylmethyloxycarbonyl (FMOC), acetyl (Ac), benzoyl (Bz), benzyl (Bn), carbamate, p- methoxybenzyl ether (PMB), 3,4-dimethoxybenzyl (DMPM), p-methoxyphenyl (PMP), pivaloyl (Piv), tosyl (Ts), and phthalimide.
  • Cbz carbobenzyloxy
  • Moz or MeOZ p- methoxybenzyl carbonyl
  • BOC ter/-butyl oxycarbonyl
  • FMOC 9- fluorenylmethyloxycarbonyl
  • acetyl Ac
  • benzoyl (Bz) benzy
  • variable e.g., moiety or linker
  • a compound or of a compound genus e.g., a genus described herein
  • the unfilled valence(s) of the variable will be dictated by the context in which the variable is used.
  • variable of a compound as described herein when a variable of a compound as described herein is connected (e.g., bonded) to the remainder of the compound through a single bond, that variable is understood to represent a monovalent form (i.e., capable of forming a single bond due to an unfilled valence) of a standalone compound (e.g., if the variable is named “methane” in an embodiment but the variable is known to be attached by a single bond to the remainder of the compound, a person of ordinary skill in the art would understand that the variable is actually a monovalent form of methane, i.e., methyl or -CH3).
  • variable is the divalent form of a standalone compound (e.g., if the variable is assigned to “PEG” or “polyethylene glycol” in an embodiment but the variable is connected by two separate bonds to the remainder of the compound, a person of ordinary skill in the art would understand that the variable is a divalent (i.e., capable of forming two bonds through two unfilled valences) form of PEG instead of the standalone compound PEG).
  • exogenous refers to a molecule or substance (e.g., a compound, nucleic acid or protein) that originates from outside a given cell or organism.
  • an "exogenous promoter” as referred to herein is a promoter that does not originate from the plant it is expressed by.
  • endogenous or endogenous promoter refers to a molecule or substance that is native to, or originates within, a given cell or organism.
  • lipid moiety is used in accordance with its ordinary meaning in chemistry and refers to a hydrophobic molecule which is typically characterized by an aliphatic hydrocarbon chain.
  • the lipid moiety includes a carbon chain of 3 to 100 carbons.
  • the lipid moiety includes a carbon chain of 5 to 50 carbons.
  • the lipid moiety includes a carbon chain of 5 to 25 carbons.
  • the lipid moiety includes a carbon chain of 8 to 25 carbons.
  • Lipid moieties may include saturated or unsaturated carbon chains, and may be optionally substituted.
  • the lipid moiety is optionally substituted with a charged moiety at the terminal end.
  • the lipid moiety is an alkyl or heteroalkyl optionally substituted with a carboxylic acid moiety at the terminal end.
  • a charged moiety refers to a functional group possessing an abundance of electron density (i.e. electronegative) or is deficient in electron density (i.e. electropositive).
  • Nonlimiting examples of a charged moiety includes carboxylic acid, alcohol, phosphate, aldehyde, and sulfonamide.
  • a charged moiety is capable of forming hydrogen bonds.
  • the term “coupling reagent” is used in accordance with its plain ordinary meaning in the arts and refers to a substance (e.g., a compound or solution) which participates in chemical reaction and results in the formation of a covalent bond (e.g., between bioconjugate reactive moieties, between a bioconjugate reactive moiety and the coupling reagent).
  • a covalent bond e.g., between bioconjugate reactive moieties, between a bioconjugate reactive moiety and the coupling reagent.
  • the level of reagent is depleted in the course of a chemical reaction. This is in contrast to a solvent, which typically does not get consumed over the course of the chemical reaction.
  • Non-limiting examples of coupling reagents include benzotriazol-l-yl- oxytripyrrolidinophosphonium hexafluorophosphate (PyBOP), 7-Azabenzotriazol-l- yloxy)tripyrrolidinophosphonium hexafluorophosphate (PyAOP), 6-Chloro-benzotriazole-l- yloxy-tris-pyrrolidinophosphonium hexafluorophosphate (PyClock), 1- [Bis(dimethylamino)methylene] - 1 H- 1 ,2,3 -triazolo [4, 5 -b]pyridinium 3 -oxid hexafluorophosphate (HATU), or 2-(lH-benzotriazol-l-yl)-l,l,3,3-tetramethyluronium hexafluorophosphate (HBTU).
  • PyBOP benzotriazol-l-yl
  • solution is used in accor and refers to a liquid mixture in which the minor component (e.g., a solute or compound) is uniformly distributed within the major component (e.g., a solvent).
  • minor component e.g., a solute or compound
  • organic solvent as used herein is used in accordance with its ordinary meaning in chemistry and refers to a solvent which includes carbon.
  • organic solvents include acetic acid, acetone, acetonitrile, benzene, 1 -butanol, 2-butanol, 2-butanone, t-butyl alcohol, carbon tetrachloride, chlorobenzene, chloroform, cyclohexane, 1,2-dichloroethane, diethylene glycol, diethyl ether, diglyme (diethylene glycol , dimethyl ether), 1,2-dimethoxyethane (glyme, DME), dimethylformamide (DMF), dimethyl sulfoxide (DMSO), 1,4-dioxane, ethanol, ethyl acetate, ethylene glycol, glycerin, heptane, hexamethylphosphoramide (HMPA), hexamethylphosphorous,
  • salt refers to acid or base salts of the compounds used in the methods of the present invention.
  • acceptable salts are mineral acid (hydrochloric acid, hydrobromic acid, phosphoric acid, and the like) salts, organic acid (acetic acid, propionic acid, glutamic acid, citric acid and the like) salts, quaternary ammonium (methyl iodide, ethyl iodide, and the like) salts.
  • salts are meant to include salts of the active compounds that are prepared with relatively nontoxic acids or bases, depending on the particular substituents found on the compounds described herein.
  • base addition salts can be obtained by contacting the neutral form of such compounds with a sufficient amount of the desired base, either neat or in a suitable inert solvent.
  • pharmaceutically acceptable base addition salts include sodium, potassium, calcium, ammonium, organic amino, or magnesium salt, or a similar salt.
  • acid addition salts can be obtained by contacting the neutral form of such compounds with a sufficient amount of the desired acid, either neat or in a suitable inert solvent.
  • Examples of pharmaceutically acceptable acid addition salts include those derived from inorganic acids like hydrochloric, hydrobromic, nitric, carbonic, monohydrogencarbonic, phosphoric, monohydrogenphosphoric, dihydrogenphosphoric, sulfuric, monohydrogensulfuric, hydriodic, or phosphorous acids and the like, as well as the salts derived from relatively nontoxic organic acids like acetic, propionic, isobutyric, maleic, malonic, benzoic, succinic, suberic, fumaric, lactic, mandelic, phthalic, benzenesulfonic, p- tolylsulfonic, citric, tartaric, oxalic, methanesulfonic, and the like.
  • inorganic acids like hydrochloric, hydrobromic, nitric, carbonic, monohydrogencarbonic, phosphoric, monohydrogenphosphoric, dihydrogenphosphoric, sulfuric, monohydrogensulfuric, hydriodic,
  • salts of amino acids such as arginate and the like, and salts of organic acids like glucuronic or galactunoric acids and the like (see, for example, Berge et al, “Pharmaceutical Salts”, Journal of Pharmaceutical Science, 1977, 66, 1-19).
  • Certain specific compounds of the present disclosure contain both basic and acidic functionalities that allow the compounds to be converted into either base or acid addition salts.
  • the compounds of the present disclosure may exist as salts, such as with pharmaceutically acceptable acids.
  • the present disclosure includes such salts.
  • Non-limiting examples of such salts include hydrochlorides, hydrobromides, phosphates, sulfates, methanesulfonates, nitrates, maleates, acetates, citrates, fumarates, proprionates, tartrates (e.g., (+)-tartrates, (-)-tartrates, or mixtures thereof including racemic mixtures), succinates, benzoates, and salts with amino acids such as glutamic acid, and quaternary ammonium salts (e.g. methyl iodide, ethyl iodide, and the like). These salts may be prepared by methods known to those skilled in the art.
  • the neutral forms of the compounds are preferably regenerated by contacting the salt with a base or acid and isolating the parent compound in the conventional manner.
  • the parent form of the compound may differ from the various salt forms in certain physical properties, such as solubility in polar solvents.
  • the present disclosure provides compounds, which are in a prodrug form.
  • Prodrugs of the compounds described herein are those compounds that readily undergo chemical changes under physiological conditions to provide the compounds of the present disclosure.
  • Prodrugs of the compounds described herein may be converted in vivo after administration.
  • prodrugs can be converted to the compounds of the present disclosure by chemical or biochemical methods in an ex vivo environment, such as, for example, when contacted with a suitable enzyme or chemical reagent.
  • Certain compounds of the present disclosure can exist in unsolvated forms as well as solvated forms, including hydrated forms. In general, the solvated forms are equivalent to unsolvated forms and are encompassed within the scope of the present disclosure. Certain compounds of the present disclosure may exist in multiple crystalline or amorphous forms. In general, all physical forms are equivalent for the uses contemplated by the present disclosure and are intended to be within the scope of the present disclosure.
  • “Pharmaceutically acceptable excipient” and “pharmaceutically acceptable carrier” refer to a substance that aids the administration of an active agent to and absorption by a subject and can be included in the compositions of the present disclosure without causing a significant adverse toxicological effect on the patient.
  • Non-limiting examples of pharmaceutically acceptable excipients include water, NaCl, normal saline solutions, lactated Ringer’s, normal sucrose, normal glucose, binders, fillers, disintegrants, lubricants, coatings, sweeteners, flavors, salt solutions (such as Ringer's solution), alcohols, oils, gelatins, carbohydrates such as lactose, amylose or starch, fatty acid esters, hydroxymethycellulose, polyvinyl pyrrolidine, and colors, and the like.
  • Such preparations can be sterilized and, if desired, mixed with auxiliary agents such as lubricants, preservatives, stabilizers, wetting agents, emulsifiers, salts for influencing osmotic pressure, buffers, coloring, and/or aromatic substances and the like that do not deleteriously react with the compounds of the disclosure.
  • auxiliary agents such as lubricants, preservatives, stabilizers, wetting agents, emulsifiers, salts for influencing osmotic pressure, buffers, coloring, and/or aromatic substances and the like that do not deleteriously react with the compounds of the disclosure.
  • auxiliary agents such as lubricants, preservatives, stabilizers, wetting agents, emulsifiers, salts for influencing osmotic pressure, buffers, coloring, and/or aromatic substances and the like that do not deleteriously react with the compounds of the disclosure.
  • preparation is intended to include the formulation of the active compound with encapsulating material as a carrier providing a capsule in which the active component with or without other carriers, is surrounded by a carrier, which is thus in association with it.
  • carrier providing a capsule in which the active component with or without other carriers, is surrounded by a carrier, which is thus in association with it.
  • cachets and lozenges are included. Tablets, powders, capsules, pills, cachets, and lozenges can be used as solid dosage forms suitable for oral administration.
  • the term "about” means a range of values including the specified value, which a person of ordinary skill in the art would consider reasonably similar to the specified value. In embodiments, about means within a standard deviation using measurements generally acceptable in the art. In embodiments, about means a range extending to +/- 10% of the specified value. In embodiments, about includes the specified value.
  • a “synergistic amount” as used herein refers to the sum of a first amount (e.g., an amount of a compound provided herein) and a second amount (e.g., a therapeutic agent) that results in a synergistic effect (i.e. an effect greater than an additive effect). Therefore, the terms “synergy”, “synergism”, “synergistic”, “combined synergistic amount”, and “synergistic therapeutic effect” which are used herein interchangeably, refer to a measured effect of the compound administered in combination where the measured effect is greater than the sum of the individual effects of each of the compounds provided herein administered alone as a single agent.
  • a synergistic amount may be about 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, 1.0, 1.1, 1.2, 1.3, 1.4, 1.5, 1.6, 1.7, 1.8, 1.9, 2.0, 2.1, 2.2, 2.3, 2.4, 2.5, 2.6, 2.7, 2.8,
  • a synergistic amount may be about 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, 1.0, 1.1, 1.2, 1.3, 1.4, 1.5, 1.6, 1.7, 1.8, 1.9, 2.0, 2.1, 2.2, 2.3, 2.4, 2.5, 2.6,
  • EC50 half maximal effective concentration
  • concentration of a molecule e.g., antibody, chimeric antigen receptor or bispecific antibody
  • the EC50 is the concentration of a molecule (e.g., antibody, chimeric antigen receptor or bispecific antibody) that produces 50% of the maximal possible effect of that molecule.
  • bound atoms or molecules may be direct, e.g., by covalent bond or linker (e.g. a first linker or second linker), or indirect, e.g., by non-covalent bond (e.g. electrostatic interactions (e.g. ionic bond, hydrogen bond, halogen bond), van der Waals interactions (e.g. dipole-dipole, dipole-induced dipole, London dispersion), ring stacking (pi effects), hydrophobic interactions and the like).
  • covalent bond or linker e.g. a first linker or second linker
  • non-covalent bond e.g. electrostatic interactions (e.g. ionic bond, hydrogen bond, halogen bond), van der Waals interactions (e.g. dipole-dipole, dipole-induced dipole, London dispersion), ring stacking (pi effects), hydrophobic interactions and the like).
  • the term “capable of binding” as used herein refers to a moiety (e.g. a compound as described herein) that is able to measurably bind to a target (e.g., GNAS).
  • a target e.g., GNAS
  • the moiety is capable of binding with a Kd of less than about 10 mM, 5 mM, 1 mM, 500 nM, 250 nM, 100 nM, 75 nM, 50 nM, 25 nM, 15 nM, 10 nM, 5 nM, 1 nM, or about 0.1 nM.
  • conjugated when referring to two moieties means the two moieties are bonded, wherein the bond or bonds connecting the two moieties may be covalent or non-covalent.
  • the two moieties are covalently bonded to each other (e.g. directly or through a covalently bonded intermediary).
  • the two moieties are non-covalently bonded (e.g. through ionic bond(s), van der waal’s bond(s)/interactions, hydrogen bond(s), polar bond(s), or combinations or mixtures thereof).
  • non-nucleophilic base refers to any sterically hindered base that is a poor nucleophile.
  • nucleophile refers to a chemical species that donates an electron pair to an electrophile to form a chemical bond in relation to a reaction. All molecules or ions with a free pair of electrons or at least one pi bond can act as nucleophiles.
  • strong acid refers to an acid that is completely dissociated or ionized in an aqueous solution.
  • strong acids include hydrochloric acid (HC1), nitric acid (HNO3), sulfuric acid (H2SO4), hydrobromic acid (HBr), hydroiodic acid (HI), perchloric acid (HCIO4), or chloric acid (HCIO3).
  • carbocation stabilizing solvent refers to any polar protic solvent capable of forming dipole-dipole interactions with a carbocation, thereby stabilizing the carbocation.
  • amino acid refers to naturally occurring and synthetic amino acids, as well as amino acid analogs and amino acid mimetics that function in a manner similar to the naturally occurring amino acids.
  • Naturally occurring amino acids are those encoded by the genetic code, as well as those amino acids that are later modified, e.g., hydroxyproline, g- carboxyglutamate, and O-phosphoserine.
  • Amino acid analogs refers to compounds that have the same basic chemical structure as a naturally occurring amino acid, i.e., an a carbon that is bound to a hydrogen, a carboxyl group, an amino group, and an R group, e.g., homoserine, norleucine, methionine sulfoxide, methionine methyl sulfonium. Such analogs have modified R groups (e.g. , norleucine) or modified peptide backbones, but retain the same basic chemical structure as a naturally occurring amino acid.
  • Amino acid mimetics refers to chemical compounds that have a structure that is different from the general chemical structure of an amino acid, but that functions in a manner similar to a naturally occurring amino acid.
  • the terms “non-naturally occurring amino acid” and “unnatural amino acid” refer to amino acid analogs, synthetic amino acids, and amino acid mimetics which are not found in nature.
  • Amino acids may be referred to herein by either their commonly known three letter symbols or by the one-letter symbols recommended by the IUPAC-IUB Biochemical Nomenclature Commission. Nucleotides, likewise, may be referred to by their commonly accepted single-letter codes.
  • polypeptide peptide
  • protein protein
  • amino acid polymers in which one or more amino acid residue is an artificial chemical mimetic of a corresponding naturally occurring amino acid, as well as to naturally occurring amino acid polymers and non-naturally occurring amino acid polymers.
  • amino acid or nucleotide base “position” is denoted by a number that sequentially identifies each amino acid (or nucleotide base) in the reference sequence based on its position relative to the N-terminus (or 5'-end).
  • An amino acid residue in a protein “corresponds” to a given residue when it occupies the same essential structural position within the protein as the given residue. Due to deletions, insertions, truncations, fusions, and the like that must be taken into account when determining an optimal alignment, in general the amino acid residue number in a test sequence determined by simply counting from the N- terminus will not necessarily be the same as the number of its corresponding position in the reference sequence.
  • a variant has a deletion relative to an aligned reference sequence
  • that insertion will not correspond to a numbered amino acid position in the reference sequence.
  • truncations or fusions there can be stretches of amino acids in either the reference or aligned sequence that do not correspond to any amino acid in the corresponding sequence.
  • numbered with reference to refers to the numbering of the residues of a specified reference sequence when the given amino acid or polynucleotide sequence is compared to the reference sequence.
  • nucleic acid As may be used herein, the terms “nucleic acid,” “nucleic acid molecule,” “nucleic acid oligomer,” “oligonucleotide,” “nucleic acid sequence,” “nucleic acid fragment” and “polynucleotide” are used interchangeably and are intended to include, but are not limited to, a polymeric form of nucleotides covalently linked together that may have various lengths, either deoxyribonucleotides or ribonucleotides, or analogs, derivatives or modifications thereof. Different polynucleotides may have different three-dimensional structures, and may perform various functions, known or unknown.
  • Non-limiting examples of polynucleotides include a gene, a gene fragment, an exon, an intron, intergenic DNA (including, without limitation, heterochromatic DNA), messenger RNA (mRNA), transfer RNA, ribosomal RNA, a ribozyme, cDNA, a recombinant polynucleotide, a branched polynucleotide, a plasmid, a vector, isolated DNA of a sequence, isolated RNA of a sequence, a nucleic acid probe, and a primer.
  • Polynucleotides useful in the methods of the disclosure may include natural nucleic acid sequences and variants thereof, artificial nucleic acid sequences, or a combination of such sequences.
  • a polynucleotide is typically composed of a specific sequence of four nucleotide bases: adenine (A); cytosine (C); guanine (G); and thymine (T) (uracil (U) for thymine (T) when the polynucleotide is RNA).
  • A adenine
  • C cytosine
  • G guanine
  • T thymine
  • U uracil
  • T thymine
  • polynucleotide sequence is the alphabetical representation of a polynucleotide molecule; alternatively, the term may be applied to the polynucleotide molecule itself. This alphabetical representation can be input into databases in a computer having a central processing unit and used for bioinformatics applications such as functional genomics and homology searching.
  • Polynucleotides may optionally include one or more non-standard nucleotide(s), nucleotide analog(s) and/or modified nucleo
  • an “inhibitor” refers to a compound (e.g. compounds described herein) that reduces activity when compared to a control, such as absence of the compound or a compound with known inactivity.
  • the term “Gas small molecule inhibitor” as used herein refers to a low molecular weight organic compound capable of binding to and decreasing the activity of Gas.
  • the Gas small molecule inhibitor is a compound that weighs less than 1000 daltons.
  • the Gas small molecule inhibitor is a compound that weighs less than 900 daltons.
  • the Gas small molecule inhibitor is a compound that weighs less than 800 daltons.
  • the Gas small molecule inhibitor is a compound that weighs less than 700 daltons.
  • the Gas small molecule inhibitor is a compound that weighs less than 600 daltons.
  • the Gas small molecule inhibitor is a compound that weighs less than 500 daltons.
  • the Gas small molecule inhibitor is a compound that weighs less than 450 daltons.
  • the Gas small molecule inhibitor is a compound that weighs less than 400 daltons.
  • Contacting is used in accordance with its plain ordinary meaning and refers to the process of allowing at least two distinct species (e.g. chemical compounds including biomolecules or cells) to become sufficiently proximal to react, interact or physically touch.
  • species e.g. chemical compounds including biomolecules or cells
  • the resulting reaction product can be produced directly from a reaction between the added reagents or from an intermediate from one or more of the added reagents that can be produced in the reaction mixture.
  • contacting may include allowing two species to react, interact, or physically touch, wherein the two species may be a compound as described herein and a protein or enzyme. In some embodiments contacting includes allowing a compound described herein to interact with a protein or enzyme that is involved in a signaling pathway.
  • activation means positively affecting (e.g. increasing) the activity or function of the protein relative to the activity or function of the protein in the absence of the activator.
  • activation means positively affecting (e.g. increasing) the concentration or levels of the protein relative to the concentration or level of the protein in the absence of the activator.
  • the terms may reference activation, or activating, sensitizing, or up-regulating signal transduction or enzymatic activity or the amount of a protein decreased in a disease.
  • activation may include, at least in part, partially or totally increasing stimulation, increasing or enabling activation, or activating, sensitizing, or up-regulating signal transduction or enzymatic activity or the amount of a protein associated with a disease (e.g., a protein which is decreased in a disease relative to a non-diseased control).
  • Activation may include, at least in part, partially or totally increasing stimulation, increasing or enabling activation, or activating, sensitizing, or up-regulating signal transduction or enzymatic activity or the amount of a protein
  • agonist refers to a substance capable of detectably increasing the expression or activity of a given gene or protein.
  • the agonist can increase expression or activity 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90% or more in comparison to a control in the absence of the agonist.
  • expression or activity is 1.5-fold, 2-fold, 3-fold, 4-fold, 5-fold, 10-fold or higher than the expression or activity in the absence of the agonist.
  • the term “inhibition”, “inhibit”, “inhibiting” and the like in reference to a protein-inhibitor interaction means negatively affecting (e.g. decreasing) the activity or function of the protein relative to the activity or function of the protein in the absence of the inhibitor. In embodiments inhibition means negatively affecting (e.g. decreasing) the concentration or levels of the protein relative to the concentration or level of the protein in the absence of the inhibitor. In embodiments inhibition refers to reduction of a disease or symptoms of disease. In embodiments, inhibition refers to a reduction in the activity of a particular protein target.
  • inhibition includes, at least in part, partially or totally blocking stimulation, decreasing, preventing, or delaying activation, or inactivating, desensitizing, or down-regulating signal transduction or enzymatic activity or the amount of a protein.
  • inhibition refers to a reduction of activity of a target protein resulting from a direct interaction (e.g. an inhibitor binds to the target protein).
  • inhibition refers to a reduction of activity of a target protein from an indirect interaction (e.g. an inhibitor binds to a protein that activates the target protein, thereby preventing target protein activation).
  • the “Gas cysteine 201 covalent inhibitor” as used herein refers to a compound (e.g., small molecule, antibody, peptide, therapeutic agent, polymer, or the like) which can form a covalent bond with cysteine 201 residue of mutant Gas protein (R201C mutant of human Gas protein (SEQ ID NO: 1), or mutants thereof) or a cysteine residue corresponding to cysteine 201 (e.g. in a homologous Gas mutant protein).
  • a compound e.g., small molecule, antibody, peptide, therapeutic agent, polymer, or the like
  • the compound e.g., compound of Formula (I), (II), (Ill-a), (Ill-b), (III-c), (IV), (V-a), (V-b), (VI), (VII), or (VIII)
  • the Gas protein e.g., human Gas, or R201C mutant of human Gas protein (SEQ ID NO: 1)
  • the “Gas cysteine 237 covalent inhibitor” as used herein refers to a compound (e.g., small molecule, antibody, peptide, therapeutic agent, polymer, or the like) which can form a covalent bond with cysteine 237 residue of Gas protein (e.g., human Gas, protein represented by SEQ ID NO: 1, or mutants thereof) or a cysteine residue corresponding to cysteine Til (e.g. ina homologous Gas protein).
  • Gas protein e.g., human Gas, protein represented by SEQ ID NO: 1, or mutants thereof
  • cysteine residue corresponding to cysteine Til e.g. ina homologous Gas protein
  • the compound e.g., compound of Formula (I), (II), (Ill-a), (Ill-b), (III-c), (IV), (V-a), (V-b), (VI), (VII), or (VIII)
  • the Gas protein e.g., human Gas, protein represented by SEQ ID NO: 1, or mutants thereof.
  • inhibitor refers to a substance capable of detectably decreasing the expression or activity of a given gene or protein.
  • the antagonist can decrease expression or activity 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90% or more in comparison to a control in the absence of the antagonist. In certain instances, expression or activity is 1.5-fold, 2-fold, 3- fold, 4-fold, 5 -fold, 10-fold or lower than the expression or activity in the absence of the antagonist.
  • modulator refers to a composition that increases or decreases the level of a target molecule or the function of a target molecule or the physical state of the target of the molecule (e.g., a target may be a cellular component (e.g., protein, ion, lipid, virus, lipid droplet, nucleic acid, nucleotide, amino acid, protein, particle, organelle, cellular compartment, microorganism, vesicle, small molecule, protein complex, protein aggregate, or macromolecule)) relative to the absence of the composition.
  • a target may be a cellular component (e.g., protein, ion, lipid, virus, lipid droplet, nucleic acid, nucleotide, amino acid, protein, particle, organelle, cellular compartment, microorganism, vesicle, small molecule, protein complex, protein aggregate, or macromolecule)) relative to the absence of the composition.
  • a target may be a cellular component (e.g., protein, ion
  • modulate is used in accordance with its plain ordinary meaning and refers to the act of changing or varying one or more properties. “Modulation” refers to the process of changing or varying one or more properties. For example, as applied to the effects of a modulator on a target protein, to modulate means to change by increasing or decreasing a property or function of the target molecule or the amount of the target molecule.
  • expression includes any step involved in the production of the polypeptide including, but not limited to, transcription, post-transcriptional modification, translation, post-translational modification, and secretion. Expression can be detected using conventional techniques for detecting protein (e.g., ELISA, Western blotting, flow cytometry, immunofluorescence, immunohistochemistry, etc.).
  • a “therapeutic agent” or “drug agent” as used herein refers to an agent (e.g., compound or composition) that when administered to a subject will have the intended prophylactic effect, e.g., preventing or delaying the onset (or reoccurrence) of an injury, disease, pathology or condition, or reducing the likelihood of the onset (or reoccurrence) of an injury, disease, pathology, or condition, or their symptoms or the intended therapeutic effect, e.g., treatment or amelioration of an injury, disease, pathology or condition, or their symptoms including any objective or subjective parameter of treatment such as abatement; remission; diminishing of symptoms or making the injury, pathology or condition more tolerable to the patient; slowing in the rate of degeneration or decline; making the final point of degeneration less debilitating; or improving a patient’s physical or mental well-being.
  • a drug moiety is a monovalent drug.
  • a therapeutic moiety is a monovalent therapeutic agent.
  • the terms “disease” or “condition” refer to a state of being or health status of a patient or subject capable of being treated with the compounds or methods provided herein.
  • the disease may be a cancer.
  • cancer refers to human cancers and carcinomas, sarcomas, adenocarcinomas, lymphomas, leukemias, etc., including solid and lymphoid cancers, kidney, breast, lung, bladder, colon, ovarian, prostate, pancreas, stomach, brain, head and neck, skin, uterine, testicular, glioma, esophagus, and liver cancer, including hepatocarcinoma, lymphoma, including B -acute lymphoblastic lymphoma, non- Hodgkin’s lymphomas (e.g., Burkitt’s, Small Cell, and Large Cell lymphomas), Hodgkin’s lymphoma, leukemia (including AML, ALL, and CML), or multiple myedgkin’s lymph
  • cancer refers to all types of cancer, neoplasm or malignant tumors found in mammals (e.g. humans), including leukemias, lymphomas, carcinomas and sarcomas.
  • exemplary cancers that may be treated with a compound or method provided herein include brain cancer, glioma, glioblastoma, neuroblastoma, prostate cancer, colorectal cancer, pancreatic cancer, Medulloblastoma, melanoma, cervical cancer, gastric cancer, ovarian cancer, lung cancer, cancer of the head, Hodgkin's Disease, and Non- Hodgkin's Lymphomas.
  • Exemplary cancers that may be treated with a compound or method provided herein include cancer of the thyroid, endocrine system, brain, breast, cervix, colon, head & neck, liver, kidney, lung, ovary, pancreas, rectum, stomach, and uterus.
  • Additional examples include, thyroid carcinoma, cholangiocarcinoma, pancreatic adenocarcinoma, skin cutaneous melanoma, colon adenocarcinoma, rectum adenocarcinoma, stomach adenocarcinoma, esophageal carcinoma, head and neck squamous cell carcinoma, breast invasive carcinoma, lung adenocarcinoma, lung squamous cell carcinoma, non-small cell lung carcinoma, mesothelioma, multiple myeloma, neuroblastoma, glioma, glioblastoma multiforme, ovarian cancer, rhabdomyosarcoma, primary thrombocytosis, primary macroglobulinemia, primary brain tumors, malignant pancreatic insulanoma, malignant carcinoid, urinary bladder cancer, premalignant skin lesions, testicular cancer, thyroid cancer, neuroblastoma, esophageal cancer, genitourinary tract
  • leukemia refers broadly to progressive, malignant diseases of the blood- forming organs and is generally characterized by a distorted proliferation and development of leukocytes and their precursors in the blood and bone marrow. Leukemia is generally clinically classified on the basis of (1) the duration and character of the disease-acute or chronic; (2) the type of cell involved; myeloid (myelogenous), lymphoid (lymphogenous), or monocytic; and (3) the increase or non-increase in the number abnormal cells in the blood- leukemic or aleukemic (subleukemic).
  • Exemplary leukemias that may be treated with a compound or method provided herein include, for example, acute nonlymphocytic leukemia, chronic lymphocytic leukemia, acute granulocytic leukemia, chronic granulocytic leukemia, acute promyelocytic leukemia, adult T-cell leukemia, aleukemic leukemia, a leukocythemic leukemia, basophylic leukemia, blast cell leukemia, bovine leukemia, chronic myelocytic leukemia, leukemia cutis, embryonal leukemia, eosinophilic leukemia, Gross' leukemia, hairy-cell leukemia, hemoblastic leukemia, hemocytoblastic leukemia, histiocytic leukemia, stem cell leukemia, acute monocytic leukemia, leukopenic leukemia, lymphatic leukemia, lymphoblastic leukemia, lymphocytic leukemia, lymphogenous leukemia,
  • lymphoma refers to a group of cancers affecting hematopoietic and lymphoid tissues. It begins in lymphocytes, the blood cells that are found primarily in lymph nodes, spleen, thymus, and bone marrow. Two main types of lymphoma are non-Hodgkin lymphoma and Hodgkin’s disease. Hodgkin’s disease represents approximately 15% of all diagnosed lymphomas. This is a cancer associated with Reed- Sternberg malignant B lymphocytes. Non-Hodgkin’s lymphomas (NHL) can be classified based on the rate at which cancer grows and the type of cells involved.
  • B-cell lymphomas that may be treated with a compound or method provided herein include, but are not limited to, small lymphocytic lymphoma, Mantle cell lymphoma, follicular lymphoma, marginal zone lymphoma, extranodal (MALT) lymphoma, nodal (monocytoid B-cell) lymphoma, splenic lymphoma, diffuse large cell B-lymphoma, Burkitt’s lymphoma, lymphoblastic lymphoma, immunoblastic large cell lymphoma, or precursor B -lymphoblastic lymphoma.
  • small lymphocytic lymphoma Mantle cell lymphoma
  • follicular lymphoma marginal zone lymphoma
  • MALT extranodal lymphoma
  • nodal lymphoma nodal lymphocytoid B-cell lymphoma
  • splenic lymphoma diffuse large cell B-lymphoma
  • Exemplary T- cell lymphomas that may be treated with a compound or method provided herein include, but are not limited to, cunateous T-cell lymphoma, peripheral T-cell lymphoma, anaplastic large cell lymphoma, mycosis fungoides, and precursor T-lymphoblastic lymphoma.
  • sarcoma generally refers to a tumor which is made up of a substance like the embryonic connective tissue and is generally composed of closely packed cells embedded in a fibrillar or homogeneous substance.
  • Sarcomas that may be treated with a compound or method provided herein include a chondrosarcoma, fibrosarcoma, lymphosarcoma, melanosarcoma, myxosarcoma, osteosarcoma, Abemethy's sarcoma, adipose sarcoma, liposarcoma, alveolar soft part sarcoma, ameloblastic sarcoma, botryoid sarcoma, chloroma sarcoma, chorio carcinoma, embryonal sarcoma, Wilms' tumor sarcoma, endometrial sarcoma, stromal sarcoma, Ewing's sarcoma, fascial sar
  • melanoma is taken to mean a tumor arising from the melanocytic system of the skin and other organs.
  • Melanomas that may be treated with a compound or method provided herein include, for example, acral-lentiginous melanoma, amelanotic melanoma, benign juvenile melanoma, Cloudman's melanoma, S91 melanoma, Harding-Passey melanoma, juvenile melanoma, lentigo maligna melanoma, malignant melanoma, nodular melanoma, subungal melanoma, or superficial spreading melanoma.
  • carcinoma refers to a malignant new growth made up of epithelial cells tending to infiltrate the surrounding tissues and give rise to metastases.
  • exemplary carcinomas that may be treated with a compound or method provided herein include, for example, medullary thyroid carcinoma, familial medullary thyroid carcinoma, acinar carcinoma, acinous carcinoma, adenocystic carcinoma, adenoid cystic carcinoma, carcinoma adenomatosum, carcinoma of adrenal cortex, alveolar carcinoma, alveolar cell carcinoma, basal cell carcinoma, carcinoma basocellulare, basaloid carcinoma, basosquamous cell carcinoma, bronchioalveolar carcinoma, bronchiolar carcinoma, bronchogenic carcinoma, cerebriform carcinoma, cholangiocellular carcinoma, chorionic carcinoma, colloid carcinoma, comedo carcinoma, corpus carcinoma, cribriform carcinoma, carcinoma en cuirasse, carcinoma cutaneum, cylindrical carcinoma, cylindrical cell carcinoma, duct carcinoma, carcinoma durum, embryonal carcinoma, encephaloid
  • the terms “metastasis,” “metastatic,” and “metastatic cancer” can be used interchangeably and refer to the spread of a proliferative disease or disorder, e.g., cancer, from one organ or another non-adjacent organ or body part. “Metastatic cancer” is also called “Stage IV cancer.” Cancer occurs at an originating site, e.g., breast, which site is referred to as a primary tumor, e.g., primary breast cancer. Some cancer cells in the primary tumor or originating site acquire the ability to penetrate and infiltrate surrounding normal tissue in the local area and/or the ability to penetrate the walls of the lymphatic system or vascular system circulating through the system to other sites and tissues in the body.
  • a second clinically detectable tumor formed from cancer cells of a primary tumor is referred to as a metastatic or secondary tumor.
  • the metastatic tumor and its cells are presumed to be similar to those of the original tumor.
  • the secondary tumor in the breast is referred to a metastatic lung cancer.
  • metastatic cancer refers to a disease in which a subject has or had a primary tumor and has one or more secondary tumors.
  • nonmetastatic cancer or subjects with cancer that is not metastatic refers to diseases in which subjects have a primary tumor but not one or more secondary tumors.
  • metastatic lung cancer refers to a disease in a subject with or with a history of a primary lung tumor and with one or more secondary tumors at a second location or multiple locations, e.g., in the breast.
  • cutaneous metastasis or “skin metastasis” refer to secondary malignant cell growths in the skin, wherein the malignant cells originate from a primary cancer site (e.g., breast).
  • a primary cancer site e.g., breast
  • cancerous cells from a primary cancer site may migrate to the skin where they divide and cause lesions. Cutaneous metastasis may result from the migration of cancer cells from breast cancer tumors to the skin.
  • visceral metastasis refers to secondary malignant cell growths in the interal organs (e.g., heart, lungs, liver, pancreas, intestines) or body cavities (e.g., pleura, peritoneum), wherein the malignant cells originate from a primary cancer site (e.g., head and neck, liver, breast).
  • a primary cancer site e.g., head and neck, liver, breast.
  • a primary cancer site e.g., head and neck, liver, breast
  • Visceral metastasis may result from the migration of cancer cells from liver cancer tumors or head and neck tumors to internal organs.
  • G protein associated cancer refers to a cancer caused by aberrant activity or signaling of G protein or one or more of its subunits (e.g., alpha (a)-, beta (b)-, or gamma (g) subunits; Gas, ⁇ bb, or Gys).
  • a “cancer associated with aberrant Gas activity” is a cancer caused by aberrant Gas activity or signaling (e.g. a mutant Gas).
  • a “cancer associated with aberrant Gps activity” is a cancer caused by aberrant Gps activity or signaling (e.g. a mutant Gps).
  • a “cancer associated with aberrant Gys activity” is a cancer caused by aberrant Gys activity or signaling (e.g. a mutant Gys).
  • some cancers that are associated with aberrant activity of one or more of G protein or its subunits (Gas, ⁇ bb, or Gys), mutant G protein, or mutants subunits (Gas, ⁇ bb, or Gys) are well known in the art and determining such cancers are within the skill of a person of skill in the art.
  • some cancers may be sensitive to Gas inhibition.
  • the cancer that may be sensitive to Gas inhibition may include a solid cancer or a tumor.
  • the cancer that may be sensitive to Gas inhibition may include a pancreatic cancer, a brain tumor, a pituitary tumor, or a bone tumor.
  • the Gas related cancers may include a pancreatic cancer, a brain tumor, a pituitary tumor, or a bone tumor.
  • G protein-associated disease refers to a cancer caused by aberrant activity or signaling of G protein or one or more of its subunits (e.g., alpha (a)-, beta (b)-, or gamma (y) subunits; Gas, ⁇ bb, or Gys).
  • a “disease associated with aberrant Gas activity” is a cancer caused by aberrant Gas activity or signaling (e.g., a mutant Gas).
  • a “disease associated with aberrant ⁇ bb activity” is a disease caused by aberrant ⁇ bb activity or signaling (e.g., a mutant ⁇ bb).
  • a “disease associated with aberrant Gys activity” is a disease caused by aberrant Gys activity or signaling (e.g., a mutant Gys).
  • G protein or its subunits G protein or its subunits
  • mutant G protein, or mutants subunits Gas, ⁇ bb, or Gys
  • some diseases may be sensitive to Gas inhibition.
  • G-protein refers to one or more of the family of proteins that are bound to GTP (“on” state) or GDP (“off’ state”) so the proteins can regulate their activity involved in signaling pathway of a cell.
  • G protein includes subunits, alpha (a)-, beta (b)-, and gamma (g) subunits (Gas, GPs, or Gys).
  • human “Gas” as used herein refers to a G-protein- alpha-subunit having nucleotide sequences as set forth or corresponding to Entrez 2778, UniProt Q59FM5, UniProt P63092 (e.g., UniProt P6309-1 and UniProt P63092-2), RefSeq (protein) NP 000507.1, RefSeq (protein) NP 001070956.1, RefSeq (protein)
  • NP 001070957.1 RefSeq (protein) NP_001070958.1
  • RefSeq (protein) NP_001296769.1 RefSeq (protein) NP 536350.2
  • RefSeq (protein) NP 536351.1 RefSeq (protein) NP 536351.1
  • the GNAS gene has the nucleic acid sequence set forth in RefSeq (mRNA) NM 000516.5, RefSeq (mRNA) NM 001077488.3, RefSeq (mRNA) NM 001077489.3, RefSeq (mRNA) NM 001077490.2, RefSeq (mRNA) NM 001309840.1, RefSeq (mRNA) NM 080425.3, or RefSeq (mRNA) NM 080426.3.
  • the amino acid sequence or nucleic acid sequence is the sequence known at the time of filing of the present application.
  • the term “Gas” includes both the wild-type form of the nucleotide sequences or proteins as well as any mutants thereof.
  • the human Gas refers to the protein including (e.g., consisting of) the amino acid sequence corresponding to UniProt P63092-1 (SEQ ID NO: 1).
  • the human Gas includes the sequence below with one or more mutations (e.g., R201C and C237S at the underlined position at SEQ ID NO: 1):
  • the human Gas has the sequence of residues 7-380 of the short isoform of of human Gas corresponding to UniProt P63092-2 (SEQ ID NO: 2).
  • the human Gas includes the sequence below with one or more mutations (e.g., at R187 and/or C223 at the underlined position at SEQ ID NO: 2)
  • An amino acid residue in Gas “corresponds” to a given residue when it occupies the same essential structural position within the protein as the given residue.
  • a selected residue in a selected protein corresponds to R201 of Gas protein when the selected residue occupies the same essential spatial or other structural relationship as R201 of Gas protein.
  • the position in the aligned selected protein aligning with R201 is said to correspond to R201.
  • a selected residue in a selected protein corresponds to C237 of Gas protein when the selected residue occupies the same essential spatial or other structural relationship as C237 of Gas protein.
  • a selected protein is aligned for maximum homology with the Gas protein
  • the position in the aligned selected protein aligning with C237 is said to correspond to C237.
  • a three dimensional structural alignment can also be used, e.g., where the structure of the selected protein is aligned for maximum correspondence with the Gas protein and the overall structures compared.
  • an amino acid that occupies the same essential position as R201 in the structural model is said to correspond to the R201 residue
  • an amino acid that occupies the same essential position as C237 in the structural model is said to correspond to the C237 residue.
  • R201 in SEQ ID NO: 1 corresponds to R187 in SEQ ID NO: 2
  • C237 in SEQ ID NO: 1 corresponds to C223 in SEQ ID NO: 2.
  • bone condition refers to a disease, disorder or condition caused by abnormal bone tissues (e.g., osteoblast, osteoclast, osteocyte, and hematopoietic).
  • the bone condition is caused by, but not limited to, cancerous or non- cancerous tissues, infection, osteoporosis, tumor, blood cells, and fibrous tissues, which is developed in various sites of bones of a subject such as thighbone, skull, ribs, pelvis, humerus, shinbone, trunk, sternum, wrist bones, tarsals, spine, shoulder blade, collar bone, radius, ulna, metacarpals, phalanges, kneecap, fibula, metatarsals and phalanges.
  • the bone condition may be caused by cancerous bone tissues or noncancerous bone tissues.
  • the bone condition may be related to abnormal fibrous tissue development/occurrence in place of normal bone.
  • administering is used in accordance with its plain and ordinary meaning and includes oral administration, administration as a suppository, topical contact, intravenous, intraperitoneal, intramuscular, intralesional, intrathecal, intranasal or subcutaneous administration, or the implantation of a slow-release device, e.g., a mini- osmotic pump, to a subject.
  • Parenteral administration is by any route, including parenteral and transmucosal (e.g., buccal, sublingual, palatal, gingival, nasal, vaginal, rectal, or transdermal).
  • Parenteral administration includes, e.g., intravenous, intramuscular, intraarteriole, intradermal, subcutaneous, intraperitoneal, intraventricular, and intracranial.
  • Other modes of delivery include, but are not limited to, the use of liposomal formulations, intravenous infusion, transdermal patches, etc.
  • co-administer it is meant that a composition described herein is administered at the same time, just prior to, or just after the administration of one or more additional therapies, for example cancer therapies such as chemotherapy, hormonal therapy, radiotherapy, or immunotherapy.
  • compositions of the present invention can be delivered by transdermally, by a topical route, formulated as applicator sticks, solutions, suspensions, emulsions, gels, creams, ointments, pastes, jellies, paints, powders, and aerosols.
  • administering means administering a compound that decreases the activity or level (e.g. amount) of a signaling pathway of Gas to a subject.
  • Administration may include, without being limited by mechanism, allowing sufficient time for the Gas inhibitor to reduce the activity of the Gas protein or for the Gas inhibitor to reduce one or more symptoms of a disease (e.g. cancer, wherein the Gas inhibitor may arrest the cell cycle, slow the cell cycle, reduce DNA replication, reduce cell replication, reduce cell growth, reduce metastasis, or cause cell death).
  • the administering does not include administration of any active agent (e.g., a compound or Gas inhibitor) other than the recited active agent.
  • aberrant refers to different from normal. When used to describe enzymatic activity, aberrant refers to activity that is greater or less than a normal control or the average of normal non-diseased control samples. Aberrant activity may refer to an amount of activity that results in a disease, wherein returning the aberrant activity to a normal or non-disease-associated amount (e.g. by administering a compound or using a method as described herein), results in reduction of the disease or one or more disease symptoms.
  • electrophilic chemical moiety is used in accordance with its plain ordinary chemical meaning and refers to a monovalent chemical group that is electrophilic.
  • treating refers to any indicia of success in the therapy or amelioration of an injury, disease, pathology or condition, including any objective or subjective parameter such as abatement; remission; diminishing of symptoms or making the injury, pathology or condition more tolerable to the patient; slowing in the rate of degeneration or decline; making the final point of degeneration less debilitating; improving a patient’s physical or mental well-being.
  • the treatment or amelioration of symptoms can be based on objective or subjective parameters; including the results of a physical examination, neuropsychiatric exams, and/or a psychiatric evaluation.
  • the term "treating" and conjugations thereof, may include prevention of an injury, pathology, condition, or disease.
  • treating is preventing.
  • treating does not include preventing.
  • Treating” or “treatment” as used herein also broadly includes any approach for obtaining beneficial or desired results in a subject’s condition, including clinical results.
  • beneficial or desired clinical results can include, but are not limited to, alleviation or amelioration of one or more symptoms or conditions, diminishment of the extent of a disease, stabilizing (i.e., not worsening) the state of disease, prevention of a disease’s transmission or spread, delay or slowing of disease progression, amelioration or palliation of the disease state, diminishment of the reoccurrence of disease, and remission, whether partial or total and whether detectable or undetectable.
  • treatment includes any cure, amelioration, or prevention of a disease. Treatment may prevent the disease from occurring; inhibit the disease’s spread; relieve the disease’s symptoms, fully or partially remove the disease’s underlying cause, shorten a disease’s duration, or do a combination of these things.
  • Treating” and “treatment” as used herein include prophylactic treatment.
  • Treatment methods include administering to a subject a therapeutically effective amount of an active agent.
  • the administering step may consist of a single administration or may include a series of administrations.
  • the length of the treatment period depends on a variety of factors, such as the severity of the condition, the age of the patient, the concentration of active agent, the activity of the compositions used in the treatment, or a combination thereof.
  • the effective dosage of an agent used for the treatment or prophylaxis may increase or decrease over the course of a particular treatment or prophylaxis regime. Changes in dosage may result and become apparent by standard diagnostic assays known in the art.
  • chronic administration may be required.
  • the compositions are administered to the subject in an amount and for a duration sufficient to treat the patient.
  • the treating or treatment is not prophylactic treatment.
  • the term “sensitive” or “sensitive to” as used herein refers to a high degree of change in substance activity, biomarker indication, or condition associated with a disease (e.g. cancer) or a symptom of the disease (e.g., cancer) in response to a change introduced by treatment with or contact to an agent.
  • a disease e.g. cancer
  • a symptom of the disease e.g., cancer
  • an agent e.g., Gas inhibitor or Gas mutant inhibitor
  • the substance activity, biomarker indication, or condition associated with a disease (e.g. cancer) or a symptom of the disease (e.g., cancer) varies substantially compared to those in absence of any treatment or contacting to the agent.
  • a disease e.g.
  • cancer may be sensitive to a causative agent or inhibitory agent that may cause the disease.
  • a cancer relevant to or associated with aberrant protein activity e.g., increased/suppressed protein activity or function
  • a cancer caused or developed in association with aberrant Gas activity e.g., increased/suppressed Gas activity or function
  • the term “prevent” refers to a decrease in the occurrence of disease symptoms in a patient. As indicated above, the prevention may be complete (no detectable symptoms) or partial, such that fewer symptoms are observed than would likely occur absent treatment.
  • “Patient” or “subject in need thereof’ refers to a living organism suffering from or prone to a disease or condition that can be treated by administration of a pharmaceutical composition as provided herein.
  • Non-limiting examples include humans, other mammals, bovines, rats, mice, dogs, monkeys, goat, sheep, cows, deer, and other non-mammalian animals.
  • a patient is human.
  • an “effective amount” is an amount sufficient for a compound to accomplish a stated purpose relative to the absence of the compound (e.g. achieve the effect for which it is administered, treat a disease, reduce enzyme activity, increase enzyme activity, reduce a signaling pathway, or reduce one or more symptoms of a disease or condition).
  • An example of an “effective amount” is an amount sufficient to contribute to the treatment, prevention, or reduction of a symptom or symptoms of a disease, which could also be referred to as a “therapeutically effective amount.”
  • a “reduction” of a symptom or symptoms means decreasing of the severity or frequency of the symptom(s), or elimination of the symptom(s).
  • a “prophylactically effective amount” of a drug is an amount of a drug that, when administered to a subject, will have the intended prophylactic effect, e.g., preventing or delaying the onset (or reoccurrence) of an injury, disease, pathology or condition, or reducing the likelihood of the onset (or reoccurrence) of an injury, disease, pathology, or condition, or their symptoms.
  • the hill prophylactic effect does not necessarily occur by administration of one dose, and may occur only after administration of a series of doses.
  • a prophylactically effective amount may be administered in one or more administrations.
  • An “activity decreasing amount,” as used herein, refers to an amount of antagonist required to decrease the activity of an enzyme relative to the absence of the antagonist.
  • a “function disrupting amount,” as used herein, refers to the amount of antagonist required to disrupt the function of an enzyme or protein relative to the absence of the antagonist. The exact amounts will depend on the purpose of the treatment, and will be ascertainable by one skilled in the art using known techniques ⁇ see, e.g., Lieberman, Pharmaceutical Dosage Forms (vols. 1-3, 1992); Lloyd, The Art, Science and Technology of Pharmaceutical Compounding (1999); Pickar, Dosage Calculations (1999); and Remington: The Science and Practice of Pharmacy, 20th Edition, 2003, Gennaro, Ed., Lippincott, Williams & Wilkins).
  • Control or “control experiment” is used in accordance with its plain ordinary meaning and refers to an experiment in which the subjects or reagents of the experiment are treated as in a parallel experiment except for omission of a procedure, reagent, or variable of the experiment. In some instances, the control is used as a standard of comparison in evaluating experimental effects. In some embodiments, a control is the measurement of the activity (e.g., signaling pathway) of a protein in the absence of a compound as described herein (including embodiments, examples, figures, or Tables).
  • activity e.g., signaling pathway
  • the therapeutically effective amount can be initially determined from cell culture assays.
  • Target concentrations will be those concentrations of active compound(s) that are capable of achieving the methods described herein, as measured using the methods described herein or known in the art.
  • therapeutically effective amounts for use in humans can also be determined from animal models.
  • a dose for humans can be formulated to achieve a concentration that has been found to be effective in animals.
  • the dosage in humans can be adjusted by monitoring compounds effectiveness and adjusting the dosage upwards or downwards, as described above. Adjusting the dose to achieve maximal efficacy in humans based on the methods described above and other methods is well within the capabilities of the ordinarily skilled artisan.
  • a therapeutically effective amount refers to that amount of the therapeutic agent sufficient to ameliorate the disorder, as described above.
  • a therapeutically effective amount will show an increase or decrease of at least 5%, 10%, 15%, 20%, 25%, 40%, 50%, 60%, 75%, 80%, 90%, or at least 100%.
  • Therapeutic efficacy can also be expressed as “-fold” increase or decrease.
  • a therapeutically effective amount can have at least a 1.2-fold, 1.5-fold, 2-fold, 5-fold, or more effect over a control.
  • Dosages may be varied depending upon the requirements of the patient and the compound being employed.
  • the dose administered to a patient should be sufficient to effect a beneficial therapeutic response in the patient over time.
  • the size of the dose also will be determined by the existence, nature, and extent of any adverse side-effects. Determination of the proper dosage for a particular situation is within the skill of the practitioner. Generally, treatment is initiated with smaller dosages which are less than the optimum dose of the compound. Thereafter, the dosage is increased by small increments until the optimum effect under circumstances is reached. Dosage amounts and intervals can be adjusted individually to provide levels of the administered compound effective for the particular clinical indication being treated. This will provide a therapeutic regimen that is commensurate with the severity of the individual's disease state.
  • administering means oral administration, administration as a suppository, topical contact, intravenous, parenteral, intraperitoneal, intramuscular, intralesional, intrathecal, intranasal or subcutaneous administration, or the implantation of a slow-release device, e.g., a mini-osmotic pump, to a subject.
  • Administration is by any route, including parenteral and transmucosal (e.g., buccal, sublingual, palatal, gingival, nasal, vaginal, rectal, or transdermal).
  • Parenteral administration includes, e.g., intravenous, intramuscular, intra-arteriole, intradermal, subcutaneous, intraperitoneal, intraventricular, and intracranial.
  • Other modes of delivery include, but are not limited to, the use of liposomal formulations, intravenous infusion, transdermal patches, etc.
  • the administering does not include administration of any active agent other than the recited active agent.
  • compositions described herein are administered at the same time, just prior to, or just after the administration of one or more additional therapies.
  • the compounds provided herein can be administered alone or can be coadministered to the patient. Coadministration is meant to include simultaneous or sequential administration of the compounds individually or in combination (more than one compound).
  • the preparations can also be combined, when desired, with other active substances (e.g. to reduce metabolic degradation).
  • the compositions of the present disclosure can be delivered transdermally, by a topical route, or formulated as applicator sticks, solutions, suspensions, emulsions, gels, creams, ointments, pastes, jellies, paints, powders, and aerosols.
  • a cell can be identified by well-known methods in the art including, for example, presence of an intact membrane, staining by a particular dye, ability to produce progeny or, in the case of a gamete, ability to combine with a second gamete to produce a viable offspring.
  • Cells may include prokaryotic and eukaroytic cells.
  • Prokaryotic cells include but are not limited to bacteria.
  • Eukaryotic cells include but are not limited to yeast cells and cells derived from plants and animals, for example mammalian, insect (e.g., spodoptera) and human cells. Cells may be useful when they are naturally nonadherent or have been treated not to adhere to surfaces, for example by trypsinization.
  • co-administration includes administering one active agent within 0.5, 1, 2, 4, 6, 8, 10, 12, 16, 20, or 24 hours of a second active agent.
  • Coadministration includes administering two active agents simultaneously, approximately simultaneously (e.g., within about 1, 5, 10, 15, 20, or 30 minutes of each other), or sequentially in any order.
  • co-administration can be accomplished by co-formulation, i.e., preparing a single pharmaceutical composition including both active agents.
  • the active agents can be formulated separately.
  • the active and/or adjunctive agents may be linked or conjugated to one another.
  • Anti-cancer agent is used in accordance with its plain ordinary meaning and refers to a composition (e.g., compound, drug, antagonist, inhibitor, modulator) having antineoplastic properties or the ability to inhibit the growth or proliferation of cells.
  • an anti-cancer agent is a chemotherapeutic.
  • an anticancer agent is an agent identified herein having utility in methods of treating cancer.
  • an anti-cancer agent is an agent approved by the FDA or similar regulatory agency of a country other than the USA, for treating cancer.
  • an anti-cancer agent is an agent with antineoplastic properties that has not (e.g., yet) been approved by the FDA or similar regulatory agency of a country other than the USA, for treating cancer.
  • anti-cancer agents include, but are not limited to, MEK (e.g., MEK1, MEK2, or MEK1 and MEK2) inhibitors (e.g., XL518, CI-1040, PD035901, selumetinib/AZD6244, GSK1120212/trametinib, GDC-0973, ARRY-162, ARRY-300, AZD8330, PD0325901, U0126, PD98059, TAK-733, PD318088, AS703026, BAY 869766), alkylating agents (e.g., cyclophosphamide, ifosfamide, chlorambucil, busulfan, melphalan, mechlorethamine, uramustine, thio
  • a moiety of an anti-cancer agent is a monovalent anti-cancer agent (e.g., a monovalent form of an agent listed above).
  • compound utilized in the pharmaceutical compositions of the present invention may be administered at the initial dosage of about 0.001 mg/kg to about 1000 mg/kg daily.
  • the dosages may be varied depending upon the requirements of the patient, the severity of the condition being treated, and the compound or drug being employed.
  • dosages can be empirically determined considering the type and stage of cancer diagnosed in a particular patient.
  • the dose administered to a patient, in the context of the present invention, should be sufficient to affect a beneficial therapeutic response in the patient over time.
  • the size of the dose will also be determined by the existence, nature, and extent of any adverse side effects that accompany the administration of a compound in a particular patient. Determination of the proper dosage for a particular situation is within the skill of the practitioner. Generally, treatment is initiated with smaller dosages which are less than the optimum dose of the compound. Thereafter, the dosage is increased by small increments until the optimum effect under circumstances is reached.
  • the total daily dosage may be divided and administered in portions during the day, if desired.
  • the compounds described herein can be used in combination with one another, with other active agents known to be useful in treating cancer or with adjunctive agents that may not be effective alone, but may contribute to the efficacy of the active agent.
  • a disease e.g., a protein associated disease, disease associated with a cellular component
  • the disease e.g., cancer
  • a symptom of the disease is caused by (in whole or in part) the substance or substance activity or function or the disease or a symptom of the disease may be treated by modulating (e.g., inhibiting or activating) the substance (e.g., cellular component).
  • modulating e.g., inhibiting or activating
  • Cancer model organism is an organism exhibiting a phenotype indicative of cancer, or the activity of cancer causing elements, within the organism.
  • the term cancer is defined above.
  • a wide variety of organisms may serve as cancer model organisms, and include for example, cancer cells and mammalian organisms such as rodents (e.g. mouse or rat) and primates (such as humans).
  • Cancer cell lines are widely understood by those skilled in the art as cells exhibiting phenotypes or genotypes similar to in vivo cancers. Cancer cell lines as used herein includes cell lines from animals (e.g. mice) and from humans.
  • an “anticancer agent” as used herein refers to a molecule (e.g. compound, peptide, protein, nucleic acid) used to treat cancer through destruction or inhibition of cancer cells or tissues. Anticancer agents may be selective for certain cancers or certain tissues. In embodiments, anticancer agents herein may include epigenetic inhibitors and single- or multikinase inhibitors (e.g., G-protein inhibitor or Gas inhibitor).
  • the compounds may be state-selective Gas labeling molecules, for example, based on disulfide tethering.
  • the compounds may lable the somatic cysteine mutant selectively over all other cysteines present in the Gas protein, for example, forming a covalent irreversible bonding to the protein.
  • R 1 is independently halogen, -CX’a, -CUX ] 2 , -CH2X 1 , -OCX 1 3, - OCH2X 1 , -OCHX ⁇ , -CN, -SO existenceiR 1D , -SO vi NR 1A R 1B , -NR 1C NR 1A R 1B , -ONR 1A R 1b , -NHC(0)NR 1C NR 1A R 1B , -NHC(0)NR 1A R 1b , -N(0) mi , -NR 1A R 1B , -C(0)R 1c , -C(0)-OR lc , -C (0)NR 1A R 1b , -OR 1d , -NR 1A S0 2 R 1d , -NR 1A C(0)R 1c , -NR 1A C(0)OR 1c , -NR 1A OR 1c , -N 3 , substituted or unsub
  • variable zl is an integer from 0 to 6.
  • Ring A is aryl or heteroaryl.
  • L 1 is a bond, -NH-, -0-, -S-, -C(O)-, -C(0)NH-, -NHC(O)-, -NHC(0)NH-, -C(0)0-, -OC(O)-, substituted or unsubstituted alkylene, substituted or unsubstituted heteroalkylene, substituted or unsubstituted cycloalkylene, substituted or unsubstituted heterocycloalkylene, substituted or unsubstituted arylene, or substituted or unsubstituted heteroarylene.
  • L 2 is a bond, -NH-, -0-, -S-, -C(O)-, -C(0)NH-, -NHC(O)-, -NHC(0)NH-, -C(0)0-, -OC(O)-, substituted or unsubstituted alkylene, substituted or unsubstituted heteroalkylene, substituted or unsubstituted cycloalkylene, substituted or unsubstituted heterocycloalkylene, substituted or unsubstituted arylene, or substituted or unsubstituted heteroarylene.
  • R 2 is an electrophilic moiety.
  • R 1A , R 1b , R 1C , and R 1D are independently hydrogen, -CX3, -CHX2, -CH2X, -CN, -OH, -COOH, -CONH2, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl; R 1A and R 1B substituents bonded to the same nitrogen atom may optionally be joined to form a substituted or unsubstituted heterocycloalkyl or substituted or unsubstituted heteroaryl.
  • X and X 1 are independently -F, -Cl, -Br, or -I.
  • nl is independently an integer from 0 to 4.
  • ml and vl are independently 1 or 2.
  • zl is an integer from 1 to 3. In embodiments, zl is 0. In embodiments, zl is 1. In embodiments, zl is 2. In embodiments, zl is 3.
  • Ring A is phenyl or 5 to 6-membered heteroaryl. In embodiments, Ring A is phenyl. In embodiments, Ring A is 5 to 6-membered heteroaryl. In embodiments, Ring A is 5-membered heteroaryl. In embodiments, Ring A is 6-membered heteroaryl. In embodiments, Ring A is 5-membered heteroaryl containing at least one nitrogen atom. In embodiments, Ring A is 6-membered heteroaryl containing at least one nitrogen atom.
  • the compound has the formula: [0228]
  • Each R 1 1 , R 1 ⁇ 2 , R 1 ⁇ 3 , R 1 ⁇ 4 , and R 1,5 is independently hydrogen, halogen, -CX ⁇ , - CHX -CH2X 1 , -OCX’s, -OCH2X 1 , -OCHX’2, -CN, -SO MaskIR 1d , -SO V INR 1A R 1b , -NR 1C NR 1A R 1B , -ONR 1A R 1b ,
  • R 1A , R 1b , R 1C , and R 1D are independently hydrogen, -CX3, -CHX2, -CH2X, -CN, -OH, -COOH, -CONH2, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl; R 1A and R 1B substituents bonded to the same nitrogen atom may optionally be joined to form a substituted or unsubstituted heterocycloalkyl or substituted or unsubstituted heteroaryl.
  • X and X 1 are independently -F, -Cl, -Br, or -I.
  • nl is independently an integer from 0 to 4.
  • ml and vl are independently 1 or 2.
  • L 1 is a bond, -NH-, -0-, -S-, -C(O)-, -C(0)NH-, -NHC(O)-, -NHC(0)NH-, -C(0)0-, -OC(O)-, substituted or unsubstituted alkylene, or substituted or unsubstituted heteroalkylene.
  • L 1 is a bond, -NH-, -0-, -S-, -C(O)-, -C(0)NH-, -NHC(O)-, -NHC(0)NH-, -C(0)0-, -OC(O)-, substituted or unsubstituted C1-C6 alkylene, or substituted or unsubstituted 2 to 6 membered heteroalkylene.
  • L 1 is a bond. In embodiments, L 1 is -NH-. In embodiments, L 1 is -0-. In embodiments, L 1 is -S-. In embodiments, L 1 is -C(O)-. In embodiments, L 1 is -C(0)NH-. In embodiments, L 1 is -NHC(O)-. In embodiments, L 1 is -NHC(0)NH-. In embodiments, L 1 is -C(0)0-. In embodiments, L 1 is -OC(O)-.
  • L 1 is substituted or unsubstituted C 1 -C 6 alkylene. In embodiments, L 1 is substituted C 1 -C 6 alkylene. In embodiments, L 1 is unsubstituted C 1 -C 6 alkylene. In embodiments, L 1 is substituted or unsubstituted C 1 -C 4 alkylene. In embodiments, L 1 is substituted C 1 -C 4 alkylene. In embodiments, L 1 is unsubstituted C 1 -C 4 alkylene. In embodiments, L 1 is substituted or unsubstituted C 1 -C 3 alkylene. In embodiments, L 1 is substituted C 1 -C 3 alkylene.
  • L 1 is unsubstituted C 1 -C 3 alkylene. In embodiments, L 1 is substituted or unsubstituted methylene. In embodiments, L 1 is substituted methylene. In embodiments, L 1 is unsubstituted methylene. In embodiments, L 1 is substituted or unsubstituted ethylene. In embodiments, L 1 is substituted ethylene. In embodiments, L 1 is unsubstituted ethylene.
  • L 1 is substituted or unsubstituted 2 to 6 membered heteroalkylene. In embodiments, L 1 is substituted 2 to 6 membered heteroalkylene. In embodiments, L 1 is unsubstituted 2 to 6 membered heteroalkylene. In embodiments, L 1 is substituted or unsubstituted 2 to 5 membered heteroalkylene. In embodiments, L 1 is substituted 2 to 5 membered heteroalkylene. In embodiments, L 1 is unsubstituted 2 to 5 membered heteroalkylene. In embodiments, L 1 is substituted or unsubstituted 2 to 4 membered heteroalkylene.
  • L 1 is substituted 2 to 4 membered heteroalkylene. In embodiments, L 1 is unsubstituted 2 to 4 membered heteroalkylene. In embodiments, L 1 is substituted or unsubstituted 2 to 3 membered heteroalkylene. In embodiments, L 1 is substituted 2 to 3 membered heteroalkylene. In embodiments, L 1 is unsubstituted 2 to 3 membered heteroalkylene.
  • L 2 is an unsubstituted C1-C6 alkylene. In embodiments, L 2 is an unsubstituted C1-C5 alkylene. In embodiments, L 2 is an unsubstituted C1-C4 alkylene. In embodiments, L 2 is an unsubstituted C1-C3 alkylene. In embodiments, L 2 is an unsubstituted C1-C2 alkylene. In embodiments, L 2 is unsubstituted methylene. In embodiments, L 2 is unsubstituted ethylene. In embodiments, L 2 is unsubstituted propylene. In embodiments, L 2 is unsubstituted isopropylene.
  • L 2 is unsubstituted butylene. In embodiments, L 2 is unsubstituted isobutylene. In embodiments, L 2 is unsubstituted t- butylene. In embodiments, L 2 is unsubstituted 2-methyl propylene. In embodiments, L 2 is a bond.
  • R 1.1 is hydrogen, halogen, ( ) ( ) ( ) ( ) substituted or unsubstituted C1-C6 alkyl, substituted or unsubstituted 2 to 6 membered heteroalkyl, substituted or unsubstituted C3-C6 cycloalkyl, substituted or unsubstituted 3 to 6 membered heterocycloalkyl, substituted or unsubstituted C6-C12 aryl, or substituted or unsubstituted 5 to 12 membered heteroaryl.
  • R 12 is hydrogen, halogen, - substituted or unsubstituted C1-C6 alkyl, substituted or unsubstituted 2 to 6 membered heteroalkyl, substituted or unsubstituted C3-C6 cycloalkyl, substituted or unsubstituted 3 to 6 membered heterocycloalkyl, substituted or unsubstituted C6-C12 aryl, or substituted or unsubstituted 5 to 12 membered heteroaryl.
  • R 1 ⁇ 3 is hydrogen, halogen, substituted or unsubstituted C1-C6 alkyl, substituted or unsubstituted 2 to 6 membered heteroalkyl, substituted or unsubstituted C3-C6 cycloalkyl, substituted or unsubstituted 3 to 6 membered heterocycloalkyl, substituted or unsubstituted C6-C12 aryl, or substituted or unsubstituted 5 to 12 membered heteroaryl.
  • R 1 ⁇ 4 is hydrogen, halogen, -C(0)-0R lc , -C(0)NR 1A R 1B , -OR 1d , -NR 1A S0 2 R 1d , -NR 1A C(0)R 1c , -NR 1A C(0)0R 1c , -NR 1 A OR 1c , -N3, substituted or unsubstituted C1-C6 alkyl, substituted or unsubstituted 2 to 6 membered heteroalkyl, substituted or unsubstituted C3-C6 cycloalkyl, substituted or unsubstituted 3 to 6 membered heterocycloalkyl, substituted or unsubstituted C6-C12 aryl, or substituted or unsubstituted 5 to 12 membered heteroaryl.
  • R 1 5 is hydrogen, halogen, -CX’s, -CHX -CH2X 1 , -OCX 1 3, - OCH2X 1 , -OCHX’i, -CN, -SO existenceiR 1D , -SO vi NR 1A R 1B , -NR 1C NR 1A R 1B , -ONR 1A R 1b , -NHC(0)NR 1C NR 1A R 1b , -NHC(0)NR 1A R 1b , -N(0) mi , -NR 1A R 1B , -C(0)R 1c ,
  • R 1A is hydrogen, or substituted or unsubstituted alkyl. In embodiments, R 1A is hydrogen. In embodiments, R 1A is substituted or unsubstituted alkyl. In embodiments, R 1A is substituted alkyl. In embodiments, R 1A is unsubstituted alkyl. In embodiments, R 1A is substituted or unsubstituted C1-C6 alkyl. In embodiments, R 1A is unsubstituted C1-C6 alkyl. In embodiments, R 1A is substituted or unsubstituted C1-C5 alkyl.
  • R 1A is unsubstituted C1-C5 alkyl. In embodiments, R 1A is substituted or unsubstituted C1-C4 alkyl. In embodiments, R 1A is unsubstituted C1-C4 alkyl. In embodiments, R 1A is methyl. In embodiments, R 1A is ethyl. In embodiments, R 1A is propyl. In embodiments, R 1A is is isopropyl. In embodiments, R 1A is butyl. In embodiments, R 1A is t- butyl.
  • R 1B is hydrogen, or substituted or unsubstituted alkyl. In embodiments, R 1B is hydrogen. In embodiments, R 1B is substituted or unsubstituted alkyl. In embodiments, R 1B is substituted alkyl. In embodiments, R 1B is unsubstituted alkyl. In embodiments, R 1B is substituted or unsubstituted C1-C6 alkyl. In embodiments, R 1B is unsubstituted C1-C6 alkyl. In embodiments, R 1B is substituted or unsubstituted C1-C5 alkyl.
  • R 1B is unsubstituted C1-C5 alkyl. In embodiments, R 1B is substituted or unsubstituted C1-C4 alkyl. In embodiments, R 1B is unsubstituted C1-C4 alkyl. In embodiments, R 1B is methyl. In embodiments, R 1B is ethyl. In embodiments, R 1B is propyl. In embodiments, R 1B is isopropyl. In embodiments, R 1B is butyl. In embodiments, R 1B is t- butyl.
  • R 1C is hydrogen, or substituted or unsubstituted alkyl. In embodiments, R 1C is hydrogen. In embodiments, R 1C is substituted or unsubstituted alkyl. In embodiments, R 1C is substituted alkyl. In embodiments, R 1C is unsubstituted alkyl. In embodiments, R 1C is substituted or unsubstituted C1-C6 alkyl. In embodiments, R 1C is unsubstituted C1-C6 alkyl. In embodiments, R 1C is substituted or unsubstituted C1-C5 alkyl.
  • R 1C is unsubstituted C1-C5 alkyl. In embodiments, R 1C is substituted or unsubstituted C1-C4 alkyl. In embodiments, R 1C is unsubstituted C1-C4 alkyl. In embodiments, R 1C is methyl. In embodiments, R 1C is ethyl. In embodiments, R 1C is propyl. In embodiments, R 1C is isopropyl. In embodiments, R 1C is butyl. In embodiments, R 1C is t- butyl.
  • R 1D is hydrogen, or substituted or unsubstituted alkyl. In embodiments, R 1D is hydrogen. In embodiments, R 1D is substituted or unsubstituted alkyl. In embodiments, R 1D is substituted alkyl. In embodiments, R 1D is unsubstituted alkyl. In embodiments, R 1D is substituted or unsubstituted C1-C6 alkyl. In embodiments, R 1D is unsubstituted C1-C6 alkyl. In embodiments, R 1D is substituted or unsubstituted C1-C5 alkyl.
  • R 1D is unsubstituted C 1 -C 5 alkyl. In embodiments, R 1D is substituted or unsubstituted C 1 -C 4 alkyl. In embodiments, R 1D is unsubstituted C 1 -C 4 alkyl. In embodiments, R 1D is methyl. In embodiments, R 1D is ethyl. In embodiments, R 1D is propyl. In embodiments, R 1D is isopropyl. In embodiments, R 1D is butyl. In embodiments, R 1D is t- butyl.
  • R u is -CN.
  • R 1 1 is hydrogen.
  • R 1,2 is halogen (e.g., -F, -Cl, -Br, or -I) or -CN.
  • R 1,2 is -F.
  • R 1,2 is -Cl.
  • R 1,2 is -Br.
  • R 1,2 is -I.
  • R 1,2 is -CN.
  • R 1,2 is hydrogen.
  • R 1,2 is -OR 1D .
  • R 1D is hydrogen, or substituted or unsubstituted C 1 -C 4 alkyl. In embodiments, R 1D is hydrogen. In embodiments, R 1D is substituted or unsubstituted C 1 -C 4 alkyl. In embodiments, R 1D is unsubstituted C 1 -C 4 alkyl.
  • R 1D is methyl. In embodiments, R 1D is ethyl. In embodiments, R 1D is propyl. In embodiments, R 1D is isopropyl. In embodiments, R 1D is butyl. In embodiments, R 1D is t-butyl. In embodiments, R 1 2 is -OH. In embodiments, R 1 2 is -OCH3. In embodiments, R 1 2 is -OCH2CH3.
  • R 1,3 is halogen, -CN, substituted or unsubstituted C1-C6 alkyl, or substituted or unsubstituted 2 to 6 membered heteroalkyl.
  • R 1,3 is -F.
  • R 1,3 is -Cl.
  • R 1,3 is -Br.
  • R 1,3 is -I.
  • R 1,3 is -CN.
  • R 1,3 is hydrogen.
  • R 1,3 is substituted or unsubstituted C 1 -C 6 alkyl. In embodiments, R 1 ⁇ 3 is substituted C 1 -C 6 alkyl. In embodiments, R 1,3 is unsubstituted C 1 -C 6 alkyl. In embodiments, R 1,3 is substituted or unsubstituted C1-C5 alkyl. In embodiments, R 1,3 is substituted C1-C5 alkyl. In embodiments, R 1,3 is unsubstituted C1-C5 alkyl. In embodiments, R 1 ⁇ 3 is substituted or unsubstituted C 1 -C 4 alkyl.
  • R 1,3 is substituted C 1 -C 4 alkyl. In embodiments, R 1,3 is unsubstituted C 1 -C 4 alkyl. In embodiments, R 1 ⁇ 3 is substituted or unsubstituted C 2 -C 4 alkyl. In embodiments, R 1 ⁇ 3 is substituted C 2 -C 4 alkyl. In embodiments, R 1 ⁇ 3 is unsubstituted C 2 -C 4 alkyl. In embodiments, R 1 ⁇ 3 is substituted or unsubstituted C1-C3 alkyl. In embodiments, R 1 ⁇ 3 is substituted C1-C3 alkyl.
  • R 1 ⁇ 3 is unsubstituted C1-C3 alkyl. In embodiments, R 1 ⁇ 3 is OH-substituted C1-C6 alkyl. In embodiments, R 1 ⁇ 3 is OH-substituted C 1 -C 4 alkyl. In embodiments, R 1 ⁇ 3 is -CH 2 OH. In embodiments, R 1 3 is -CH 2 CH 2 OH. In embodiments, R 1 3 is -CH 2 CH 2 CH 2 OH. In embodiments, R 1 3 is -CH 2 CH 2 CH 2 CH 2 OH.
  • R 1 ⁇ 3 is substituted or unsubstituted 2 to 6 membered heteroalkyl.
  • R 1 ⁇ 3 is substituted 2 to 6 membered heteroalkyl. In embodiments, R 1 ⁇ 3 is unsubstituted 2 to 6 membered heteroalkyl. In embodiments, R 1 ⁇ 3 is substituted or unsubstituted 2 to 5 membered heteroalkyl. In embodiments, R 1 ⁇ 3 is substituted 2 to 5 membered heteroalkyl. In embodiments, R 1 ⁇ 3 is unsubstituted 2 to 5 membered heteroalkyl.
  • R 1 ⁇ 3 is substituted or unsubstituted 2 to 4 membered heteroalkyl. In embodiments, R 1 ⁇ 3 is substituted 2 to 4 membered heteroalkyl. In embodiments, R 1 ⁇ 3 is unsubstituted 2 to 4 membered heteroalkyl. In embodiments, R 1 ⁇ 3 is substituted or unsubstituted 3 to 6 membered heteroalkyl. In embodiments, R 1 ⁇ 3 is substituted 3 to 6 membered heteroalkyl. In embodiments, R 1 ⁇ 3 is unsubstituted 3 to 6 membered heteroalkyl.
  • R 1 ⁇ 3 is substituted or unsubstituted 3 to 5 membered heteroalkyl. In embodiments, R 1 ⁇ 3 is substituted 3 to 5 membered heteroalkyl. In embodiments, R 1 ⁇ 3 is unsubstituted 3 to 5 membered heteroalkyl. In embodiments, R 1 ⁇ 3 is substituted or unsubstituted 3 to 4 membered heteroalkyl. In embodiments, R 1 3 is substituted 3 to 4 membered heteroalkyl. In embodiments, R 1,3 is unsubstituted 3 to 4 membered heteroalkyl.
  • R 1,3 is -CH2OH. In embodiments, R 1,3 is -CH2CH2OH. In embodiments,
  • R 1 3 is -CH2CH2CH2OH. In embodiments, R 1 3 is -CH2CH2CH2CH2OH.
  • R 1,3 is -C(0)R lc , or -C(0)-0R lc . In embodiments, R 1,3 is -C(0)R lc . In embodiments, R 1,3 is -C(0)-0R lc . In embodiments, R 1C is hydrogen, or substituted or unsubstituted C1-C4 alkyl. In embodiments, R 1C is hydrogen. In embodiments, R 1C is substituted or unsubstituted C1-C4 alkyl. In embodiments, R 1C is unsubstituted C1-C4 alkyl. In embodiments, R 1C is methyl. In embodiments, R 1C is ethyl.
  • R 1C is propyl. In embodiments, R 1C is isopropyl. In embodiments, R 1C is butyl. In embodiments, R 1C is t-butyl. In embodiments, R 1,3 is -C(0)H. In embodiments, R 1,3 is -C(0)CH 3 . In embodiments, R 1 3 is -C(0)CH 2 CH 3 . In embodiments, R 1 3 is -C(0)CH 2 CH 2 CH 3 . In embodiments, R 1 3 is -C(0)CH 2 CH 2 CH 2 CH 3 . In embodiments, R 1 3 is -C(0)0H. In embodiments, R 1 3 is -C(0)0CH 3 . In embodiments, R 1 3 is -C(0)0CH 2 CH 3 . In embodiments, R 1 3 is -C(0)0CH 2 CH 2 CH 3 . In embodiments, R 1 3 is -C(0)0CH 2 CH 2 CH 3 . In embodiments, R 1 3 is -C(0)0CH 2 CH 2 CH 3 . In
  • R 1,3 is -OR 1D .
  • R 1D is hydrogen, or substituted or unsubstituted C 1 -C 4 alkyl. In embodiments, R 1D is hydrogen. In embodiments, R 1D is substituted or unsubstituted C 1 -C 4 alkyl. In embodiments, R 1D is unsubstituted C 1 -C 4 alkyl.
  • R 1D is methyl. In embodiments, R 1D is ethyl. In embodiments, R 1D is propyl. In embodiments, R 1D is isopropyl. In embodiments, R 1D is butyl. In embodiments, R 1D is phenyl. In embodiments, R 1D is t-butyl. In embodiments, R 1 ⁇ 3 is -OH. In embodiments, R 1 ⁇ 3 is -OCH 3 . In embodiments, R 1 ⁇ 3 is -OCH2CH 3 . In embodiments, R 1 ⁇ 3 is -
  • R 1 3 is -OCX ⁇ , -OCH2X 1 , or -OCHX ⁇ . In embodiments, R 1 3 is -OCXV In embodiments, R 1 ⁇ 3 is -OCH2X 1 . In embodiments, R 1 ⁇ 3 is -OCHX ⁇ . In embodiments, R 1 3 is -OCF 3 , -OCCl 3 , -OCBr 3 , or -OCI 3 . In embodiments, R 1 3 is -OCHF2, - OCHCl 2 ,-OCHBr 2 , or -OCHI2. In embodiments, R 1 3 is -OCH2F, -OCH2CI, -OCH 2 Br, or - OCH2I. In embodiments, R 1 3 is -OCF 3 .
  • R 1,4 is halogen (e.g., -F, -Cl, -Br, or -I) or -CN.
  • halogen e.g., -F, -Cl, -Br, or -I
  • R 1,4 is -F. In embodiments, R 1,4 is -Cl. In embodiments, R 1 ⁇ 4 is -Br. In embodiments, R 1 ⁇ 4 is -I. In embodiments, R 1 ⁇ 4 is -CN. In embodiments, R 1 ⁇ 4 is hydrogen. [0257] In embodiments, R 1 4 is -OR 1D . In embodiments, R 1D is hydrogen, or substituted or unsubstituted C1-C4 alkyl. In embodiments, R 1D is hydrogen. In embodiments, R 1D is substituted or unsubstituted C1-C4 alkyl. In embodiments, R 1D is unsubstituted C1-C4 alkyl.
  • R 1D is methyl. In embodiments, R 1D is ethyl. In embodiments, R 1D is propyl. In embodiments, R 1D is isopropyl. In embodiments, R 1D is butyl. In embodiments, R 1D is t-butyl. In embodiments, R 1,4 is -OH. In embodiments, R 1,4 is -OCH3. In embodiments, R 1 4 is -OCH2CH3.
  • R 1,5 is -CN. In embodiments, R 1,5 is hydrogen.
  • R 1,2 and R 1,4 are hydrogen; and R 1,3 is substituted or unsubstituted 2 to 6 membered heteroalkyl.
  • R 1 1 , R 1,2 , R 1,4 and R 1,5 are hydrogen; and R 1,3 is substituted or unsubstituted 2 to 6 membered heteroalkyl.
  • R 1 1 , R 1,2 , R 1,4 and R 1 5 is hydrogen; and R 1 3 is -CH2OH, -CH2CH2OH, -CH 2 CH 2 CH 2 OH, or - CH2CH2CH2CH2OH.
  • R 1 1 , R 12 , R 1 4 and R 1 5 is hydrogen; and R 1 3 is - CH2CH2OH.
  • R 1,2 and R 1,4 is hydrogen; and R 1,3 is -CN.
  • R 1,2 is halogen (e.g., -F, -Cl, -Br, or -I); and R 1,5 is -CN.
  • R 1,2 is -Cl, and R 1,5 is -CN.
  • R 1,2 is halogen (e.g., -F, -Cl, -Br, or -I); R 1 ⁇ 3 is hydrogen, and R 1 ⁇ 5 is -CN.
  • R 1,2 is -Cl; R 1 ⁇ 3 is hydrogen; and R 1 ⁇ 5 is -CN.
  • R 1 1 , R 1,3 , and R 1,4 are hydrogen; R 1 ⁇ 2 is halogen (e.g., -F, -Cl, - Br, or -I); and R 1 ⁇ 5 is -CN.
  • R 1 1 , R 1,3 , and R 1,4 are hydrogen; R 1 ⁇ 2 is -Cl; and R 1 5 is -CN.
  • R 1 1 is -CN; and R 1,4 is halogen (e.g., -F, -Cl, -Br, or -I).
  • R u is -CN; and R 1 ⁇ 4 is -Cl.
  • R u is -CN; R 1 ⁇ 3 is hydrogen; and R 1,4 is halogen (e.g., -F, -Cl, -Br, or -I).
  • R u is -CN; R 1 ⁇ 3 is hydrogen; and R 1,4 is -Cl.
  • R u is -CN; R 1,2 , R 1 ⁇ 3 , and R 1 ⁇ 5 are hydrogen; and R 1,4 is halogen (e.g., -F, -Cl, -Br, or -I).
  • R u is -CN; R 1,2 , R 1 ⁇ 3 , and R 1,5 are hydrogen; and R 1,4 is -Cl.
  • R 1,2 is -CN; and R 1 ⁇ 3 is halogen (e.g., -F, -Cl, -Br, or -I).
  • R 1,2 is -CN; and R 1 ⁇ 3 is -F.
  • R u and R 1 ⁇ 5 are hydrogen; R 1 ⁇ 2 is -CN; and R 1,3 is halogen (e.g., -F, -Cl, -Br, or -I).
  • R u and R 1 ⁇ 5 are hydrogen; R 1 ⁇ 2 is -CN; and R 1,3 is -F.
  • R 1 1 , R 1,4 and R 1,5 are hydrogen; R 1 ⁇ 2 is -CN; and R 1 3 is halogen (e.g., -F, -Cl, -Br, or -I).
  • R u , R 1 4 and R 1 5 are hydrogen; R 1 ⁇ 2 is -CN; and R 1,3 is -F.
  • R 1,3 is halogen (e.g., -F, -Cl, -Br, or -I); and R 1,4 is -CN.
  • R 1,3 is -F; and R 1,4 is -CN.
  • R u and R 1,5 are hydrogen; R 1 ⁇ 3 is halogen (e.g., -F, -Cl, -Br, or -I); and and R 1,4 is -CN.
  • R u and R 1,5 are hydrogen; R 1 ⁇ 3 is -F; and R 1,4 is -CN.
  • R 1 1 , R 1,2 and R 1 ⁇ 5 are hydrogen; R 1 ⁇ 3 is halogen (e.g., -F, -Cl, -Br, or -I); and R 1 ⁇ 4 is -CN.
  • R 1 1 , R 1,2 and R 1,5 are hydrogen; R 1 ⁇ 3 is -F; and R 1,4 is -CN.
  • R 1 3 is -C(0)0CH 3 ; and R 1 4 is -OCH 3 .
  • R 1 1 and R 1 ⁇ 5 are hydrogen; R 1 ⁇ 3 is -C(0)0CH 3 ; and R 1,4 is -OCH 3 .
  • R 1 1 , R 1,2 , and R 1 5 are hydrogen; R 1 3 is -C(0)0CH 3 ; and R 1 4 is -OCH 3 .
  • R 1 3 is -C(0)0CH 3 ; and R 1,2 is -OCH 3 .
  • R u and R 1 ⁇ 5 are hydrogen; R 1 ⁇ 3 is -C(0)0CH 3 ; and R 1,2 is -OCH 3 .
  • R 1 1 , R 1 ⁇ 4 , and R 1 ⁇ 5 are hydrogen; R 1 ⁇ 2 is -C(0)0CH 3 ; and R 1 4 is -OCH3.
  • R 1 3 is -C(0)0H; and R 1 4 is -OCH 3 .
  • R 1 1 and R 1 ⁇ 5 are hydrogen; R 1 ⁇ 3 is -C(0)0H; and R 1 ⁇ 4 is -OCH 3 .
  • R 1 1 , R 1,2 , and R 1 ⁇ 5 are hydrogen; R 1 3 is -C(0)0H; and R 1 4 is -OCH 3 .
  • R 1 3 is -C(0)0H; and R 1 ⁇ 2 is -OCH 3 .
  • R u and R 1 ⁇ 5 are hydrogen; R 1 ⁇ 3 is -C(0)0H; and R 1 ⁇ 2 is - OCH 3 .
  • R 1 1 , R 1 ⁇ 4 , and R 1 ⁇ 5 are hydrogen; R 1 ⁇ 2 is -C(0)0H; and R 1,4 is - OCH3.
  • R 17 is hydrogen, halogen, -CX 17 3 , -CHX 17 2 , -CH 2 X 17 , -CN, -SO n i 7 R 17D , -SO V I 7 NR 17A R 17B , -NHNR R 17B , -ONR 17A R 17B , -NHC(O)NHNR 17A R 17B ,
  • R 18 is hydrogen, halogen, -CX 18 3 , -CHX 18 2 , -CH 2 X 18 , -CN, -SO n18 R 18D , -SO V18 NR 18A R 18A R 18B -ONR 18A R 18B , -NHC(O)NHNR 18A R 18B , , -OCH 2 X 18 , substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl.
  • R 19 is hydrogen, halogen, -CX 19 3 , -CHX 19 2 , -CH 2 X 19 , -CN, -SO StammI 9 R 19D , -SO VI9 NR 19A R 19B , -NHNR 19A R 19B , -ONR 19A R 19B , -NHC(0)NHNR 19A R 19B ,
  • R 19C , and R 19D are independently hydrogen, -CX 3 , -CHX 2 , -CH 2 X, -CN, -OH, -COOH, -CONH 2 , substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl.
  • R 16A and R 16B substituents bonded to the same nitrogen atom may optionally be joined to form a substituted or unsubstituted heterocycloalkyl or substituted or unsubstituted heteroaryl.
  • R 17A and R 17B substituents bonded to the same nitrogen atom may optionally be joined to form a substituted or unsubstituted heterocycloalkyl or substituted or unsubstituted heteroaryl.
  • R 18A and R 18B substituents bonded to the same nitrogen atom may optionally be joined to form a substituted or unsubstituted heterocycloalkyl or substituted or unsubstituted heteroaryl.
  • R 19A and R 19B substituents bonded to the same nitrogen atom may optionally be joined to form a substituted or unsubstituted heterocycloalkyl or substituted or unsubstituted heteroaryl.
  • X 16 , X 17 , X 18 , and X 19 are independently -F, -Cl, -Br, or -I.
  • nl 6, nl 7, nl 8, and nl 9 are independently an integer from 0 to 4.
  • ml 6, ml 7, ml 8, ml 9, vl6, vl7, vl8, and vl9 are independently 1 or 2.
  • R 16A and R 16B substituents bonded to the same nitrogen atom are joined to form a substituted or unsubstituted 5 to 6-membered heterocycloalkyl. In embodiments, R 16A and R 16B substituents bonded to the same nitrogen atom are joined to form a substituted or unsubstituted 5-membered heterocycloalkyl. In embodiments, R 16A and R 16B substituents bonded to the same nitrogen atom are joined to form a substituted 5- membered heterocycloalkyl. In embodiments, R 16A and R 16B substituents bonded to the same nitrogen atom are joined to form an unsubstituted 5-membered heterocycloalkyl.
  • R 16A and R 16B substituents bonded to the same nitrogen atom are joined to form a substituted or unsubstituted 6-membered heterocycloalkyl. In embodiments, R 16A and R 16B substituents bonded to the same nitrogen atom are joined to form a substituted 6- membered heterocycloalkyl. In embodiments, R 16A and R 16B substituents bonded to the same nitrogen atom are joined to form an unsubstituted 6-membered heterocycloalkyl.
  • R 17A and R 17B substituents bonded to the same nitrogen atom are joined to form a substituted or unsubstituted 5 to 6-membered heterocycloalkyl. In embodiments, R 17A and R 17B substituents bonded to the same nitrogen atom are joined to form a substituted or unsubstituted 5-membered heterocycloalkyl. In embodiments, R 17A and R 17B substituents bonded to the same nitrogen atom are joined to form a substituted 5- membered heterocycloalkyl. In embodiments, R 17A and R 17B substituents bonded to the same nitrogen atom are joined to form an unsubstituted 5-membered heterocycloalkyl.
  • R 17A and R 17B substituents bonded to the same nitrogen atom are joined to form a substituted or unsubstituted 6-membered heterocycloalkyl. In embodiments, R 17A and R 17B substituents bonded to the same nitrogen atom are joined to form a substituted 6- membered heterocycloalkyl. In embodiments, R 17A and R 17B substituents bonded to the same nitrogen atom are joined to form an unsubstituted 6-membered heterocycloalkyl.
  • R 18A and R 18B substituents bonded to the same nitrogen atom are joined to form a substituted or unsubstituted 5 to 6-membered heterocycloalkyl. In embodiments, R 18A and R 18B substituents bonded to the same nitrogen atom are joined to form a substituted or unsubstituted 5-membered heterocycloalkyl. In embodiments, R 18A and R 18B substituents bonded to the same nitrogen atom are joined to form a substituted 5- membered heterocycloalkyl. In embodiments, R 18A and R 18B substituents bonded to the same nitrogen atom are joined to form an unsubstituted 5-membered heterocycloalkyl.
  • R 18A and R 18B substituents bonded to the same nitrogen atom are joined to form a substituted or unsubstituted 6-membered heterocycloalkyl. In embodiments, R 18A and R 18B substituents bonded to the same nitrogen atom are joined to form a substituted 6- membered heterocycloalkyl. In embodiments, R 18A and R 18B substituents bonded to the same nitrogen atom are joined to form an unsubstituted 6-membered heterocycloalkyl. [0279] In embodiments, R 19A and R 19B substituents bonded to the same nitrogen atom are joined to form a substituted or unsubstituted 5 to 6-membered heterocycloalkyl.
  • R 19A and R 19B substituents bonded to the same nitrogen atom are joined to form a substituted or unsubstituted 5-membered heterocycloalkyl. In embodiments, R 19A and R 19B substituents bonded to the same nitrogen atom are joined to form a substituted 5- membered heterocycloalkyl. In embodiments, R 19A and R 19B substituents bonded to the same nitrogen atom are joined to form an unsubstituted 5-membered heterocycloalkyl. In embodiments, R 19A and R 19B substituents bonded to the same nitrogen atom are joined to form a substituted or unsubstituted 6-membered heterocycloalkyl.
  • R 19A and R 19B substituents bonded to the same nitrogen atom are joined to form a substituted 6- membered heterocycloalkyl. In embodiments, R 19A and R 19B substituents bonded to the same nitrogen atom are joined to form an unsubstituted 6-membered heterocycloalkyl.
  • R 2 is -CN. In embodiments, R 2 is . In embodiments, R 2 is r18 . In embodiments, R 2 is r18 . In embodiments, R 2 is
  • R 2 is , embodiments, embodiments, embodiments, embodiments, R 2 is . In embodiments, R 2 , . In embodiments, R 2 is ,
  • R 16 is hydrogen, unsubstituted C 1 -C 4 alkyl, or unsubstituted C 3 -C 6 cycloalkyl. In embodiments, R 16 is hydrogen. In embodiments, R 16 is unsubstituted C 1 -C 4 alkyl. In embodiments, R 16 is unsubstituted C 1 -C 3 alkyl. In embodiments, R 16 is unsubstituted methyl. In embodiments, R 16 is unsubstituted ethyl. In embodiments, R 16 is unsubstituted propyl. In embodiments, R 16 is unsubstituted isopropyl. In embodiments, R 16 is unsubstituted butyl.
  • R 16 is unsubstituted isobutyl. In embodiments, R 16 is unsubstituted 2-methyl propyl. In embodiments, R 16 is unsubstituted t-butyl. In embodiments, R 16 is unsubstituted C 3 -C 6 cycloalkyl. In embodiments, R 16 is unsubstituted C 3 -C 5 cycloalkyl. In embodiments, R 16 is unsubstituted C 3 -C 4 cycloalkyl. In embodiments, R 16 is unsubstituted C5-C6 cycloalkyl. In embodiments, R 16 is unsubstituted cyclopropyl. In embodiments, R 16 is unsubstituted cyclobutyl. In embodiments, R 16 is unsubstituted cyclopentyl. In embodiments, R 16 is unsubstituted cyclohexyl.
  • R 17 is hydrogen, unsubstituted C 1 -C 4 alkyl, or unsubstituted C 3 -C 6 cycloalkyl. In embodiments, R 17 is hydrogen. In embodiments, R 17 is unsubstituted C 1 -C 4 alkyl. In embodiments, R 17 is unsubstituted C 1 -C 3 alkyl. In embodiments, R 17 is unsubstituted methyl. In embodiments, R 17 is unsubstituted ethyl. In embodiments, R 17 is unsubstituted propyl. In embodiments, R 17 is unsubstituted isopropyl. In embodiments, R 17 is unsubstituted butyl.
  • R 17 is unsubstituted isobutyl. In embodiments, R 17 is unsubstituted 2-methyl propyl. In embodiments, R 17 is unsubstituted t-butyl. In embodiments, R 17 is unsubstituted C 3 -C 6 cycloalkyl. In embodiments, R 17 is unsubstituted C 3 -C 5 cycloalkyl. In embodiments, R 17 is unsubstituted C 3 -C 4 cycloalkyl. In embodiments, R 17 is unsubstituted C5-C6 cycloalkyl. In embodiments, R 17 is unsubstituted cyclopropyl.
  • R 17 is unsubstituted cyclobutyl. In embodiments, R 17 is unsubstituted cyclopentyl. In embodiments, R 17 is unsubstituted cyclohexyl.
  • R 18 is hydrogen, unsubstituted C 1 -C 4 alkyl, or unsubstituted C 3 -C 6 cycloalkyl. In embodiments, R 18 is hydrogen. In embodiments, R 18 is unsubstituted C 1 -C 4 alkyl. In embodiments, R 18 is unsubstituted C 1 -C 3 alkyl. In embodiments, R 18 is unsubstituted methyl.
  • R 18 is unsubstituted ethyl. In embodiments, R 18 is unsubstituted propyl. In embodiments, R 18 is unsubstituted isopropyl. In embodiments, R 18 is unsubstituted butyl. In embodiments, R 18 is unsubstituted isobutyl. In embodiments, R 18 is unsubstituted 2-methyl propyl. In embodiments, R 18 is unsubstituted t-butyl. In embodiments, R 18 is unsubstituted C 3 -C 6 cycloalkyl. In embodiments, R 18 is unsubstituted C 3 -C 5 cycloalkyl.
  • R 18 is unsubstituted C 3 -C 4 cycloalkyl. In embodiments, R 18 is unsubstituted C 5 -C 6 cycloalkyl. In embodiments, R 18 is unsubstituted cyclopropyl. In embodiments, R 18 is unsubstituted cyclobutyl. In embodiments, R 18 is unsubstituted cyclopentyl. In embodiments, R 18 is unsubstituted cyclohexyl.
  • R 16 is hydrogen or unsubstituted C 1 -C 4 alkyl
  • R 17 is hydrogen or unsubstituted C 1 -C 4 alkyl
  • R 18 is hydrogen or unsubstituted C 1 -C 4 alkyl.
  • R 16 is hydrogen; R 17 is hydrogen or unsubstituted C 1 -C 4 alkyl; and R 18 is hydrogen or unsubstituted C 1 -C 4 alkyl.
  • R 16 is unsubstituted C 1 -C 4 alkyl; R 17 is hydrogen or unsubstituted C 1 -C 4 alkyl; and R 18 is hydrogen or unsubstituted Ci- C 4 alkyl.
  • R 16 is hydrogen or unsubstituted C 1 -C 4 alkyl; R 17 is hydrogen; and R 18 is hydrogen or unsubstituted C 1 -C 4 alkyl.
  • R 16 is hydrogen or unsubstituted C 1 -C 4 alkyl; R 17 is unsubstituted C 1 -C 4 alkyl; and R 18 is hydrogen or unsubstituted C 1 -C 4 alkyl.
  • R 16 is hydrogen or unsubstituted C 1 -C 4 alkyl; R 17 is hydrogen or unsubstituted C 1 -C 4 alkyl; and R 18 is hydrogen.
  • R 16 is hydrogen or unsubstituted C 1 -C 4 alkyl; R 17 is hydrogen or unsubstituted C 1 -C 4 alkyl; and R 18 is unsubstituted C1-C4 alkyl.
  • R 16 is hydrogen; R 17 is hydrogen; and R 18 is hydrogen or unsubstituted C 1 -C 4 alkyl.
  • R 16 is hydrogen; R 17 is unsubstituted C 1 -C 4 alkyl; and R 18 is hydrogen or unsubstituted C 1 -C 4 alkyl.
  • R 16 is unsubstituted C 1 -C 4 alkyl; R 17 is hydrogen; and R 18 is hydrogen or unsubstituted C 1 -C 4 alkyl.
  • R 16 is unsubstituted C 1 -C 4 alkyl; R 17 is unsubstituted C 1 -C 4 alkyl; and R 18 is hydrogen or unsubstituted C 1 -C 4 alkyl.
  • R 16 is hydrogen; R 17 is hydrogen; and R 18 is hydrogen.
  • R 16 is hydrogen; R 17 is hydrogen; and R 18 is unsubstituted C 1 -C 4 alkyl.
  • R 16 is hydrogen; R 17 is unsubstituted C 1 -C 4 alkyl; and R 18 is hydrogen.
  • R 16 is hydrogen; R 17 is unsubstituted C 1 -C 4 alkyl; and R 18 is unsubstituted C 1 -C 4 alkyl. In embodiments, R 16 is unsubstituted C 1 -C 4 alkyl; R 17 is hydrogen; and R 18 is hydrogen. In embodiments, R 16 is unsubstituted C 1 -C 4 alkyl; R 17 is hydrogen; and R 18 is unsubstituted C 1 -C 4 alkyl. In embodiments, R 16 is unsubstituted Ci- C 4 alkyl; R 17 is unsubstituted C 1 -C 4 alkyl; and R 18 is hydrogen.
  • R 16 is unsubstituted C1-C4 alkyl
  • R 17 is unsubstituted C1-C4 alkyl
  • R 18 is unsubstituted C1-C4 alkyl.
  • R 16 , R 17 , and R 18 are hydrogen.
  • R 1 ⁇ 3 is substituted or unsubstituted 2 to 6 membered heteroalkyl.
  • R 1 ⁇ 3 is -CN.
  • R u and R 1 ⁇ 5 are hydrogen; and R 1 ⁇ 3 is -CN.
  • R u and R 1 ⁇ 5 are hydrogen; and R 1 ⁇ 3 is -CN.
  • R 1 1 , R 1 ⁇ 4 and R 1 ⁇ 5 are hydrogen; and R 1 ⁇ 3 is -CN.
  • R 1 1 , R 1,2 and R 1 ⁇ 5 is hydrogen; and R 1 ⁇ 3 is -CN.
  • R 1,2 is substituted or unsubstituted alkyl.
  • R 1,2 is hydrogen.
  • R 1,2 is substituted or unsubstituted alkyl.
  • R 1,2 is substituted alkyl.
  • R 1,2 is unsubstituted alkyl.
  • R 1,2 is substituted or unsubstituted C 1 -C 6 alkyl.
  • R 1,2 is unsubstituted C 1 -C 6 alkyl.
  • R 1,2 is substituted or unsubstituted C 1 -C 5 alkyl. In embodiments, R 1,2 is unsubstituted C 1 -C 5 alkyl. In embodiments, R 1,2 is substituted or unsubstituted C 1 -C 4 alkyl.
  • R 1,2 is unsubstituted C 1 -C 4 alkyl. In embodiments, R 1,2 is methyl. In embodiments, R 1,2 is ethyl. In embodiments, R 1,2 is propyl. In embodiments, R 1,2 is isopropyl. In embodiments, R 1,2 is butyl. In embodiments, R 1,2 is t-butyl.
  • R 1,2 is -OR 1D .
  • R 1D is hydrogen, or substituted or unsubstituted C 1 -C 4 alkyl. In embodiments, R 1D is hydrogen. In embodiments, R 1D is substituted or unsubstituted C 1 -C 4 alkyl. In embodiments, R 1D is unsubstituted C 1 -C 4 alkyl.
  • R 1D is methyl. In embodiments, R 1D is ethyl. In embodiments, R 1D is propyl. In embodiments, R 1D is isopropyl. In embodiments, R 1D is butyl. In embodiments, R 1D is t-butyl. In embodiments, R 1,2 is -OH. In embodiments, R 1,2 is -OCH 3 . In embodiments, R 1 2 is -OCH 2 CH 3 . [0294] In embodiments, R 1 4 is substituted or unsubstituted alkyl. In embodiments, R 1 4 is hydrogen. In embodiments, R 1,4 is substituted or unsubstituted alkyl. In embodiments, R 1,4 is substituted alkyl.
  • R 1,4 is unsubstituted alkyl. In embodiments, R 1,4 is substituted or unsubstituted C 1 -C 6 alkyl. In embodiments, R 1,4 is unsubstituted C 1 -C 6 alkyl.
  • R 1,4 is substituted or unsubstituted C 1 -C 5 alkyl. In embodiments, R 1,4 is unsubstituted C 1 -C 5 alkyl. In embodiments, R 1,4 is substituted or unsubstituted C 1 -C 4 alkyl.
  • R 1,4 is unsubstituted C 1 -C 4 alkyl. In embodiments, R 1,4 is methyl. In embodiments, R 1,4 is ethyl. In embodiments, R 1,4 is propyl. In embodiments, R 1,4 is isopropyl. In embodiments, R 1,4 is butyl. In embodiments, R 1,4 is t-butyl.
  • R 1,4 is -OR 1D .
  • R 1D is hydrogen, or substituted or unsubstituted C 1 -C 4 alkyl. In embodiments, R 1D is hydrogen. In embodiments, R 1D is substituted or unsubstituted C 1 -C 4 alkyl. In embodiments, R 1D is unsubstituted C 1 -C 4 alkyl.
  • R 1D is methyl. In embodiments, R 1D is ethyl. In embodiments, R 1D is propyl. In embodiments, R 1D is isopropyl. In embodiments, R 1D is butyl. In embodiments, R 1D is t-butyl. In embodiments, R 1 ⁇ 4 is -OH. In embodiments, R 1 ⁇ 4 is -OCH 3 . In embodiments, R 1 4 is -OCH 2 CH 3 .
  • R 1,2 is unsubstituted C 1 -C 4 alkyl and R 1,4 is -OR 1D .
  • R 1,2 is methyl and R 1 ⁇ 4 is -OH.
  • R 1 ⁇ 2 is methyl and R 1 ⁇ 4 is - OCH 3 .
  • R 1,2 is ethyl and R 1 ⁇ 4 is -OCH 3 .
  • R 1,2 is ethyl and R 1 ⁇ 4 is -OCH 2 CH 3 .
  • R 1,2 is -OR 1D and R 1 ⁇ 4 is unsubstituted C 1 -C 4 alkyl.
  • R 1,2 is -OH and R 1 ⁇ 4 is methyl. In embodiments, R 1,2 is -OCH 3 and R 1 ⁇ 4 is methyl. In embodiments, R 1,2 is -OCH 3 and R 1 ⁇ 4 is ethyl. In embodiments, R 1,2 is -OCH 2 CH 3 and R 1,4 is ethyl.
  • R 1,2 is substituted or unsubstituted alkyl.
  • R 1,2 is hydrogen.
  • R 1,2 is substituted or unsubstituted alkyl.
  • R 1,2 is substituted alkyl.
  • R 1,2 is unsubstituted alkyl.
  • R 1,2 is substituted or unsubstituted C1-C6 alkyl.
  • R 1,2 is unsubstituted C1-C6 alkyl.
  • R 1,2 is substituted or unsubstituted C 1 -C 5 alkyl. In embodiments, R 1,2 is unsubstituted C 1 -C 5 alkyl. In embodiments, R 1,2 is substituted or unsubstituted C 1 -C 4 alkyl.
  • R 1,2 is unsubstituted C 1 -C 4 alkyl. In embodiments, R 1,2 is methyl. In embodiments, R 1,2 is ethyl. In embodiments, R 1,2 is propyl. In embodiments, R 1,2 is isopropyl. In embodiments, R 1,2 is butyl. In embodiments, R 1,2 is t-butyl.
  • R 1,3 is substituted or unsubstituted alkyl. In embodiments, R 1,3 is hydrogen. In embodiments, R 1,3 is substituted or unsubstituted alkyl. In embodiments, R 1,3 is substituted alkyl. In embodiments, R 1,3 is unsubstituted alkyl. In embodiments, R 1,3 is substituted or unsubstituted C1-C6 alkyl. In embodiments, R 1,3 is unsubstituted C1-C6 alkyl.
  • R 1,3 is substituted or unsubstituted C 1 -C 5 alkyl. In embodiments, R 1,3 is unsubstituted C 1 -C 5 alkyl. In embodiments, R 1,3 is substituted or unsubstituted C 1 -C 4 alkyl.
  • R 1,3 is unsubstituted C 1 -C 4 alkyl.
  • R 1 ⁇ 3 is methyl.
  • R 1 ⁇ 3 is ethyl.
  • R 1 ⁇ 3 is propyl.
  • R 1 ⁇ 3 is isopropyl.
  • R 1 ⁇ 3 is butyl.
  • R 1 ⁇ 3 is t-butyl.
  • R 1 ⁇ 4 is substituted or unsubstituted alkyl.
  • R 1 ⁇ 4 is hydrogen.
  • R 1 ⁇ 4 is substituted or unsubstituted alkyl.
  • R 1 ⁇ 4 is substituted alkyl.
  • R 1 ⁇ 4 is unsubstituted alkyl.
  • R 1 ⁇ 4 is substituted or unsubstituted C1-C6 alkyl.
  • R 1 ⁇ 4 is unsubstituted C1-C6 alkyl.
  • R 1 ⁇ 4 is substituted or unsubstituted C 1 -C 5 alkyl. In embodiments, R 1 ⁇ 4 is unsubstituted C 1 -C 5 alkyl. In embodiments, R 1 ⁇ 4 is substituted or unsubstituted C 1 -C 4 alkyl.
  • R 1 ⁇ 4 is unsubstituted C 1 -C 4 alkyl. In embodiments, R 1 ⁇ 4 is methyl. In embodiments, R 1,4 is ethyl. In embodiments, R 1,4 is propyl. In embodiments, R 1,4 is isopropyl. In embodiments, R 1,4 is butyl. In embodiments, R 1,4 is t-butyl.
  • R 1,2 and R 1,3 are independently hydrogen or unsubstituted C 1 -C 4 alkyl. In embodiments, R 1,2 and R 1,3 are independently unsubstituted C 1 -C 4 alkyl. In embodiments, R 1,2 and R 1,3 are independently methyl or ethyl. In embodiments, R 1,2 and R 1,3 are methyl. In embodiments, R 1,3 and R 1,4 are independently hydrogen or unsubstituted C 1 -C 4 alkyl. In embodiments, R 1,3 and R 1,4 are independently unsubstituted C 1 -C 4 alkyl. In embodiments, R 1 ⁇ 3 and R 1 ⁇ 4 are independently methyl or ethyl. In embodiments, R 1 ⁇ 3 and R 1 ⁇ 4 are methyl.
  • R 1 ⁇ 3 is hydrogen, or substituted or unsubstituted alkyl. In embodiments, R 1 ⁇ 3 is substituted or unsubstituted alkyl. In embodiments, R 1 ⁇ 3 is hydrogen. In embodiments, R 1 ⁇ 3 is substituted or unsubstituted alkyl. In embodiments, R 1 ⁇ 3 is substituted alkyl. In embodiments, R 1 ⁇ 3 is unsubstituted alkyl. In embodiments, R 1 ⁇ 3 is substituted or unsubstituted C 1 -C 6 alkyl. In embodiments, R 1 ⁇ 3 is unsubstituted C 1 -C 6 alkyl.
  • R 1 ⁇ 3 is substituted or unsubstituted C 1 -C 5 alkyl. In embodiments, R 1 ⁇ 3 is unsubstituted C 1 -C 5 alkyl. In embodiments, R 1 ⁇ 3 is substituted or unsubstituted C 1 -C 4 alkyl.
  • R 1 ⁇ 3 is unsubstituted C 1 -C 4 alkyl. In embodiments, R 1 ⁇ 3 is methyl. In embodiments, R 1 ⁇ 3 is ethyl. In embodiments, R 1 ⁇ 3 is propyl. In embodiments, R 1 ⁇ 3 is isopropyl. In embodiments, R 1 ⁇ 3 is butyl. In embodiments, R 1 ⁇ 3 is t-butyl. In embodiments, R 1 ⁇ 3 is hydrogen.
  • R 1 ⁇ 4 is hydrogen, or substituted or unsubstituted alkyl. In embodiments, R 1 ⁇ 4 is substituted or unsubstituted alkyl. In embodiments, R 1,4 is hydrogen. In embodiments, R 1,4 is substituted or unsubstituted alkyl. In embodiments, R 1,4 is substituted alkyl. In embodiments, R 1,4 is unsubstituted alkyl. In embodiments, R 1,4 is substituted or unsubstituted C 1 -C 6 alkyl. In embodiments, R 1 4 is unsubstituted C 1 -C 6 alkyl.
  • R 1,4 is substituted or unsubstituted C 1 -C 5 alkyl. In embodiments, R 1,4 is unsubstituted C 1 -C 5 alkyl. In embodiments, R 1,4 is substituted or unsubstituted C 1 -C 4 alkyl. In embodiments, R 1,4 is unsubstituted C 1 -C 4 alkyl. In embodiments, R 1,4 is methyl. In embodiments, R 1,4 is ethyl. In embodiments, R 1,4 is propyl. In embodiments, R 1,4 is is isopropyl. In embodiments, R 1,4 is butyl. In embodiments, R 1,4 is t-butyl. In embodiments, R 1 ⁇ 4 is hydrogen.
  • R 1,3 and R 1,4 are independently hydrogen or unsubstituted C 1 -C 4 alkyl.
  • R 1,3 is hydrogen and R 1,4 is unsubstituted C 1 -C 4 alkyl.
  • R 1 ⁇ 3 is unsubstituted C 1 -C 4 alkyl and R 1 ⁇ 4 is hydrogen.
  • R 1 ⁇ 3 is hydrogen and R 1 ⁇ 4 is methyl or ethyl.
  • R 1 ⁇ 3 is methyl or ethyl and R 1 ⁇ 4 is hydrogen.
  • R 1 ⁇ 4 is hydrogen, or substituted or unsubstituted alkyl. In embodiments, R 1 ⁇ 4 is substituted or unsubstituted alkyl. In embodiments, R 1 ⁇ 4 is hydrogen. In embodiments, R 1 ⁇ 4 is substituted or unsubstituted alkyl. In embodiments, R 1 ⁇ 4 is substituted alkyl. In embodiments, R 1 ⁇ 4 is unsubstituted alkyl. In embodiments, R 1 ⁇ 4 is substituted or unsubstituted C 1 -C 6 alkyl. In embodiments, R 1 ⁇ 4 is unsubstituted C 1 -C 6 alkyl.
  • R 1 ⁇ 4 is substituted or unsubstituted C 1 -C 5 alkyl. In embodiments, R 1 ⁇ 4 is unsubstituted C 1 -C 5 alkyl. In embodiments, R 1 ⁇ 4 is substituted or unsubstituted C 1 -C 4 alkyl. In embodiments, R 1 ⁇ 4 is unsubstituted C 1 -C 4 alkyl. In embodiments, R 1 ⁇ 4 is methyl. In embodiments, R 1 ⁇ 4 is ethyl. In embodiments, R 1 ⁇ 4 is propyl. In embodiments, R 1 ⁇ 4 is isopropyl. In embodiments, R 1 ⁇ 4 is butyl. In embodiments, R 1 ⁇ 4 is t-butyl. In embodiments, R 1 ⁇ 4 is hydrogen.
  • R 1,2 is hydrogen, or substituted or unsubstituted alkyl. In embodiments, R 1,2 is substituted or unsubstituted alkyl. In embodiments, R 1,2 is hydrogen. In embodiments, R 1,2 is substituted or unsubstituted alkyl. In embodiments, R 1,2 is substituted alkyl. In embodiments, R 1,2 is unsubstituted alkyl. In embodiments, R 1,2 is substituted or unsubstituted C 1 -C 6 alkyl. In embodiments, R 1,2 is unsubstituted C 1 -C 6 alkyl.
  • R 1,2 is substituted or unsubstituted C 1 -C 5 alkyl. In embodiments, R 1,2 is unsubstituted C 1 -C 5 alkyl. In embodiments, R 1,2 is substituted or unsubstituted C 1 -C 4 alkyl. In embodiments, R 1,2 is unsubstituted C 1 -C 4 alkyl. In embodiments, R 1,2 is methyl. In embodiments, R 1 ⁇ 2 is ethyl. In embodiments, R 1 ⁇ 2 is propyl. In embodiments, R 1 ⁇ 2 is isopropyl. In embodiments, R 1,2 is butyl. In embodiments, R 1,2 is t-butyl. In embodiments, R 1 ⁇ 2 is hydrogen.
  • R 1,3 is hydrogen, or substituted or unsubstituted alkyl. In embodiments, R 1,3 is substituted or unsubstituted alkyl. In embodiments, R 1,3 is hydrogen. In embodiments, R 1,3 is substituted or unsubstituted alkyl. In embodiments, R 1,3 is substituted alkyl. In embodiments, R 1,3 is unsubstituted alkyl. In embodiments, R 1,3 is substituted or unsubstituted C 1 -C 6 alkyl. In embodiments, R 1,3 is unsubstituted C 1 -C 6 alkyl. In embodiments, R 1,3 is substituted or unsubstituted C 1 -C 5 alkyl.
  • R 1,3 is unsubstituted C 1 -C 5 alkyl. In embodiments, R 1,3 is substituted or unsubstituted C 1 -C 4 alkyl. In embodiments, R 1 ⁇ 3 is unsubstituted C 1 -C 4 alkyl. In embodiments, R 1 ⁇ 3 is methyl. In embodiments, R 1 ⁇ 3 is ethyl. In embodiments, R 1 ⁇ 3 is propyl. In embodiments, R 1 ⁇ 3 is isopropyl. In embodiments, R 1 ⁇ 3 is butyl. In embodiments, R 1 ⁇ 3 is t-butyl. In embodiments, R 1 ⁇ 3 is hydrogen.
  • R 1,2 and R 1 ⁇ 3 are independently hydrogen or unsubstituted C 1 -C 4 alkyl.
  • R 1,2 is hydrogen and R 1 ⁇ 3 is unsubstituted C 1 -C 4 alkyl.
  • R 1,2 is hydrogen and R 1 ⁇ 3 is methyl.
  • R 1,2 is hydrogen and R 1 ⁇ 3 is ethyl.
  • R 1 2 is hydrogen and R 1 3 is propyl.
  • R 1 2 is hydrogen and R 1,3 is isopropyl.
  • R 1,2 is hydrogen and R 1,3 is butyl.
  • R 1,2 is hydrogen and R 1,3 is t-butyl.
  • R 1,2 is unsubstituted Ci- C4 alkyl and R 1,3 is hydrogen.
  • R 1,2 is methyl and R 1,3 is hydrogen.
  • R 1,2 is ethyl and R 1,3 is hydrogen.
  • R 1,2 is propyl and R 1,3 is hydrogen.
  • R 1,2 is isopropyl and R 1,3 is hydrogen.
  • R 1,2 is butyl and R 1,3 is hydrogen.
  • R 1,2 is t-butyl and R 1,3 is hydrogen.
  • moiety in Formula (I) is N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl
  • moiety in Formula (I) is In embodiments, moiety in Formula (I) is In embodiments, moiety in Formula (I).
  • moiety in Formula (I) is N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl
  • moiety in Formula (I) is V NH In embodiments, moiety in Formula (I) is V NH In embodiments, moiety in Formula (I) is V NH In embodiments, moiety in Formula (I) is V NH In embodiments, moiety in Formula (I) is V NH In embodiments, moiety in Formula (I) is V NH In embodiments, moiety in Formula (I) is V NH In embodiments, moiety in Formula (I)
  • R 1 is independently halogen -NHC(0)NHCH 3 ), -N(0)mi (e.g., -NO, or-N0 2 ), -NR 1A R 1B (e.g., -NH 2 , or - NHCHs), -C(0)R lc (e.g., -C(0)H or -C(0)CH 3 ), -C(0)-0R lc (e.g., -C(0)0H or - C(0)0CH 3 ), -C(0)NR 1A R 1B (e.g., -C(0)NH 2 or -C(O) NHCH 3 ), -OR 1D (e.g., -OH, or - OCH 3 ), -NR 1A S0 2 R 1D (e.g., -NHS0 2 H), -NR 1A C(0)R lc (e.g., -NHCOH), -NR 1A C(0)0R lc (
  • a substituted R 1 is substituted with at least one substituent group, size-limited substituent group, or lower substituent group; wherein if the substituted R 1 is substituted with a plurality of groups selected from substituent groups, size-limited substituent groups, and lower substituent groups; each substituent group, size-limited substituent group, and/or lower substituent group may optionally be different.
  • R 1 when R 1 is substituted, it is substituted with at least one substituent group.
  • R 1 when R 1 is substituted, it is substituted with at least one size-limited substituent group. In embodiments, when R 1 is substituted, it is substituted with at least one lower substituent group.
  • each R 1 is independently -F, -Cl, -Br, -I, -CF 3 , -CHF 2 , -CH 2 F, - CC1 3 ,-CHC1 2 , -CH 2 C1, -CBr 3 , -CHBr 2 , -CH 2 Br, -CI 3 , -CHI 2 , -CH 2 I, -OCF 3 , -OCCl 3 , - OCBr 3 , -OCI 3 , -OCHF 2 , -OCHCk, -OCHBr 2 , -OCHI 2 , -OCH 2 F, -OCH 2 Cl, -OCH 2 Br, - OCH 2 I, -N 3 , -CN, -SH, -SCH 3 , -S0 2 H, -SC CHs, -S0 2 NH 2 , -SC NHCHs, -NHC(0)NH
  • each R 1 is independently -F, -Cl, -Br, -I, -CF 3 , -CHF 2 , -CH 2 F, -CC1 3 ,-CHC1 2 , -CH 2 C1, -CBr 3 , CHBr 2 , -CH 2 Br, -CI 3 , -CHI 2 , -CH 2 I, -OCF 3 , -OCCl 3 , - OCBr 3 , -OCI 3 , -OCHF 2 , -OCHCk, -OCHBr 2 , -OCHI 2 , -OCH 2 F, -OCH 2 Cl, -OCH 2 Br, - OCH 2 I, -N 3 , -CN, -SH, -SCH 3 , -S0 2 H, -S0 2 CH 3 , -S0 2 NH 2 , -S0 2 NHCH 3 , -NHC(0)NH 2,
  • each R 1 is independently -F, -Cl, -Br, -I, -CF 3 , -CHF 2 , -CH 2 F, -CC1 3 , -CHC1 2 , -CH 2 C1, - CBr 3 , CHBr 2 , -CH 2 Br, -CI 3 , -CHI 2 , -CH 2 I, -OCF 3 , -OCCl 3 , -OCBr 3 , -OCI 3 , OCHF 2 , - OCHCk, -OCHBr 2 , -OCHk, -OCH 2 F, -OCH 2 Cl, -OCH 2 Br, -OCH 2 I, -N 3 , -CN, -SH, - SCH 3 , -S0 2 H, -S0 2 CH 3 , -S0 2 NH 2 , -S0 2 NHCH 3 , -NHC(0)NH 2
  • Each R u , R 12 , R 1 3 , R 14 , and R 1 5 is independently hydrogen, halogen (e.g., -F, -Cl, SO 3 H, or -SO 4 H), -SO vi NR 1A R 1B (e.g., -SO 2 NH 2 , or -SO 2 NHCH 3 ), -NR 1C NR 1A R 1B (e.g., NHNH2 or NHNHCH3), -ONR 1A R 1B (e.g., -ONH 2 , or -ONHCH3), -NHC(0)NR 1C NR 1A R 1B (e.g., -NHC(0)NHNH 2 , or -NHC(0)NHNHCH 3 ), -NHC(0)NR 1A R 1B (e.g., -NHC(0)NH 2 , or -NHC(0)NHCH 3 ), -N(0) mi (e.g., -NO, or -NO), -
  • a substituted R u is substituted with at least one substituent group, size-limited substituent group, or lower substituent group; wherein if the substituted R u is substituted with a plurality of groups selected from substituent groups, size-limited substituent groups, and lower substituent groups; each substituent group, size-limited substituent group, and/or lower substituent group may optionally be different.
  • R 1 1 when R 1 1 is substituted, it is substituted with at least one substituent group.
  • R 1 1 when R 1 1 is substituted, it is substituted with at least one size-limited substituent group.
  • R u when R u is substituted, it is substituted with at least one lower substituent group.
  • a substituted R 1,2 is substituted with at least one substituent group, size-limited substituent group, or lower substituent group; wherein if the substituted R 1,2 is substituted with a plurality of groups selected from substituent groups, size-limited substituent groups, and lower substituent groups; each substituent group, size-limited substituent group, and/or lower substituent group may optionally be different.
  • R 1 ⁇ 2 when R 1 ⁇ 2 is substituted, it is substituted with at least one substituent group.
  • R 1 ⁇ 2 when R 1 ⁇ 2 is substituted, it is substituted with at least one size-limited substituent group.
  • R 1 ⁇ 2 when R 1 ⁇ 2 is substituted, it is substituted with at least one lower substituent group.
  • a substituted R 1,3 is substituted with at least one substituent group, size-limited substituent group, or lower substituent group; wherein if the substituted R 1,3 is substituted with a plurality of groups selected from substituent groups, size-limited substituent groups, and lower substituent groups; each substituent group, size-limited substituent group, and/or lower substituent group may optionally be different.
  • R 1 ⁇ 3 when R 1 ⁇ 3 is substituted, it is substituted with at least one substituent group.
  • R 1 ⁇ 3 when R 1 ⁇ 3 is substituted, it is substituted with at least one size-limited substituent group.
  • R 1 ⁇ 3 when R 1 ⁇ 3 is substituted, it is substituted with at least one lower substituent group.
  • a substituted R 1,4 is substituted with at least one substituent group, size-limited substituent group, or lower substituent group; wherein if the substituted R 1,4 is substituted with a plurality of groups selected from substituent groups, size-limited substituent groups, and lower substituent groups; each substituent group, size-limited substituent group, and/or lower substituent group may optionally be different.
  • R 1 4 when R 1 4 is substituted, it is substituted with at least one substituent group.
  • R 1 ⁇ 4 when R 1 ⁇ 4 is substituted, it is substituted with at least one size-limited substituent group. In embodiments, when R 1 ⁇ 4 is substituted, it is substituted with at least one lower substituent group.
  • a substituted R 1,5 is substituted with at least one substituent group, size-limited substituent group, or lower substituent group; wherein if the substituted R 1,5 is substituted with a plurality of groups selected from substituent groups, size-limited substituent groups, and lower substituent groups; each substituent group, size-limited substituent group, and/or lower substituent group may optionally be different.
  • R 1 ⁇ 5 when R 1 ⁇ 5 is substituted, it is substituted with at least one substituent group.
  • R 1 ⁇ 5 when R 1 ⁇ 5 is substituted, it is substituted with at least one size-limited substituent group.
  • R 1 ⁇ 5 when R 1 ⁇ 5 is substituted, it is substituted with at least one lower substituent group.
  • each R 1 1 , R 1 ⁇ 2 , R 1 ⁇ 3 , R 1 ⁇ 4 , and R 1,5 is independently hydrogen, -F, - Cl, -Br, -I, -CF 3 , -CHF 2 , -CH 2 F, -CC1 3 , -CHCk, -CH 2 C1, -CBr 3 , -CHBr 2 , -CH 2 Br, -CI 3 , - CHI 2 , -CH 2 I, -OCF 3 , -OCCl 3 , -OCBr 3 , -OCI 3 , -OCHF 2 , OCHCh, -OCHBr 2 , -OCHI 2 , - OCH 2 F, -OCH 2 Cl, -OCH 2 Br, -OCH 2 I, -N 3 , -CN, -SH, -SCH 3 , -S0 2 H, -S0 2 CH
  • each R 1 1 , R 1 ⁇ 2 , R 1 ⁇ 3 , R 1 ⁇ 4 , and R 1,5 is independently hydrogen, - F, -Cl, -Br, -I, -CF 3 , -CHF 2 , -CH 2 F, -CCI3, -CHCk, -CH 2 C1, -CBr 3 , -CHBr 2 , -CH 2 Br, - CI 3 , -CHI 2 , -CH 2 I, -OCF 3 , -OCCl 3 , -OCBr 3 , -OCI 3 , -OCHF 2 , OCHCh, -OCHBr 2 , - OCHI 2 , -OCH 2 F, -OCH 2 Cl, -OCH 2 Br, -OCH 2 I, -N 3 , -CN, -SH, -SCH 3 , -S0 2 H, -S0 2 CH 3 , -
  • R 1E -substituted alkyl e.g., Ci-C 20 , Ci- Ci 2 , C1-C8, C1-C6, C1-C4, or Ci-C 2
  • R 1E -substituted heteroalkyl e.g., 2 to 20 membered, 2 to 12 membered, 2 to 8 membered, 2 to 6 membered, 4 to 6 membered, 2 to 3 membered, or 4 to
  • R 1E -substituted cycloalkyl e.g., C 3 -Cio, C 3 -Cs, C 3 -C6, C4-C6, or C5-C6
  • R 1E - substituted heterocycloalkyl e.g., 3 to 10 membered, 3 to 8 membered, 3 to 6 membered, 4 to
  • R 1E -substituted aryl e.g., C 6 -Ci 2 , C 6 - C10, or phenyl
  • R 1E -substituted heteroaryl e.g., 5 to 12 membered, 5 to 10 membered, 5 to 9 membered, or 5 to 6 membered.
  • each R 1 ⁇ 1 , R 1 ⁇ 2 , R 1 ⁇ 3 , R 1 ⁇ 4 , and R 1 5 is independently hydrogen, -F, -Cl, -Br, -I, -CF 3 , -CHF 2 , -CH 2 F, -CC1 3 ,-CHC1 2 , -CH 2 C1, - CBr 3 , CHBr 2 , -CH 2 Br, -CI 3 , -CHI 2 , -CH 2 I, -OCF 3 , -OCCl 3 , -OCBr 3 , -OCI 3 , OCHF 2 , - OCHCh, -OCHBr 2 , -OCHI 2 , -OCH 2 F, -OCH 2 Cl, -OCH 2 Br, -OCH 2 I, -N 3 , -CN, -SH, - SCH 3 , -S0 2 H, -S0 2 CH
  • R 1E is independently oxo, halogen, -CF 3 , -CCl 3 ,-CBr 3 , -CI 3 , -CHF 2 , -CHCh,- CHBr 2 , -CHI 2 , -CH 2 F,-CH 2 C1, -CH 2 Br, -
  • R 1E is independently oxo, halogen, -CF 3 , -CCI 3 ,- CBr 3 , -CI3, -CHF 2 , -CHCl 2 ,-CHBr 2 , -CHI 2 , -CH2F,-CH 2 C1, -CH 2 Br, - CH 2 I, -CN, -OH, -NH 2 , -COOH, -CONH 2 , -NO 2 , -SH, -SCH 3 , -SO 3 H, -SO 4 H, -SO 2 NH 2 , -NHNH 2 , -ONH 2 , -NHC(0)NHNH 2 , -NHC(0)NH 2 , -NHSO 2 H, -NHC(0)H, - NHC(0)0H, -NHOH, -OCF3, -OCCI3, -OCBr 3 , -OCI3, -OCHF2, -OCHCI2, OCHBr 2
  • R 1E is independently oxo, halogen, -CF 3 , -CCI 3 , -CBr 3 , -CI 3 , - CHF 2 , -CHCl 2 ,-CHBr 2 , -CHI 2 , -CH 2 F,-CH 2 C1, -CH 2 Br, -
  • R 16 is halogen (e.g., -F, -Cl, -Br, or -I), -CX 16 3 (e.g., -CF 3 , -CCI3, -CBr 3 , or -CI3), -
  • CHX 16 2 (e.g., -CHF 2 , -CHCl 2 ,-CHBr 2, or -CHI 2 ), -CH 2 X 16 (e.g., -CH 2 F,-CH 2 C1, -CH 2 Br, or -CH2I), -OCX 16 3 (e.g., -OCF3, -OCCI3, -OCBr 3 , or-OCI 3 ), -OCH 2 X 16 (e.g., -OCH2F, - OCH2CI, -OCH 2 Br, or -OCH2I), -OCHX 16 2 (e.g., -OCHF2, -OCHCI2, -OCHBr 2 , - OCHI2), -CN, -SOmony I6 R 16D (e.g., -SH, -SCH 3 , -SO2H, -SO3H, or -SO4H), -SO VI6 NR 16A R 16B (e
  • a substituted R 16 is substituted with at least one substituent group, size-limited substituent group, or lower substituent group; wherein if the substituted R 16 is substituted with a plurality of groups selected from substituent groups, size-limited substituent groups, and lower substituent groups; each substituent group, size-limited substituent group, and/or lower substituent group may optionally be different.
  • R 16 when R 16 is substituted, it is substituted with at least one substituent group.
  • R 16 when R 16 is substituted, it is substituted with at least one size-limited substituent group. In embodiments, when R 16 is substituted, it is substituted with at least one lower substituent group.
  • R 16 is hydrogen, -F, -Cl, -Br, -I, -CF 3 , -CHF 2 , -CH 2 F, -CC1 3 , - CHCk, -CH 2 C1, -CBr 3 , -CHBr 2 , -CH 2 Br, -CI 3 , -CHI 2 , -CH 2 I, -OCF 3 , -OCCl 3 , -OCBr 3 , - OCI 3 , -OCHF 2 , -OCHCk, -OCHBr 2 , -OCHI 2 , -OCH 2 F, -OCH 2 Cl, -OCH 2 Br, - OCH 2 I, -N 3 , -CN, -SH, -SCH 3 , -S0 2 H, -S0 2 CH 3 , -S0 2 NH 2 , -S0 2 NHCH 3 , -NHCH 3 , -NH
  • R 16 is hydrogen, -F, -Cl, -Br, -I, -CF 3 , -CHF 2 , -CH 2 F, -CC1 3 , -CHCk, -CH 2 C1, -CBr 3 , CHBr 2 , -CH 2 Br, -CI 3 , -CHk, -CH 2 I, -OCF 3 , -OCCl 3 , -OCBr 3 , - OCI 3 , -OCHF 2 , -OCHCk, -OCHBr 2 , -OCHk, -OCH 2 F, -OCH 2 Cl, -OCH 2 Br, - OCH 2 I, -N 3 , -CN, -SH, -SCH 3 , -S0 2 H, -S0 2 CH 3 , -S0 2 NH 2 , -SCkNHCHs, -NHC(0)NH 2 , -NHC(0)
  • R 16 is hydrogen, -F, -Cl, -Br, -I, -CF 3 , -CHF 2 , -CH 2 F, -CC1 3 , -CHCI2, -CH2CI, -CBr 3 , CHBr 2 , -CH 2 Br, -CI3, -CHI 2 , -CH 2 I, -OCF3, -OCCI3, -OCBr 3 , - OCI3, -OCHF2, -OCHCI2, -OCHBr 2 , -OCHI2, -OCH2F, -OCH2CI, -OCH 2 Br, - OCH2I, -N 3 , -CN, -SH, -SCH3, -SO2H, -SO2CH3, -SO2NH2, -SO2NHCH3, -NHC(0)NH 2, -NHC(0)NHCH 3, -NO2, -NH 2 , -NHCH3, -C(0)H,
  • R 16E is independently oxo, halogen, -CF 3 , -CCl 3 ,-CBr 3 , -CI3, -CHF 2 , -CHCI2,- CHBr 2, - CHI2, -CH 2 F,-CH 2 C1, -CH 2 Br, -
  • R 16E is independently oxo, halogen, -CF 3 , -CCI 3 ,- CBr 3 , -CI3, -CHF 2 , -CHCl 2 ,-CHBr 2 , -CHI 2 , -CH2F,-CH 2 C1, -CH 2 Br, - CH 2 I, -CN, -OH, -NH 2 , -COOH, -CONH 2 , -NO 2 , -SH, -SCH 3 , -SO 3 H, -S0 4 H, -SO 2 NH 2 , -NHNH 2 , -ONH 2 , -NHC(0)NHNH 2 , -NHC(0)NH 2 , -NHSO 2 H, -NHC(0)H, - NHC(0)OH, -NHOH, -OCF3, -OCCI3, -OCBr 3 , -OCI3, -OCHF2, -OCHCI2, OCHBr 2
  • R 16E is independently oxo, halogen, -CF3, -CCl3,-CBr3, -CI3, ( ) , , 3, 3, 3 , 3, , , , , , unsubstituted alkyl (e.g., Ci-C 8 , Ci-C 6 , or C1-C4 alkyl), unsubstituted heteroalkyl (e.g., 2 to 8 membered, 2 to 6 membered, or 2 to 4 membered heteroalkyl), unsubstituted cycloalkyl (e.g., C3-C8, C3-C6, or C5-C6 cycloalkyl), unsubstituted heterocycloalkyl (e.g., 3 to 8 membered, 3 to 6 membered, or 5 to 6 membered heterocycloalkyl), unsubstituted aryl (e.g., C6-C10, C10 aryl, or phenyl
  • R 17 is halogen ( g ) ( ) ( g substituted (e.g., substituted with a substituent group, a size-limited substituent group, or lower substituent group) or unsubstituted alkyl (e.g., Ci-Cs, C1-C6, or C1-C4 alkyl), substituted (e.g., substituted with a substituent group, a size-limited substituent group, or lower substituent group) or unsubstituted heteroalkyl (e.g., 2 to 8 membered, 2 to 6 membered, or 2 to 4 membered heteroalkyl), substituted (e.g., substituted with a substituent group, a size-limited substituent group, or lower substituent group) or unsubstituted cycloalkyl (e.g., C3-C8, C3-C6, or C5-C6 cycloalkyl), substituted (e.g., substituted with a substituent group,
  • a substituted R 17 is substituted with at least one substituent group, size-limited substituent group, or lower substituent group; wherein if the substituted R 17 is substituted with a plurality of groups selected from substituent groups, size-limited substituent groups, and lower substituent groups; each substituent group, size-limited substituent group, and/or lower substituent group may optionally be different.
  • R 17 when R 17 is substituted, it is substituted with at least one substituent group.
  • R 17 when R 17 is substituted, it is substituted with at least one size-limited substituent group. In embodiments, when R 17 is substituted, it is substituted with at least one lower substituent group.
  • R 17 is hydrogen, -F, -Cl, -Br, -I, -CF 3 , -CHF 2 , -CH 2 F, -CCI3, - CHC1 2 , -CH 2 C1, -CBr 3 , -CHBr 2 , -CH 2 Br, -CI3, -CHI 2 , -CH 2 I, -OCF3, -OCCI3, -OCBr 3 , - OCI3, -OCHF 2 , -OCHCk, -OCHBr 2 , -OCHI 2 , -OCH 2 F, -OCH 2 Cl, -OCH 2 Br, - OCH 2 I, -N 3 , -CN, -SH, -SCH3, -S0 2 H, -S0 2 CH 3 , -S0 2 NH 2 , -S0 2 NHCH 3 , -NHC(0)NH 2, -NHC(0)NHCH
  • R 17 is hydrogen, -F, -Cl, -Br, -I, -CF 3 , -CHF 2 , -CH 2 F, -CCI 3 , -CHCI2, -CH2CI, -CBr 3 , CHBr 2 , -CH 2 Br, -CI3, -CHI 2 , -CH 2 I, -OCF3, -OCCI3, -OCBr 3 , - OCI 3 , -OCHF 2 , -OCHCI 2 , -OCHBr 2 , -OCHI 2 , -OCH 2 F, -OCH 2 CI, -OCH 2 Br, - OCH2I, -N 3 , -CN, -SH, -SCH3, -SO2H, -SO2CH3, -SO2NH2, -SO2NHCH3, -NHC(0)NH 2 , -NHC(0)NHCH 3 , -NO2, -NH 2
  • R 17 is hydrogen, -F, -Cl, -Br, -I, -CF 3 , -CHF 2 , -CH 2 F, -CCI 3 , -CHCI2, -CH2CI, -CBr 3 , CHBr 2 , -CH 2 Br, -CI3, -CHI 2 , -CH 2 I, -OCF3, -OCCI3, -OCBr 3 , - OCI3, -OCHF2, -OCHCI2, -OCHBr 2 , -OCHI2, -OCH2F, -OCH2CI, -OCH 2 Br, - OCH2I, -N 3 , -CN, -SH, -SCH3, -SO2H, -SO2CH3, -SO2NH2, -SO2NHCH3, -NHC(0)NH 2 , -NHC(0)NHCH 3 , -NO2, -NH 2 , -NHCH3, -C
  • R 17E is independently oxo, halogen, -CF 3 , -CCl 3 ,-CBr 3 , -CI3, -CHF 2 , -CHCI2,- CHBr 2, - CHI2, -CH 2 F,-CH 2 C1, -CH 2 Br, - CH 2 I, -CN, -OH, -NH 2 , -COOH, -CONH 2 , -NO 2 , -SH, -SCH 3 , -SO 3 H, -SO 4 H, -SO 2 NH 2 , -NHNH 2 , -ONH 2 , -NHC(0)NHNH 2 , -NHC(0)NH 2 , -NHSO 2 H, -NHC(0)H, - NHC(0)0H, -NHOH, -OCF3, -OCCI3, -OCBr 3 , -OCI3, -OCHF2, -OCHCI2, OCHBr 2 , - OCHI
  • R 17E is independently oxo, halogen, -CF 3 , -CCI 3 ,- CBr 3 , -CI3, -CHF 2 , -CHCl 2 ,-CHBr 2 , -CHI 2 , -CH2F,-CH 2 C1, -CH 2 Br, - CH 2 I, -CN, -OH, -NH 2 , -COOH, -CONH 2 , -NO 2 , -SH, -SCH 3 , -SO 3 H, -SO 4 H, -SO 2 NH 2 , -NHNH 2 , -ONH 2 , -NHC(0)NHNH 2 , -NHC(0)NH 2 , -NHSO 2 H, -NHC(0)H, - I3, -OCHF2, -OCHCI2, OCHBr 2 , - substituted alkyl (e.g., Ci-C 8 , Ci-C 6 , or C 1 -
  • R 17E is independently oxo, halogen, -CF 3 , -CCl 3 ,-CBr 3 , -CI 3 , CHF 2 , -CHCl 2 ,-CHBr 2 , -CHI 2 , -CH 2 F,-CH 2 C1, -CH 2 Br, -
  • substituted e.g., substituted with a substituent group, a size-limited substituent group, or lower substituent group
  • unsubstituted alkyl e.g., Ci-C 8 , C1-C6, or C1-C4 alkyl
  • substituted e.g., substituted with a substituent group, a size-limited substituent group, or lower substituent group
  • unsubstituted heteroalkyl e.g., 2 to 8 membered, 2 to 6 membered, or 2 to 4 membered heteroalkyl
  • substituted e.g., substituted with a substituent group, a size-limited substituent group, or lower substituent group
  • unsubstituted cycloalkyl e.g., C 3 -C 8 , C 3 -C 6 , or C5-C6 cycloalkyl
  • substituted e.g., substituted with a substituent group, a size-limited substituent group, or
  • a substituted R 18 is substituted with at least one substituent group, size-limited substituent group, or lower substituent group; wherein if the substituted R 18 is substituted with a plurality of groups selected from substituent groups, size-limited substituent groups, and lower substituent groups; each substituent group, size-limited substituent group, and/or lower substituent group may optionally be different.
  • R 18 when R 18 is substituted, it is substituted with at least one substituent group.
  • R 18 when R 18 is substituted, it is substituted with at least one size-limited substituent group. In embodiments, when R 18 is substituted, it is substituted with at least one lower substituent group.
  • R 18 is hydrogen, -F, -Cl, -Br, -I, -CF 3 , -CHF 2 , -CH 2 F, -CC1 3 , - CHCk, -CH 2 C1, -CBr 3 , -CHBr 2 , -CH 2 Br, -CI 3 , -CHI 2 , -CH 2 I, -OCF 3 , -OCCl 3 , -OCBr 3 , - OCI 3 , -OCHF 2 , -OCHCk, -OCHBr 2 , -OCHI 2 , -OCH 2 F, -OCH 2 Cl, -OCH 2 Br, - OCH 2 I, -N 3 , -CN, -SH, -SCH 3 , -S0 2 H, -S0 2 CH 3 , -S0 2 NH 2 , -S0 2 NHCH 3 , -NHCH 3 , -NH
  • R 18 is hydrogen, -F, -Cl, -Br, -I, -CF 3 , -CHF 2 , -CH 2 F, -CC1 3 , -CHCk, -CH 2 C1, -CBr 3 , CHBr 2 , -CH 2 Br, -CI 3 , -CHk, -CH 2 I, -OCF 3 , -OCCl 3 , -OCBr 3 , - OCI 3 , -OCHF 2 , -OCHCk, -OCHBr 2 , -OCHk, -OCH 2 F, -OCH 2 Cl, -OCH 2 Br, - OCH 2 I, -N 3 , -CN, -SH, -SCH 3 , -S0 2 H, -S0 2 CH 3 , -S0 2 NH 2 , -S0 2 NHCH 3 , -NHC(0)NH 2 , -
  • R 18 is hydrogen, -F, -Cl, -Br, -I, -CF 3 , -CHF 2 , -CH 2 F, -CCI 3 , -CHCI2, -CH2CI, -CBr 3 , CHBr 2 , -CH 2 Br, -CI3, -CHI 2 , -CH 2 I, -OCF3, -OCCI3, -OCBr 3 , - OCI3, -OCHF2, -OCHCI2, -OCHBr 2 , -OCHI2, -OCH2F, -OCH2CI, -OCH 2 Br, - OCH2I, -N 3 , -CN, -SH, -SCH3, -SO2H, -SO2CH3, -SO2NH2, -SO2NHCH3, -NHC(0)NH 2 , -NHC(0)NHCH 3 , -NO2, -NH 2 , -NHCH3, -C
  • R 18E is independently oxo, halogen, -CF 3 , -CCl 3 ,-CBr 3 , -CI3, -CHF 2 , -CHCI2,- CHBr 2, - CHI2, -CH 2 F,-CH 2 C1, -CH 2 Br, -
  • R 18E is independently oxo, halogen, -CF3, -CCI3,- CBr 3 , -CI3, -CHF 2 , -CHCl 2 ,-CHBr 2, - CHI 2 , -CH2F,-CH 2 C1, -CH 2 Br, - CH 2 I, -CN, -OH, -NH 2 , -COOH, -CONH 2 , -NO 2 , -SH, -SCH 3 , -SO 3 H, -S0 4 H, -SO 2 NH 2 , -NHNH 2 , -ONH 2 , -NHC(0)NHNH 2 , -NHC(0)NH 2 , -NHSO 2 H, -NHC(0)H, - NHC(0)OH, -NHOH, -OCF3, -OCCI3, -OCBr 3 , -OCI3, -OCHF2, -OCHCI2, OCHBr 2 , - substitute
  • R 18E is independently oxo, halogen, -CF3, -CCl3,-CBr3, -CI3, CHF 2 , -CHCk,-CHBr 2 - CHI 2 , -CH 2 F,-CH 2 C1, -CH 2 Br, -
  • a substituted R 19 is substituted with at least one substituent group, size-limited substituent group, or lower substituent group; wherein if the substituted R 19 is substituted with a plurality of groups selected from substituent groups, size-limited substituent groups, and lower substituent groups; each substituent group, size-limited substituent group, and/or lower substituent group may optionally be different.
  • R 19 when R 19 is substituted, it is substituted with at least one substituent group.
  • R 19 when R 19 is substituted, it is substituted with at least one size-limited substituent group. In embodiments, when R 19 is substituted, it is substituted with at least one lower substituent group.
  • R 19 is hydrogen, -F, -Cl, -Br, -I, -CF 3 , -CHF 2 , -CH 2 F, -CCI3, - CHC1 2 , -CH 2 C1, -CBr 3 , -CHBr 2 , -CH 2 Br, -CI3, -CHI 2 , -CH 2 I, -OCF3, -OCCI3, -OCBr 3 , - OCI3, -OCHF 2 , -OCHCk, -OCHBr 2 , -OCHI 2 , -OCH 2 F, -OCH 2 Cl, -OCH 2 Br, - OCH 2 I, -N 3 , -CN, -SH, -SCH3, -S0 2 H, -S0 2 CH 3 , -S0 2 NH 2 , -S0 2 NHCH 3 , -NHC(0)NH 2 , -NHC(0)
  • R 19 is hydrogen, -F, -Cl, -Br, -I, -CF 3 , -CHF 2 , -CH 2 F, -CCI 3 , -CHCI2, -CH2CI, -CBr 3 , CHBr 2 , -CH 2 Br, -CI3, -CHI 2 , -CH 2 I, -OCF3, -OCCI3, -OCBr 3 , - OCI 3 , -OCHF 2 , -OCHCI 2 , -OCHBr 2 , -OCHI 2 , -OCH 2 F, -OCH 2 CI, -OCH 2 Br, - OCH2I, -N 3 , -CN, -SH, -SCH3, -SO2H, -SO2CH3, -SO2NH2, -SO2NHCH3, -NHC(0)NH 2 , -NHC(0)NHCH 3 , -NO2, -NH 2
  • R 19 is hydrogen, -F, -Cl, -Br, -I, -CF 3 , -CHF 2 , -CH 2 F, -CCI 3 , -CHCI2, -CH2CI, -CBr 3 , CHBr 2 , -CH 2 Br, -CI3, -CHI 2 , -CH 2 I, -OCF3, -OCCI3, -OCBr 3 , - OCI 3 , -OCHF 2 , -OCHCI 2 , -OCHBr 2 , -OCHI 2 , -OCH 2 F, -OCH 2 CI, -OCH 2 Br, - OCH2I, -N 3 , -CN, -SH, -SCH3, -SO2H, -SO2CH3, -SO2NH2, -SO2NHCH3, -NHC(0)NH 2 , -NHC(0)NHCH 3 , -NO2, -NH 2
  • R 19E is independently oxo, halogen, -CF 3 , -CCl 3 ,-CBr 3 , -CI 3 , -CHF 2 , CHCb, CHBr 2 , -CHI 2 , -CH 2 F,-CH 2 C1, -CH 2 Br, -
  • R 19E is independently oxo, halogen, -CF 3 , -CC1 3 ,- CBr 3 , -CI 3 , -CHF 2 , -CHCb,-CHBr 2 - CHI 2 , -CH 2 F, CH 2 C1, -CH 2 Br, - CH 2 I, -CN, -OH, -NH 2 , -COOH, -CONH 2 , -N0 2 , -SH, -SCH 3 , -S0 3 H, -SO4H, -SO 2 NH 2 , -NHNH 2 , -ONH 2 , -NHC(0)NHNH 2 , -NHC(0)NH 2 , -NHS0 2 H, -NHC(0)H, - I 3 , OCHF 2 , OCHCb, OCHBr 2 , - substituted alkyl (e.g., Ci-C 8 , Ci-C 6 , or C
  • R 19E is independently oxo, halogen, -CF 3 , -CCl 3 ,-CBr 3 , -CI 3 , CHF 2 , -CHCb,-CHBr 2 - CHI 2 , -CH 2 F,-CH 2 C1, -CH 2 Br, -
  • L 1 is a bond, -NH-, -0-, -S-, -C(O)-, -C(0)NH-, -NHC(O)-, -NHC(0)NH-, -C(0)0-, -OC(O)-, substituted (e.g., substituted with a substituent group, a size-limited substituent group, or lower substituent group) or unsubstituted alkylene (e.g., Ci-Cs, C 1 -C 6 , or C 1 -C 4 alkylene), substituted (e.g., substituted with a substituent group, a size-limited substituent group, or lower substituent group) or unsubstituted heteroalkylene (e.g., 2 to 8 membered, 2 to 6 membered, or 2 to 4 membered heteroalkylene), substituted (e.g., substituted with a substituent group, a size-limited substituent group, or lower substituent group) or unsubstit
  • a substituted L 1 is substituted with at least one substituent group, size-limited substituent group, or lower substituent group; wherein if the substituted L 1 is substituted with a plurality of groups selected from substituent groups, size-limited substituent groups, and lower substituent groups; each substituent group, size-limited substituent group, and/or lower substituent group may optionally be different.
  • when L 1 is substituted it is substituted with at least one substituent group.
  • when L 1 is substituted it is substituted with at least one size-limited substituent group.
  • when L 1 is substituted it is substituted with at least one lower substituent group.
  • L 1 is a bond, -NH-, -0-, -S-, -C(O)-, -C(0)NH-, -NHC(O)-, -NHC(0)NH-, -C(0)0-, -OC(O)-, R 20 - substituted or unsubstituted alkylene (e.g., Ci-Cs, C 1 -C 6 , or C 1 -C 4 alkylene), R 20 -substituted or unsubstituted heteroalkylene (e.g., 2 to 8 membered, 2 to 6 membered, or 2 to 4 membered heteroalkylene), R 20 -substituted or unsubstituted cycloalkylene (e.g., C 3 -C 8 , C 3 -C 6 , or C 5 -C 6 cycloalkylene), R 20 -substituted or unsubstituted heterocycloalkylene (e.g., Ci-C
  • R 20 -substituted or unsubstituted arylene e.g., C 6 -C 10 , C 10 aryl, or phenylene
  • R 20 -substituted or unsubstituted heteroarylene e.g., 5 to 10 membered, 5 to 9 membered, or 5 to 6 membered heteroarylene.
  • L 1 is a bond, -NH-, -0-, -S-, -C(O)-, -C(0)NH-, -NHC(O)-, -NHC(0)NH-, -C(0)0-, -OC(O)-, R 20 - substituted alkylene (e.g., Ci-Cs, C1-C6, or C1-C4 alkylene), R 20 -substituted heteroalkylene (e.g., 2 to 8 membered, 2 to 6 membered, or 2 to 4 membered heteroalkylene), R 20 -substituted cycloalkylene (e.g., C3-C8, C3-C6, or C5-C6 cycloalkylene), R 20 -substituted heterocycloalkylene (e.g., 3 to 8 membered, 3 to 6 membered, or 5 to 6 membered heterocycloalkylene), R 20 -substituted ary
  • L 1 is a bond, -NH-, -0-, -S-, -C(O)-, -C(0)NH-, -NHC(O)-, -NHC(0)NH-, -C(0)0-, -OC(O)-, unsubstituted alkylene (e.g., Ci-Cs, C1-C6, or C1-C4 alkylene), unsubstituted heteroalkylene (e.g., 2 to 8 membered, 2 to 6 membered, or 2 to 4 membered heteroalkylene), unsubstituted cycloalkylene (e.g., C 3 -C 8 , C 3 -C 6 , or C 5 -C 6 cycloalkylene), unsubstituted heterocycloalkylene (e.g., 3 to 8 membered, 3 to 6 membered, or 5 to 6 membered heterocycloalkylene), unsubstituted arylene (e.g.,
  • R 20 is oxo, halogen, -CF 3 , -CCl 3 ,-CBr 3 , -CI3, -CHF 2 , -CHCl 2 ,-CHBr 2 - CHI 2 , - CH 2 F,-CH 2 C1, -CH 2 Br, -CH 2 I, -CN, -OH, -NH 2 , -COOH, -CONH 2 , -N0 2 , -SH, -SCH 3 , - SO3H, -SO4H, -S0 2 NH 2 , -NHNH 2 , -ONH 2 , -NHC(0)NHNH 2 , -NHC(0)NH 2 , -NHSO 2 H, - NHC(0)H, -NHC(0)OH, -NHOH, -OCF3, -OCCI3, -OCBr 3 , -OCI3, -OCHF 2 , OCHCb, - OCHBr
  • R 20 is oxo, halogen, -CF3, -CCI3, -CBr3, -CI3, - CHF 2 , -CHCl 2 ,-CHBr 2, - CHI 2 , -CH 2 F,-CH 2 C1, -CH 2 Br, -
  • R 20 is oxo, halogen, -CF 3 , -CC1 3 , -CBr 3 , -CI 3 , -CHF 2 , - CHCk,-CHBr 2 - CHI 2 , -CH 2 F,-CH 2 C1, -CH 2 Br, -
  • L 2 is a bond, -NH-, -0-, -S-, -C(O)-, -C(0)NH-, -NHC(O)-, -NHC(0)NH-, -C(0)0-, -OC(O)-, substituted (e.g., substituted with a substituent group, a size-limited substituent group, or lower substituent group) or unsubstituted alkylene (e.g., Ci-C 8 , C1-C6, or C1-C4 alkylene), substituted (e.g., substituted with a substituent group, a size-limited substituent group, or lower substituent group) or unsubstituted heteroalkylene (e.g., 2 to 8 membered, 2 to 6 membered, or 2 to 4 membered heteroalkylene), substituted (e.g., substituted with a substituent group, a size-limited substituent group, or lower substituent group) or unsubstituted
  • a substituted L 2 is substituted with at least one substituent group, size-limited substituent group, or lower substituent group; wherein if the substituted L 2 is substituted with a plurality of groups selected from substituent groups, size-limited substituent groups, and lower substituent groups; each substituent group, size-limited substituent group, and/or lower substituent group may optionally be different.
  • when L 2 is substituted it is substituted with at least one substituent group.
  • when L 2 is substituted it is substituted with at least one size-limited substituent group.
  • when L 2 is substituted it is substituted with at least one lower substituent group.
  • L 2 is a bond, -NH-, -0-, -S-, -C(O)-, -C(0)NH-, -NHC(O)-, -NHC(0)NH-, -C(0)0-, -OC(O)-, R 22 - substituted or unsubstituted alkylene (e.g., Ci-Cs, C 1 -C 6 , or C 1 -C 4 alkylene), R 22 -substituted or unsubstituted heteroalkylene (e.g., 2 to 8 membered, 2 to 6 membered, or 2 to 4 membered heteroalkylene), R 22 -substituted or unsubstituted cycloalkylene (e.g., C 3 -C 8 , C 3 -C 6 , or C 5 -C 6 cycloalkylene), R 22 -substituted or unsubstituted heterocycloalkylene (e.g., Ci-C
  • R 22 -substituted or unsubstituted arylene e.g., C 6 -C 10 , Cio aryl, or phenylene
  • R 22 -substituted or unsubstituted heteroarylene e.g., 5 to 10 membered, 5 to 9 membered, or 5 to 6 membered heteroarylene.
  • L 2 is a bond, -NH-, -0-, -S-, -C(O)-, -C(0)NH-, -NHC(O)-, -NHC(0)NH-, -C(0)0-, -OC(O)-, R 22 - substituted alkylene (e.g., Ci-Cs, C1-C6, or C1-C4 alkylene), R 22 -substituted heteroalkylene (e.g., 2 to 8 membered, 2 to 6 membered, or 2 to 4 membered heteroalkylene), R 22 -substituted cycloalkylene (e.g., C3-C8, C3-C6, or C5-C6 cycloalkylene), R 22 -substituted heterocycloalkylene (e.g., 3 to 8 membered, 3 to 6 membered, or 5 to 6 membered heterocycloalkylene), R 22 -substituted ary
  • L 2 is a bond, -NH-, -0-, -S-, -C(O)-, -C(0)NH-, -NHC(O)-, -NHC(0)NH-, -C(0)0-, -OC(O)-, unsubstituted alkylene (e.g., Ci-Cs, C1-C6, or C1-C4 alkylene), unsubstituted heteroalkylene (e.g., 2 to 8 membered, 2 to 6 membered, or 2 to 4 membered heteroalkylene), unsubstituted cycloalkylene (e.g., C3-C8, C3-C6, or C5-C6 cycloalkylene), unsubstituted heterocycloalkylene (e.g., 3 to 8 membered, 3 to 6 membered, or 5 to 6 membered heterocycloalkylene), unsubstituted arylene (e.g., C6-C10
  • R 22 is independently oxo, halogen, -CF 3 , -CCl 3 ,-CBr 3 , -CI3, -CHF 2 , -CHCI2,- CHBr 2, - CHI2, -CH 2 F,-CH 2 C1, -CH 2 Br, -
  • R 22 is independently oxo, halogen, -CF3, -CCI3, - CBr 3 , -CI3, -CHF 2 , -CHCb,-CHBr 2 - CHI 2 , -CH2F,-CH 2 C1, -CH 2 Br, - CH 2 I, -CN, -OH, -NH 2 , -COOH, -CONH 2 , -N0 2 , -SH, -SCH 3 , -SO3H, -SO4H, -S0 2 NH 2 , -NHNH 2 , -ONH 2 , -NHC(0)NHNH 2 , -NHC(0)NH 2 , -NHS0 2 H, -NHC(0)H, - NHC(0)0H, -NHOH, -OCF3, -OCCI3, -OCBr 3 , -OCI3, OCHF 2 , OCHCb, OCHBr 2 , -
  • R 22 is independently oxo, halogen, -CF3, -CC ,-CBr3, -CI3, - CHF 2 , -CHCb,-CHBr 2 - CHI 2 , -CH 2 F,-CH 2 C1, -CH 2 Br, - CH2I, -CN, -OH, -NH 2 , -COOH, -CONH2, -NO2, -SH, -SCH 3 , -SO3H, -SO4H, -SO2NH2, -NHNH2, -ONH2, -NHC(0)NHNH 2 , -NHC(0)NH 2 , -NHSO2H, -NHC(0)H, - NHC(0)0H, -NHOH, -OCF3, -OCCI3, -OCBr 3 , -OCI3, -OCHF2, -OCHCI2, OCHBr 2 , - 0CHI 2 - 0CH 2 F, -OCH2
  • Each R 1A , R 1B , R 1C , R 1D , R 16A , R 16B , R 16C , R 16D , R 17A , R 17B , R 17C , R 17D , R 18A , R 18B , R 18C , R 18D , R 19A , R 19B , R 19C , and R 19D are independently hydrogen, -CX 3 , -CHX 2 , -CH 2 X (e.g., -CF 3 , CHF 2 , -CH 2 F, -CCI 3 , -CHCI 2 , -CH 2 CI, -CBr 3 , CHBr 2 , -CH 2 Br, -CI 3 , -CHI 2 , -CH 2 I), -CN, -OH, -COOH, -CONH 2 , substituted (e.g., substituted with a substituent group, a size-limited substituent group
  • each R 1A , R 1B , R 1C , p iv ID 5 pivl6A , p ivl6B 5 pivl6C , p ivl6D 5 pivl7A , p iv 17B 5 piv 17C , p ivl7D 5 pivl8A , p ivl8B 5 pivl8C , p ivl8D 5 pivl9A , p ivl9B 5 pivl9C and R 19D are independently hydrogen, -CF 3 , -CHF 2 , -CH 2 F, -CCI 3 , -CHCI 2 , -CH 2 CI, -CBr 3 , -CHBr 2 , -CH 2 Br, -CI 3 , -CHI 2 , -CH 2 I, -CF 3 , -CF 3 , -CHF 2 , -CH 2 F, -CC
  • each are independently hydrogen, -CF 3 , -CHF 2 , -CH 2 F, -CCI 3 , -CHC1 2 , - CH 2 C1, -CBr 3 , -CHBr 2 , -CH 2 Br, -CI3, -CHI 2 , -CH 2 I, -CN, -OH, -COOH, -CONH 2 , R 24 - substituted alkyl (e.g., Ci-C 2 o, Ci-Ci 2 , Ci-Cs, C1-C6, C1-C4, or Ci-C 2 ), R 24 -substituted heteroalkyl (e.g., 2 to 20 membered, 2 to 12 membered, 2 to 8 membered, 2 to 6 membered, 4 to 6 membered, 2 to 3 membered, or 4 to 5 membered), R 24 -substituted cycloalkyl (e.g., C3- C10, C
  • each R 1A R 1B R 1C R 1D R 16A R 16B R 16C R 16D R 17A R 17B R 17C R 17D R 18A R 18B R 18C R 18D R 19A , R 19B , R 19C , and R 19D are independently hydrogen, -CF3, -CHF 2 , -CH 2 F, -CCI3, - CHC1 2 , -CH 2 C1, -CBr 3 , -CHBr 2 , -CH 2 Br, -CI3, -CHI 2 , -CH 2 I, -CN, - OH, -COOH, -CONH 2 , unsubstituted alkyl (e.g., Ci-C 20 , Ci-Ci3 ⁇ 4 Ci-C 8 , Ci-C 6 , C1-C4, or Ci- C 2 ), unsubstituted heteroalkyl (e.g., 2 to 20 membered, 2 to 12 membered, 2 to
  • unsubstituted cycloalkyl e.g., C3-C10, C3-C8, C3-C6, C4-C6, or C5-C6
  • unsubstituted heterocycloalkyl e.g.,
  • R 17C , R 17D , R 18A , R 18B , R 18C , R 18D , R 19A , R 19B , R 19C , and R 19D are independently hydrogen.
  • R 1A and R 1B , R 16A and R 16B , R 17A and R 17B , R 18A and R 18B , and R 19A and R 19B together with nitrogen attached thereto may be joined to form R 24 -substituted or unsubstituted heterocycloalkyl (e.g., 3 to 10 membered, 3 to 8 membered, 3 to 6 membered, 4 to 6 membered, 4 to 5 membered, or 5 to 6 membered), or R 24 -substituted or unsubstituted heteroaryl (e.g., 5 to 12 membered, 5 to 10 membered, 5 to 9 membered, or 5 to 6 membered).
  • R 24 -substituted or unsubstituted heterocycloalkyl e.g., 3 to 10 membered, 3 to 8 membered, 3 to 6 membered, 4 to 6 membered, 4 to 5 membered, or 5 to 6 membered
  • R 1A and R 1B , R 16A and R 16B , R 17A and R 17B , R 18A and R 18B , and R 19A and R 19B together with nitrogen attached thereto may be joined to form R 24 -substituted heterocycloalkyl (e.g., 3 to 10 membered, 3 to 8 membered, 3 to 6 membered, 4 to 6 membered, 4 to 5 membered, or 5 to 6 membered), or R 24 -substituted heteroaryl (e.g., 5 to 12 membered, 5 to 10 membered, 5 to 9 membered, or 5 to 6 membered).
  • R 24 -substituted heterocycloalkyl e.g., 3 to 10 membered, 3 to 8 membered, 3 to 6 membered, 4 to 6 membered, 4 to 5 membered, or 5 to 6 membered
  • R 24 -substituted heteroaryl e.g., 5 to
  • Each R 1A and R 1B , R 16A and R 16B , R 17A and R 17B , R 18A and R 18B , and R 19A and R 19B together with nitrogen attached thereto may be joined to form unsubstituted heterocycloalkyl (e.g., 3 to 10 membered, 3 to 8 membered, 3 to 6 membered, 4 to 6 membered, 4 to 5 membered, or 5 to 6 membered), or unsubstituted heteroaryl (e.g., 5 to 12 membered, 5 to 10 membered, 5 to 9 membered, or 5 to 6 membered).
  • unsubstituted heterocycloalkyl e.g., 3 to 10 membered, 3 to 8 membered, 3 to 6 membered, 4 to 6 membered, 4 to 5 membered, or 5 to 6 membered
  • unsubstituted heteroaryl e.g., 5 to 12 membered, 5 to 10 membered
  • each R 1A and R 1B , R 16A and R 16B , R 17A and R 17B , R 18A and R 18B , and R 19A and R 19B together with nitrogen attached thereto may be joined to form R 24 -substituted or unsubstituted pyridyl.
  • each R 1A and R 1B , R 16A and R 16B , R 17A and R 17B , R 18A and R 18B , and R 19A and R 19B together with nitrogen attached thereto may be joined to form R 24 -substituted or unsubstituted piperidinyl.
  • each R 1A and R 1B , R 16A and R 16B , R 17A and R 17B , R 18A and R 18B , and R 19A and R 19B together with nitrogen attached thereto may be joined to form R 24 -substituted or unsubstituted morpholinyl.
  • each R 1A and R 1B , R 16A and R 16B , R 17A and R 17B , R 18A and R 18B , and R 19A and R 19B joined to form R 24 -substituted or unsubstituted pyrrolyl.
  • each R 1A and R 1B , R 16A and R 16B , R 17A and R 17B , R 18A and R 18B , and R 19A and R 19B together with nitrogen attached thereto may be joined to form R 24 -substituted or unsubstituted pyrimidinyl.
  • a substituted R 1A (e.g., substituted alkyl, substituted heteroalkyl, substituted cycloalkyl, substituted heterocycloalkyl, substituted aryl, and/or substituted heteroaryl) is substituted with at least one substituent group, size-limited substituent group, or lower substituent group; wherein if the substituted R 1A is substituted with a plurality of groups selected from substituent groups, size-limited substituent groups, and lower substituent groups; each substituent group, size-limited substituent group, and/or lower substituent group may optionally be different.
  • R 1A when R 1A is substituted, it is substituted with at least one substituent group.
  • R 1A when R 1A is substituted, it is substituted with at least one size-limited substituent group.
  • R 1A when R 1A is substituted, it is substituted with at least one lower substituent group.
  • a substituted R 1B (e.g., substituted alkyl, substituted heteroalkyl, substituted cycloalkyl, substituted heterocycloalkyl, substituted aryl, and/or substituted heteroaryl) is substituted with at least one substituent group, size-limited substituent group, or lower substituent group; wherein if the substituted R 1B is substituted with a plurality of groups selected from substituent groups, size-limited substituent groups, and lower substituent groups; each substituent group, size-limited substituent group, and/or lower substituent group may optionally be different.
  • R 1B when R 1B is substituted, it is substituted with at least one substituent group.
  • R 1B when R 1B is substituted, it is substituted with at least one size-limited substituent group.
  • R 1B when R 1B is substituted, it is substituted with at least one lower substituent group.
  • a substituted ring formed when R 1A and R 1B substituents bonded to the same nitrogen atom are joined e.g., substituted heterocycloalkyl and/or substituted heteroaryl
  • at least one substituent group, size-limited substituent group, or lower substituent group e.g., substituted heterocycloalkyl and/or substituted heteroaryl
  • the substituted ring formed when R 1A and R 1B substituents bonded to the same nitrogen atom are joined is substituted with a plurality of groups selected from substituent groups, size-limited substituent groups, and lower substituent groups; each substituent group, size-limited substituent group, and/or lower substituent group may optionally be different.
  • a substituted R 1C (e.g., substituted alkyl, substituted heteroalkyl, substituted cycloalkyl, substituted heterocycloalkyl, substituted aryl, and/or substituted heteroaryl) is substituted with at least one substituent group, size-limited substituent group, or lower substituent group; wherein if the substituted R 1C is substituted with a plurality of groups selected from substituent groups, size-limited substituent groups, and lower substituent groups; each substituent group, size-limited substituent group, and/or lower substituent group may optionally be different.
  • R 1C when R 1C is substituted, it is substituted with at least one substituent group.
  • R 1C when R 1C is substituted, it is substituted with at least one size-limited substituent group.
  • R 1C when R 1C is substituted, it is substituted with at least one lower substituent group.
  • a substituted R 1D (e.g., substituted alkyl, substituted heteroalkyl, substituted cycloalkyl, substituted heterocycloalkyl, substituted aryl, and/or substituted heteroaryl) is substituted with at least one substituent group, size-limited substituent group, or lower substituent group; wherein if the substituted R 1D is substituted with a plurality of groups selected from substituent groups, size-limited substituent groups, and lower substituent groups; each substituent group, size-limited substituent group, and/or lower substituent group may optionally be different.
  • R 1D when R 1D is substituted, it is substituted with at least one substituent group.
  • R 1D when R 1D is substituted, it is substituted with at least one size-limited substituent group.
  • R 1D when R 1D is substituted, it is substituted with at least one lower substituent group.
  • a substituted R 16A (e.g., substituted alkyl, substituted heteroalkyl, substituted cycloalkyl, substituted heterocycloalkyl, substituted aryl, and/or substituted heteroaryl) is substituted with at least one substituent group, size-limited substituent group, or lower substituent group; wherein if the substituted R 16A is substituted with a plurality of groups selected from substituent groups, size-limited substituent groups, and lower substituent groups; each substituent group, size-limited substituent group, and/or lower substituent group may optionally be different.
  • R 16A when R 16A is substituted, it is substituted with at least one substituent group.
  • R 16A when R 16A is substituted, it is substituted with at least one size-limited substituent group.
  • R 16A when R 16A is substituted, it is substituted with at least one lower substituent group.
  • a substituted R 16B (e.g., substituted alkyl, substituted heteroalkyl, substituted cycloalkyl, substituted heterocycloalkyl, substituted aryl, and/or substituted heteroaryl) is substituted with at least one substituent group, size-limited substituent group, or lower substituent group; wherein if the substituted R 16B is substituted with a plurality of groups selected from substituent groups, size-limited substituent groups, and lower substituent groups; each substituent group, size-limited substituent group, and/or lower substituent group may optionally be different.
  • R 16B when R 16B is substituted, it is substituted with at least one substituent group.
  • R 16B when R 16B is substituted, it is substituted with at least one size-limited substituent group.
  • R 16B when R 16B is substituted, it is substituted with at least one lower substituent group.
  • a substituted ring formed when R 16A and R 16B substituents bonded to the same nitrogen atom are joined e.g., substituted heterocycloalkyl and/or substituted heteroaryl
  • at least one substituent group, size-limited substituent group, or lower substituent group e.g., substituted heterocycloalkyl and/or substituted heteroaryl
  • the substituted ring formed when R 16A and R 16B substituents bonded to the same nitrogen atom are joined is substituted with a plurality of groups selected from substituent groups, size-limited substituent groups, and lower substituent groups; each substituent group, size-limited substituent group, and/or lower substituent group may optionally be different.
  • a substituted R 16C (e.g., substituted alkyl, substituted heteroalkyl, substituted cycloalkyl, substituted heterocycloalkyl, substituted aryl, and/or substituted heteroaryl) is substituted with at least one substituent group, size-limited substituent group, or lower substituent group; wherein if the substituted R 16C is substituted with a plurality of groups selected from substituent groups, size-limited substituent groups, and lower substituent groups; each substituent group, size-limited substituent group, and/or lower substituent group may optionally be different.
  • R 16C when R 16C is substituted, it is substituted with at least one substituent group.
  • R 16C when R 16C is substituted, it is substituted with at least one size-limited substituent group.
  • R 16C when R 16C is substituted, it is substituted with at least one lower substituent group.
  • a substituted R 16D (e.g., substituted alkyl, substituted heteroalkyl, substituted cycloalkyl, substituted heterocycloalkyl, substituted aryl, and/or substituted heteroaryl) is substituted with at least one substituent group, size-limited substituent group, or lower substituent group; wherein if the substituted R 16D is substituted with a plurality of groups selected from substituent groups, size-limited substituent groups, and lower substituent groups; each substituent group, size-limited substituent group, and/or lower substituent group may optionally be different.
  • R 16D when R 16D is substituted, it is substituted with at least one substituent group.
  • R 16D when R 16D is substituted, it is substituted with at least one size-limited substituent group.
  • R 16D when R 16D is substituted, it is substituted with at least one lower substituent group.
  • a substituted R 17A (e.g., substituted alkyl, substituted heteroalkyl, substituted cycloalkyl, substituted heterocycloalkyl, substituted aryl, and/or substituted heteroaryl) is substituted with at least one substituent group, size-limited substituent group, or lower substituent group; wherein if the substituted R 17A is substituted with a plurality of groups selected from substituent groups, size-limited substituent groups, and lower substituent groups; each substituent group, size-limited substituent group, and/or lower substituent group may optionally be different.
  • R 17A when R 17A is substituted, it is substituted with at least one substituent group.
  • R 17A when R 17A is substituted, it is substituted with at least one size-limited substituent group.
  • R 17A when R 17A is substituted, it is substituted with at least one lower substituent group.
  • a substituted R 17B (e.g., substituted alkyl, substituted heteroalkyl, substituted cycloalkyl, substituted heterocycloalkyl, substituted aryl, and/or substituted heteroaryl) is substituted with at least one substituent group, size-limited substituent group, or lower substituent group; wherein if the substituted R 17B is substituted with a plurality of groups selected from substituent groups, size-limited substituent groups, and lower substituent groups; each substituent group, size-limited substituent group, and/or lower substituent group may optionally be different.
  • R 17B when R 17B is substituted, it is substituted with at least one substituent group.
  • R 17B when R 17B is substituted, it is substituted with at least one size-limited substituent group.
  • R 17B when R 17B is substituted, it is substituted with at least one lower substituent group.
  • a substituted ring formed when R 17A and R 17B substituents bonded to the same nitrogen atom are joined e.g., substituted heterocycloalkyl and/or substituted heteroaryl
  • at least one substituent group, size-limited substituent group, or lower substituent group e.g., substituted heterocycloalkyl and/or substituted heteroaryl
  • the substituted ring formed when R 17A and R 17B substituents bonded to the same nitrogen atom are joined is substituted with a plurality of groups selected from substituent groups, size-limited substituent groups, and lower substituent groups; each substituent group, size-limited substituent group, and/or lower substituent group may optionally be different.
  • a substituted R 17C (e.g., substituted alkyl, substituted heteroalkyl, substituted cycloalkyl, substituted heterocycloalkyl, substituted aryl, and/or substituted heteroaryl) is substituted with at least one substituent group, size-limited substituent group, or lower substituent group; wherein if the substituted R 17C is substituted with a plurality of groups selected from substituent groups, size-limited substituent groups, and lower substituent groups; each substituent group, size-limited substituent group, and/or lower substituent group may optionally be different.
  • R 17C when R 17C is substituted, it is substituted with at least one substituent group.
  • R 17C when R 17C is substituted, it is substituted with at least one size-limited substituent group.
  • R 17C when R 17C is substituted, it is substituted with at least one lower substituent group.
  • a substituted R 17D (e.g., substituted alkyl, substituted heteroalkyl, substituted cycloalkyl, substituted heterocycloalkyl, substituted aryl, and/or substituted heteroaryl) is substituted with at least one substituent group, size-limited substituent group, or lower substituent group; wherein if the substituted R 17D is substituted with a plurality of groups selected from substituent groups, size-limited substituent groups, and lower substituent groups; each substituent group, size-limited substituent group, and/or lower substituent group may optionally be different.
  • R 17D when R 17D is substituted, it is substituted with at least one substituent group.
  • R 17D when R 17D is substituted, it is substituted with at least one size-limited substituent group.
  • R 17D when R 17D is substituted, it is substituted with at least one lower substituent group.
  • a substituted R 18A (e.g., substituted alkyl, substituted heteroalkyl, substituted cycloalkyl, substituted heterocycloalkyl, substituted aryl, and/or substituted heteroaryl) is substituted with at least one substituent group, size-limited substituent group, or lower substituent group; wherein if the substituted R 18A is substituted with a plurality of groups selected from substituent groups, size-limited substituent groups, and lower substituent groups; each substituent group, size-limited substituent group, and/or lower substituent group may optionally be different.
  • R 18A when R 18A is substituted, it is substituted with at least one substituent group.
  • R 18A when R 18A is substituted, it is substituted with at least one size-limited substituent group.
  • R 18A when R 18A is substituted, it is substituted with at least one lower substituent group.
  • a substituted R 18B (e.g., substituted alkyl, substituted heteroalkyl, substituted cycloalkyl, substituted heterocycloalkyl, substituted aryl, and/or substituted heteroaryl) is substituted with at least one substituent group, size-limited substituent group, or lower substituent group; wherein if the substituted R 18B is substituted with a plurality of groups selected from substituent groups, size-limited substituent groups, and lower substituent groups; each substituent group, size-limited substituent group, and/or lower substituent group may optionally be different.
  • R 18B when R 18B is substituted, it is substituted with at least one substituent group.
  • R 18B when R 18B is substituted, it is substituted with at least one size-limited substituent group.
  • R 18B when R 18B is substituted, it is substituted with at least one lower substituent group.
  • a substituted ring formed when R 18A and R 18B substituents bonded to the same nitrogen atom are joined e.g., substituted heterocycloalkyl and/or substituted heteroaryl
  • at least one substituent group, size-limited substituent group, or lower substituent group e.g., substituted heterocycloalkyl and/or substituted heteroaryl
  • the substituted ring formed when R 18A and R 18B substituents bonded to the same nitrogen atom are joined is substituted with a plurality of groups selected from substituent groups, size-limited substituent groups, and lower substituent groups; each substituent group, size-limited substituent group, and/or lower substituent group may optionally be different.
  • a substituted R 18C (e.g., substituted alkyl, substituted heteroalkyl, substituted cycloalkyl, substituted heterocycloalkyl, substituted aryl, and/or substituted heteroaryl) is substituted with at least one substituent group, size-limited substituent group, or lower substituent group; wherein if the substituted R 18C is substituted with a plurality of groups selected from substituent groups, size-limited substituent groups, and lower substituent groups; each substituent group, size-limited substituent group, and/or lower substituent group may optionally be different.
  • R 18C when R 18C is substituted, it is substituted with at least one substituent group.
  • R 18C when R 18C is substituted, it is substituted with at least one size-limited substituent group.
  • R 18C when R 18C is substituted, it is substituted with at least one lower substituent group.
  • a substituted R 18D (e.g., substituted alkyl, substituted heteroalkyl, substituted cycloalkyl, substituted heterocycloalkyl, substituted aryl, and/or substituted heteroaryl) is substituted with at least one substituent group, size-limited substituent group, or lower substituent group; wherein if the substituted R 18D is substituted with a plurality of groups selected from substituent groups, size-limited substituent groups, and lower substituent groups; each substituent group, size-limited substituent group, and/or lower substituent group may optionally be different.
  • R 18D when R 18D is substituted, it is substituted with at least one substituent group.
  • R 18D when R 18D is substituted, it is substituted with at least one size-limited substituent group.
  • R 18D when R 18D is substituted, it is substituted with at least one lower substituent group.
  • a substituted R 19A (e.g., substituted alkyl, substituted heteroalkyl, substituted cycloalkyl, substituted heterocycloalkyl, substituted aryl, and/or substituted heteroaryl) is substituted with at least one substituent group, size-limited substituent group, or lower substituent group; wherein if the substituted R 19A is substituted with a plurality of groups selected from substituent groups, size-limited substituent groups, and lower substituent groups; each substituent group, size-limited substituent group, and/or lower substituent group may optionally be different.
  • R 19A when R 19A is substituted, it is substituted with at least one substituent group.
  • R 19A when R 19A is substituted, it is substituted with at least one size-limited substituent group.
  • R 19A when R 19A is substituted, it is substituted with at least one lower substituent group.
  • a substituted R 19B (e.g., substituted alkyl, substituted heteroalkyl, substituted cycloalkyl, substituted heterocycloalkyl, substituted aryl, and/or substituted heteroaryl) is substituted with at least one substituent group, size-limited substituent group, or lower substituent group; wherein if the substituted R 19B is substituted with a plurality of groups selected from substituent groups, size-limited substituent groups, and lower substituent groups; each substituent group, size-limited substituent group, and/or lower substituent group may optionally be different.
  • R 19B when R 19B is substituted, it is substituted with at least one substituent group.
  • R 19B when R 19B is substituted, it is substituted with at least one size-limited substituent group.
  • R 19B when R 19B is substituted, it is substituted with at least one lower substituent group.
  • a substituted ring formed when R 19A and R 19B substituents bonded to the same nitrogen atom are joined e.g., substituted heterocycloalkyl and/or substituted heteroaryl
  • at least one substituent group, size-limited substituent group, or lower substituent group e.g., substituted heterocycloalkyl and/or substituted heteroaryl
  • the substituted ring formed when R 19A and R 19B substituents bonded to the same nitrogen atom are joined is substituted with a plurality of groups selected from substituent groups, size-limited substituent groups, and lower substituent groups; each substituent group, size-limited substituent group, and/or lower substituent group may optionally be different.
  • a substituted R 19C (e.g., substituted alkyl, substituted heteroalkyl, substituted cycloalkyl, substituted heterocycloalkyl, substituted aryl, and/or substituted heteroaryl) is substituted with at least one substituent group, size-limited substituent group, or lower substituent group; wherein if the substituted R 19C is substituted with a plurality of groups selected from substituent groups, size-limited substituent groups, and lower substituent groups; each substituent group, size-limited substituent group, and/or lower substituent group may optionally be different.
  • R 19C when R 19C is substituted, it is substituted with at least one substituent group.
  • R 19C when R 19C is substituted, it is substituted with at least one size-limited substituent group.
  • R 19C when R 19C is substituted, it is substituted with at least one lower substituent group.
  • a substituted R 19D (e.g., substituted alkyl, substituted heteroalkyl, substituted cycloalkyl, substituted heterocycloalkyl, substituted aryl, and/or substituted heteroaryl) is substituted with at least one substituent group, size-limited substituent group, or lower substituent group; wherein if the substituted R 19D is substituted with a plurality of groups selected from substituent groups, size-limited substituent groups, and lower substituent groups; each substituent group, size-limited substituent group, and/or lower substituent group may optionally be different.
  • R 19D when R 19D is substituted, it is substituted with at least one substituent group.
  • R 19D when R 19D is substituted, it is substituted with at least one size-limited substituent group.
  • R 19D when R 19D is substituted, it is substituted with at least one lower substituent group.
  • R 1F , R 16F , R 17F , R 18F , R 19F , R 21 , R 23 , and R 24 are independently oxo, halogen, -CF3, - CCl 3 ,-CBr 3 , -CI 3 , -CHF 2 , -CHCl 2 ,-CHBr 2 - CHI 2 , -CH 2 F,-CH 2 C1, -CH 2 Br, - CH 2 I, -CN, -OH, -NH 2 , -COOH, -CONH 2 , -N0 2 , -SH, -SCH 3 , -S0 3 H, -SO4H, -SO 2 NH 2 , -NHNH 2 , -ONH 2 , -NHC(0)NHNH 2 , -NHC(0)NH 2 , -NHS0 2 H, -NHC(0)H, - NHC(0)0H, -NHOH, -OC
  • X, X 1 , X 16 , X 17 , X 18 , are X 19 are independently -F, -Cl, -Br, or -I. In embodiments,
  • X is -F. In embodiments, X is -Cl. In embodiments, X is -Br. In embodiments, X is -I. In embodiments, X 1 is -F. In embodiments, X 1 is -Cl. In embodiments, X 1 is -Br. In embodiments, X 1 is -I. In embodiments, X 16 is -F. In embodiments, X 16 is -Cl. In embodiments, X 16 is -Br. In embodiments, X 16 is -I. In embodiments, X 17 is -F. In embodiments, X 17 is -Cl. In embodiments, X 17 is -Br. In embodiments, X 17 is -I.
  • X 18 is -F. In embodiments, X 18 is -Cl. In embodiments, X 18 is -Br. In embodiments, X 18 is -I. In embodiments, X 19 is -F. In embodiments, X 19 is -Cl. In embodiments, X 19 is -Br. In embodiments, X 19 is -I.
  • nl, nl6, nl7, nl8, and nl9 are independently an integer from 0 to 4 (e.g. 0).
  • nl is 0.
  • nl is 1.
  • nl is 2.
  • nl is 3.
  • nl is 4.
  • nl6 is 0.
  • nl 6 is 1.
  • nl6 is 2.
  • nl 6 is 3.
  • nl6 is 4.
  • nl7 is 0.
  • nl 7 is 1.
  • nl7 is 2.
  • nl 7 is 3.
  • nl7 is 4.
  • nl8 is 0. In embodiments, nl 8 is 1. In embodiments, nl8 is 2. In embodiments, nl 8 is 3. In embodiments, nl8 is 4. In embodiments, nl9 is 0. In embodiments, nl 9 is 1. In embodiments, nl9 is 2. In embodiments, nl 9 is 3. In embodiments, nl9 is 4.
  • ml, ml 6, ml 7, ml 8, and ml 9 are independently an integer from 1 to 2.
  • ml is 1.
  • ml is 2.
  • m2 is 1.
  • ml 6 is 1.
  • ml 6 is 2.
  • ml 7 is 1.
  • ml 7 is 2.
  • ml 8 is 1. In embodiments, ml 8 is 2. In embodiments, ml 9 is 1. In embodiments, ml 9 is 2.
  • vl, vl6, vl7, vl8, and vl9 are independently an integer from 1 to 2.
  • vl is 1.
  • vl is 2.
  • vl 6 is 1.
  • vl 6 is 2.
  • vl 7 is 1.
  • vl7 is 2.
  • vl 8 is 1.
  • vl8 is 2.
  • vl 9 is 1.
  • vl9 is 2.
  • the compound is useful as a comparator compound.
  • the comparator compound can be used to assess the activity of a test compound as set forth in an assay described herein (e.g., in the examples section, figures, or tables).
  • the compound is a compound as described herein, including in embodiments.
  • the compound is a compound described herein (e.g., in the examples section, figures, tables, or claims).
  • a compound as described herein may form a covalent bond with an amino acid moiety of a Gas protein (e.g., human Gas).
  • a Gas protein covalently bonded to a compound as described herein.
  • the Gas is in the GTP state.
  • the Gas is in the GDP state.
  • the compound is bonded to a cysteine residue of the protein.
  • the Gas protein as being covalently bonded to the compound has the structure:
  • W together with the -CH2S- to which it is attached form said Gas protein covalently bonded to a compound; and L 3 is substituted or unsubstituted alkylene or substituted or unsubstituted heteroalkylene.
  • L 1 , L 2 , R 1 , and zl are as described above.
  • R 19 are as described above.
  • L 3 is In embodiments, L 3 is . In embodiments, L 3 is In embodiments, L 3 is embo embodiments embodiments, embodiments, L 3 is . In embodiments, L 3 is , , embodiments, L 3 is , embodiments,
  • L 3 is a substituted (e.g., substituted with a substituent group, a size-limited substituent group, or lower substituent group) or unsubstituted alkylene (e.g., Ci- C 8 , Ci-C 6 , or C1-C4 alkylene), substituted (e.g., substituted with a substituent group, a size-limited substituent group, or lower substituent group) or unsubstituted heteroalkylene (e.g., 2 to 8 membered, 2 to 6 membered, or 2 to 4 membered heteroalkylene).
  • alkylene e.g., Ci- C 8 , Ci-C 6 , or C1-C4 alkylene
  • substituted e.g., substituted with a substituent group, a size- limited substituent group, or lower substituent group
  • unsubstituted heteroalkylene e.g., 2 to 8 membered, 2 to 6 membered, or 2 to 4 membered
  • L 3 is a substituted (e.g., substituted with a substituent group, a size-limited substituent group, or lower substituent group) or unsubstituted alkylene (e.g., Ci-Cs, C1-C6, or C1-C4 alkylene).
  • L 3 is a substituted (e.g., substituted with a substituent group, a size-limited substituent group, or lower substituent group) or unsubstituted heteroalkylene (e.g., 2 to 8 membered, 2 to 6 membered, or 2 to 4 membered heteroalkylene).
  • a substituted L 3 is substituted with at least one substituent group, size-limited substituent group, or lower substituent group; wherein if the substituted L 3 is substituted with a plurality of groups selected from substituent groups, size-limited substituent groups, and lower substituent groups; each substituent group, size-limited substituent group, and/or lower substituent group may optionally be different.
  • when L 3 is substituted it is substituted with at least one substituent group.
  • when L 3 is substituted it is substituted with at least one size-limited substituent group.
  • when L 3 is substituted it is substituted with at least one lower substituent group.
  • L 3 is a substituted (e.g., substituted with a substituent group, a size-limited substituent group, or lower substituent group) or unsubstituted Ci-Cs alkylene.
  • L 3 is a substituted (e.g., substituted with a substituent group, a size-limited substituent group, or lower substituent group) Ci-Cs alkylene. In embodiments, L 3 is an unsubstituted Ci-Cs alkylene. In embodiments, L 3 is a substituted (e.g., substituted with a substituent group, a size-limited substituent group, or lower substituent group) or unsubstituted C1-C6 alkylene. In embodiments, L 3 is a substituted (e.g., substituted with a substituent group, a size-limited substituent group, or lower substituent group) C1-C6 alkylene.
  • L 3 is an unsubstituted C1-C6 alkylene. In embodiments, L 3 is a substituted (e.g., substituted with a substituent group, a size-limited substituent group, or lower substituent group) or unsubstituted C1-C4 alkylene. In embodiments, L 3 is a substituted (e.g., substituted with a substituent group, a size-limited substituent group, or lower substituent group) C1-C4 alkylene. In embodiments, L 3 is an unsubstituted C1-C4 alkylene.
  • L 3 is a substituted (e.g., substituted with a substituent group, a size-limited substituent group, or lower substituent group) or unsubstituted 2 to 8 membered heteroalkylene.
  • L 3 is a substituted (e.g., substituted with a substituent group, a size-limited substituent group, or lower substituent group) 2 to 8 membered heteroalkylene.
  • L 3 is an unsubstituted 2 to 8 membered heteroalkylene.
  • L 3 is a substituted (e.g., substituted with a substituent group, a size-limited substituent group, or lower substituent group) or unsubstituted 2 to 6 membered heteroalkylene. In embodiments, L 3 is a substituted (e.g., substituted with a substituent group, a size-limited substituent group, or lower substituent group) 2 to 6 membered heteroalkylene. In embodiments, L 3 is an unsubstituted 2 to 6 membered heteroalkylene.
  • L 3 is a substituted (e.g., substituted with a substituent group, a size-limited substituent group, or lower substituent group) or unsubstituted 2 to 4 membered heteroalkylene. In embodiments, L 3 is a substituted (e.g., substituted with a substituent group, a size-limited substituent group, or lower substituent group) 2 to 4 membered heteroalkylene. In embodiments, L 3 is an unsubstituted 2 to 4 membered heteroalkylene.
  • L 3 is a R 25 -substituted or unsubstituted Ci-Cs alkylene. In embodiments, L 3 is a R 25 -substituted Ci-Cs alkylene. In embodiments, L 3 is an unsubstituted Ci-Cs alkylene. In embodiments, L 3 is a R 25 -substituted or unsubstituted C1-C6 alkylene. In embodiments, L 3 is a R 25 -substituted C1-C6 alkylene. In embodiments, L 3 is an unsubstituted Ci-Ce alkylene.
  • L 3 is a R 25 -substituted or unsubstituted C1-C4 alkylene. In embodiments, L 3 is a R 25 -substituted C1-C4 alkylene. In embodiments, L 3 is an unsubstituted C1-C4 alkylene.
  • L 3 is a R 25 -substituted or unsubstituted 2 to 8 membered heteroalkylene. In embodiments, L 3 is a R 25 -substituted 2 to 8 membered heteroalkylene. In embodiments, L 3 is an unsubstituted 2 to 8 membered heteroalkylene. In embodiments, L 3 is a R 25 -substituted or unsubstituted 2 to 6 membered heteroalkylene. In embodiments, L 3 is a R 25 -substituted 2 to 6 membered heteroalkylene. In embodiments, L 3 is an unsubstituted 2 to 6 membered heteroalkylene.
  • L 3 is a R 25 -substituted or unsubstituted 2 to 4 membered heteroalkylene. In embodiments, L 3 is a R 25 -substituted 2 to 4 membered heteroalkylene. In embodiments, L 3 is an unsubstituted 2 to 4 membered heteroalkylene.
  • R 25 is independently oxo, halogen, -CF 3 , -CCl 3 ,-CBr 3 , -CI 3 , -CHF 2 , -CHCI2,- CHBr 2 , -CHI2, -CH 2 F,-CH 2 C1, -CH 2 Br, -
  • R 25 is independently oxo, halogen, -CF3, -CCI3, - CBr 3 , -CI3, -CHF 2 , -CHCl 2 ,-CHBr 2, - CHI 2 , -CH 2 F, CH 2 C1, -CH 2 Br, - CH 2 I, -CN, -OH, -NH 2 , -COOH, -CONH 2 , -N0 2 , -SH, -SCH3, -SO3H, -SO4H, -SO 2 NH 2 , -NHNH 2 , -ONH 2 , -NHC(0)NHNH 2 , -NHC(0)NH 2 , -NHS0 2 H, -NHC(0)H, - NHC(0)0H, -NHOH, -OCF3, -OCCI3, -OCBr 3 , -OCI3, OCHF 2 , OCHCb, OCHBr 2 , - 0
  • R 25 is independently oxo, halogen, -CF3, -CCl3,-CBr3, -CI3, - CHF 2 , -CHCb,-CHBr 2 - CHI 2 , -CH 2 F,-CH 2 C1, -CH 2 Br, -
  • R 26 is independently oxo, halogen, -CF 3 , -CCl 3 ,-CBr 3 , -CI3, -CHF 2 , -CHCb,- CHBr 2, - CHb, -CH 2 F,-CH 2 C1, -CH 2 Br, -
  • the Gas protein has the amino acid sequence of SEQ ID NO: 1 including the sequence below with one or more mutations (e.g., R201C and C237S).
  • the amino acids, R201 and C237, in the SEQ ID NO: 1 may be where the mutations (e.g., R201C and C237S) can occur.
  • the Gas protein includes R201C mutation in SEQ ID NO: 1. In embodiments, the Gas protein includes Cys201. In embodiments, the Gas protein does not include Cys237.
  • the compound is bonded to Cys201 of the mutant human Gas (e.g., R201C mutation in SEQ ID NO: 1) or a selected residue in a selected protein corresponding to Cys201.
  • the compound is bonded to cysteine 201 of the mutant human Gas (e.g., R201C mutation in SEQ ID NO: 1).
  • the compound is bonded to an amin acid residue corresponding to Cys201 in the selected Gas.
  • the compound is bonded to Cys237 of the mutant human Gas (e.g., C237 in SEQ ID NO: 1) or a selected residue in a selected protein corresponding to Cys237.
  • the compound is bonded to cysteine 237 of the human Gas (e.g., C237 in SEQ ID NO: 1).
  • the compound is bonded to an amin acid residue corresponding to cystein237 in the selected Gas.
  • the Gas protein has the amino acid sequence of SEQ ID NO:2 including the sequence below with one or more mutations (e.g., R187C and C223S).
  • the amino acids, R187 and C223, in the SEQ ID NO: 1 may be where the mutations (e.g., R187C and C223S) can occur.
  • the Gas protein includes R187C mutation in SEQ ID NO: 2. In embodiments, the Gas protein includes Cysl87. In embodiments, the Gas protein does not include Cys223.
  • the compound is bonded to Cysl 87 of the mutant human Gas (e.g., R187C mutation in SEQ ID NO: 2) or a selected residue in a selected protein corresponding to Cysl 87.
  • the compound is bonded to Cysl 87 of the mutant human Gas (e.g., R187C mutation in SEQ ID NO: 2).
  • the compound is bonded to an amin acid residue corresponding to Cysl87 in the selected Gas.
  • the compound is bonded to Cys223 of the human Gas (e.g., C223 in SEQ ID NO: 2) or a selected residue in a selected protein corresponding to Cys223.
  • the compound is bonded to Cys223 of the human Gas (e.g., C223 in SEQ ID NO: 2).
  • the compound is bonded to an amin acid residue corresponding to Cys223 in the selected Gas.
  • the Gas protein is covalently bonded to a Gas small molecule inhibitor **not defined** at R201C.
  • the Gas protein is a GTP-bound Gas protein.
  • the Gas protein is a GDP-bound Gas protein.
  • the Gas protein is covalently bonded to a human Gas small molecule inhibitor at R201C.
  • the Gas protein is a GTP-bound human Gas protein.
  • the Gas protein is a GDP-bound human Gas protein.
  • the Gas protein is covalently bonded to a human Gas small molecule inhibitor at a corresponding residue of R201C in SEQ ID NO: 1.
  • the Gas protein is a GTP-bound human Gas protein.
  • the Gas protein is a GDP-bound human Gas protein.
  • the Gas protein covalently bonded to a Gas small molecule inhibitor at C237.
  • the Gas protein is a GTP-bound Gas protein.
  • the Gas protein is a GDP-bound Gas protein.
  • the Gas protein covalently bonded to a human Gas small molecule inhibitor at C237.
  • the Gas protein is a GTP-bound human Gas protein.
  • the Gas protein is a GDP-bound human Gas protein.
  • the Gas protein covalently bonded to a human Gas small molecule inhibitor at a corresponding residue of C237 in SEQ ID NO: 1.
  • the Gas protein is a GTP-bound human Gas protein.
  • the Gas protein is a GDP- bound human Gas protein.
  • the Gas protein is covalently bonded to a human Gas small molecule inhibitor at a corresponding residue of R187C in SEQ ID NO: 2.
  • the Gas protein is a GTP -bound human Gas protein.
  • the Gas protein is a GDP-bound human Gas protein.
  • the Gas protein covalently bonded to a human Gas small molecule inhibitor at a corresponding residue of C223 in SEQ ID NO: 2.
  • the Gas protein is a GTP-bound human Gas protein.
  • the Gas protein is a GDP- bound human Gas protein.
  • the compound described herein e.g., Formula (I), (II), (IH-a), (III- b), (III-c), (IV), (V-a), (V-b), (VI), (VII), or (VIII)
  • the compound as described herein e.g., Formula (I), (II), (Ill-a), (Ill-b), (III- c), (IV), (V-a), (V-b), (VI), (VII), or (VIII)
  • a pharmaceutically suitable or acceptable carrier also referred to herein as a pharmaceutically suitable (or acceptable) excipient, physiologically suitable (or acceptable) excipient, or physiologically suitable (or acceptable) carrier
  • a pharmaceutically suitable or acceptable carrier also referred to herein as a pharmaceutically suitable (or acceptable) excipient, physiologically suitable (or acceptable) excipient, or physiologically suitable (or acceptable) carrier
  • the compound of Formula (I), (II), (Ill-a), (Ill-b), (III-c), (IV), (V-a), (V-b), (VI), (VII), or (VIII) as described herein is administered as a pure chemical.
  • the compound of Formula (I), (II), (Ill-a), (Ill-b), (III-c), (IV), (V-a), (V-b), (VI), (VII), or (VIII) described herein is combined with a pharmaceutically suitable or acceptable carrier (also referred to herein as a pharmaceutically suitable (or acceptable) excipient, physiologically suitable (or acceptable) excipient, or physiologically suitable (or acceptable) carrier) selected on the basis of a chosen route of administration and standard pharmaceutical practice as described, for example, in Gennaro,
  • a pharmaceutical composition including at least one compound of Formula (I), (II), (Ill-a), (Ill-b), (III-c), (IV), (V-a), (V-b), (VI), (VII), or (Vlll)described herein, or a pharmaceutically acceptable salt or solvate thereof, together with one or more pharmaceutically acceptable carriers.
  • the carrier(s) or excipient(s)
  • a pharmaceutical composition including at least one compound of Formula (I), (II), (Ill-a), (Ill-b), (III-c), (IV), (V-a), (V-b), (VI), (VII), or (VIII) described herein, or a pharmaceutically acceptable salt or solvate thereof, together with one or more pharmaceutically acceptable carriers.
  • the carrier(s) or excipient(s)
  • the compound described herein e.g., of Formula (I), (II), (Ill-a), (Ill-b), (III-c), (IV), (V-a), (V-b), (VI), (VII), or (VIII)
  • the compound of Formula (I), (II), (Ill-a), (Ill-b), (III-c), (IV), (V-a), (V-b), (VI), (VII), or (VIII) as described herein is substantially pure, in that it contains less than about 5%, or less than about 1%, or less than about 0.1%, of other organic small molecules, such as contaminating intermediates or by-products that are created, for example, in one or more of the steps of a synthesis method.
  • compositions include those suitable for oral, rectal, topical, buccal, parenteral (e.g., subcutaneous, intramuscular, intradermal, or intravenous), vaginal, ophthalmic, or aerosol administration.
  • parenteral e.g., subcutaneous, intramuscular, intradermal, or intravenous
  • vaginal e.g., vaginal, ophthalmic, or aerosol administration.
  • Exemplary pharmaceutical compositions are used in the form of a pharmaceutical preparation, for example, in solid, semisolid or liquid form, which includes one or more of a disclosed compound, as an active ingredient, in a mixture with an organic or inorganic carrier or excipient suitable for external, enteral or parenteral applications.
  • the active ingredient is compounded, for example, with the usual non-toxic, pharmaceutically acceptable carriers for tablets, pellets, capsules, suppositories, solutions, emulsions, suspensions, and any other form suitable for use.
  • the active compound is included in the pharmaceutical composition in an amount sufficient to produce the desired effect upon the process or condition of the disease.
  • the dose of the composition including at least one compound described herein differs, depending upon the patient’s (e.g., human) condition, that is, stage of the disease, general health status, age, and other factors.
  • the dose of the composition including at least one compound of Formula (I), (II), (Ill-a), (Ill-b), (III-c), (IV), (V-a), (V-b), (VI), (VII), or (VIII) as described herein differs, depending upon the patient’s (e.g., human) condition, that is, stage of the disease, general health status, age, and other factors.
  • patient e.g., human
  • compositions are administered in a manner appropriate to the disease to be treated (or prevented).
  • An appropriate dose and a suitable duration and frequency of administration will be determined by such factors as the condition of the patient, the type and severity of the patient’s disease, the particular form of the active ingredient, and the method of administration.
  • an appropriate dose and treatment regimen provides the composition(s) in an amount sufficient to provide therapeutic and/or prophylactic benefit (e.g., an improved clinical outcome, such as more frequent complete or partial remissions, or longer disease-free and/or overall survival, or a lessening of symptom severity.
  • Optimal doses are generally determined using experimental models and/or clinical trials. In some embodiments, the optimal dose depends upon the body mass, weight, or blood volume of the patient.
  • Oral doses typically range from about 1.0 mg to about 1000 mg, one to four times, or more, per day.
  • Disclosed compounds are administered to subjects or patients (animals and humans) in need of such treatment in dosages that will provide optimal pharmaceutical efficacy. It will be appreciated that the dose required for use in any particular application will vary from patient to patient, not only with the particular compound or composition selected, but also with the route of administration, the nature of the condition being treated, the age and condition of the patient, concurrent medication or special diets then being followed by the patient, and other factors, with the appropriate dosage ultimately being at the discretion of the attendant physician.
  • a contemplated compound disclosed herein is administered orally, subcutaneously, topically, parenterally, by inhalation spray or rectally in dosage unit formulations containing conventional non-toxic pharmaceutically acceptable carriers, adjuvants and vehicles. Parenteral administration include subcutaneous injections, intravenous or intramuscular injections or infusion techniques.
  • the pharmaceutical composition may include compositions wherein the active ingredient is contained in a therapeutically effective amount, i.e., in an amount effective to achieve its intended purpose.
  • a therapeutically effective amount i.e., in an amount effective to achieve its intended purpose.
  • the actual amount effective for a particular application will depend, inter alia, on the condition being treated.
  • the dosage and frequency (single or multiple doses) of compounds administered can vary depending upon a variety of factors, including route of administration; size, age, sex, health, body weight, body mass index, and diet of the recipient; nature and extent of symptoms of the disease being treated; presence of other diseases or other health-related problems; kind of concurrent treatment; and complications from any disease or treatment regimen.
  • Other therapeutic regimens or agents can be used in conjunction with the methods and compounds disclosed herein.
  • therapeutically effective amounts for use in humans can also be determined from animal models.
  • a dose for humans can be formulated to achieve a concentration that has been found to be effective in animals.
  • the dosage in humans can be adjusted by monitoring compounds effectiveness and adjusting the dosage upwards or downwards, as described above. Adjusting the dose to achieve maximal efficacy in humans based on the methods described above and other methods is well within the capabilities of the ordinarily skilled artisan.
  • Dosages may be varied depending upon the requirements of the subject and the compound being employed.
  • the dose administered to a subject should be sufficient to effect a beneficial therapeutic response in the subject over time.
  • the size of the dose also will be determined by the existence, nature, and extent of any adverse side effects. Generally, treatment is initiated with smaller dosages, which are less than the optimum dose of the compound. Thereafter, the dosage is increased by small increments until the optimum effect under circumstances is reached.
  • Dosage amounts and intervals can be adjusted individually to provide levels of the administered compounds effective for the particular clinical indication being treated. This will provide a therapeutic regimen that is commensurate with the severity of the individual's disease state.
  • an effective prophylactic or therapeutic treatment regimen can be planned that does not cause substantial toxicity and yet is entirely effective to treat the clinical symptoms demonstrated by the particular patient.
  • This planning should involve the careful choice of active compound by considering factors such as compound potency, relative bioavailability, patient body weight, presence and severity of adverse side effects, preferred mode of administration, and the toxicity profile of the selected agent.
  • a method of treating cancer includes administering to a subject in need thereof an effective amount of a compound as described herein.
  • the subject is a human.
  • the cancer is selected from human cancers and carcinomas, sarcomas, adenocarcinomas, lymphomas, leukemias, and the like.
  • the cancer is a solid cancer or tumor.
  • the cancer is pancreatic cancer.
  • the cancer is a pituitary tumor.
  • the cancer is a bone tumor.
  • the cancer or cancer cell is sensitive to Gas inhibition.
  • a method of treating a bone condition includes administering to a subject in need thereof an effective amount of a compound as described herein.
  • the bone condition is fibrous dysplasia.
  • the fibrous dysplasia is monostotic fibrous dysplasia or polystotic fibrous dysplasia.
  • the fibrous dysplasia is monostotic fibrous dysplasia.
  • the fibrous dysplasia is polystotic fibrous dysplasia.
  • a method of treating McCune-Albright Syndrome includes administering to a subject in need thereof an effective amount of a compound as described herein.
  • a method of treating cancer include administering a Gas cysteine 201 covalent inhibitor.
  • the Gas cysteine 201 covalent inhibitor is a compound as described herein.
  • a method of treating cancer include administering a Gas cysteine 237 covalent inhibitor.
  • the Gas cysteine 237 covalent inhibitor is a compound as described herein.
  • Embodiment PI A compound having the formula: wherein,
  • R 1 is independently halogen, -CX’s, -CRX -CH2X 1 , -OCX’s, - OCH2X 1 , -OCHX’ 2 , -CN, -SO Figure I R 1d , -SO vi NR 1A R 1B , -NR 1C NR 1A R 1B , -ONR 1A R 1b , -NHC(0)NR 1C NR 1A R 1B , -NHC(0)NR 1A R 1b , -N(0) mi , -NR 1A R 1B , -C(0)R 1c , -C(0)-0R 1c , -C (0)NR 1A R 1b , -OR 1d , -NR 1A S0 2 R 1d , -NR 1A C(0)R 1c , -NR 1A C(0)0R 1c , -NR 1A OR 1c , -N 3 , substituted or unsubstituted
  • Ring A is aryl or heteroaryl
  • L 1 is a bond, -NH-, -0-, -S-, -C(O)-, -C(0)NH-, -NHC(O)-, -NHC(0)NH-, -C(0)0-, -OC(O)-, substituted or unsubstituted alkylene, substituted or unsubstituted heteroalkylene, substituted or unsubstituted cycloalkylene, substituted or unsubstituted heterocycloalkylene, substituted or unsubstituted arylene, or substituted or unsubstituted heteroarylene;
  • L 2 is a bond, -NH-, -0-, -S-, -C(O)-, -C(0)NH-, -NHC(O)-, -NHC(0)NH-, -C(0)0-, -OC(O)-, substituted or unsubstituted alkylene, substituted or unsubstituted heteroalkylene, substituted or unsub
  • R 2 is an electrophilic moiety
  • R 1A , R 1b , R 1C , and R 1D are independently hydrogen, -CX3, -CHX2, -CH2X, -CN, -OH, -COOH, -CONH2, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl; R 1A and R 1B substituents bonded to the same nitrogen atom may optionally be joined to form a substituted or unsubstituted heterocycloalkyl or substituted or unsubstituted heteroaryl;
  • X and X 1 are independently -F, -Cl, -Br, or -I; nl is independently an integer from 0 to 4; and ml and vl are independently 1 or 2.
  • Embodiment P2 The compound of Embodiment 1, wherein zl is an integer from 1 to 3.
  • Embodiment P3 The compound of Embodiment 1, wherein zl is 0.
  • Embodiment P4 The compound of one of Embodiments 1 to 3, wherein Ring A is phenyl or 5 to 6-membered heteroaryl.
  • Embodiments P5. The compound of one of Embodiments 1 to 4, having the formula: wherein;
  • Each R 1 ⁇ 1 , R 1 ⁇ 2 , R 1 3 , R 1 4 , and R 1 5 is independently hydrogen, halogen, -CX ⁇ , -
  • R 1A , R 1b , R 1C , and R 1D are independently hydrogen, -CX3, -CHX2, -CH2X, -CN, -OH, -COOH, -CONH2, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl; R 1A and R 1B substituents bonded to the same nitrogen atom may optionally be joined to form a substituted or unsubstituted heterocycloalkyl or substituted or unsubstituted heteroaryl;
  • X and X 1 are independently -F, -Cl, -Br, or -I; nl is independently an integer from 0 to 4; and ml and vl are independently 1 or 2.
  • Embodiment P6 The compound of one of Embodiments 1 to 5, wherein L 1 is a bond, -NH-, -0-, -S-, -C(O)-, -C(0)NH-, -NHC(O)-, -NHC(0)NH-, -C(0)0-, -OC(O)-, substituted or unsubstituted alkylene, or substituted or unsubstituted heteroalkylene.
  • Embodiment P7 The compound of one of Embodiments 1 to 5, wherein L 1 is a bond, -NH-, -0-, -S-, -C(O)-, -C(0)NH-, -NHC(O)-, -NHC(0)NH-, -C(0)0-, -OC(O)-, substituted or unsubstituted C1-C6 alkylene, or substituted or unsubstituted 2 to 6 membered heteroalkylene.
  • L 1 is a bond, -NH-, -0-, -S-, -C(O)-, -C(0)NH-, -NHC(O)-, -NHC(0)NH-, -C(0)0-, -OC(O)-, substituted or unsubstituted C1-C6 alkylene, or substituted or unsubstituted 2 to 6 membered heteroalkylene.
  • Embodiment P8 The compound of one of Embodiments 1 to 5, wherein L 1 is a bond.
  • Embodiment P9 The compound of one of Embodiments 1 to 8, wherein L 2 is a bond, -NH-, -0-, -S-, -C(O)-, -C(0)NH-, -NHC(O)-, -NHC(0)NH-, -C(0)0-, -OC(O)-, substituted or unsubstituted alkylene, or substituted or unsubstituted heteroalkylene.
  • Embodiment P10 The compound of one of Embodiments 1 to 8, wherein L 2 is a bond, -NH-, -0-, -S-, -C(O)-, -C(0)NH-, -NHC(O)-, -NHC(0)NH-, -C(0)0-, -OC(O)-, substituted or unsubstituted C1-C6 alkylene, or substituted or unsubstituted 2 to 6 membered heteroalkylene.
  • Embodiment Pll The compound of one of Embodiments 1 to 8, wherein L 2 is an unsubstituted C1-C6 alkylene.
  • Embodiment P12 The compound of one of Embodiments 1 to 8, wherein L 2 is a bond.
  • Embodiment P13 The compound of one of Embodiments 1 to 12, wherein R 2 is
  • R 16 is hydrogen, halogen, -CX 16 3 , -CHX 16 2 , -CH 2 X 16 , -CN, -SO ni6 R 16D , -SO V I 6 NR 16A R 16B , -NHNR 16A R 16B , -ONR 16A R 16B , -NHC(0)NHNR 16A R 16B ,
  • R 17 is hydrogen, halogen, -CX 17 3 , -CHX 17 2 , -CH 2 X 17 , -CN, -SO StammI 7 R 17D , -SO v17 NR 17A R 17B , -NHNR 17A R 17B , -ONR 17A R 17B , -NHC(0)NHNR 17A R 17B ,
  • R 18 is hydrogen, halogen, -ONR 18A R 18B , -NHC(0)NHNR 18A R 18B , -OR , -OCH 2 X 18 , substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl;
  • R 19 is hydrogen, halogen, -CX 19 3 , -CHX 19 2 , -CH 2 X 19 , -CN, -SOmony I9 R 19D , -SO VI9 NR 19A R 19B , -NHNR 19A R 19B , -ONR 19A R 19B , -NHC(0)NHNR 19A R 19B , , -OCH 2 X 19 , substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl; and R 19D are independently hydrogen, -CX 3 , -CHX 2 , -CH 2 X, -CN, -OH, -COOH, -CONH 2 , substituted or unsubstituted
  • X 16 , X 17 , X 18 , and X 19 are independently -F, -Cl, -Br, or -I; nl6, nl7, nl8, and nl9 are independently an integer from 0 to 4; and ml6, ml7, ml8, ml9, vl6, vl7, vl8, and vl9 are independently 1 or 2.
  • Embodiment P14 The compound of one of Embodiments 1 to 12, wherein R 2 is
  • Embodiment P15 The compound of one of Embodiments 1 to 14, wherein:
  • R 16 is hydrogen, unsubstituted C1-C4 alkyl, or unsubstituted C3-C6 cycloalkyl;
  • R 17 is hydrogen, unsubstituted C1-C4 alkyl, or unsubstituted C3-C6 cycloalkyl; and R 18 is hydrogen, unsubstituted C1-C4 alkyl, or unsubstituted C3-C6 cycloalkyl.
  • Embodiment P16 The compound of one of Embodiments 1 to 14, wherein:
  • R 16 is hydrogen or unsubstituted C 1 -C 4 alkyl
  • R 17 is hydrogen or unsubstituted C 1 -C 4 alkyl; and R 18 is hydrogen or unsubstituted C 1 -C 4 alky.
  • Embodiment P17 The compound of one of Embodiments 1 to 14, wherein R 16 , R 17 , and R 18 are hydrogen.
  • Embodiment P18 A pharmaceutical composition comprising the compound of any one of Embodiments 1 to 17 and a pharmaceutically acceptable excipient.
  • Embodiment P19 A method of inhibiting Gas protein activity, said method comprising: contacting the Gas protein with a compound of one of Embodiments 1 to 17.
  • Embodiment P20 A method of treating cancer, said method comprising administering to a subject in need thereof an effective amount of a compound of one of Embodiments 1 to 17.
  • Embodiment P21 The method of Embodiment 20, wherein the cancer is pancreatic cancer, a pituitary tumor, or a bone tumor.
  • Embodiment P22 The method of Embodiment 20, wherein the cancer is sensitive to Gas inhibition.
  • Embodiment P23 A method of treating a bone condition, said method comprising administering to a subject in need thereof an effective amount of a compound of one of Embodiments 1 to 17.
  • Embodiment P24 The method of Embodiment 23, wherein the bone condition is fibrous dysplasia.
  • Embodiment P25 The method of Embodiment 24, wherein the fibrous dysplasia is monostotic fibrous dysplasia or polystotic fibrous dysplasia.
  • Embodiment P26 A method of treating McCune-Albright Syndrome, said method comprising administering to a subject in need thereof an effective amount of a compound of one of Embodiments 1 to 17.
  • Embodiment P27 A Gas protein covalently bonded to a compound of one of Embodiments 1 to 17.
  • Embodiment P28 The Gas protein of Embodiment 27, wherein Gas is in the GTP state.
  • Embodiment P29 The Gas protein of Embodiment 27, wherein Gas is in the GDP state.
  • Embodiment P30 The Gas protein of Embodiment 27, wherein the compound is bonded to a cysteine residue of the protein.
  • Embodiment P31 The Gas protein of Embodiment 27, having the structure:
  • Embodiment P32 The Gas protein of Embodiment 31, wherein L 3 is f- NH
  • Embodiment P33 The Gas protein of Embodiment 30, wherein the compound is bonded to cysteine 201.
  • Embodiment P34 The Gas protein of Embodiment 30, wherein the compound is bonded to cysteine 237.
  • Embodiment P35 A Gas protein covalently bonded to a portion of a compound of one of Embodiments 1 to 17.
  • Embodiment P36 A Gas protein covalently bonded to a Gas small molecule inhibitor at R201C.
  • Embodiment P37 The Gas protein of Embodiment 36, wherein the Gas protein is a GTP-bound Gas protein.
  • Embodiment P38 The Gas protein of Embodiment 36, wherein the Gas protein is a GDP-bound Gas protein.
  • Embodiment P39 A Gas protein covalently bonded to a Gas small molecule inhibitor at C237.
  • Embodiment P40 The Gas protein of Embodiment 39, wherein the Gas protein is a GTP-bound Gas protein.
  • Embodiment P41 The Gas protein of Embodiment 39, wherein the Gas protein is a GDP-bound Gas protein.
  • Embodiment P42 A method of treating cancer comprising administering a Gas cysteine 201 covalent inhibitor.
  • Embodiment P43 The method of Embodiment 42, wherein the Gas cysteine 201 covalent inhibitor is a compound of one of Embodiments 1 to 17.
  • Embodiment P44 A method of treating cancer comprising administering a Gas cysteine 237 covalent inhibitor.
  • Embodiment P45 The method of Embodiment 44, wherein the Gas cysteine 237 covalent inhibitor is a compound of one of Embodiments 1 to 17.
  • leading compounds can lable the somatic cysteine mutant selectively over all other cysteines present in the protein. Based on (i) the structure activity relationships and (ii)GDP orGTP state dependent labelling, the leading compounds are excellent starting points for discovery of covalent irreversible (likely acrylamide) based drug candidates, which can yield enhanced drug candidate for Gas associated cancer or disease. In particular, the leading compounds may be used to treat a cancer caused by mutations (e.g., R201C) in the GNAS gene.
  • mutations e.g., R201C
  • GNAS which encodes the a-subunit of the stimulatory G protein (Gas).
  • GNAS was first proved to be a putative oncogene that was abnormally activated in human growth hormone (GH) -secreting pituitary tumors in 1987 [2, 3]; activating mutations were identified in about 43% of 42 GH-secreting pituitary tumors, and they were responsible for the high secretory activity of such tumors [4] . Since then, activating mutations of GNAS have been revealed to contribute to progression and metastasis of several other kinds of cancers.
  • GH human growth hormone
  • IPMN intraductal papillary mucinous neoplasm
  • Jian Wu et al. searched the mutations in IPMN patients, and found that 66% of 132 patients carried activating mutations at codon 201 of GNAS [5 According to the catalogue of somatic mutations in cancer (COSMIC) v62, approximately 4.2% of all cancer types harbor activating mutations in GNAS [] About 64% of such GNAS mutations result in R201C [1] .
  • Arg201 can stabilize the pentavalent phosphate intermediate thus facilitates GTP hydrolysis; therefore mutation of this residue disrupts the GTPase activity of Gas, keeping Gas in a constitutively active state [6, 7] .
  • Such a design is based on the structure of Gaq with a non-covalent inhibitor [8] , and the crystal structures of K-Ras(G12C) with inhibitors that’s covalently linked with Cysl2 [9 11] .
  • Activity assays are also proposed to evaluate the potency of the designed inhibitors.
  • the G-proteins are composed of Ga, ⁇ b and Gy subunits. Among them, Ga can form a heterotrimer with ⁇ bg when one molecule of GDP is located in the nucleotide-binding pocket of Ga. The GDP-bound Ga is inactive, and can be activated by the corresponding GPCR. As for Gas, it can be activated by b2 adrenergic receptor ⁇ 2AR).
  • G-protein inhibitors have been reported. They targeted different steps of G-protein activation. Some of them could disrupt the interaction between G- proteins and their receptors. For example, A small peptide, pGlu-Gln-D-Trp-Phe-D-Trp-D- Trp-Met-NIL ⁇ , was reported to competitively inhibit the binding of Gi (or Go) to M2 muscarinic cholinergic receptor or the binding of Gs to P2AR [15] ⁇ Another compound, BIM- 46187, was first reported to bind to the Ga subunit and block the receptor-G protein interaction with a poor selectivity [16] ’ but in a recent study, BIM-46187 preferentially inhibited Gaq by blocking GTP entry [17] ⁇ Some other compounds were used to inhibit replacement of GDP with GTP, such as compound YM-254890, which was reported to selectively block GDP-GTP exchange of Gaq/n [18] Suramin and its analogue
  • the specific aims include 1) design of leading compounds that bind Gas; 2) modification of the compounds to covalently bond Cys201 of Gas(R201C); 3) structural analysis of the binding of these compounds with Gas(R201C); 4) evaluation of the potency of these compounds in cellular models.
  • Gaq shares a sequence identity of 42.5% with Gas.
  • G-proteins show similar features to other GTPase, such as the Ras family proteins. Their GDP-bound state is inactive, while the GTP-bound state is active in signal transduction. Structural analysis of Ras proteins revealed that two regions largely switched during the replacement of GDP with GTP [22] ⁇ The two regions, named switch I and II, are also involved in nucleotide-exchange in G-proteins [7, i3].
  • YM254890 a cyclic depsipeptide produced by Chromobacterium sp. QS3666, was first identified as a platelet aggregation inhibitor [23] , then it turned out to be a novel Gaq/11 -selective inhibitor [18] .
  • the cyclic scaffold of YM254890 is linked by ester bonds and amide bonds, and the nitrogen atoms of the amides are highly methylated.
  • the moiety around the cyclic scaffold consists of aliphatic and aromatic residues, indicating that hydrophobic interactions involve in YM254890- Gaq binding [24] .
  • (2S,3R)-N,0-Me2Thr could be replaced with hydrophilic residues to bind K91 and D94 in Gas.
  • the isopropyl group of (2 S , 3 R) - b-HyLeu- 2 interact with 1190 in Gaq, but replacement of 1190 with F206 in Gas narrows the pocket.
  • K-Ras an important member in the Ras family, also has cancer-associated mutants.
  • G12C disrupts the GTPase activity of K-Ras, keeping K-Ras in a GTP-bound state.
  • Small molecule inhibitors specifically target the mutant but not wild-type K-Ras have been reported by two groups [9 11] ⁇ These inhibitors harbor electrophilic groups that can be covalently linked with Cysl2 of the mutant K-Ras. Such electrophilic groups guarantee the specificity of the inhibitors.
  • a surface grove lays between the helical domain and Ras-like domain; R183 and (2S,3R)-N,0-Me2Thr can be connected by a linker across this grove (FIG. IE). Therefore, a linker would be added to the side chain or main chain of (2S,3R)-N,0-Me2Thr; the other head of the linker would be linked with various cysteine-reactive groups. The length and composition of the linker would be varied to acquire a better inhibitor. [0498] Specifically, a long linker is needed because the distance between the a-carbon of R183 and the main chain of (2S,3R)-N,0-Me2Thr is nearly 10 A (FIG. IF).
  • a linker with certain hydrophilicity would be used. Such a linker might also increase the binding affinity of the inhibitor, and fix switch I in an inactive conformation.
  • cysteine-reactive groups because cysteine has long been an ideal residue for selective modification of proteins, several classes of reactive groups have been developed to chemically modify cysteine residues, such as a-halocarbonyls (e.g., iodoacetamides), maleimides, vinyl sulfones, etc. [25, 26]. Besides, a series of cysteine proteases inhibitors that can covalently modify the cysteine residue have been reported, such as epoxysuccinyl derivatives and O-acyl hydroxamates [27]. These reactive groups can be employed to link the leading compounds with Cys201.
  • a-halocarbonyls e.g., iodoacetamides
  • maleimides e.g., iodoacetamides
  • vinyl sulfones etc.
  • cysteine proteases inhibitors that can covalently modify the cysteine residue have been reported, such as epoxysuccinyl derivatives and O-acyl hydrox
  • Gas can be easily over-expressed in E. coli [28] and in insect cells [29] .
  • Crystal structures of Gas -GTPyS complex, Gas-adenylyl cyclase complex, and the ternary complex of Gas-G y- 2AR, have been reported [7, 13, 29] . So the crystal structure of Gas or Gas(R201C) in complex with its inhibitor may be obtained.
  • An in vitro assay system can be used to evaluate the inhibition effects of the designed compounds on the activities of Gas and the cancer-associated mutant Gas(R201C).
  • Covalent modification of Gas(R201C) can be detected by mass spectrometry as described in the study of K-Ras(G12C) inhibitors that carried by Kevan Shokat’s laboratory in 2013 [11] ⁇
  • nucleotide exchange rates on Gas can be determined by a fluorescence- based assay [30, 31] .
  • Somatic mutations of GNAS occur in approximately 4.2% of all cancer types [1] .
  • statistics show that 11.8% of 473 pancreas cancer samples and 27.9% of 816 pituitary cancer samples harbor GNAS mutations [1] ; 66% of 132 intraductal papillary mucinous neoplasm (IPMN) patients carried a GNAS mutation [5] .
  • IPMN intraductal papillary mucinous neoplasm
  • These mutations lead to constitutive activation of Gas, and promote tumourigenesis.
  • About 64% of the cancer- associated mutations of GNAS change Arg201 of Gas to a cysteine residue (R201C). Therefore, specific inhibitors of the R201C mutant of Gas would be effective tools for cancer therapies. Development of such inhibitors is just the aim of the proposed research.
  • Somatic mutations of GNAS occur in approximately 4.2% of all cancer types [1] .
  • statistics show that 11.8% of 473 pancreas cancer samples and 27.9% of 816 pituitary cancer samples harbor GNAS mutations [1] ; 66% of 132 intraductal papillary mucinous neoplasm (IPMN) patients carried a GNAS mutation [5] .
  • IPMN intraductal papillary mucinous neoplasm
  • These mutations lead to constitutive activation of Gas, and promote tumourigenesis.
  • About 64% of the cancer- associated mutations of GNAS change Arg201 of Gas to a cysteine residue (R201C). Therefore, specific inhibitors of the R201C mutant of Gas would be effective tools for cancer therapies. Development of such inhibitors is just the aim of the proposed research.
  • the R201C mutant Gas can bypass the need for GTP binding by directly activating GDP-bound Gas through stabilization of an intramolecular hydrogen bond network between the P-loop, switch III and switch II of Gas.
  • the single turnover GTP hydrolysis rate (feat) and the GDP dissociation rate (kos) of R201C and wild-type Gas were measured and compared.
  • the ratio of Gas in the GTP-bound state should be less than koif/(koif+ f e at) when the GTP binding and hydrolysis cycle reaches a steady state. In the presence of excess GOy subunits and millimolar Mg 2+ , only 11% of the R201C mutant was in the GTP state without stimulation by GPCRs.
  • FIG. 2 The calculation using a [y- 32 P]GTP binding assay is shown in FIG. 2.
  • the R201C mutant was pre-incubated in a low Mg 2+ buffer (1 mM EDTA + 0.1 mM MgCh) with 400 mM GTP that is close to the physiological concentration of GTP; 20 nM [y- 32 P]GTP was added as an internal standard. After the binding of [y- 32 P]GTP to the R201C mutant reached a maximum, the concentration of free Mg 2+ was increased to about 1.1 mM (1 mM EDTA +
  • FIG. 1A A crystal structure of the R201C/C237S mutant was solved and shown in FIG. 1A. Structure analysis indicates the importance of the interactions between E50 and ammonium h ⁇ and t
  • the R201C mutation results in the loss of ammonium h ⁇ and t
  • acrylamidine can modify Cys237 and Cys201 in the R201C mutant.
  • Cys201 can be modified by Acr. This modification converts cysteine to an arginine mimic (FIG. 3A).
  • a tethering screening was used to identify compounds that can covalently modify C201. Untagged recombinant Gas(R201C) at 2 mM was reacted with 200 mM fragment and 200 pM bME in 20 mM HEPES, pH 8.0, 150 mM NaCl, 30 pM MgC12, 50 pM GDP for 2 h at ambient temperature. The extent of modification was assessed by electrospray mass spectrometry using a Waters LCT-Premier LC/ESI-MS.
  • Chemotherapy is one of the mainstays of cancer treatment.
  • this approach is often troubled by severe side effects mainly because anti -cancer drugs target both cancer cells and healthy cells.
  • Cancer is caused by mutations in genes that accelerate (oncogenes) or suppress (tumor suppressors) tumor growth.
  • Specifically targeting the mutant genes or the mutant proteins encoded by these genes is theoretically an ideal strategy to decrease the side effects of anti-cancer drugs but usually cannot be achieved.
  • inhibitors that covalently modify the cysteine residue have shown great selectivity of the mutant proteins over the normal proteins.
  • GNAS oncogene
  • a small molecule named acrylamidine can correct the misactivation of Gas(R201C) by converting Cys201 to an arginine mimic.
  • a disulphide fragment that preferentially modifies Cys201 in the active GTP-bound form of Gas. Both small molecules are not drug-like molecules, however, they are good starting point for development of drug-like molecules.
  • Proteins were diluted in 20 mM HEPES 8.0, 150 mM NaCl, 5 mM MgCh, 1 mM EDTA as indicated in Table 1.
  • the diluted protein solutions were incubated with 0.5 mM GMPPNP at room temperature for 1 hour, then MgCh was added to a final concentration of 5 mM.
  • BME was added to a final concentration of 0, 500, 1000, 1500 or 2000 pM.
  • Compounds QH2018-4, QH2018-6, , QH2018-8 or QH2018-10 (5 mM in DMSO) was added to each sample to a final concentration of 50 mM. After incubation at room temperature for 2 hours, labeling ratio of the proteins by these compounds was determined by LC/MS. The measured BME50 are shown in FIG. 6B.
  • Reactive aryl isocyate with the R 1 substitution as described herein on para position and aliphatic amine with the R 2 substituents as described herein may form an aryl urea upon reaction illustrated in Scheme 1.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Disclosed herein, inter alia, are G-alpha-s Inhibitors and uses thereof.

Description

G-alpha-s INHIBITORS AND USES THEREOF
CROSS-REFERENCES TO RELATED APPLICATIONS [0001] This application claims the benefit of U.S. Provisional Application No. 63/179,969, filed April 26, 2021, which is incorporated herein by reference in its entirety and for all purposes.
STATEMENT AS TO RIGHTS TO INVENTIONS MADE UNDER FEDERALLY SPONSORED RESEARCH AND DEVELOPMENT
[0002] This invention was made with government support under grant number R01 CA244550 awarded by the National Institutes of Health. The government has certain rights in the invention.
REFERENCE TO A "SEQUENCE LISTING," A TABLE, OR A COMPUTER PROGRAM LISTING APPENDIX SUBMITTED AS AN ASCII FILE
[0003] The Sequence Listing written in file 048536-
707001WO_Sequence_Listing_ST25.TXT, created April 19, 2022, 7,057 bytes, machine format IBM-PC, MS Windows operating system, is hereby incorporated by reference.
BACKGROUND
[0004] Guanine nucleotide-binding protein G, alpha (a) subunit (GNAS) mediates G- protein-coupled receptor (GPCR) signaling, a central mechanism by which cells sense and respond to extracellular stimuli. Multiple human cancer types exhibit recurrent gain-of- function mutations in the pathway, most frequently targeting GNAS. The most lethal tumor type where GNAS is frequently mutated is the intraductal papillary mucinous neoplasm (IPMN), a precursor of invasive pancreatic cancer.
[0005] Disclosed herein, inter alia, are solutions to these and other problems in the art.
BRIEF SUMMARY
[0006] In an aspect is provided a compound having the formula: [0007] R1 is OCH2X1, -OCHX^, -CN, -SO„iR1D, -SOviNR1AR1B, -NR1CNR1AR1B, -ONR1AR1b, -NHC(0)NR1CNR1AR1B, -NHC(0)NR1AR1b, -N(0)mi, -NR1AR1B, -C(0)R1c, -C(0)-0R1c, -C (0)NR1AR1b, -OR1d, -NR1AS02R1d, -NR1AC(0)R1c, -NR1AC(0)0R1c, -NR1AOR1c, -N3, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl; two adjacent R1 substituents may optionally be joined to form a substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl.
[0008] zl is an integer from 0 to 6.
[0009] Ring A is aryl or heteroaryl.
[0010] L1 is a bond, -NH-, -0-, -S-, -C(O)-, -C(0)NH-, -NHC(O)-, -NHC(0)NH-, -C(0)0-, -OC(O)-, substituted or unsubstituted alkylene, substituted or unsubstituted heteroalkylene, substituted or unsubstituted cycloalkylene, substituted or unsubstituted heterocycloalkylene, substituted or unsubstituted arylene, or substituted or unsubstituted heteroarylene.
[0011] L2 is a bond, -NH-, -0-, -S-, -C(O)-, -C(0)NH-, -NHC(O)-, -NHC(0)NH-, -C(0)0-, -OC(O)-, substituted or unsubstituted alkylene, substituted or unsubstituted heteroalkylene, substituted or unsubstituted cycloalkylene, substituted or unsubstituted heterocycloalkylene, substituted or unsubstituted arylene, or substituted or unsubstituted heteroarylene.
[0012] R2 is an electrophilic moiety.
[0013] R1A, R1b, R1C, and R1D are independently hydrogen, -CX3, -CHX2, -CH2X, -CN, -OH, -COOH, -CONH2, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl; R1A and R1B substituents bonded to the same nitrogen atom may optionally be joined to form a substituted or unsubstituted heterocycloalkyl or substituted or unsubstituted heteroaryl.
[0014] X and X1 are independently -F, -Cl, -Br, or -I.
[0015] nl is independently an integer from 0 to 4.
[0016] ml and vl are independently 1 or 2.
[0017] zl is an integer from 1 to 3. In embodiments, zl is 0.
[0018] In embodiments, Ring A is phenyl or 5 to 6-membered heteroaryl. [0019] In embodiments, the compound has the formula:
Figure imgf000004_0001
[0020] Each Ru, R1 2, R1 3, R1 4, and R1 5 is independently hydrogen, halogen, -CX^, - CHX -CH2X1, -OCX1:!, -OCH2X1, -OCHX’i, -CN, -SO„iR1D, -SOviNR1AR1B, -NR1CNR1AR1B, -ONR1AR1b,
-NHC(0)NRlcNR1AR1B, -NHC(0)NR1AR1b, -N(0)mi, -NR1AR1B, -C(0)R1c, -C(0)-ORlc, -C (0)NR1AR1b, -OR1d, -NR1AS02R1d, -NR1AC(0)R1c, -NR1AC(0)OR1c, -NR1AOR1c, -N3, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl.
[0021] R1A, R1b, R1C, and R1D are independently hydrogen, -CX3, -CHX2, -CH2X, -CN, -OH, -COOH, -CONH2, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl; R1A and R1B substituents bonded to the same nitrogen atom may optionally be joined to form a substituted or unsubstituted heterocycloalkyl or substituted or unsubstituted heteroaryl.
[0022] X and X1 are independently -F, -Cl, -Br, or -I.
[0023] nl is independently an integer from 0 to 4.
[0024] ml and vl are independently 1 or 2.
[0025] L1 is a bond, -NH-, -O-, -S-, -C(O)-, -C(0)NH-, -NHC(O)-, -NHC(0)NH-, -C(0)0-, -OC(O)-, substituted or unsubstituted alkylene, or substituted or unsubstituted heteroalkylene.
[0026] L2 is a bond, -NH-, -O-, -S-, -C(O)-, -C(0)NH-, -NHC(O)-, -NHC(0)NH-, -C(0)0-, -OC(O)-, substituted or unsubstituted alkylene, or substituted or unsubstituted heteroalkylene.
Figure imgf000005_0001
[0028] R16 is hydrogen, halogen, -CX16 3, -CHX16 2, -CH2X16, -CN, -SOni6R16D, -SOVI6NR16AR16B, -NHNR16AR16B, -ONR16AR16B, -NHC(0)NHNR16AR16B,
-NHC(0)NR16AR16B, -N(0)mi6, -NR16AR16B, -C(0)R16C, -C(0)-OR16C, -C(0)NR16AR16B, -OR 16D, -NR16AS02R16B, -NR16AC(0)R16C, -NR16AC(0)0R16C, -NR16A0R16D, -OCX16 3, -OCHX16 2 , -OCH2X16, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl.
[0029] R17 is hydrogen, halogen, -CX17 3, -CHX17 2, -CH2X17, -CN, -SO„17R17D, -SOvi7NR17AR17B, -NHNR17AR17B, -ONR17AR17B, -NHC(0)NHNR17AR17B,
-NHC(0)NR17AR17B, -N(0)mi7, -NR17AR17B, -C(0)R17C, -C(0)-0R17C, -C(0)NR17AR17B, -OR 17D, -NR17AS02R17B, -NR17AC(0)R17C, -NR17AC(0)0R17C, -NR17AOR17D, -OCX17 3, -OCHX17 2 , -OCH2X17, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl.
[0030] R18 is hydrogen, halogen, -CX18 3, -CHX18 2, -CH2X18, -CN, -SO„I8R18D, -SOVI8NR18AR18B, -NHNR18AR18B, -ONR18AR18B, -NHC(0)NHNR18AR18B,
-NHC(0)NR18AR18B, -N(0)mis, -NR18AR18B, -C(0)R18C, -C(0)-OR18C, -C(0)NR18AR18B, -OR 18D, -NR18AS02R18B, -NR18AC(0)R18C, -NR18AC(0)0R18C, -NR18AOR18D, -OCX18 3, -OCHX18 2 , -OCH2X18, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl.
[0031] R19 is hydrogen, halogen, -CX19 3, -CHX19 2, -CH2X19, -CN, -SO„I9R19D, -SOVI9NR19AR19B, -NHNR19AR19B, -0NR19AR19B, -NHC(0)NHNR19AR19B,
-NHC(0)NR19AR19B, -N(0)mi9, -NR19AR19B, -C(0)R19C, -C(0)-OR19C, -C(0)NR19AR19B, -OR 19D, -NR19AS02R19B, -NR19AC(0)R19C, -NR19AC(0)0R19C, -NR19AOR19D, -OCX19 3, -OCHX19 2 , -OCH2X19, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl.
Figure imgf000006_0001
R19C, and R19D are independently hydrogen, -CX3, -CHX2, -CH2X, -CN, -OH, -COOH, -CONH2, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl.
[0033] R16A and R16B substituents bonded to the same nitrogen atom may optionally be joined to form a substituted or unsubstituted heterocycloalkyl or substituted or unsubstituted heteroaryl; R17A and R17B substituents bonded to the same nitrogen atom may optionally be joined to form a substituted or unsubstituted heterocycloalkyl or substituted or unsubstituted heteroaryl; R18A and R18B substituents bonded to the same nitrogen atom may optionally be joined to form a substituted or unsubstituted heterocycloalkyl or substituted or unsubstituted heteroaryl; R19A and R19B substituents bonded to the same nitrogen atom may optionally be joined to form a substituted or unsubstituted heterocycloalkyl or substituted or unsubstituted heteroaryl.
[0034] X16, X17, X18, and X19 are independently -F, -Cl, -Br, or -I.
[0035] nl 6, nl 7, nl 8, and nl 9 are independently an integer from 0 to 4.
[0036] ml 6, ml 7, ml 8, ml 9, vl6, vl7, vl8, and vl9 are independently 1 or 2.
[0037] In an aspect is provided a pharmaceutical composition comprising the compound as decribed herein and a pharmaceutically acceptable excipient.
[0038] In an aspect is provided a method of inhibiting Gas protein activity, said method comprising: contacting the Gas protein with a compound as described herein.
[0039] In an aspect is provided a method of treating cancer, said method including administering to a subject in need thereof an effective amount of a compound as described herein.
[0040] In embodiments, the cancer is pancreatic cancer, a pituitary tumor, or a bone tumor. The cancer is sensitive to Gas inhibition.
[0041] In an aspect is provided a method of treating a bone condition, said method including administering to a subject in need thereof an effective amount of a compound as described herein. In embodiments, the bone condition is fibrous dysplasia. In embodiments, the fibrous dysplasia is monostotic fibrous dysplasia or polystotic fibrous dysplasia. [0042] In an aspect is provided a method of treating McCune-Albright Syndrome, said method including administering to a subject in need thereof an effective amount of a compound described herein.
[0043] In an aspect is provided a Gas protein covalently bonded to a compound as described herein. Gas is in the GTP state. In embodiments, Gas is in the GDP state. In embodiments, the compound is bonded to a cysteine residue of the protein.
[0044] In embodiments, the Gas protein has the structure:
Figure imgf000008_0001
[0045] W together with the -CH2S- to which it is attached form said Gas protein covalently bonded to a compound.
[0046] L3 is substituted or unsubstituted alkylene or substituted or unsubstituted heteroalkylene.
Figure imgf000008_0002
[0048] In embodiments, the compound is bonded to cysteine 201. In embodiments, the compound is bonded to cysteine 237.
[0049] In an aspect is provided a Gas protein covalently bonded to a portion of a compound of as described herein.
[0050] In an aspect is provided a Gas protein covalently bonded to a Gas small molecule inhibitor at R201C. In embodiments, the Gas protein is a GTP-bound Gas protein. In embodiments, the Gas protein is a GDP-bound Gas protein.
[0051] In an aspect is provided a A Gas protein covalently bonded to a Gas small molecule inhibitor at C237.
[0052] In embodiments, the Gas protein is a GTP-bound Gas protein. In embbodiments, the Gas protein is a GDP-bound Gas protein.
[0053] In an aspect is provided a method of treating cancer including administering a Gas cysteine 201 covalent inhibitor. The Gas cysteine 201 covalent inhibitor is a compound as described herein.
[0054] In an aspect is provided a method of treating cancer including administering a Gas cysteine 237 covalent inhibitor. The Gas cysteine 237 covalent inhibitor is a compound as described herein.
[0055] Other aspects are disclosed infra.
BRIEF DESCRIPTION OF THE DRAWINGS
[0056] FIG. 1A shows that crystal structure of GNAS(R201C) GDP shows Cys 201, switch-I, switch-II, and switch-III (PDB: 6AU6).
[0057] FIGS. 1B-1D show alignment of crystal structure of Gaq-GDP-YM254890 (PDB code 3AH8) with that of Gas-GTPyS (PDB code 1AZT). FIG. IB shows YM254890 bound into a pocket surrounded by switch I and the a-helix and b-sheet linked by switch I. FIG. 1C shows that crystal structure of Gas-GTPyS complex has a very similar domain-arrangement to that of Gaq-GDP-YM254890 complex. FIG. ID shows comparison with the local structure of YM254890-binding pocket in Gaq reveals a similar binding pocket in Gas.
[0058] FIGS. 1E-1G show structural information for design of a linker to connect YM254890 or its analogues with the cysteine mutation. FIG. IE shows that the electrostatic surface of Gaq reveals a grove between the helical domain and Ras-like domain (PDB code 3AH8). FIG. IF shows that local structure of YM254890-binding pocket of Gaq and the distance between R183 and YM254890. FIG. 1G shows that YM254890 is aligned at where the potential inhibitor-binding pocket in Gas. The hydrophilic residues in the grove between the helical domain and Ras-like domain are showed as sticks.
[0059] FIG. 2 shows evaluation of the GTP occupancy of the R201C mutant in the presence of excess GTP.
[0060] FIGS. 3A-3C show motidification of C201 by acrylamide. FIG. 3A shows that the reaction between the cysteine side chain and acrylamidine (Acr). FIG. 3B shows that modification of C201 by Acr decreased the adenylyl cyclase-activating activity of the GDP- bound R201C/C237S mutant in the presence Gpi/y2(C68S). The data represents the mean ± SE of three independent measurements. FIG. 3C shows that modification of C201 by Acr increased the single turnover GTPase activity of the R201C/C237S mutant to a level close to that of the C237S mutant. The data represents the mean ± SD of at least three independent measurements.
[0061] FIG. 4A shows a class of compounds with a urea moiety were identified in a tethering screen, in which 2 mM GDP-bound Gas(R201C/C237S) was incubated with 200 mM tethering compound and 200 pM b-mercaptoethanol (BME) at room temperature for 2 hours.
[0062] FIG. 4B shows evaluation of the reactivity of compound 1H11 against Gas using a competition assay. 2 pM Wild-type or the R201C/C237S mutant Gas in the GDP or GNP (5'-Guanylyl imidodiphosphate)-bound state was incubated with 50 pM compound 1H11 and various concentration of BME at room temperature for 2 hours.
[0063] FIGS. 5A-5B show preliminary structure-activity relationship (SAR) analysis of 1H11. Covalent molecules from the tethering library (FIG. 5 A) were tested for their ability to label different Gas mutants (FIG. 5B).
[0064] FIGS. 6A-6B show preliminary structure-activity relationship (SAR) analysis of 1H11. Covalent molecules containing an aryl urea moiety (FIG. 6 A) were tested for their BME50 values (FIG. 6B). DETAILED DESCRIPTION
I. Definitions
[0065] The abbreviations used herein have their conventional meaning within the chemical and biological arts. The chemical structures and formulae set forth herein are constructed according to the standard rules of chemical valency known in the chemical arts.
[0066] Where substituent groups are specified by their conventional chemical formulae, written from left to right, they equally encompass the chemically identical substituents that would result from writing the structure from right to left, e.g., -CH2O- is equivalent to - OCH2-.
[0067] The term “alkyl,” by itself or as part of another substituent, means, unless otherwise stated, a straight (i.e., unbranched) or branched carbon chain (or carbon), or combination thereof, which may be fully saturated, mono- or polyunsaturated and can include mono-, di- and multivalent radicals. The alkyl may include a designated number of carbons (e.g., C1-C10 means one to ten carbons). In embodiments, the alkyl is fully saturated. In embodiments, the alkyl is monounsaturated. In embodiments, the alkyl is polyunsaturated. Alkyl is an uncyclized chain. Examples of saturated hydrocarbon radicals include, but are not limited to, groups such as methyl, ethyl, n-propyl, isopropyl, n-butyl, t-butyl, isobutyl, sec-butyl, methyl, homologs and isomers of, for example, n-pentyl, n-hexyl, n-heptyl, n-octyl, and the like. An unsaturated alkyl group is one having one or more double bonds or triple bonds. Examples of unsaturated alkyl groups include, but are not limited to, vinyl, 2-propenyl, crotyl, 2- isopentenyl, 2-(butadienyl), 2,4-pentadienyl, 3-(l,4-pentadienyl), ethynyl, 1- and 3-propynyl, 3-butynyl, and the higher homologs and isomers. An alkoxy is an alkyl attached to the remainder of the molecule via an oxygen linker (-0-). An alkyl moiety may be an alkenyl moiety. An alkyl moiety may be an alkynyl moiety. An alkenyl includes one or more double bonds. An alkynyl includes one or more triple bonds.
[0068] The term “alkylene,” by itself or as part of another substituent, means, unless otherwise stated, a divalent radical derived from an alkyl, as exemplified, but not limited by, - CH2CH2CH2CH2-. Typically, an alkyl (or alkylene) group will have from 1 to 24 carbon atoms, with those groups having 10 or fewer carbon atoms being preferred herein. A “lower alkyl” or “lower alkylene” is a shorter chain alkyl or alkylene group, generally having eight or fewer carbon atoms. The term “alkenylene,” by itself or as part of another substituent, means, unless otherwise stated, a divalent radical derived from an alkene. The term “alkynylene” by itself or as part of another substituent, means, unless otherwise stated, a divalent radical derived from an alkyne. In embodiments, the alkylene is fully saturated. In embodiments, the alkylene is monounsaturated. In embodiments, the alkylene is polyunsaturated. An alkenylene includes one or more double bonds. An alkynylene includes one or more triple bonds.
[0069] The term “heteroalkyl,” by itself or in combination with another term, means, unless otherwise stated, a stable straight or branched chain, or combinations thereof, including at least one carbon atom and at least one heteroatom (e.g., O, N, P, Si, and S), and wherein the nitrogen and sulfur atoms may optionally be oxidized, and the nitrogen heteroatom may optionally be quatemized. The heteroatom(s) (e.g., O, N, S, Si, or P) may be placed at any interior position of the heteroalkyl group or at the position at which the alkyl group is attached to the remainder of the molecule. Heteroalkyl is an uncyclized chain. Examples include, but are not limited to: -CH2-CH2-0-CH3, -CH2-CH2-NH-CH3, -CH2-CH2-N(CH3)- CH3, -CH2-S-CH2-CH3, -CH2-S-CH2, -S(0)-CH3, -CH2-CH2-S(0)2-CH3, -CH=CH-O-CH3, - Si(CH3)3, -CH2-CH=N-OCH3, -CH=CH-N(CH3)-CH3, -0-CH3, -0-CH2-CH3, and -CN. Up to two or three heteroatoms may be consecutive, such as, for example, -CH2-NH-OCH3 and - CH2-0-Si(CH3)3. A heteroalkyl moiety may include one heteroatom (e.g., O, N, S, Si, or P). A heteroalkyl moiety may include two optionally different heteroatoms (e.g., O, N, S, Si, or P). A heteroalkyl moiety may include three optionally different heteroatoms (e.g., O, N, S,
Si, or P). A heteroalkyl moiety may include four optionally different heteroatoms (e.g., O, N, S, Si, or P). A heteroalkyl moiety may include five optionally different heteroatoms (e.g., O, N, S, Si, or P). A heteroalkyl moiety may include up to 8 optionally different heteroatoms (e.g., O, N, S, Si, or P). The term “heteroalkenyl,” by itself or in combination with another term, means, unless otherwise stated, a heteroalkyl including at least one double bond. A heteroalkenyl may optionally include more than one double bond and/or one or more triple bonds in additional to the one or more double bonds. The term “heteroalkynyl,” by itself or in combination with another term, means, unless otherwise stated, a heteroalkyl including at least one triple bond. A heteroalkynyl may optionally include more than one triple bond and/or one or more double bonds in additional to the one or more triple bonds. In embodiments, the heteroalkyl is fully saturated. In embodiments, the heteroalkyl is monounsaturated. In embodiments, the heteroalkyl is polyunsaturated. [0070] Similarly, the term “heteroalkylene,” by itself or as part of another substituent, means, unless otherwise stated, a divalent radical derived from heteroalkyl, as exemplified, but not limited by, -CH2-CH2-S-CH2-CH2- and -CH2-S-CH2-CH2-NH-CH2-. For heteroalkylene groups, heteroatoms can also occupy either or both of the chain termini (e.g., alkyleneoxy, alkylenedioxy, alkyleneamino, alkylenediamino, and the like). Still further, for alkylene and heteroalkylene linking groups, no orientation of the linking group is implied by the direction in which the formula of the linking group is written. For example, the formula - C(0)2R'- represents both -C(0)2R'- and -R'C(0)2-. As described above, heteroalkyl groups, as used herein, include those groups that are attached to the remainder of the molecule through a heteroatom, such as -C(0)R', -C(0)NR', -NR'R", -OR', -SR', and/or -SO2R'. Where “heteroalkyl” is recited, followed by recitations of specific heteroalkyl groups, such as - NR'R" or the like, it will be understood that the terms heteroalkyl and -NR'R" are not redundant or mutually exclusive. Rather, the specific heteroalkyl groups are recited to add clarity. Thus, the term “heteroalkyl” should not be interpreted herein as excluding specific heteroalkyl groups, such as -NR'R" or the like. The term “heteroalkenylene,” by itself or as part of another substituent, means, unless otherwise stated, a divalent radical derived from a heteroalkene. The term “heteroalkynylene” by itself or as part of another substituent, means, unless otherwise stated, a divalent radical derived from a heteroalkyne. In embodiments, the heteroalkylene is fully saturated. In embodiments, the heteroalkylene is monounsaturated. In embodiments, the heteroalkylene is polyunsaturated. A heteroalkenylene includes one or more double bonds. A heteroalkynylene includes one or more triple bonds.
[0071] The terms “cycloalkyl” and “heterocycloalkyl,” by themselves or in combination with other terms, mean, unless otherwise stated, cyclic versions of “alkyl” and “heteroalkyl,” respectively. Cycloalkyl and heterocycloalkyl are not aromatic. Additionally, for heterocycloalkyl, a heteroatom can occupy the position at which the heterocycle is attached to the remainder of the molecule. Examples of cycloalkyl include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, 1 -cyclohexenyl, 3-cyclohexenyl, cycloheptyl, and the like. Examples of heterocycloalkyl include, but are not limited to, 1- (1,2,5,6-tetrahydropyridyl), 1-piperidinyl, 2-piperidinyl, 3-piperidinyl, 4-morpholinyl, 3- morpholinyl, tetrahydrofuran-2-yl, tetrahydrofuran-3-yl, tetrahydrothien-2-yl, tetrahydrothien-3-yl, 1-piperazinyl, 2-piperazinyl, and the like. A “cycloalkylene” and a “heterocycloalkylene,” alone or as part of another substituent, means a divalent radical derived from a cycloalkyl and heterocycloalkyl, respectively. In embodiments, the cycloalkyl is frilly saturated. In embodiments, the cycloalkyl is monounsaturated. In embodiments, the cycloalkyl is polyunsaturated. In embodiments, the heterocycloalkyl is fully saturated. In embodiments, the heterocycloalkyl is monounsaturated. In embodiments, the heterocycloalkyl is polyunsaturated.
[0072] In embodiments, the term “cycloalkyl” means a monocyclic, bicyclic, or a multicyclic cycloalkyl ring system. In embodiments, monocyclic ring systems are cyclic hydrocarbon groups containing from 3 to 8 carbon atoms, where such groups can be saturated or unsaturated, but not aromatic. In embodiments, cycloalkyl groups are fully saturated. A bicyclic or multicyclic cycloalkyl ring system refers to multiple rings fused together wherein at least one of the fused rings is a cycloalkyl ring and wherein the multiple rings are attached to the parent molecular moiety through any carbon atom contained within a cycloalkyl ring of the multiple rings.
[0073] In embodiments, a cycloalkyl is a cycloalkenyl. The term “cycloalkenyl” is used in accordance with its plain ordinary meaning. In embodiments, a cycloalkenyl is a monocyclic, bicyclic, or a multicyclic cycloalkenyl ring system. A bicyclic or multicyclic cycloalkenyl ring system refers to multiple rings fused together wherein at least one of the fused rings is a cycloalkenyl ring and wherein the multiple rings are attached to the parent molecular moiety through any carbon atom contained within a cycloalkenyl ring of the multiple rings.
[0074] In embodiments, the term “heterocycloalkyl” means a monocyclic, bicyclic, or a multicyclic heterocycloalkyl ring system. In embodiments, heterocycloalkyl groups are fully saturated. A bicyclic or multicyclic heterocycloalkyl ring system refers to multiple rings fused together wherein at least one of the fused rings is a heterocycloalkyl ring and wherein the multiple rings are attached to the parent molecular moiety through any atom contained within a heterocycloalkyl ring of the multiple rings.
[0075] The terms “halo” or “halogen,” by themselves or as part of another substituent, mean, unless otherwise stated, a fluorine, chlorine, bromine, or iodine atom. Additionally, terms such as “haloalkyl” are meant to include monohaloalkyl and polyhaloalkyl. For example, the term “halo(Ci-C4)alkyl” includes, but is not limited to, fluoromethyl, difluoromethyl, trifluoromethyl, 2,2,2-trifluoroethyl, 4-chlorobutyl, 3-bromopropyl, and the like. [0076] The term “acyl” means, unless otherwise stated, -C(0)R where R is a substituted or unsubstituted alkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl.
[0077] The term “aryl” means, unless otherwise stated, a polyunsaturated, aromatic, hydrocarbon substituent, which can be a single ring or multiple rings (preferably from 1 to 3 rings) that are fused together (i.e., a fused ring aryl) or linked covalently. A fused ring aryl refers to multiple rings fused together wherein at least one of the fused rings is an aryl ring and wherein the multiple rings are attached to the parent molecular moiety through any carbon atom contained within an aryl ring of the multiple rings. The term “heteroaryl” refers to aryl groups (or rings) that contain at least one heteroatom such as N, O, or S, wherein the nitrogen and sulfur atoms are optionally oxidized, and the nitrogen atom(s) are optionally quatemized. Thus, the term “heteroaryl” includes fused ring heteroaryl groups (i.e., multiple rings fused together wherein at least one of the fused rings is a heteroaromatic ring and wherein the multiple rings are attached to the parent molecular moiety through any atom contained within a heteroaromatic ring of the multiple rings). A 5,6-fused ring heteroarylene refers to two rings fused together, wherein one ring has 5 members and the other ring has 6 members, and wherein at least one ring is a heteroaryl ring. Likewise, a 6,6-fused ring heteroarylene refers to two rings fused together, wherein one ring has 6 members and the other ring has 6 members, and wherein at least one ring is a heteroaryl ring. And a 6,5 -fused ring heteroarylene refers to two rings fused together, wherein one ring has 6 members and the other ring has 5 members, and wherein at least one ring is a heteroaryl ring. A heteroaryl group can be attached to the remainder of the molecule through a carbon or heteroatom. Nonlimiting examples of aryl and heteroaryl groups include phenyl, naphthyl, pyrrolyl, pyrazolyl, pyridazinyl, triazinyl, pyrimidinyl, imidazolyl, pyrazinyl, purinyl, oxazolyl, isoxazolyl, thiazolyl, furyl, thienyl, pyridyl, pyrimidyl, benzothiazolyl, benzoxazoyl benzimidazolyl, benzofuran, isobenzofuranyl, indolyl, isoindolyl, benzothiophenyl, isoquinolyl, quinoxalinyl, quinolyl, 1 -naphthyl, 2-naphthyl, 4-biphenyl, 1 -pyrrolyl, 2-pyrrolyl, 3-pyrrolyl, 3-pyrazolyl, 2-imidazolyl, 4-imidazolyl, pyrazinyl, 2-oxazolyl, 4-oxazolyl, 2-phenyl-4-oxazolyl, 5- oxazolyl, 3-isoxazolyl, 4-isoxazolyl, 5-isoxazolyl, 2-thiazolyl, 4-thiazolyl, 5-thiazolyl, 2- furyl, 3 -furyl, 2-thienyl, 3 -thienyl, 2-pyridyl, 3 -pyridyl, 4-pyridyl, 2-pyrimidyl, 4-pyrimidyl,
5 -benzothiazolyl, purinyl, 2-benzimidazolyl, 5-indolyl, 1 -isoquinolyl, 5 -isoquinolyl, 2- quinoxalinyl, 5-quinoxalinyl, 3-quinolyl, and 6-quinolyl. Substituents for each of the above noted aryl and heteroaryl ring systems are selected from the group of acceptable substituents described below. An “arylene” and a “heteroarylene,” alone or as part of another substituent, mean a divalent radical derived from an aryl and heteroaryl, respectively. A heteroaryl group substituent may be -O- bonded to a ring heteroatom nitrogen.
[0078] A fused ring heterocyloalkyl-aryl is an aryl fused to a heterocycloalkyl. A fused ring heterocycloalkyl-heteroaryl is a heteroaryl fused to a heterocycloalkyl. A fused ring heterocycloalkyl-cycloalkyl is a heterocycloalkyl fused to a cycloalkyl. A fused ring heterocycloalkyl-heterocycloalkyl is a heterocycloalkyl fused to another heterocycloalkyl. Fused ring heterocycloalkyl-aryl, fused ring heterocycloalkyl-heteroaryl, fused ring heterocycloalkyl-cycloalkyl, or fused ring heterocycloalkyl-heterocycloalkyl may each independently be unsubstituted or substituted with one or more of the substituents described herein.
[0079] Spirocyclic rings are two or more rings wherein adjacent rings are attached through a single atom. The individual rings within spirocyclic rings may be identical or different. Individual rings in spirocyclic rings may be substituted or unsubstituted and may have different substituents from other individual rings within a set of spirocyclic rings. Possible substituents for individual rings within spirocyclic rings are the possible substituents for the same ring when not part of spirocyclic rings (e.g. substituents for cycloalkyl or heterocycloalkyl rings). Spirocylic rings may be substituted or unsubstituted cycloalkyl, substituted or unsubstituted cycloalkylene, substituted or unsubstituted heterocycloalkyl or substituted or unsubstituted heterocycloalkylene and individual rings within a spirocyclic ring group may be any of the immediately previous list, including having all rings of one type (e.g. all rings being substituted heterocycloalkylene wherein each ring may be the same or different substituted heterocycloalkylene). When referring to a spirocyclic ring system, heterocyclic spirocyclic rings means a spirocyclic rings wherein at least one ring is a heterocyclic ring and wherein each ring may be a different ring. When referring to a spirocyclic ring system, substituted spirocyclic rings means that at least one ring is substituted and each substituent may optionally be different.
[0080] The symbol “ . ” denotes the point of attachment of a chemical moiety to the remainder of a molecule or chemical formula. [0081] The term “oxo,” as used herein, means an oxygen that is double bonded to a carbon atom.
[0082] The term “alkylsulfonyl,” as used herein, means a moiety having the formula -S(02)-R', where R' is a substituted or unsubstituted alkyl group as defined above. R' may have a specified number of carbons (e.g., “C1-C4 alkylsulfonyl”).
[0083] The term “alkylarylene” as an arylene moiety covalently bonded to an alkylene moiety (also referred to herein as an alkylene linker). In embodiments, the alkylarylene group has the formula:
Figure imgf000017_0001
[0084] An alkylarylene moiety may be substituted (e.g. with a substituent group) on the alkylene moiety or the arylene linker (e.g. at carbons 2, 3, 4, or 6) with halogen, oxo, -N3, - CF3, -CCI3, -CBr3, -CI3, -CN, -CHO, -OH, -NH2, -COOH, -CONH2, -NO2, -SH, -S02CH3 - S03H, , -OSOsH, -SO2NH2, -NHNH2, -ONH2, -NHC(0)NHNH2, substituted or unsubstituted C1-C5 alkyl or substituted or unsubstituted 2 to 5 membered heteroalkyl). In embodiments, the alkylarylene is unsubstituted.
[0085] Each of the above terms (e.g., “alkyl,” “heteroalkyl,” “cycloalkyl,” “heterocycloalkyl,” “aryl,” and “heteroaryl”) includes both substituted and unsubstituted forms of the indicated radical. Preferred substituents for each type of radical are provided below.
[0086] Substituents for the alkyl and heteroalkyl radicals (including those groups often referred to as alkylene, alkenyl, heteroalkylene, heteroalkenyl, alkynyl, cycloalkyl, heterocycloalkyl, cycloalkenyl, and heterocycloalkenyl) can be one or more of a variety of groups selected from, but not limited to, -OR', =0, =NR', =N-OR', -NR'R", -SR', -halogen, - SiR'R"R'", -OC(0)R', -C(0)R', -CO2R', -CONR'R", -OC(0)NR'R", -NR"C(0)R', -NR'- C(0)NR"R'", -NR"C(0)2R', -NR-C(NR'R"R'")=NR"", -NR-C(NR'R")=NR'", -S(0)R', - S(0)2R', -S(0)2NR'R", -NRSO2R', -NR'NR"R'", -ONR'R", -NR'C(0)NR"NR'"R"", -CN, - NO2, -NR'SOiR", -NR'C(0)R", -NR'C(0)-OR", -NR'OR", in a number ranging from zero to (2m'+l), where m' is the total number of carbon atoms in such radical. R, R', R", R'", and R"" each preferably independently refer to hydrogen, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl (e.g., aryl substituted with 1-3 halogens), substituted or unsubstituted heteroaryl, substituted or unsubstituted alkyl, alkoxy, or thioalkoxy groups, or arylalkyl groups. When a compound described herein includes more than one R group, for example, each of the R groups is independently selected as are each R', R", R'", and R"" group when more than one of these groups is present. When R' and R" are attached to the same nitrogen atom, they can be combined with the nitrogen atom to form a 4-, 5-, 6-, or 7- membered ring. For example, -NR'R" includes, but is not limited to, 1-pyrrolidinyl and 4- morpholinyl. From the above discussion of substituents, one of skill in the art will understand that the term “alkyl” is meant to include groups including carbon atoms bound to groups other than hydrogen groups, such as haloalkyl (e.g., -CF3 and -CH2CF3) and acyl (e.g., - C(0)CH3, -C(0)CF3, -C(0)CH20CH3, and the like).
[0087] Similar to the substituents described for the alkyl radical, substituents for the aryl and heteroaryl groups are varied and are selected from, for example: -OR', -NR'R", -SR', - halogen, -SiR'R"R'", -0C(0)R', -C(0)R', -CO2R', -CONR'R", -0C(0)NR'R", -NR"C(0)R', - NR'-C(0)NR"R'", -NR"C(0)2R', -NR-C(NR'R"R'")=NR"", -NR-C(NR'R")=NR'", -S(0)R', - S(0)2R', -S(0)2NR'R", -NRSO2R', -NR'NR"R'", -ONR'R", -NR'C(0)NR"NR'"R"", -CN, - NO2, -R', -N3, -CH(Ph)2, fluoro(Ci-C4)alkoxy, and fluoro(Ci-C4)alkyl, -NR'S02R", - NR'C(0)R", -NR'C(0)-0R", -NR'OR", in a number ranging from zero to the total number of open valences on the aromatic ring system; and where R', R", R'", and R"" are preferably independently selected from hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, and substituted or unsubstituted heteroaryl. When a compound described herein includes more than one R group, for example, each of the R groups is independently selected as are each R', R", R'", and R"" groups when more than one of these groups is present.
[0088] Substituents for rings (e.g. cycloalkyl, heterocycloalkyl, aryl, heteroaryl, cycloalkylene, heterocycloalkylene, arylene, or heteroarylene) may be depicted as substituents on the ring rather than on a specific atom of a ring (commonly referred to as a floating substituent). In such a case, the substituent may be attached to any of the ring atoms (obeying the rules of chemical valency) and in the case of fused rings or spirocyclic rings, a substituent depicted as associated with one member of the fused rings or spirocyclic rings (a floating substituent on a single ring), may be a substituent on any of the fused rings or spirocyclic rings (a floating substituent on multiple rings). When a substituent is attached to a ring, but not a specific atom (a floating substituent), and a subscript for the substituent is an integer greater than one, the multiple substituents may be on the same atom, same ring, different atoms, different fused rings, different spirocyclic rings, and each substituent may optionally be different. Where a point of attachment of a ring to the remainder of a molecule is not limited to a single atom (a floating substituent), the attachment point may be any atom of the ring and in the case of a fused ring or spirocyclic ring, any atom of any of the fused rings or spirocyclic rings while obeying the rules of chemical valency. Where a ring, fused rings, or spirocyclic rings contain one or more ring heteroatoms and the ring, fused rings, or spirocyclic rings are shown with one more floating substituents (including, but not limited to, points of attachment to the remainder of the molecule), the floating substituents may be bonded to the heteroatoms. Where the ring heteroatoms are shown bound to one or more hydrogens (e.g. a ring nitrogen with two bonds to ring atoms and a third bond to a hydrogen) in the structure or formula with the floating substituent, when the heteroatom is bonded to the floating substituent, the substituent will be understood to replace the hydrogen, while obeying the rules of chemical valency.
[0089] Two or more substituents may optionally be joined to form aryl, heteroaryl, cycloalkyl, or heterocycloalkyl groups. Such so-called ring-forming substituents are typically, though not necessarily, found attached to a cyclic base structure. In one embodiment, the ring-forming substituents are attached to adjacent members of the base structure. For example, two ring-forming substituents attached to adjacent members of a cyclic base structure create a fused ring structure. In another embodiment, the ring-forming substituents are attached to a single member of the base structure. For example, two ring-forming substituents attached to a single member of a cyclic base structure create a spirocyclic structure. In yet another embodiment, the ring-forming substituents are attached to non- adjacent members of the base structure.
[0090] Two of the substituents on adjacent atoms of the aryl or heteroaryl ring may optionally form a ring of the formula -T-C(0)-(CRR')q-U-, wherein T and U are independently -NR-, -0-, -CRR'-, or a single bond, and q is an integer of from 0 to 3. Alternatively, two of the substituents on adjacent atoms of the aryl or heteroaryl ring may optionally be replaced with a substituent of the formula -A-(CH2)r-B-, wherein A and B are independently -CRR'-, -0-, -NR-, -S-, -S(O) -, -S(0)2-, -S(0)2NR'-, or a single bond, and r is an integer of from 1 to 4. One of the single bonds of the new ring so formed may optionally be replaced with a double bond. Alternatively, two of the substituents on adjacent atoms of the aryl or heteroaryl ring may optionally be replaced with a substituent of the formula - (CRR')s-X'- (C"R"R"')d-, where s and d are independently integers of from 0 to 3, and X' is - 0-, -NR'-, -S-, -S(O)-, -S(0)2-, or -S(0)2NR'-. The substituents R, R', R", and R'" are preferably independently selected from hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, and substituted or unsubstituted heteroaryl.
[0091] As used herein, the terms “heteroatom” or “ring heteroatom” are meant to include oxygen (O), nitrogen (N), sulfur (S), phosphorus (P), selenium (Se), and silicon (Si). In embodiments, the terms “heteroatom” or “ring heteroatom” are meant to include oxygen (O), nitrogen (N), sulfur (S), phosphorus (P), and silicon (Si).
[0092] A “substituent group,” as used herein, means a group selected from the following moieties:
(A) oxo, halogen, -CCI3, -CBr3, -CF3, -CI3, CHCk, -CHBr2, -CHF2, -CHI2, - CH2CI, -CH2Br, -CH2F, -CH2I, -CN, -OH, -NH2, -C(0)OH, -C(0)NH2, -NO2, -SH, -S 03H, -SO4H, -SO2NH2, -NHNH2, -ONH2, -NHC(0)NHNH2, -
NHC(0)NH2, -NHSO2H,
-NHC(0)H, -NHC(0)OH, -NHOH, -OCCl3, -OCF3, -OCBr3, -OCI3,-OCHCl2, -OCH Br2, -OCHI2, -OCHF2, -OCH2CI, -OCH2Br, -OCH2I, -OCH2F, -N3, unsubstituted alkyl (e.g., Ci-Cs alkyl, C1-C6 alkyl, or C1-C4 alkyl), unsubstituted heteroalkyl (e.g., 2 to 8 membered heteroalkyl, 2 to 6 membered heteroalkyl, or 2 to 4 membered heteroalkyl), unsubstituted cycloalkyl (e.g., C3-Cs cycloalkyl, C3-C6 cycloalkyl, or C5- C6 cycloalkyl), unsubstituted heterocycloalkyl (e.g., 3 to 8 membered heterocycloalkyl, 3 to 6 membered heterocycloalkyl, or 5 to 6 membered heterocycloalkyl), unsubstituted aryl (e.g., C6-C10 aryl, C10 aryl, or phenyl), or unsubstituted heteroaryl (e.g., 5 to 10 membered heteroaryl, 5 to 9 membered heteroaryl, or 5 to 6 membered heteroaryl), and
(B) alkyl (e.g., Ci-Cs alkyl, C1-C6 alkyl, or C1-C4 alkyl), heteroalkyl (e.g., 2 to 8 membered heteroalkyl, 2 to 6 membered heteroalkyl, or 2 to 4 membered heteroalkyl), cycloalkyl (e.g., C3-Cs cycloalkyl, C3-C6 cycloalkyl, or C5-C6 cycloalkyl), heterocycloalkyl (e.g., 3 to 8 membered heterocycloalkyl, 3 to 6 membered heterocycloalkyl, or 5 to 6 membered heterocycloalkyl), aryl (e.g., C6-C10 aryl, C10 aryl, or phenyl), heteroaryl (e.g., 5 to 10 membered heteroaryl, 5 to 9 membered heteroaryl, or 5 to 6 membered heteroaryl), substituted with at least one substituent selected from:
(i) oxo, halogen, -CCI3, -CBr3, -CF3, -CI3, CHC12, -CHBr2, -CHF2, -CHI2, - CH2CI, -CH2Br, -CH2F, -CH2I, -CN, -OH, -NH2, -C(0)0H, -C(0)NH2, -NO2, -SH, -SO3H, -SO4H, -SO2NH2, -NHNH2, -ONH2,
-NHC(0)NHNH2,-NHC(0)NH2, -NHSO2H,
-NHC(0)H, -NHC(0)0H, -NHOH, -OCCI3, -OCF3, -OCBr3, -OCI3,-OCHCl2, -OC HBr2, -OCHI2, -OCHF2, -OCH2CI, -OCH2Br, -OCH2I, -OCH2F, -N3, unsubstituted alkyl (e.g., Ci-Cs alkyl, C1-C6 alkyl, or C1-C4 alkyl), unsubstituted heteroalkyl (e.g., 2 to 8 membered heteroalkyl, 2 to 6 membered heteroalkyl, or 2 to 4 membered heteroalkyl), unsubstituted cycloalkyl (e.g., C3-C8 cycloalkyl, C3-C6 cycloalkyl, or C5-C6 cycloalkyl), unsubstituted heterocycloalkyl (e.g., 3 to 8 membered heterocycloalkyl, 3 to 6 membered heterocycloalkyl, or 5 to 6 membered heterocycloalkyl), unsubstituted aryl (e.g., C6-C10 aryl, C10 aryl, or phenyl), or unsubstituted heteroaryl (e.g., 5 to 10 membered heteroaryl, 5 to 9 membered heteroaryl, or 5 to 6 membered heteroaryl), and
(ii) alkyl (e.g., Ci-Cs alkyl, C1-C6 alkyl, or C1-C4 alkyl), heteroalkyl (e.g., 2 to 8 membered heteroalkyl, 2 to 6 membered heteroalkyl, or 2 to 4 membered heteroalkyl), cycloalkyl (e.g., C3-C8 cycloalkyl, C3-C6 cycloalkyl, or C5-C6 cycloalkyl), heterocycloalkyl (e.g., 3 to 8 membered heterocycloalkyl, 3 to 6 membered heterocycloalkyl, or 5 to 6 membered heterocycloalkyl), aryl (e.g., C6- C10 aryl, C10 aryl, or phenyl), heteroaryl (e.g., 5 to 10 membered heteroaryl, 5 to 9 membered heteroaryl, or 5 to 6 membered heteroaryl), substituted with at least one substituent selected from:
(a) oxo, halogen, -CCI3, -CBr3, -CF3, -CI3, CHC12, -CHBr2, -CHF2, -CHI2, - CH2CI, -CH2Br, -CH2F, -CH2I, -CN, -OH, -NH2, -C(0)OH, -C(0)NH2, -NO2, -SH
-SO3H, -SO4H, -SO2NH2, -NHNH2, -0NH2, -NHC(0)NHNH2,-NHC(0)NH2, -NHSO2H, -NHC(0)H, -NHC(0)0H, -NHOH, -OCCI3, -OCF3, -OCBr3, -OCI3,-0 CHCk, -OCHBr2, -0CHI2, -0CHF2, -0CH2CI, -OCH2Br, -OCH2I, -OCH2F, -N3, unsubstituted alkyl (e.g., Ci-Cs alkyl, C1-C6 alkyl, or C1-C4 alkyl), unsubstituted heteroalkyl (e.g., 2 to 8 membered heteroalkyl, 2 to 6 membered heteroalkyl, or 2 to 4 membered heteroalkyl), unsubstituted cycloalkyl (e.g., C3-C8 cycloalkyl, C3- C6 cycloalkyl, or C5-C6 cycloalkyl), unsubstituted heterocycloalkyl (e.g., 3 to 8 membered heterocycloalkyl, 3 to 6 membered heterocycloalkyl, or 5 to 6 membered heterocycloalkyl), unsubstituted aryl (e.g., C6-C10 aryl, C10 aryl, or phenyl), or unsubstituted heteroaryl (e.g., 5 to 10 membered heteroaryl, 5 to 9 membered heteroaryl, or 5 to 6 membered heteroaryl), and
(b) alkyl (e.g., Ci-Cs alkyl, C1-C6 alkyl, or C1-C4 alkyl), heteroalkyl (e.g., 2 to 8 membered heteroalkyl, 2 to 6 membered heteroalkyl, or 2 to 4 membered heteroalkyl), cycloalkyl (e.g., C3-C8 cycloalkyl, C3-C6 cycloalkyl, or C5-C6 cycloalkyl), heterocycloalkyl (e.g., 3 to 8 membered heterocycloalkyl, 3 to 6 membered heterocycloalkyl, or 5 to 6 membered heterocycloalkyl), aryl (e.g., C6- C10 aryl, C10 aryl, or phenyl), heteroaryl (e.g., 5 to 10 membered heteroaryl, 5 to 9 membered heteroaryl, or 5 to 6 membered heteroaryl), substituted with at least one substituent selected from: oxo, halogen, -CCI3, -CBr3, -CF3, -CI3,
CHCk, -CHBr2, -CHF2, -CHk, -
CH2CI, -CH2Br, -CH2F, -CH2I, -CN, -OH, -NH2, -C(0)0H, -C(0)NH2, -NO2, -SH, -SO3H,
-SO4H, -SO2NH2, -NHNH2, -ONH2, -NHC(0)NHNH2, -NHC(0)NH2, -NHSO2H, -NHC(0)H, -NHC(0)0H, -NHOH, -OCCI3, -OCF3, -OCBr3, -OCI3,-OCHCl2, -OC HBr2,
-OCHk, -OCHF2, -OCH2CI, -OCH2Br, -OCH2I, -OCH2F, -N3, unsubstituted alkyl (e.g., Ci-Cs alkyl, C1-C6 alkyl, or C1-C4 alkyl), unsubstituted heteroalkyl (e.g., 2 to 8 membered heteroalkyl, 2 to 6 membered heteroalkyl, or 2 to 4 membered heteroalkyl), unsubstituted cycloalkyl (e.g., C3-C8 cycloalkyl, C3-C6 cycloalkyl, or C5-C6 cycloalkyl), unsubstituted heterocycloalkyl (e.g., 3 to 8 membered heterocycloalkyl, 3 to 6 membered heterocycloalkyl, or 5 to 6 membered heterocycloalkyl), unsubstituted aryl (e.g., C6-C10 aryl, C10 aryl, or phenyl), or unsubstituted heteroaryl (e.g., 5 to 10 membered heteroaryl, 5 to 9 membered heteroaryl, or 5 to 6 membered heteroaryl). [0093] A “size-limited substituent” or “ size-limited substituent group,” as used herein, means a group selected from all of the substituents described above for a “substituent group,” wherein each substituted or unsubstituted alkyl is a substituted or unsubstituted C1-C20 alkyl, each substituted or unsubstituted heteroalkyl is a substituted or unsubstituted 2 to 20 membered heteroalkyl, each substituted or unsubstituted cycloalkyl is a substituted or unsubstituted C3-C8 cycloalkyl, each substituted or unsubstituted heterocycloalkyl is a substituted or unsubstituted 3 to 8 membered heterocycloalkyl, each substituted or unsubstituted aryl is a substituted or unsubstituted C6-C10 aryl, and each substituted or unsubstituted heteroaryl is a substituted or unsubstituted 5 to 10 membered heteroaryl.
[0094] A “lower substituent” or “ lower substituent group,” as used herein, means a group selected from all of the substituents described above for a “substituent group,” wherein each substituted or unsubstituted alkyl is a substituted or unsubstituted Ci-Cs alkyl, each substituted or unsubstituted heteroalkyl is a substituted or unsubstituted 2 to 8 membered heteroalkyl, each substituted or unsubstituted cycloalkyl is a substituted or unsubstituted C3- C7 cycloalkyl, each substituted or unsubstituted heterocycloalkyl is a substituted or unsubstituted 3 to 7 membered heterocycloalkyl, each substituted or unsubstituted aryl is a substituted or unsubstituted phenyl, and each substituted or unsubstituted heteroaryl is a substituted or unsubstituted 5 to 6 membered heteroaryl.
[0095] In some embodiments, each substituted group described in the compounds herein is substituted with at least one substituent group. More specifically, in some embodiments, each substituted alkyl, substituted heteroalkyl, substituted cycloalkyl, substituted heterocycloalkyl, substituted aryl, substituted heteroaryl, substituted alkylene, substituted heteroalkylene, substituted cycloalkylene, substituted heterocycloalkylene, substituted arylene, and/or substituted heteroarylene described in the compounds herein are substituted with at least one substituent group. In other embodiments, at least one or all of these groups are substituted with at least one size-limited substituent group. In other embodiments, at least one or all of these groups are substituted with at least one lower substituent group.
[0096] In other embodiments of the compounds herein, each substituted or unsubstituted alkyl may be a substituted or unsubstituted C1-C20 alkyl, each substituted or unsubstituted heteroalkyl is a substituted or unsubstituted 2 to 20 membered heteroalkyl, each substituted or unsubstituted cycloalkyl is a substituted or unsubstituted C3-C8 cycloalkyl, each substituted or unsubstituted heterocycloalkyl is a substituted or unsubstituted 3 to 8 membered heterocycloalkyl, each substituted or unsubstituted aryl is a substituted or unsubstituted C6- Cio aryl, and/or each substituted or unsubstituted heteroaryl is a substituted or unsubstituted 5 to 10 membered heteroaryl. In some embodiments of the compounds herein, each substituted or unsubstituted alkylene is a substituted or unsubstituted C1-C20 alkylene, each substituted or unsubstituted heteroalkylene is a substituted or unsubstituted 2 to 20 membered heteroalkylene, each substituted or unsubstituted cycloalkylene is a substituted or unsubstituted C3-C8 cycloalkylene, each substituted or unsubstituted heterocycloalkylene is a substituted or unsubstituted 3 to 8 membered heterocycloalkylene, each substituted or unsubstituted arylene is a substituted or unsubstituted C6-C10 arylene, and/or each substituted or unsubstituted heteroarylene is a substituted or unsubstituted 5 to 10 membered heteroarylene.
[0097] In some embodiments, each substituted or unsubstituted alkyl is a substituted or unsubstituted Ci-Cs alkyl, each substituted or unsubstituted heteroalkyl is a substituted or unsubstituted 2 to 8 membered heteroalkyl, each substituted or unsubstituted cycloalkyl is a substituted or unsubstituted C3-C7 cycloalkyl, each substituted or unsubstituted heterocycloalkyl is a substituted or unsubstituted 3 to 7 membered heterocycloalkyl, each substituted or unsubstituted aryl is a substituted or unsubstituted C6-C10 aryl, and/or each substituted or unsubstituted heteroaryl is a substituted or unsubstituted 5 to 9 membered heteroaryl. In some embodiments, each substituted or unsubstituted alkylene is a substituted or unsubstituted Ci-Cs alkylene, each substituted or unsubstituted heteroalkylene is a substituted or unsubstituted 2 to 8 membered heteroalkylene, each substituted or unsubstituted cycloalkylene is a substituted or unsubstituted C3-C7 cycloalkylene, each substituted or unsubstituted heterocycloalkylene is a substituted or unsubstituted 3 to 7 membered heterocycloalkylene, each substituted or unsubstituted arylene is a substituted or unsubstituted C6-C10 arylene, and/or each substituted or unsubstituted heteroarylene is a substituted or unsubstituted 5 to 9 membered heteroarylene. In some embodiments, the compound is a chemical species set forth in the Examples section, figures, or tables below.
[0098] In embodiments, a substituted or unsubstituted moiety (e.g., substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted alkylene, substituted or unsubstituted heteroalkylene, substituted or unsubstituted cycloalkylene, substituted or unsubstituted heterocycloalkylene, substituted or unsubstituted arylene, and/or substituted or unsubstituted heteroarylene) is unsubstituted (e.g., is an unsubstituted alkyl, unsubstituted heteroalkyl, unsubstituted cycloalkyl, unsubstituted heterocycloalkyl, unsubstituted aryl, unsubstituted heteroaryl, unsubstituted alkylene, unsubstituted heteroalkylene, unsubstituted cycloalkylene, unsubstituted heterocycloalkylene, unsubstituted arylene, and/or unsubstituted heteroarylene, respectively). In embodiments, a substituted or unsubstituted moiety (e.g., substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted alkylene, substituted or unsubstituted heteroalkylene, substituted or unsubstituted cycloalkylene, substituted or unsubstituted heterocycloalkylene, substituted or unsubstituted arylene, and/or substituted or unsubstituted heteroarylene) is substituted (e.g., is a substituted alkyl, substituted heteroalkyl, substituted cycloalkyl, substituted heterocycloalkyl, substituted aryl, substituted heteroaryl, substituted alkylene, substituted heteroalkylene, substituted cycloalkylene, substituted heterocycloalkylene, substituted arylene, and/or substituted heteroarylene, respectively).
[0099] In embodiments, a substituted moiety (e.g., substituted alkyl, substituted heteroalkyl, substituted cycloalkyl, substituted heterocycloalkyl, substituted aryl, substituted heteroaryl, substituted alkylene, substituted heteroalkylene, substituted cycloalkylene, substituted heterocycloalkylene, substituted arylene, and/or substituted heteroarylene) is substituted with at least one substituent group, wherein if the substituted moiety is substituted with a plurality of substituent groups, each substituent group may optionally be different. In embodiments, if the substituted moiety is substituted with a plurality of substituent groups, each substituent group is different.
[0100] In embodiments, a substituted moiety (e.g., substituted alkyl, substituted heteroalkyl, substituted cycloalkyl, substituted heterocycloalkyl, substituted aryl, substituted heteroaryl, substituted alkylene, substituted heteroalkylene, substituted cycloalkylene, substituted heterocycloalkylene, substituted arylene, and/or substituted heteroarylene) is substituted with at least one size-limited substituent group, wherein if the substituted moiety is substituted with a plurality of size-limited substituent groups, each size-limited substituent group may optionally be different. In embodiments, if the substituted moiety is substituted with a plurality of size-limited substituent groups, each size-limited substituent group is different.
[0101] In embodiments, a substituted moiety (e.g., substituted alkyl, substituted heteroalkyl, substituted cycloalkyl, substituted heterocycloalkyl, substituted aryl, substituted heteroaryl, substituted alkylene, substituted heteroalkylene, substituted cycloalkylene, substituted heterocycloalkylene, substituted arylene, and/or substituted heteroarylene) is substituted with at least one lower substituent group, wherein if the substituted moiety is substituted with a plurality of lower substituent groups, each lower substituent group may optionally be different. In embodiments, if the substituted moiety is substituted with a plurality of lower substituent groups, each lower substituent group is different.
[0102] In embodiments, a substituted moiety (e.g., substituted alkyl, substituted heteroalkyl, substituted cycloalkyl, substituted heterocycloalkyl, substituted aryl, substituted heteroaryl, substituted alkylene, substituted heteroalkylene, substituted cycloalkylene, substituted heterocycloalkylene, substituted arylene, and/or substituted heteroarylene) is substituted with at least one substituent group, size-limited substituent group, or lower substituent group; wherein if the substituted moiety is substituted with a plurality of groups selected from substituent groups, size-limited substituent groups, and lower substituent groups; each substituent group, size-limited substituent group, and/or lower substituent group may optionally be different. In embodiments, if the substituted moiety is substituted with a plurality of groups selected from substituent groups, size-limited substituent groups, and lower substituent groups; each substituent group, size-limited substituent group, and/or lower substituent group is different.
[0103] Certain compounds of the present disclosure possess asymmetric carbon atoms (optical or chiral centers) or double bonds; the enantiomers, racemates, diastereomers, tautomers, geometric isomers, stereoisometric forms that may be defined, in terms of absolute stereochemistry, as (i?)-or ( S )- or, as (D)- or (L)- for amino acids, and individual isomers are encompassed within the scope of the present disclosure. The compounds of the present disclosure do not include those that are known in art to be too unstable to synthesize and/or isolate. The present disclosure is meant to include compounds in racemic and optically pure forms. Optically active (R)- and ( S )-, or (D)- and (L)-isomers may be prepared using chiral synthons or chiral reagents, or resolved using conventional techniques. When the compounds described herein contain olefinic bonds or other centers of geometric asymmetry, and unless specified otherwise, it is intended that the compounds include both E and Z geometric isomers.
[0104] As used herein, the term “isomers” refers to compounds having the same number and kind of atoms, and hence the same molecular weight, but differing in respect to the structural arrangement or configuration of the atoms.
[0105] The term “tautomer,” as used herein, refers to one of two or more structural isomers which exist in equilibrium and which are readily converted from one isomeric form to another.
[0106] It will be apparent to one skilled in the art that certain compounds of this disclosure may exist in tautomeric forms, all such tautomeric forms of the compounds being within the scope of the disclosure.
[0107] Unless otherwise stated, structures depicted herein are also meant to include all stereochemical forms of the structure; i.e., the R and S configurations for each asymmetric center. Therefore, single stereochemical isomers as well as enantiomeric and diastereomeric mixtures of the present compounds are within the scope of the disclosure.
[0108] Unless otherwise stated, structures depicted herein are also meant to include compounds which differ only in the presence of one or more isotopically enriched atoms. For example, compounds having the present structures except for the replacement of a hydrogen by a deuterium or tritium, or the replacement of a carbon by 13C- or 14C-enriched carbon are within the scope of this disclosure.
[0109] The compounds of the present disclosure may also contain unnatural proportions of atomic isotopes at one or more of the atoms that constitute such compounds. For example, the compounds may be radiolabeled with radioactive isotopes, such as for example tritium (3H), iodine-125 (125I), or carbon-14 (14C). All isotopic variations of the compounds of the present disclosure, whether radioactive or not, are encompassed within the scope of the present disclosure.
[0110] It should be noted that throughout the application that alternatives are written in Markush groups, for example, each amino acid position that contains more than one possible amino acid. It is specifically contemplated that each member of the Markush group should be considered separately, thereby including another embodiment, and the Markush group is not to be read as a single unit. [0111] As used herein, the terms “bioconjugate” and “bioconjugate reactive moiety” refers to the resulting association between atoms or molecules of bioconjugate reactive groups. The association can be direct or indirect. For example, a conjugate between a first bioconjugate reactive group (e.g., -N¾, -C(0)0H, -N-hydroxysuccinimide, or -maleimide) and a second bioconjugate reactive group (e.g., sulfhydryl, sulfur-containing amino acid, amine, amine sidechain containing amino acid, or carboxylate) provided herein can be direct, e.g., by covalent bond or linker (e.g. a first linker of second linker), or indirect, e.g., by non-covalent bond (e.g. electrostatic interactions (e.g. ionic bond, hydrogen bond, halogen bond), van der Waals interactions (e.g. dipole-dipole, dipole-induced dipole, London dispersion), ring stacking (pi effects), hydrophobic interactions and the like). In embodiments, bioconjugates or bioconjugate linkers are formed using bioconjugate chemistry (i.e. the association of two bioconjugate reactive groups) including, but are not limited to nucleophilic substitutions (e.g., reactions of amines and alcohols with acyl halides, active esters), electrophilic substitutions (e.g., enamine reactions) and additions to carbon-carbon and carbon-heteroatom multiple bonds (e.g., Michael reaction, Diels-Alder addition). These and other useful reactions are discussed in, for example, March, ADVANCED ORGANIC CHEMISTRY, 3rd Ed., John Wiley & Sons, New York, 1985; Hermanson, BIOCONJUGATE TECHNIQUES, Academic Press, San Diego, 1996; and Feeney et al., MODIFICATION OF PROTEINS; Advances in Chemistry Series, Vol. 198, American Chemical Society, Washington, D.C., 1982. In embodiments, the first bioconjugate reactive group (e.g., maleimide moiety) is covalently attached to the second bioconjugate reactive group (e.g. a sulfhydryl). In embodiments, the first bioconjugate reactive group (e.g., haloacetyl moiety) is covalently attached to the second bioconjugate reactive group (e.g. a sulfhydryl). In embodiments, the first bioconjugate reactive group (e.g., pyridyl moiety) is covalently attached to the second bioconjugate reactive group (e.g. a sulfhydryl). In embodiments, the first bioconjugate reactive group (e.g., -N-hydroxysuccinimide moiety) is covalently attached to the second bioconjugate reactive group (e.g. an amine). In embodiments, the first bioconjugate reactive group (e.g., maleimide moiety) is covalently attached to the second bioconjugate reactive group (e.g. a sulfhydryl). In embodiments, the first bioconjugate reactive group (e.g., -sulfo-N- hydroxysuccinimide moiety) is covalently attached to the second bioconjugate reactive group (e.g. an amine). [0112] Useful bioconjugate reactive moieties used for bioconjugate chemistries herein include, for example:
(a) carboxyl groups and various derivatives thereof including, but not limited to, N-hydroxysuccinimide esters, N-hydroxybenztriazole esters, acid halides, acyl imidazoles, thioesters, p-nitrophenyl esters, alkyl, alkenyl, alkynyl and aromatic esters;
(b) hydroxyl groups which can be converted to esters, ethers, aldehydes, etc.
(c) haloalkyl groups wherein the halide can be later displaced with a nucleophilic group such as, for example, an amine, a carboxylate anion, thiol anion, carbanion, or an alkoxide ion, thereby resulting in the covalent attachment of a new group at the site of the halogen atom;
(d) dienophile groups which are capable of participating in Diels-Alder reactions such as, for example, maleimido or maleimide groups;
(e) aldehyde or ketone groups such that subsequent derivatization is possible via formation of carbonyl derivatives such as, for example, imines, hydrazones, semicarbazones or oximes, or via such mechanisms as Grignard addition or alkyllithium addition;
(f) sulfonyl halide groups for subsequent reaction with amines, for example, to form sulfonamides;
(g) thiol groups, which can be converted to disulfides, reacted with acyl halides, or bonded to metals such as gold, or react with maleimides;
(h) amine or sulfhydryl groups (e.g., present in cysteine), which can be, for example, acylated, alkylated or oxidized;
(i) alkenes, which can undergo, for example, cycloadditions, acylation, Michael addition, etc;
(j) epoxides, which can react with, for example, amines and hydroxyl compounds;
(k) phosphoramidites and other standard functional groups useful in nucleic acid synthesis;
(1) metal silicon oxide bonding; and (m) metal bonding to reactive phosphorus groups (e.g. phosphines) to form, for example, phosphate diester bonds.
(n) azides coupled to alkynes using copper catalyzed cycloaddition click chemistry.
(o) biotin conjugate can react with avidin or strepavidin to form an avidin- biotin complex or streptavidin-biotin complex.
[0113] The bioconjugate reactive groups can be chosen such that they do not participate in, or interfere with, the chemical stability of the conjugate described herein. Alternatively, a reactive functional group can be protected from participating in the crosslinking reaction by the presence of a protecting group. In embodiments, the bioconjugate comprises a molecular entity derived from the reaction of an unsaturated bond, such as a maleimide, and a sulfhydryl group.
[0114] “Analog,” or “analogue” is used in accordance with its plain ordinary meaning within Chemistry and Biology and refers to a chemical compound that is structurally similar to another compound (i.e., a so-called “reference” compound) but differs in composition, e.g., in the replacement of one atom by an atom of a different element, or in the presence of a particular functional group, or the replacement of one functional group by another functional group, or the absolute stereochemistry of one or more chiral centers of the reference compound. Accordingly, an analog is a compound that is similar or comparable in function and appearance but not in structure or origin to a reference compound.
[0115] The terms "a" or "an," as used in herein means one or more. In addition, the phrase "substituted with a[n]," as used herein, means the specified group may be substituted with one or more of any or all of the named substituents. For example, where a group, such as an alkyl or heteroaryl group, is "substituted with an unsubstituted C1-C20 alkyl, or unsubstituted 2 to 20 membered heteroalkyl," the group may contain one or more unsubstituted C1-C20 alkyls, and/or one or more unsubstituted 2 to 20 membered heteroalkyls.
[0116] Moreover, where a moiety is substituted with an R substituent, the group may be referred to as “R-substituted.” Where a moiety is R-substituted, the moiety is substituted with at least one R substituent and each R substituent is optionally different. Where a particular R group is present in the description of a chemical genus (such as Formula (I)), a Roman alphabetic symbol may be used to distinguish each appearance of that particular R group. For example, where multiple R13 substituents are present, each R13 substituent may be distinguished as R13A, R13B, R13C, R13D, etc., wherein each of R13A, R13B, R13C, R13D, etc. is defined within the scope of the definition of R13 and optionally differently.
[0117] “Oxidizing agent” is used in accordance with its ordinary plain meaning within chemistry and biology and refers to a substance that has the ability to oxidize other substances (i.e. removes electrons from the substance). The term “oxidizing agent” is a substance that, in the course of a chemical redox reaction, removes one or more electrons from a substance (e.g., the reactant), wherein the oxidizing agent gains one or more electrons from the substrate. In embodiments, an oxidizing agent is a chemical species that transfers electronegative atoms to another substrate (e.g., a reactant). In embodiments, the oxidizing agent is analogous to the term “electron acceptor” and may be used herein interchangeably. Non-limiting examples of oxidizing agents include oxygen (O2), ozone (O3), hydrogen peroxide (H2O2), nitric acid (HNO3), sulfuric acid (H2SO4), hexavalent chromium, pyridinium chlorochromate (PCC), iV-methylmorpholine-iV-oxide (NMO), chromium trioxide (CrC>3, Jones reagent), potassium permanganate (K2Mhq4), potassium nitrate (KNO3), Dess- Martin periodinane (DMP), 2-iodoxybenzoic acid (IBX), 2,2,6,6-tetramethylpiperidinyloxy (TEMPO), and Selectfluor® (F-TEDA-BF4, chloromethyl-4-fluoro-l,4- diazoniabicyclo[2.2.2]octane bis(tetrafluoroborate), potassium perchlorate, or ammonium persulfate.
[0118] The term “halogenating agent” is used in accordance with its ordinary plain meaning within chemistry and refers to a substance (e.g., compound or composition) that has the ability to incorporate one or more halogen atoms (e.g. bromination, dibromination tribromination, chlorination, dichlorination, trichlorination, iodination, diiodination, triiodination, fluorination, difluorination, trifluorination, etc.) into another substance (e.g., compound or composition). Halogenating agents include chlorinating agents, brominating agents, iodinating agents and fluorinating agents, wherein a chlorinating agent incorporates a chlorine atom, a brominating agent incorporates a bromine atom, an iodinating agent incorporates an iodine atom, or a fluorinating agent incorporates a fluorine atom.
Brominating agents include, but are not limited to, iV-bromosuccinimide (NBS), dibromoisocyanuric acid (DBI), bromine, bromotrichloromethane, l,2-dibromo-l,l,2,2- tetrachloroethane, carbon tetrabromide, tetrabutylammonium tribromide, trimethylphenylammonium tribromide, benzyltrimethylammonium tribromide, pyridinium bromide perbromide, 4-dimethylaminopyridinium bromide perbromide, 1 -butyl-3 - methylimidazolium tribromide, l,8-diazabicyclo[5.4.0]-7-undecene, hydrogen tribromide, N- bromophthalimide, iV-bromosaccharin, iV-bromoacetamide, 2-bromo-2-cyano-iVrV- dimethylacetamide, l,3-dibromo-5,5-dimethylhydantoin, monosodium bromoisocyanurate hydrate, boron tribromide, phosphorus tribromide, bromodimethylsulfonium bromide, 5,5- dibromomeldrum's acid, 2,4,4,6-tetrabromo-2,5-cyclohexadienone, or bis(2,4,6- trimethylpyridine)-bromonium hexafluorophosphate. Chlorinating agents include, but are not limited to, iV-chlorosuccinimide (NCS), thionyl chloride, methanesulfonyl chloride, trichloromethanesulfonyl chloride, tert- butyl hypochlorite, chloromethyl methyl ether, dichloromethyl methyl ether, methoxyacetyl chloride, oxalyl chloride, cyanuric chloride, N- chlorophthalimide, sodium dichloroisocyanurate, trichloroisocyanuric acid, chloramine B hydrate, o-chloramine T dihydrate, chloramine T trihydrate, dichloramine B, dichloramine T, benzyhrimethylammonium, tetrachloroiodate. Iodinating agents include, but are not limited to, iV-iodosuccinimide (NIS), l,3-diodo-5,5'-dimethylhidantoin (DIH), iodine, hydriodic acid, diiodomethane, l-chloro-2-iodoethane, carbon tetraiodide, tetramethylammonium dichloroiodate, benzyltrimethylammonium dichloroiodate, pyridine iodine monochloride, iV,iV-dimethyl-iV-(methylsulfanylmethylene)-ammonium iodide, iV-iodosaccharin, trimethylsilyl iodide, bis(pyridine)iodonium tetrafluoroborate, bis(2,4,6-trimethylpyridine)- iodonium hexafluorophosphate. In embodiments, the halogenating agent is not a fluorinating agent.
[0119] Descriptions of compounds of the present disclosure are limited by principles of chemical bonding known to those skilled in the art. Accordingly, where a group may be substituted by one or more of a number of substituents, such substitutions are selected so as to comply with principles of chemical bonding and to give compounds which are not inherently unstable and/or would be known to one of ordinary skill in the art as likely to be unstable under ambient conditions, such as aqueous, neutral, and several known physiological conditions. For example, a heterocycloalkyl or heteroaryl is attached to the remainder of the molecule via a ring heteroatom in compliance with principles of chemical bonding known to those skilled in the art thereby avoiding inherently unstable compounds.
[0120] The term “leaving group” is used in accordance with its ordinary meaning in chemistry and refers to a moiety (e.g., atom, functional group, molecule) that separates from the molecule following a chemical reaction (e.g., bond formation, reductive elimination, condensation, cross-coupling reaction) involving an atom or chemical moiety to which the leaving group is attached, also referred to herein as the “leaving group reactive moiety”, and a complementary reactive moiety (i.e. a chemical moiety that reacts with the leaving group reactive moiety) to form a new bond between the remnants of the leaving groups reactive moiety and the complementary reactive moiety. Thus, the leaving group reactive moiety and the complementary reactive moiety form a complementary reactive group pair. Non limiting examples of leaving groups include hydrogen, hydroxide, organotin moieties (e.g., organotin heteroalkyl), halogen (e.g., Br), perfluoroalkylsulfonates (e.g. triflate), tosylates, mesylates, water, alcohols, nitrate, phosphate, thioether, amines, ammonia, fluoride, carboxylate, phenoxides, boronic acid, boronate esters, and alkoxides. In embodiments, two molecules with leaving groups are allowed to contact, and upon a reaction and/or bond formation (e.g., acyloin condensation, aldol condensation, Claisen condensation, Stille reaction) the leaving groups separates from their respective molecule. In embodiments, a leaving group is a bioconjugate reactive moiety. In embodiments, at least two leaving groups (e.g., R1 and R13) are allowed to contact such that the leaving groups are sufficiently proximal to react, interact or physically touch. In embodiments, the leaving group is designed to facilitate the reaction.
[0121] The term “protecting group” is used in accordance with its ordinary meaning in organic chemistry and refers to a moiety covalently bound to a heteroatom to prevent reactivity of the heteroatom during one or more chemical reactions performed prior to removal of the protecting group. In embodiments, the protecting group is covalently bound to a heteroatom that is part of a heteroalkyl, heterocycloalkyl or heteroaryl moiety. Typically a protecting group is bound to a heteroatom (e.g., O) during a part of a multistep synthesis wherein it is not desired to have the heteroatom react (e.g., a chemical reduction) with a reagent. Following protection the protecting group may be removed (e.g., by modulating the pH). In embodiments the protecting group is an alcohol protecting group. Non-limiting examples of alcohol protecting groups include acetyl, benzoyl, benzyl, methoxymethyl ether (MOM), tetrahydropyranyl (THP), and silyl ether (e.g., trimethylsilyl (TMS), tert- butyl dimethylsilyl (TBS)). In embodiments the protecting group is an amine protecting group. Non-limiting examples of amine protecting groups include carbobenzyloxy (Cbz), p- methoxybenzyl carbonyl (Moz or MeOZ), ter/-butyl oxycarbonyl (BOC), 9- fluorenylmethyloxycarbonyl (FMOC), acetyl (Ac), benzoyl (Bz), benzyl (Bn), carbamate, p- methoxybenzyl ether (PMB), 3,4-dimethoxybenzyl (DMPM), p-methoxyphenyl (PMP), pivaloyl (Piv), tosyl (Ts), and phthalimide.
[0122] A person of ordinary skill in the art will understand when a variable (e.g., moiety or linker) of a compound or of a compound genus (e.g., a genus described herein) is described by a name or formula of a standalone compound with all valencies filled, the unfilled valence(s) of the variable will be dictated by the context in which the variable is used. For example, when a variable of a compound as described herein is connected (e.g., bonded) to the remainder of the compound through a single bond, that variable is understood to represent a monovalent form (i.e., capable of forming a single bond due to an unfilled valence) of a standalone compound (e.g., if the variable is named “methane” in an embodiment but the variable is known to be attached by a single bond to the remainder of the compound, a person of ordinary skill in the art would understand that the variable is actually a monovalent form of methane, i.e., methyl or -CH3). Likewise, for a linker variable (e.g., L1, L2, or L3 as described herein), a person of ordinary skill in the art will understand that the variable is the divalent form of a standalone compound (e.g., if the variable is assigned to “PEG” or “polyethylene glycol” in an embodiment but the variable is connected by two separate bonds to the remainder of the compound, a person of ordinary skill in the art would understand that the variable is a divalent (i.e., capable of forming two bonds through two unfilled valences) form of PEG instead of the standalone compound PEG).
[0123] The term “exogenous” refers to a molecule or substance (e.g., a compound, nucleic acid or protein) that originates from outside a given cell or organism. For example, an "exogenous promoter" as referred to herein is a promoter that does not originate from the plant it is expressed by. Conversely, the term "endogenous" or "endogenous promoter" refers to a molecule or substance that is native to, or originates within, a given cell or organism.
[0124] The term “lipid moiety” is used in accordance with its ordinary meaning in chemistry and refers to a hydrophobic molecule which is typically characterized by an aliphatic hydrocarbon chain. In embodiments, the lipid moiety includes a carbon chain of 3 to 100 carbons. In embodiments, the lipid moiety includes a carbon chain of 5 to 50 carbons. In embodiments, the lipid moiety includes a carbon chain of 5 to 25 carbons. In embodiments, the lipid moiety includes a carbon chain of 8 to 25 carbons. Lipid moieties may include saturated or unsaturated carbon chains, and may be optionally substituted. In embodiments, the lipid moiety is optionally substituted with a charged moiety at the terminal end. In embodiments, the lipid moiety is an alkyl or heteroalkyl optionally substituted with a carboxylic acid moiety at the terminal end.
[0125] A charged moiety refers to a functional group possessing an abundance of electron density (i.e. electronegative) or is deficient in electron density (i.e. electropositive). Nonlimiting examples of a charged moiety includes carboxylic acid, alcohol, phosphate, aldehyde, and sulfonamide. In embodiments, a charged moiety is capable of forming hydrogen bonds.
[0126] The term “coupling reagent” is used in accordance with its plain ordinary meaning in the arts and refers to a substance (e.g., a compound or solution) which participates in chemical reaction and results in the formation of a covalent bond (e.g., between bioconjugate reactive moieties, between a bioconjugate reactive moiety and the coupling reagent). In embodiments, the level of reagent is depleted in the course of a chemical reaction. This is in contrast to a solvent, which typically does not get consumed over the course of the chemical reaction. Non-limiting examples of coupling reagents include benzotriazol-l-yl- oxytripyrrolidinophosphonium hexafluorophosphate (PyBOP), 7-Azabenzotriazol-l- yloxy)tripyrrolidinophosphonium hexafluorophosphate (PyAOP), 6-Chloro-benzotriazole-l- yloxy-tris-pyrrolidinophosphonium hexafluorophosphate (PyClock), 1- [Bis(dimethylamino)methylene] - 1 H- 1 ,2,3 -triazolo [4, 5 -b]pyridinium 3 -oxid hexafluorophosphate (HATU), or 2-(lH-benzotriazol-l-yl)-l,l,3,3-tetramethyluronium hexafluorophosphate (HBTU).
[0127] The term “solution” is used in accor and refers to a liquid mixture in which the minor component (e.g., a solute or compound) is uniformly distributed within the major component (e.g., a solvent).
[0128] The term “organic solvent” as used herein is used in accordance with its ordinary meaning in chemistry and refers to a solvent which includes carbon. Non-limiting examples of organic solvents include acetic acid, acetone, acetonitrile, benzene, 1 -butanol, 2-butanol, 2-butanone, t-butyl alcohol, carbon tetrachloride, chlorobenzene, chloroform, cyclohexane, 1,2-dichloroethane, diethylene glycol, diethyl ether, diglyme (diethylene glycol , dimethyl ether), 1,2-dimethoxyethane (glyme, DME), dimethylformamide (DMF), dimethyl sulfoxide (DMSO), 1,4-dioxane, ethanol, ethyl acetate, ethylene glycol, glycerin, heptane, hexamethylphosphoramide (HMPA), hexamethylphosphorous, triamide (HMPT), hexane, methanol, methyl t-butyl ether (MTBE), methylene chloride, N-methyl-2- pyrrolidinone (NMP), nitromethane, pentane, petroleum ether (ligroine), 1 -propanol, 2- propanol, pyridine, tetrahydrofuran (THF), toluene, triethyl amine, o-xylene, m-xylene, or p- xylene. In embodiments, the organic solvent is or includes chloroform, dichloromethane, methanol, ethanol, tetrahydrofuran, or dioxane.
[0129] As used herein, the term “salt” refers to acid or base salts of the compounds used in the methods of the present invention. Illustrative examples of acceptable salts are mineral acid (hydrochloric acid, hydrobromic acid, phosphoric acid, and the like) salts, organic acid (acetic acid, propionic acid, glutamic acid, citric acid and the like) salts, quaternary ammonium (methyl iodide, ethyl iodide, and the like) salts.
[0130] The term “pharmaceutically acceptable salts” is meant to include salts of the active compounds that are prepared with relatively nontoxic acids or bases, depending on the particular substituents found on the compounds described herein. When compounds of the present disclosure contain relatively acidic functionalities, base addition salts can be obtained by contacting the neutral form of such compounds with a sufficient amount of the desired base, either neat or in a suitable inert solvent. Examples of pharmaceutically acceptable base addition salts include sodium, potassium, calcium, ammonium, organic amino, or magnesium salt, or a similar salt. When compounds of the present disclosure contain relatively basic functionalities, acid addition salts can be obtained by contacting the neutral form of such compounds with a sufficient amount of the desired acid, either neat or in a suitable inert solvent. Examples of pharmaceutically acceptable acid addition salts include those derived from inorganic acids like hydrochloric, hydrobromic, nitric, carbonic, monohydrogencarbonic, phosphoric, monohydrogenphosphoric, dihydrogenphosphoric, sulfuric, monohydrogensulfuric, hydriodic, or phosphorous acids and the like, as well as the salts derived from relatively nontoxic organic acids like acetic, propionic, isobutyric, maleic, malonic, benzoic, succinic, suberic, fumaric, lactic, mandelic, phthalic, benzenesulfonic, p- tolylsulfonic, citric, tartaric, oxalic, methanesulfonic, and the like. Also included are salts of amino acids such as arginate and the like, and salts of organic acids like glucuronic or galactunoric acids and the like (see, for example, Berge et al, “Pharmaceutical Salts”, Journal of Pharmaceutical Science, 1977, 66, 1-19). Certain specific compounds of the present disclosure contain both basic and acidic functionalities that allow the compounds to be converted into either base or acid addition salts. [0131] Thus, the compounds of the present disclosure may exist as salts, such as with pharmaceutically acceptable acids. The present disclosure includes such salts. Non-limiting examples of such salts include hydrochlorides, hydrobromides, phosphates, sulfates, methanesulfonates, nitrates, maleates, acetates, citrates, fumarates, proprionates, tartrates (e.g., (+)-tartrates, (-)-tartrates, or mixtures thereof including racemic mixtures), succinates, benzoates, and salts with amino acids such as glutamic acid, and quaternary ammonium salts (e.g. methyl iodide, ethyl iodide, and the like). These salts may be prepared by methods known to those skilled in the art.
[0132] The neutral forms of the compounds are preferably regenerated by contacting the salt with a base or acid and isolating the parent compound in the conventional manner. The parent form of the compound may differ from the various salt forms in certain physical properties, such as solubility in polar solvents.
[0133] In addition to salt forms, the present disclosure provides compounds, which are in a prodrug form. Prodrugs of the compounds described herein are those compounds that readily undergo chemical changes under physiological conditions to provide the compounds of the present disclosure. Prodrugs of the compounds described herein may be converted in vivo after administration. Additionally, prodrugs can be converted to the compounds of the present disclosure by chemical or biochemical methods in an ex vivo environment, such as, for example, when contacted with a suitable enzyme or chemical reagent.
[0134] Certain compounds of the present disclosure can exist in unsolvated forms as well as solvated forms, including hydrated forms. In general, the solvated forms are equivalent to unsolvated forms and are encompassed within the scope of the present disclosure. Certain compounds of the present disclosure may exist in multiple crystalline or amorphous forms. In general, all physical forms are equivalent for the uses contemplated by the present disclosure and are intended to be within the scope of the present disclosure.
[0135] “Pharmaceutically acceptable excipient” and “pharmaceutically acceptable carrier” refer to a substance that aids the administration of an active agent to and absorption by a subject and can be included in the compositions of the present disclosure without causing a significant adverse toxicological effect on the patient. Non-limiting examples of pharmaceutically acceptable excipients include water, NaCl, normal saline solutions, lactated Ringer’s, normal sucrose, normal glucose, binders, fillers, disintegrants, lubricants, coatings, sweeteners, flavors, salt solutions (such as Ringer's solution), alcohols, oils, gelatins, carbohydrates such as lactose, amylose or starch, fatty acid esters, hydroxymethycellulose, polyvinyl pyrrolidine, and colors, and the like. Such preparations can be sterilized and, if desired, mixed with auxiliary agents such as lubricants, preservatives, stabilizers, wetting agents, emulsifiers, salts for influencing osmotic pressure, buffers, coloring, and/or aromatic substances and the like that do not deleteriously react with the compounds of the disclosure. One of skill in the art will recognize that other pharmaceutical excipients are useful in the present disclosure.
[0136] The term "preparation" is intended to include the formulation of the active compound with encapsulating material as a carrier providing a capsule in which the active component with or without other carriers, is surrounded by a carrier, which is thus in association with it. Similarly, cachets and lozenges are included. Tablets, powders, capsules, pills, cachets, and lozenges can be used as solid dosage forms suitable for oral administration.
[0137] As used herein, the term "about” means a range of values including the specified value, which a person of ordinary skill in the art would consider reasonably similar to the specified value. In embodiments, about means within a standard deviation using measurements generally acceptable in the art. In embodiments, about means a range extending to +/- 10% of the specified value. In embodiments, about includes the specified value.
[0138] A “synergistic amount” as used herein refers to the sum of a first amount (e.g., an amount of a compound provided herein) and a second amount (e.g., a therapeutic agent) that results in a synergistic effect (i.e. an effect greater than an additive effect). Therefore, the terms "synergy", "synergism", "synergistic", "combined synergistic amount", and "synergistic therapeutic effect" which are used herein interchangeably, refer to a measured effect of the compound administered in combination where the measured effect is greater than the sum of the individual effects of each of the compounds provided herein administered alone as a single agent.
[0139] In embodiments, a synergistic amount may be about 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, 1.0, 1.1, 1.2, 1.3, 1.4, 1.5, 1.6, 1.7, 1.8, 1.9, 2.0, 2.1, 2.2, 2.3, 2.4, 2.5, 2.6, 2.7, 2.8,
2.9, 3.0, 3.1, 3.2, 3.3, 3.4, 3.5, 3.6, 3.7, 3.8, 3.9, 4.0, 4.1, 4.2, 4.3, 4.4, 4.5, 4.6, 4.7, 4.8, 4.9,
5.0, 5.1, 5.2, 5.3, 5.4, 5.5, 5.6, 5.7, 5.8, 5.9, 6.0, 6.1, 6.2, 6.3, 6.4, 6.5, 6.6, 6.7, 6.8, 6.9, 7.0,
7.1, 7.2, 7.3, 7.4, 7.5, 7.6, 7.7, 7.8, 7.9, 8.0, 8.1, 8.2, 8.3, 8.4, 8.5, 8.6, 8.7, 8.8, 8.9, 9.0, 9.1,
9.2, 9.3, 9.4, 9.5, 9.6, 9.7, 9.8, 9.9, 10.0, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49,
50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74,
75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, or
99% of the amount of the compound provided herein when used separately from the therapeutic agent. In embodiments, a synergistic amount may be about 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, 1.0, 1.1, 1.2, 1.3, 1.4, 1.5, 1.6, 1.7, 1.8, 1.9, 2.0, 2.1, 2.2, 2.3, 2.4, 2.5, 2.6,
2.7, 2.8, 2.9, 3.0, 3.1, 3.2, 3.3, 3.4, 3.5, 3.6, 3.7, 3.8, 3.9, 4.0, 4.1, 4.2, 4.3, 4.4, 4.5, 4.6, 4.7,
4.8, 4.9, 5.0, 5.1, 5.2, 5.3, 5.4, 5.5, 5.6, 5.7, 5.8, 5.9, 6.0, 6.1, 6.2, 6.3, 6.4, 6.5, 6.6, 6.7, 6.8,
6.9, 7.0, 7.1, 7.2, 7.3, 7.4, 7.5, 7.6, 7.7, 7.8, 7.9, 8.0, 8.1, 8.2, 8.3, 8.4, 8.5, 8.6, 8.7, 8.8, 8.9,
9.0, 9.1, 9.2, 9.3, 9.4, 9.5, 9.6, 9.7, 9.8, 9.9, 10.0, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22,
23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47,
48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72,
73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97,
98, or 99% of the amount of the therapeutic agent when used separately from the compound provided herein.
[0140] The term “EC50” or “half maximal effective concentration” as used herein refers to the concentration of a molecule (e.g., antibody, chimeric antigen receptor or bispecific antibody) capable of inducing a response which is halfway between the baseline response and the maximum response after a specified exposure time. In embodiments, the EC50 is the concentration of a molecule (e.g., antibody, chimeric antigen receptor or bispecific antibody) that produces 50% of the maximal possible effect of that molecule.
[0141] The terms “bind” and “bound” as used herein is used in accordance with its plain and ordinary meaning and refers to the association between atoms or molecules. The association can be direct or indirect. For example, bound atoms or molecules may be direct, e.g., by covalent bond or linker (e.g. a first linker or second linker), or indirect, e.g., by non-covalent bond (e.g. electrostatic interactions (e.g. ionic bond, hydrogen bond, halogen bond), van der Waals interactions (e.g. dipole-dipole, dipole-induced dipole, London dispersion), ring stacking (pi effects), hydrophobic interactions and the like).
[0142] The term “capable of binding” as used herein refers to a moiety (e.g. a compound as described herein) that is able to measurably bind to a target (e.g., GNAS). In embodiments, where a moiety is capable of binding a target, the moiety is capable of binding with a Kd of less than about 10 mM, 5 mM, 1 mM, 500 nM, 250 nM, 100 nM, 75 nM, 50 nM, 25 nM, 15 nM, 10 nM, 5 nM, 1 nM, or about 0.1 nM.
[0143] As used herein, the term "conjugated” when referring to two moieties means the two moieties are bonded, wherein the bond or bonds connecting the two moieties may be covalent or non-covalent. In embodiments, the two moieties are covalently bonded to each other (e.g. directly or through a covalently bonded intermediary). In embodiments, the two moieties are non-covalently bonded (e.g. through ionic bond(s), van der waal’s bond(s)/interactions, hydrogen bond(s), polar bond(s), or combinations or mixtures thereof).
[0144] The term “non-nucleophilic base” as used herein refers to any sterically hindered base that is a poor nucleophile.
[0145] The term “nucleophile” as used herein refers to a chemical species that donates an electron pair to an electrophile to form a chemical bond in relation to a reaction. All molecules or ions with a free pair of electrons or at least one pi bond can act as nucleophiles.
[0146] The term “strong acid” as used herein refers to an acid that is completely dissociated or ionized in an aqueous solution. Examples of common strong acids include hydrochloric acid (HC1), nitric acid (HNO3), sulfuric acid (H2SO4), hydrobromic acid (HBr), hydroiodic acid (HI), perchloric acid (HCIO4), or chloric acid (HCIO3).
[0147] The term “carbocation stabilizing solvent” as used herein refers to any polar protic solvent capable of forming dipole-dipole interactions with a carbocation, thereby stabilizing the carbocation.
[0148] The term "amino acid" refers to naturally occurring and synthetic amino acids, as well as amino acid analogs and amino acid mimetics that function in a manner similar to the naturally occurring amino acids. Naturally occurring amino acids are those encoded by the genetic code, as well as those amino acids that are later modified, e.g., hydroxyproline, g- carboxyglutamate, and O-phosphoserine. Amino acid analogs refers to compounds that have the same basic chemical structure as a naturally occurring amino acid, i.e., an a carbon that is bound to a hydrogen, a carboxyl group, an amino group, and an R group, e.g., homoserine, norleucine, methionine sulfoxide, methionine methyl sulfonium. Such analogs have modified R groups (e.g. , norleucine) or modified peptide backbones, but retain the same basic chemical structure as a naturally occurring amino acid. Amino acid mimetics refers to chemical compounds that have a structure that is different from the general chemical structure of an amino acid, but that functions in a manner similar to a naturally occurring amino acid. The terms “non-naturally occurring amino acid” and “unnatural amino acid” refer to amino acid analogs, synthetic amino acids, and amino acid mimetics which are not found in nature.
[0149] Amino acids may be referred to herein by either their commonly known three letter symbols or by the one-letter symbols recommended by the IUPAC-IUB Biochemical Nomenclature Commission. Nucleotides, likewise, may be referred to by their commonly accepted single-letter codes.
[0150] The terms "polypeptide," "peptide" and "protein" are used interchangeably herein to refer to a polymer of amino acid residues, wherein the polymer may In embodiments be conjugated to a moiety that does not consist of amino acids. The terms apply to amino acid polymers in which one or more amino acid residue is an artificial chemical mimetic of a corresponding naturally occurring amino acid, as well as to naturally occurring amino acid polymers and non-naturally occurring amino acid polymers.
[0151] An amino acid or nucleotide base “position” is denoted by a number that sequentially identifies each amino acid (or nucleotide base) in the reference sequence based on its position relative to the N-terminus (or 5'-end). An amino acid residue in a protein “corresponds” to a given residue when it occupies the same essential structural position within the protein as the given residue. Due to deletions, insertions, truncations, fusions, and the like that must be taken into account when determining an optimal alignment, in general the amino acid residue number in a test sequence determined by simply counting from the N- terminus will not necessarily be the same as the number of its corresponding position in the reference sequence. For example, in a case where a variant has a deletion relative to an aligned reference sequence, there will be no amino acid in the variant that corresponds to a position in the reference sequence at the site of deletion. Where there is an insertion in an aligned reference sequence, that insertion will not correspond to a numbered amino acid position in the reference sequence. In the case of truncations or fusions there can be stretches of amino acids in either the reference or aligned sequence that do not correspond to any amino acid in the corresponding sequence.
[0152] The terms “numbered with reference to” or “corresponding to,” when used in the context of the numbering of a given amino acid or polynucleotide sequence, refers to the numbering of the residues of a specified reference sequence when the given amino acid or polynucleotide sequence is compared to the reference sequence. [0153] As may be used herein, the terms “nucleic acid,” “nucleic acid molecule,” “nucleic acid oligomer,” “oligonucleotide,” “nucleic acid sequence,” “nucleic acid fragment” and “polynucleotide” are used interchangeably and are intended to include, but are not limited to, a polymeric form of nucleotides covalently linked together that may have various lengths, either deoxyribonucleotides or ribonucleotides, or analogs, derivatives or modifications thereof. Different polynucleotides may have different three-dimensional structures, and may perform various functions, known or unknown. Non-limiting examples of polynucleotides include a gene, a gene fragment, an exon, an intron, intergenic DNA (including, without limitation, heterochromatic DNA), messenger RNA (mRNA), transfer RNA, ribosomal RNA, a ribozyme, cDNA, a recombinant polynucleotide, a branched polynucleotide, a plasmid, a vector, isolated DNA of a sequence, isolated RNA of a sequence, a nucleic acid probe, and a primer. Polynucleotides useful in the methods of the disclosure may include natural nucleic acid sequences and variants thereof, artificial nucleic acid sequences, or a combination of such sequences.
[0154] A polynucleotide is typically composed of a specific sequence of four nucleotide bases: adenine (A); cytosine (C); guanine (G); and thymine (T) (uracil (U) for thymine (T) when the polynucleotide is RNA). Thus, the term “polynucleotide sequence” is the alphabetical representation of a polynucleotide molecule; alternatively, the term may be applied to the polynucleotide molecule itself. This alphabetical representation can be input into databases in a computer having a central processing unit and used for bioinformatics applications such as functional genomics and homology searching. Polynucleotides may optionally include one or more non-standard nucleotide(s), nucleotide analog(s) and/or modified nucleotides.
[0155] An “inhibitor” refers to a compound (e.g. compounds described herein) that reduces activity when compared to a control, such as absence of the compound or a compound with known inactivity.
[0156] The term “Gas small molecule inhibitor” as used herein refers to a low molecular weight organic compound capable of binding to and decreasing the activity of Gas. In embodiments, the Gas small molecule inhibitor is a compound that weighs less than 1000 daltons. In embodiments, the Gas small molecule inhibitor is a compound that weighs less than 900 daltons. In embodiments, the Gas small molecule inhibitor is a compound that weighs less than 800 daltons. In embodiments, the Gas small molecule inhibitor is a compound that weighs less than 700 daltons. In embodiments, the Gas small molecule inhibitor is a compound that weighs less than 600 daltons. In embodiments, the Gas small molecule inhibitor is a compound that weighs less than 500 daltons. In embodiments, the Gas small molecule inhibitor is a compound that weighs less than 450 daltons. In embodiments, the Gas small molecule inhibitor is a compound that weighs less than 400 daltons.
[0157] “Contacting” is used in accordance with its plain ordinary meaning and refers to the process of allowing at least two distinct species (e.g. chemical compounds including biomolecules or cells) to become sufficiently proximal to react, interact or physically touch.
It should be appreciated; however, the resulting reaction product can be produced directly from a reaction between the added reagents or from an intermediate from one or more of the added reagents that can be produced in the reaction mixture.
[0158] The term “contacting” may include allowing two species to react, interact, or physically touch, wherein the two species may be a compound as described herein and a protein or enzyme. In some embodiments contacting includes allowing a compound described herein to interact with a protein or enzyme that is involved in a signaling pathway.
[0159] As defined herein, the term “activation”, “activate”, “activating”, “activator” and the like in reference to a protein-inhibitor interaction means positively affecting (e.g. increasing) the activity or function of the protein relative to the activity or function of the protein in the absence of the activator. In embodiments activation means positively affecting (e.g. increasing) the concentration or levels of the protein relative to the concentration or level of the protein in the absence of the activator. The terms may reference activation, or activating, sensitizing, or up-regulating signal transduction or enzymatic activity or the amount of a protein decreased in a disease. Thus, activation may include, at least in part, partially or totally increasing stimulation, increasing or enabling activation, or activating, sensitizing, or up-regulating signal transduction or enzymatic activity or the amount of a protein associated with a disease (e.g., a protein which is decreased in a disease relative to a non-diseased control). Activation may include, at least in part, partially or totally increasing stimulation, increasing or enabling activation, or activating, sensitizing, or up-regulating signal transduction or enzymatic activity or the amount of a protein
[0160] The terms “agonist,” “activator,” “upregulator,” etc. refer to a substance capable of detectably increasing the expression or activity of a given gene or protein. The agonist can increase expression or activity 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90% or more in comparison to a control in the absence of the agonist. In certain instances, expression or activity is 1.5-fold, 2-fold, 3-fold, 4-fold, 5-fold, 10-fold or higher than the expression or activity in the absence of the agonist.
[0161] As defined herein, the term “inhibition”, “inhibit”, “inhibiting” and the like in reference to a protein-inhibitor interaction means negatively affecting (e.g. decreasing) the activity or function of the protein relative to the activity or function of the protein in the absence of the inhibitor. In embodiments inhibition means negatively affecting (e.g. decreasing) the concentration or levels of the protein relative to the concentration or level of the protein in the absence of the inhibitor. In embodiments inhibition refers to reduction of a disease or symptoms of disease. In embodiments, inhibition refers to a reduction in the activity of a particular protein target. Thus, inhibition includes, at least in part, partially or totally blocking stimulation, decreasing, preventing, or delaying activation, or inactivating, desensitizing, or down-regulating signal transduction or enzymatic activity or the amount of a protein. In embodiments, inhibition refers to a reduction of activity of a target protein resulting from a direct interaction (e.g. an inhibitor binds to the target protein). In embodiments, inhibition refers to a reduction of activity of a target protein from an indirect interaction (e.g. an inhibitor binds to a protein that activates the target protein, thereby preventing target protein activation).
[0162] The “Gas cysteine 201 covalent inhibitor” as used herein refers to a compound (e.g., small molecule, antibody, peptide, therapeutic agent, polymer, or the like) which can form a covalent bond with cysteine 201 residue of mutant Gas protein (R201C mutant of human Gas protein (SEQ ID NO: 1), or mutants thereof) or a cysteine residue corresponding to cysteine 201 (e.g. in a homologous Gas mutant protein). In particular, the compound (e.g., compound of Formula (I), (II), (Ill-a), (Ill-b), (III-c), (IV), (V-a), (V-b), (VI), (VII), or (VIII)), by forming a covalent bond with the -SH group of that cysteine, can inhibit, suppress or downregulate the function of the Gas protein (e.g., human Gas, or R201C mutant of human Gas protein (SEQ ID NO: 1)).
[0163] The “Gas cysteine 237 covalent inhibitor” as used herein refers to a compound (e.g., small molecule, antibody, peptide, therapeutic agent, polymer, or the like) which can form a covalent bond with cysteine 237 residue of Gas protein (e.g., human Gas, protein represented by SEQ ID NO: 1, or mutants thereof) or a cysteine residue corresponding to cysteine Til (e.g. ina homologous Gas protein). In particular, the compound (e.g., compound of Formula (I), (II), (Ill-a), (Ill-b), (III-c), (IV), (V-a), (V-b), (VI), (VII), or (VIII)), by forming a covalent bond with the -SH group of that cysteine, can inhibit, suppress or downregulate the function of the Gas protein (e.g., human Gas, protein represented by SEQ ID NO: 1, or mutants thereof).
[0164] The terms “inhibitor,” “repressor” or “antagonist” or “downregulator” interchangeably refer to a substance capable of detectably decreasing the expression or activity of a given gene or protein. The antagonist can decrease expression or activity 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90% or more in comparison to a control in the absence of the antagonist. In certain instances, expression or activity is 1.5-fold, 2-fold, 3- fold, 4-fold, 5 -fold, 10-fold or lower than the expression or activity in the absence of the antagonist.
[0165] The term “modulator” refers to a composition that increases or decreases the level of a target molecule or the function of a target molecule or the physical state of the target of the molecule (e.g., a target may be a cellular component (e.g., protein, ion, lipid, virus, lipid droplet, nucleic acid, nucleotide, amino acid, protein, particle, organelle, cellular compartment, microorganism, vesicle, small molecule, protein complex, protein aggregate, or macromolecule)) relative to the absence of the composition.
[0166] The term “modulate” is used in accordance with its plain ordinary meaning and refers to the act of changing or varying one or more properties. “Modulation” refers to the process of changing or varying one or more properties. For example, as applied to the effects of a modulator on a target protein, to modulate means to change by increasing or decreasing a property or function of the target molecule or the amount of the target molecule.
[0167] The term “expression” includes any step involved in the production of the polypeptide including, but not limited to, transcription, post-transcriptional modification, translation, post-translational modification, and secretion. Expression can be detected using conventional techniques for detecting protein (e.g., ELISA, Western blotting, flow cytometry, immunofluorescence, immunohistochemistry, etc.).
[0168] A “therapeutic agent” or “drug agent” as used herein refers to an agent (e.g., compound or composition) that when administered to a subject will have the intended prophylactic effect, e.g., preventing or delaying the onset (or reoccurrence) of an injury, disease, pathology or condition, or reducing the likelihood of the onset (or reoccurrence) of an injury, disease, pathology, or condition, or their symptoms or the intended therapeutic effect, e.g., treatment or amelioration of an injury, disease, pathology or condition, or their symptoms including any objective or subjective parameter of treatment such as abatement; remission; diminishing of symptoms or making the injury, pathology or condition more tolerable to the patient; slowing in the rate of degeneration or decline; making the final point of degeneration less debilitating; or improving a patient’s physical or mental well-being. A drug moiety is a monovalent drug. A therapeutic moiety is a monovalent therapeutic agent.
[0169] The terms “disease” or “condition” refer to a state of being or health status of a patient or subject capable of being treated with the compounds or methods provided herein. The disease may be a cancer. In some further instances, “cancer” refers to human cancers and carcinomas, sarcomas, adenocarcinomas, lymphomas, leukemias, etc., including solid and lymphoid cancers, kidney, breast, lung, bladder, colon, ovarian, prostate, pancreas, stomach, brain, head and neck, skin, uterine, testicular, glioma, esophagus, and liver cancer, including hepatocarcinoma, lymphoma, including B -acute lymphoblastic lymphoma, non- Hodgkin’s lymphomas (e.g., Burkitt’s, Small Cell, and Large Cell lymphomas), Hodgkin’s lymphoma, leukemia (including AML, ALL, and CML), or multiple myeloma.
[0170] As used herein, the term "cancer" refers to all types of cancer, neoplasm or malignant tumors found in mammals (e.g. humans), including leukemias, lymphomas, carcinomas and sarcomas. Exemplary cancers that may be treated with a compound or method provided herein include brain cancer, glioma, glioblastoma, neuroblastoma, prostate cancer, colorectal cancer, pancreatic cancer, Medulloblastoma, melanoma, cervical cancer, gastric cancer, ovarian cancer, lung cancer, cancer of the head, Hodgkin's Disease, and Non- Hodgkin's Lymphomas. Exemplary cancers that may be treated with a compound or method provided herein include cancer of the thyroid, endocrine system, brain, breast, cervix, colon, head & neck, liver, kidney, lung, ovary, pancreas, rectum, stomach, and uterus. Additional examples include, thyroid carcinoma, cholangiocarcinoma, pancreatic adenocarcinoma, skin cutaneous melanoma, colon adenocarcinoma, rectum adenocarcinoma, stomach adenocarcinoma, esophageal carcinoma, head and neck squamous cell carcinoma, breast invasive carcinoma, lung adenocarcinoma, lung squamous cell carcinoma, non-small cell lung carcinoma, mesothelioma, multiple myeloma, neuroblastoma, glioma, glioblastoma multiforme, ovarian cancer, rhabdomyosarcoma, primary thrombocytosis, primary macroglobulinemia, primary brain tumors, malignant pancreatic insulanoma, malignant carcinoid, urinary bladder cancer, premalignant skin lesions, testicular cancer, thyroid cancer, neuroblastoma, esophageal cancer, genitourinary tract cancer, malignant hypercalcemia, endometrial cancer, adrenal cortical cancer, neoplasms of the endocrine or exocrine pancreas, medullary thyroid cancer, medullary thyroid carcinoma, melanoma, colorectal cancer, papillary thyroid cancer, hepatocellular carcinoma, or prostate cancer.
[0171] The term "leukemia" refers broadly to progressive, malignant diseases of the blood- forming organs and is generally characterized by a distorted proliferation and development of leukocytes and their precursors in the blood and bone marrow. Leukemia is generally clinically classified on the basis of (1) the duration and character of the disease-acute or chronic; (2) the type of cell involved; myeloid (myelogenous), lymphoid (lymphogenous), or monocytic; and (3) the increase or non-increase in the number abnormal cells in the blood- leukemic or aleukemic (subleukemic). Exemplary leukemias that may be treated with a compound or method provided herein include, for example, acute nonlymphocytic leukemia, chronic lymphocytic leukemia, acute granulocytic leukemia, chronic granulocytic leukemia, acute promyelocytic leukemia, adult T-cell leukemia, aleukemic leukemia, a leukocythemic leukemia, basophylic leukemia, blast cell leukemia, bovine leukemia, chronic myelocytic leukemia, leukemia cutis, embryonal leukemia, eosinophilic leukemia, Gross' leukemia, hairy-cell leukemia, hemoblastic leukemia, hemocytoblastic leukemia, histiocytic leukemia, stem cell leukemia, acute monocytic leukemia, leukopenic leukemia, lymphatic leukemia, lymphoblastic leukemia, lymphocytic leukemia, lymphogenous leukemia, lymphoid leukemia, lymphosarcoma cell leukemia, mast cell leukemia, megakaryocytic leukemia, micromyeloblastic leukemia, monocytic leukemia, myeloblastic leukemia, myelocytic leukemia, myeloid granulocytic leukemia, myelomonocytic leukemia, Naegeli leukemia, plasma cell leukemia, multiple myeloma, plasmacytic leukemia, promyelocytic leukemia, Rieder cell leukemia, Schilling's leukemia, stem cell leukemia, subleukemic leukemia, or undifferentiated cell leukemia.
[0172] As used herein, the term “lymphoma” refers to a group of cancers affecting hematopoietic and lymphoid tissues. It begins in lymphocytes, the blood cells that are found primarily in lymph nodes, spleen, thymus, and bone marrow. Two main types of lymphoma are non-Hodgkin lymphoma and Hodgkin’s disease. Hodgkin’s disease represents approximately 15% of all diagnosed lymphomas. This is a cancer associated with Reed- Sternberg malignant B lymphocytes. Non-Hodgkin’s lymphomas (NHL) can be classified based on the rate at which cancer grows and the type of cells involved. There are aggressive (high grade) and indolent (low grade) types of NHL. Based on the type of cells involved, there are B-cell and T-cell NHLs. Exemplary B-cell lymphomas that may be treated with a compound or method provided herein include, but are not limited to, small lymphocytic lymphoma, Mantle cell lymphoma, follicular lymphoma, marginal zone lymphoma, extranodal (MALT) lymphoma, nodal (monocytoid B-cell) lymphoma, splenic lymphoma, diffuse large cell B-lymphoma, Burkitt’s lymphoma, lymphoblastic lymphoma, immunoblastic large cell lymphoma, or precursor B -lymphoblastic lymphoma. Exemplary T- cell lymphomas that may be treated with a compound or method provided herein include, but are not limited to, cunateous T-cell lymphoma, peripheral T-cell lymphoma, anaplastic large cell lymphoma, mycosis fungoides, and precursor T-lymphoblastic lymphoma.
[0173] The term "sarcoma" generally refers to a tumor which is made up of a substance like the embryonic connective tissue and is generally composed of closely packed cells embedded in a fibrillar or homogeneous substance. Sarcomas that may be treated with a compound or method provided herein include a chondrosarcoma, fibrosarcoma, lymphosarcoma, melanosarcoma, myxosarcoma, osteosarcoma, Abemethy's sarcoma, adipose sarcoma, liposarcoma, alveolar soft part sarcoma, ameloblastic sarcoma, botryoid sarcoma, chloroma sarcoma, chorio carcinoma, embryonal sarcoma, Wilms' tumor sarcoma, endometrial sarcoma, stromal sarcoma, Ewing's sarcoma, fascial sarcoma, fibroblastic sarcoma, giant cell sarcoma, granulocytic sarcoma, Hodgkin's sarcoma, idiopathic multiple pigmented hemorrhagic sarcoma, immunoblastic sarcoma of B cells, lymphoma, immunoblastic sarcoma of T-cells, Jensen's sarcoma, Kaposi's sarcoma, Kupffer cell sarcoma, angiosarcoma, leukosarcoma, malignant mesenchymoma sarcoma, parosteal sarcoma, reticulocytic sarcoma, Rous sarcoma, serocystic sarcoma, synovial sarcoma, or telangiectaltic sarcoma.
[0174] The term "melanoma" is taken to mean a tumor arising from the melanocytic system of the skin and other organs. Melanomas that may be treated with a compound or method provided herein include, for example, acral-lentiginous melanoma, amelanotic melanoma, benign juvenile melanoma, Cloudman's melanoma, S91 melanoma, Harding-Passey melanoma, juvenile melanoma, lentigo maligna melanoma, malignant melanoma, nodular melanoma, subungal melanoma, or superficial spreading melanoma. [0175] The term "carcinoma" refers to a malignant new growth made up of epithelial cells tending to infiltrate the surrounding tissues and give rise to metastases. Exemplary carcinomas that may be treated with a compound or method provided herein include, for example, medullary thyroid carcinoma, familial medullary thyroid carcinoma, acinar carcinoma, acinous carcinoma, adenocystic carcinoma, adenoid cystic carcinoma, carcinoma adenomatosum, carcinoma of adrenal cortex, alveolar carcinoma, alveolar cell carcinoma, basal cell carcinoma, carcinoma basocellulare, basaloid carcinoma, basosquamous cell carcinoma, bronchioalveolar carcinoma, bronchiolar carcinoma, bronchogenic carcinoma, cerebriform carcinoma, cholangiocellular carcinoma, chorionic carcinoma, colloid carcinoma, comedo carcinoma, corpus carcinoma, cribriform carcinoma, carcinoma en cuirasse, carcinoma cutaneum, cylindrical carcinoma, cylindrical cell carcinoma, duct carcinoma, carcinoma durum, embryonal carcinoma, encephaloid carcinoma, epiermoid carcinoma, carcinoma epitheliale adenoides, exophytic carcinoma, carcinoma ex ulcere, carcinoma fibrosum, gelatinifomi carcinoma, gelatinous carcinoma, giant cell carcinoma, carcinoma gigantocellulare, glandular carcinoma, granulosa cell carcinoma, hair-matrix carcinoma, hematoid carcinoma, hepatocellular carcinoma, Hurthle cell carcinoma, hyaline carcinoma, hypemephroid carcinoma, infantile embryonal carcinoma, carcinoma in situ, intraepidermal carcinoma, intraepithelial carcinoma, Krompecher's carcinoma, Kulchitzky- cell carcinoma, large-cell carcinoma, lenticular carcinoma, carcinoma lenticulare, lipomatous carcinoma, lymphoepithelial carcinoma, carcinoma medullare, medullary carcinoma, melanotic carcinoma, carcinoma molle, mucinous carcinoma, carcinoma muciparum, carcinoma mucocellulare, mucoepidermoid carcinoma, carcinoma mucosum, mucous carcinoma, carcinoma myxomatodes, nasopharyngeal carcinoma, oat cell carcinoma, carcinoma ossificans, osteoid carcinoma, papillary carcinoma, periportal carcinoma, preinvasive carcinoma, prickle cell carcinoma, pultaceous carcinoma, renal cell carcinoma of kidney, reserve cell carcinoma, carcinoma sarcomatodes, Schneiderian carcinoma, scirrhous carcinoma, carcinoma scroti, signet-ring cell carcinoma, carcinoma simplex, small-cell carcinoma, solanoid carcinoma, spheroidal cell carcinoma, spindle cell carcinoma, carcinoma spongiosum, squamous carcinoma, squamous cell carcinoma, string carcinoma, carcinoma telangiectaticum, carcinoma telangiectodes, transitional cell carcinoma, carcinoma tuberosum, tuberous carcinoma, verrucous carcinoma, or carcinoma villosum. [0176] As used herein, the terms "metastasis," "metastatic," and "metastatic cancer" can be used interchangeably and refer to the spread of a proliferative disease or disorder, e.g., cancer, from one organ or another non-adjacent organ or body part. “Metastatic cancer” is also called “Stage IV cancer.” Cancer occurs at an originating site, e.g., breast, which site is referred to as a primary tumor, e.g., primary breast cancer. Some cancer cells in the primary tumor or originating site acquire the ability to penetrate and infiltrate surrounding normal tissue in the local area and/or the ability to penetrate the walls of the lymphatic system or vascular system circulating through the system to other sites and tissues in the body. A second clinically detectable tumor formed from cancer cells of a primary tumor is referred to as a metastatic or secondary tumor. When cancer cells metastasize, the metastatic tumor and its cells are presumed to be similar to those of the original tumor. Thus, if lung cancer metastasizes to the breast, the secondary tumor at the site of the breast consists of abnormal lung cells and not abnormal breast cells. The secondary tumor in the breast is referred to a metastatic lung cancer. Thus, the phrase metastatic cancer refers to a disease in which a subject has or had a primary tumor and has one or more secondary tumors. The phrases nonmetastatic cancer or subjects with cancer that is not metastatic refers to diseases in which subjects have a primary tumor but not one or more secondary tumors. For example, metastatic lung cancer refers to a disease in a subject with or with a history of a primary lung tumor and with one or more secondary tumors at a second location or multiple locations, e.g., in the breast.
[0177] The terms “cutaneous metastasis” or “skin metastasis” refer to secondary malignant cell growths in the skin, wherein the malignant cells originate from a primary cancer site (e.g., breast). In cutaneous metastasis, cancerous cells from a primary cancer site may migrate to the skin where they divide and cause lesions. Cutaneous metastasis may result from the migration of cancer cells from breast cancer tumors to the skin.
[0178] The term “visceral metastasis” refer to secondary malignant cell growths in the interal organs (e.g., heart, lungs, liver, pancreas, intestines) or body cavities (e.g., pleura, peritoneum), wherein the malignant cells originate from a primary cancer site (e.g., head and neck, liver, breast). In visceral metastasis, cancerous cells from a primary cancer site may migrate to the internal organs where they divide and cause lesions. Visceral metastasis may result from the migration of cancer cells from liver cancer tumors or head and neck tumors to internal organs. [0179] “G protein associated cancer” (also referred to herein as “G-protein related cancer”) refers to a cancer caused by aberrant activity or signaling of G protein or one or more of its subunits (e.g., alpha (a)-, beta (b)-, or gamma (g) subunits; Gas, ΰbb, or Gys). In certain embodiments, a “cancer associated with aberrant Gas activity” (also referred to herein as “Gas related cancer”) is a cancer caused by aberrant Gas activity or signaling (e.g. a mutant Gas). In certain embodiments, a “cancer associated with aberrant Gps activity” (also referred to herein as “Gps related cancer”) is a cancer caused by aberrant Gps activity or signaling (e.g. a mutant Gps). In certain embodiments, a “cancer associated with aberrant Gys activity” (also referred to herein as “Gys related cancer”) is a cancer caused by aberrant Gys activity or signaling (e.g. a mutant Gys). In certain embodiments, some cancers that are associated with aberrant activity of one or more of G protein or its subunits (Gas, ΰbb, or Gys), mutant G protein, or mutants subunits (Gas, ΰbb, or Gys) are well known in the art and determining such cancers are within the skill of a person of skill in the art. In certain embodiments, some cancers may be sensitive to Gas inhibition. In certain embodiments, the cancer that may be sensitive to Gas inhibition may include a solid cancer or a tumor. In certain embodiments, the cancer that may be sensitive to Gas inhibition may include a pancreatic cancer, a brain tumor, a pituitary tumor, or a bone tumor. In certain embodiments, the Gas related cancers may include a pancreatic cancer, a brain tumor, a pituitary tumor, or a bone tumor.
[0180] “G protein-associated disease” (also referred to herein as “G protein-related disease”) refers to a cancer caused by aberrant activity or signaling of G protein or one or more of its subunits (e.g., alpha (a)-, beta (b)-, or gamma (y) subunits; Gas, ΰbb, or Gys). In certain embodiments, a “disease associated with aberrant Gas activity” (also referred to herein as “Gas related disease”) is a cancer caused by aberrant Gas activity or signaling (e.g., a mutant Gas). In certain embodiments, a “disease associated with aberrant ΰbb activity” (also referred to herein as “ΰbb related disease”) is a disease caused by aberrant ΰbb activity or signaling (e.g., a mutant ΰbb). In certain embodiments, a “disease associated with aberrant Gys activity” (also referred to herein as “Gys related disease”) is a disease caused by aberrant Gys activity or signaling (e.g., a mutant Gys). In certain embodiments, some diseases that are associated with aberrant activity of one or more of G protein or its subunits (Gas, ϋbb, or Gys), mutant G protein, or mutants subunits (Gas, ΰbb, or Gys) are well known in the art and determining such diseases are within the skill of a person of skill in the art. In certain embodiments, some diseases may be sensitive to Gas inhibition. [0181] The term “guanine nucleotide-binding proteins” or “G-protein” refers to one or more of the family of proteins that are bound to GTP (“on” state) or GDP (“off’ state”) so the proteins can regulate their activity involved in signaling pathway of a cell. In certain embodiments, G protein includes subunits, alpha (a)-, beta (b)-, and gamma (g) subunits (Gas, GPs, or Gys). In particular, the term human “Gas” as used herein refers to a G-protein- alpha-subunit having nucleotide sequences as set forth or corresponding to Entrez 2778, UniProt Q59FM5, UniProt P63092 (e.g., UniProt P6309-1 and UniProt P63092-2), RefSeq (protein) NP 000507.1, RefSeq (protein) NP 001070956.1, RefSeq (protein)
NP 001070957.1, RefSeq (protein) NP_001070958.1, RefSeq (protein) NP_001296769.1, RefSeq (protein) NP 536350.2, or RefSeq (protein) NP 536351.1. In embodiments, the GNAS gene has the nucleic acid sequence set forth in RefSeq (mRNA) NM 000516.5, RefSeq (mRNA) NM 001077488.3, RefSeq (mRNA) NM 001077489.3, RefSeq (mRNA) NM 001077490.2, RefSeq (mRNA) NM 001309840.1, RefSeq (mRNA) NM 080425.3, or RefSeq (mRNA) NM 080426.3. In embodiments, the amino acid sequence or nucleic acid sequence is the sequence known at the time of filing of the present application.
[0182] The term “Gas” includes both the wild-type form of the nucleotide sequences or proteins as well as any mutants thereof. In certain embodiments, the human Gas refers to the protein including (e.g., consisting of) the amino acid sequence corresponding to UniProt P63092-1 (SEQ ID NO: 1). In embodiments, the human Gas includes the sequence below with one or more mutations (e.g., R201C and C237S at the underlined position at SEQ ID NO: 1):
1 MGCLGNSKTE DQRNEEKAQR EANKKIEKQL QKDKQVYRAT HRLLLLGAGE SGKSTIVKQM
61 RILHVNGFNG EGGEEDPQAA RSNSDGEKAT KVQDIKNNLK EAIETIVAAM SNLVPPVELA
121 NPENQFRVDY ILSVMNVPDF DFPPEFYEHA KALWEDEGVR ACYERSNEYQ LIDCAQYFLD
181 KIDVIKQADY VPSDQDLLRC RVLTSGIFET KFQVDKVNFH MFDVGGQRDE RRKWIQCFND
241 VTAIIFWAS SSYNMVIRED NQTNRLQEAL NLFKSIWNNR WLRTISVILF LNKQDLLAEK
301 VLAGKSKIED YFPEFARYTT PEDATPEPGE DPRVTRAKYF IRDEFLRIST ASGDGRHYCY
361 PHFTCAVDTE NIRRVFNDCR DIIQRMHLRQ YELL (SEQ ID NO: 1)
[0183] In embodiments, the human Gas has the sequence of residues 7-380 of the short isoform of of human Gas corresponding to UniProt P63092-2 (SEQ ID NO: 2). In embodiments, the human Gas includes the sequence below with one or more mutations (e.g., at R187 and/or C223 at the underlined position at SEQ ID NO: 2)
HMGCLGNSKTEDQRNEEKAQREANKKIEKQLQKDKQVYRATHRLLLLGAGESGKSTIVKQMRILHVNG
FNGDSEKATKVQDIKNNLKEAIETIVAAMSNLVPPVELANPENQFRVDYILSVMNVPDFDFPPEFYEH AKALWEDEGVRACYERSNEYQLIDCAQYFLDKIDVIKQADYVPSDQDLLRCRVLTSGIFETKFQVDKV NFHMFDVGGQRDERRKWIQCFNDVTAIIFW ASSSYNMVIREDNQTNRLQEALNLFKSIWNNRWLRTI SVILFLNKQDLLAEKVLAGKSKIEDYFPEFARYTTPEDATPEPGEDPRVTRAKYFIRDEFLRISTASG DGRHYCYPHFTCAVDTENIRRVFNDCRDIIQRMHLRQYELL (SEQ ID NO:2)
[0184] An amino acid residue in Gas “corresponds” to a given residue when it occupies the same essential structural position within the protein as the given residue. For example, a selected residue in a selected protein corresponds to R201 of Gas protein when the selected residue occupies the same essential spatial or other structural relationship as R201 of Gas protein. In some embodiments, where a selected protein is aligned for maximum homology with the Gas protein, the position in the aligned selected protein aligning with R201 is said to correspond to R201. Further, a selected residue in a selected protein corresponds to C237 of Gas protein when the selected residue occupies the same essential spatial or other structural relationship as C237 of Gas protein. In some embodiments, where a selected protein is aligned for maximum homology with the Gas protein, the position in the aligned selected protein aligning with C237 is said to correspond to C237. Instead of a primary sequence alignment, a three dimensional structural alignment can also be used, e.g., where the structure of the selected protein is aligned for maximum correspondence with the Gas protein and the overall structures compared. In this case, an amino acid that occupies the same essential position as R201 in the structural model is said to correspond to the R201 residue, and an amino acid that occupies the same essential position as C237 in the structural model is said to correspond to the C237 residue. For example, R201 in SEQ ID NO: 1 corresponds to R187 in SEQ ID NO: 2, and C237 in SEQ ID NO: 1 corresponds to C223 in SEQ ID NO: 2.
[0185] The term “bone condition” as used herein refers to a disease, disorder or condition caused by abnormal bone tissues (e.g., osteoblast, osteoclast, osteocyte, and hematopoietic). In embodiments, the bone condition is caused by, but not limited to, cancerous or non- cancerous tissues, infection, osteoporosis, tumor, blood cells, and fibrous tissues, which is developed in various sites of bones of a subject such as thighbone, skull, ribs, pelvis, humerus, shinbone, trunk, sternum, wrist bones, tarsals, spine, shoulder blade, collar bone, radius, ulna, metacarpals, phalanges, kneecap, fibula, metatarsals and phalanges. In certain embodiments, the bone condition may be caused by cancerous bone tissues or noncancerous bone tissues. In certain embodiments, the bone condition may be related to abnormal fibrous tissue development/occurrence in place of normal bone. [0186] As used herein, the term “administering” is used in accordance with its plain and ordinary meaning and includes oral administration, administration as a suppository, topical contact, intravenous, intraperitoneal, intramuscular, intralesional, intrathecal, intranasal or subcutaneous administration, or the implantation of a slow-release device, e.g., a mini- osmotic pump, to a subject. Administration is by any route, including parenteral and transmucosal (e.g., buccal, sublingual, palatal, gingival, nasal, vaginal, rectal, or transdermal). Parenteral administration includes, e.g., intravenous, intramuscular, intraarteriole, intradermal, subcutaneous, intraperitoneal, intraventricular, and intracranial. Other modes of delivery include, but are not limited to, the use of liposomal formulations, intravenous infusion, transdermal patches, etc. By “co-administer” it is meant that a composition described herein is administered at the same time, just prior to, or just after the administration of one or more additional therapies, for example cancer therapies such as chemotherapy, hormonal therapy, radiotherapy, or immunotherapy. The compounds of the invention can be administered alone or can be co-administered to the patient. Coadministration is meant to include simultaneous or sequential administration of the compounds individually or in combination (more than one compound). Thus, the preparations can also be combined, when desired, with other active substances (e.g., to reduce metabolic degradation). The compositions of the present invention can be delivered by transdermally, by a topical route, formulated as applicator sticks, solutions, suspensions, emulsions, gels, creams, ointments, pastes, jellies, paints, powders, and aerosols.
[0187] The term “administer (or administering) a Gas inhibitor” means administering a compound that decreases the activity or level (e.g. amount) of a signaling pathway of Gas to a subject. Administration may include, without being limited by mechanism, allowing sufficient time for the Gas inhibitor to reduce the activity of the Gas protein or for the Gas inhibitor to reduce one or more symptoms of a disease (e.g. cancer, wherein the Gas inhibitor may arrest the cell cycle, slow the cell cycle, reduce DNA replication, reduce cell replication, reduce cell growth, reduce metastasis, or cause cell death). In embodiments, the administering does not include administration of any active agent (e.g., a compound or Gas inhibitor) other than the recited active agent.
[0188] The term “aberrant” as used herein refers to different from normal. When used to describe enzymatic activity, aberrant refers to activity that is greater or less than a normal control or the average of normal non-diseased control samples. Aberrant activity may refer to an amount of activity that results in a disease, wherein returning the aberrant activity to a normal or non-disease-associated amount (e.g. by administering a compound or using a method as described herein), results in reduction of the disease or one or more disease symptoms.
[0189] The term “electrophilic chemical moiety” is used in accordance with its plain ordinary chemical meaning and refers to a monovalent chemical group that is electrophilic.
[0190] The terms “treating”, or “treatment” refers to any indicia of success in the therapy or amelioration of an injury, disease, pathology or condition, including any objective or subjective parameter such as abatement; remission; diminishing of symptoms or making the injury, pathology or condition more tolerable to the patient; slowing in the rate of degeneration or decline; making the final point of degeneration less debilitating; improving a patient’s physical or mental well-being. The treatment or amelioration of symptoms can be based on objective or subjective parameters; including the results of a physical examination, neuropsychiatric exams, and/or a psychiatric evaluation. The term "treating" and conjugations thereof, may include prevention of an injury, pathology, condition, or disease. In embodiments, treating is preventing. In embodiments, treating does not include preventing.
[0191] “Treating” or “treatment” as used herein (and as well-understood in the art) also broadly includes any approach for obtaining beneficial or desired results in a subject’s condition, including clinical results. Beneficial or desired clinical results can include, but are not limited to, alleviation or amelioration of one or more symptoms or conditions, diminishment of the extent of a disease, stabilizing (i.e., not worsening) the state of disease, prevention of a disease’s transmission or spread, delay or slowing of disease progression, amelioration or palliation of the disease state, diminishment of the reoccurrence of disease, and remission, whether partial or total and whether detectable or undetectable. In other words, "treatment" as used herein includes any cure, amelioration, or prevention of a disease. Treatment may prevent the disease from occurring; inhibit the disease’s spread; relieve the disease’s symptoms, fully or partially remove the disease’s underlying cause, shorten a disease’s duration, or do a combination of these things.
[0192] "Treating" and "treatment" as used herein include prophylactic treatment.
Treatment methods include administering to a subject a therapeutically effective amount of an active agent. The administering step may consist of a single administration or may include a series of administrations. The length of the treatment period depends on a variety of factors, such as the severity of the condition, the age of the patient, the concentration of active agent, the activity of the compositions used in the treatment, or a combination thereof. It will also be appreciated that the effective dosage of an agent used for the treatment or prophylaxis may increase or decrease over the course of a particular treatment or prophylaxis regime. Changes in dosage may result and become apparent by standard diagnostic assays known in the art. In some instances, chronic administration may be required. For example, the compositions are administered to the subject in an amount and for a duration sufficient to treat the patient. In embodiments, the treating or treatment is not prophylactic treatment.
[0193] The term “sensitive” or “sensitive to” as used herein refers to a high degree of change in substance activity, biomarker indication, or condition associated with a disease (e.g. cancer) or a symptom of the disease (e.g., cancer) in response to a change introduced by treatment with or contact to an agent. For example, by treating with or contacting with an agent (e.g., Gas inhibitor or Gas mutant inhibitor), the substance activity, biomarker indication, or condition associated with a disease (e.g. cancer) or a symptom of the disease (e.g., cancer) varies substantially compared to those in absence of any treatment or contacting to the agent. In some embodiments, a disease (e.g. cancer) may be sensitive to a causative agent or inhibitory agent that may cause the disease. In some embodiments, a cancer relevant to or associated with aberrant protein activity (e.g., increased/suppressed protein activity or function) or mutation thereof may be sensitive to the inhibition of the protein. In some embodiments, a cancer caused or developed in association with aberrant Gas activity (e.g., increased/suppressed Gas activity or function) or mutation thereof may be sensitive to the inhibition of the Gas or its mutants.
[0194] The term “prevent” refers to a decrease in the occurrence of disease symptoms in a patient. As indicated above, the prevention may be complete (no detectable symptoms) or partial, such that fewer symptoms are observed than would likely occur absent treatment.
[0195] “Patient” or “subject in need thereof’ refers to a living organism suffering from or prone to a disease or condition that can be treated by administration of a pharmaceutical composition as provided herein. Non-limiting examples include humans, other mammals, bovines, rats, mice, dogs, monkeys, goat, sheep, cows, deer, and other non-mammalian animals. In some embodiments, a patient is human.
[0196] An “effective amount” is an amount sufficient for a compound to accomplish a stated purpose relative to the absence of the compound (e.g. achieve the effect for which it is administered, treat a disease, reduce enzyme activity, increase enzyme activity, reduce a signaling pathway, or reduce one or more symptoms of a disease or condition). An example of an “effective amount” is an amount sufficient to contribute to the treatment, prevention, or reduction of a symptom or symptoms of a disease, which could also be referred to as a “therapeutically effective amount.” A “reduction” of a symptom or symptoms (and grammatical equivalents of this phrase) means decreasing of the severity or frequency of the symptom(s), or elimination of the symptom(s). A “prophylactically effective amount” of a drug is an amount of a drug that, when administered to a subject, will have the intended prophylactic effect, e.g., preventing or delaying the onset (or reoccurrence) of an injury, disease, pathology or condition, or reducing the likelihood of the onset (or reoccurrence) of an injury, disease, pathology, or condition, or their symptoms. The hill prophylactic effect does not necessarily occur by administration of one dose, and may occur only after administration of a series of doses. Thus, a prophylactically effective amount may be administered in one or more administrations. An “activity decreasing amount,” as used herein, refers to an amount of antagonist required to decrease the activity of an enzyme relative to the absence of the antagonist. A “function disrupting amount,” as used herein, refers to the amount of antagonist required to disrupt the function of an enzyme or protein relative to the absence of the antagonist. The exact amounts will depend on the purpose of the treatment, and will be ascertainable by one skilled in the art using known techniques {see, e.g., Lieberman, Pharmaceutical Dosage Forms (vols. 1-3, 1992); Lloyd, The Art, Science and Technology of Pharmaceutical Compounding (1999); Pickar, Dosage Calculations (1999); and Remington: The Science and Practice of Pharmacy, 20th Edition, 2003, Gennaro, Ed., Lippincott, Williams & Wilkins).
[0197] “Control” or “control experiment” is used in accordance with its plain ordinary meaning and refers to an experiment in which the subjects or reagents of the experiment are treated as in a parallel experiment except for omission of a procedure, reagent, or variable of the experiment. In some instances, the control is used as a standard of comparison in evaluating experimental effects. In some embodiments, a control is the measurement of the activity (e.g., signaling pathway) of a protein in the absence of a compound as described herein (including embodiments, examples, figures, or Tables).
[0198] For any compound described herein, the therapeutically effective amount can be initially determined from cell culture assays. Target concentrations will be those concentrations of active compound(s) that are capable of achieving the methods described herein, as measured using the methods described herein or known in the art.
[0199] As is well known in the art, therapeutically effective amounts for use in humans can also be determined from animal models. For example, a dose for humans can be formulated to achieve a concentration that has been found to be effective in animals. The dosage in humans can be adjusted by monitoring compounds effectiveness and adjusting the dosage upwards or downwards, as described above. Adjusting the dose to achieve maximal efficacy in humans based on the methods described above and other methods is well within the capabilities of the ordinarily skilled artisan.
[0200] The term “therapeutically effective amount,” as used herein, refers to that amount of the therapeutic agent sufficient to ameliorate the disorder, as described above. For example, for the given parameter, a therapeutically effective amount will show an increase or decrease of at least 5%, 10%, 15%, 20%, 25%, 40%, 50%, 60%, 75%, 80%, 90%, or at least 100%. Therapeutic efficacy can also be expressed as “-fold” increase or decrease. For example, a therapeutically effective amount can have at least a 1.2-fold, 1.5-fold, 2-fold, 5-fold, or more effect over a control.
[0201] Dosages may be varied depending upon the requirements of the patient and the compound being employed. The dose administered to a patient, in the context of the present disclosure, should be sufficient to effect a beneficial therapeutic response in the patient over time. The size of the dose also will be determined by the existence, nature, and extent of any adverse side-effects. Determination of the proper dosage for a particular situation is within the skill of the practitioner. Generally, treatment is initiated with smaller dosages which are less than the optimum dose of the compound. Thereafter, the dosage is increased by small increments until the optimum effect under circumstances is reached. Dosage amounts and intervals can be adjusted individually to provide levels of the administered compound effective for the particular clinical indication being treated. This will provide a therapeutic regimen that is commensurate with the severity of the individual's disease state.
[0202] As used herein, the term "administering" means oral administration, administration as a suppository, topical contact, intravenous, parenteral, intraperitoneal, intramuscular, intralesional, intrathecal, intranasal or subcutaneous administration, or the implantation of a slow-release device, e.g., a mini-osmotic pump, to a subject. Administration is by any route, including parenteral and transmucosal (e.g., buccal, sublingual, palatal, gingival, nasal, vaginal, rectal, or transdermal). Parenteral administration includes, e.g., intravenous, intramuscular, intra-arteriole, intradermal, subcutaneous, intraperitoneal, intraventricular, and intracranial. Other modes of delivery include, but are not limited to, the use of liposomal formulations, intravenous infusion, transdermal patches, etc. In embodiments, the administering does not include administration of any active agent other than the recited active agent.
[0203] "Co-administer" it is meant that a composition described herein is administered at the same time, just prior to, or just after the administration of one or more additional therapies. The compounds provided herein can be administered alone or can be coadministered to the patient. Coadministration is meant to include simultaneous or sequential administration of the compounds individually or in combination (more than one compound). Thus, the preparations can also be combined, when desired, with other active substances (e.g. to reduce metabolic degradation). The compositions of the present disclosure can be delivered transdermally, by a topical route, or formulated as applicator sticks, solutions, suspensions, emulsions, gels, creams, ointments, pastes, jellies, paints, powders, and aerosols.
[0204] A “cell” as used herein, refers to a cell carrying out metabolic or other function sufficient to preserve or replicate its genomic DNA. A cell can be identified by well-known methods in the art including, for example, presence of an intact membrane, staining by a particular dye, ability to produce progeny or, in the case of a gamete, ability to combine with a second gamete to produce a viable offspring. Cells may include prokaryotic and eukaroytic cells. Prokaryotic cells include but are not limited to bacteria. Eukaryotic cells include but are not limited to yeast cells and cells derived from plants and animals, for example mammalian, insect (e.g., spodoptera) and human cells. Cells may be useful when they are naturally nonadherent or have been treated not to adhere to surfaces, for example by trypsinization.
[0205] The compounds described herein can be used in combination with one another, with other active agents known to be useful in treating a disease associated with cells expressing a disease associated cellular component, or with adjunctive agents that may not be effective alone, but may contribute to the efficacy of the active agent. [0206] In some embodiments, co-administration includes administering one active agent within 0.5, 1, 2, 4, 6, 8, 10, 12, 16, 20, or 24 hours of a second active agent. Coadministration includes administering two active agents simultaneously, approximately simultaneously (e.g., within about 1, 5, 10, 15, 20, or 30 minutes of each other), or sequentially in any order. In some embodiments, co-administration can be accomplished by co-formulation, i.e., preparing a single pharmaceutical composition including both active agents. In other embodiments, the active agents can be formulated separately. In another embodiment, the active and/or adjunctive agents may be linked or conjugated to one another.
[0207] “Anti-cancer agent” is used in accordance with its plain ordinary meaning and refers to a composition (e.g., compound, drug, antagonist, inhibitor, modulator) having antineoplastic properties or the ability to inhibit the growth or proliferation of cells. In some embodiments, an anti-cancer agent is a chemotherapeutic. In some embodiments, an anticancer agent is an agent identified herein having utility in methods of treating cancer. In some embodiments, an anti-cancer agent is an agent approved by the FDA or similar regulatory agency of a country other than the USA, for treating cancer. In embodiments, an anti-cancer agent is an agent with antineoplastic properties that has not (e.g., yet) been approved by the FDA or similar regulatory agency of a country other than the USA, for treating cancer. Examples of anti-cancer agents include, but are not limited to, MEK (e.g., MEK1, MEK2, or MEK1 and MEK2) inhibitors (e.g., XL518, CI-1040, PD035901, selumetinib/AZD6244, GSK1120212/trametinib, GDC-0973, ARRY-162, ARRY-300, AZD8330, PD0325901, U0126, PD98059, TAK-733, PD318088, AS703026, BAY 869766), alkylating agents (e.g., cyclophosphamide, ifosfamide, chlorambucil, busulfan, melphalan, mechlorethamine, uramustine, thiotepa, nitrosoureas, nitrogen mustards (e.g., mechloroethamine, cyclophosphamide, chlorambucil, meiphalan), ethylenimine and methylmelamines (e.g., hexamethlymelamine, thiotepa), alkyl sulfonates (e.g., busulfan), nitrosoureas (e.g., carmustine, lomustine, semustine, streptozocin), triazenes (decarbazine)), anti-metabolites (e.g., 5- azathioprine, leucovorin, capecitabine, fludarabine, gemcitabine, pemetrexed, raltitrexed, folic acid analog (e.g., methotrexate), or pyrimidine analogs (e.g., fluorouracil, floxouridine, Cytarabine), purine analogs (e.g., mercaptopurine, thioguanine, pentostatin), etc.), plant alkaloids (e.g., vincristine, vinblastine, vinorelbine, vindesine, podophyllotoxin, paclitaxel, docetaxel, etc.), topoisomerase inhibitors (e.g., irinotecan, topotecan, amsacrine, etoposide (VP 16), etoposide phosphate, teniposide, etc.), antitumor antibiotics (e.g., doxorubicin, adriamycin, daunorubicin, epirubicin, actinomycin, bleomycin, mitomycin, mitoxantrone, plicamycin, etc.), platinum-based compounds (e.g., cisplatin, oxaloplatin, carboplatin), anthracenedione (e.g., mitoxantrone), substituted urea (e.g., hydroxyurea), methyl hydrazine derivative (e.g., procarbazine), adrenocortical suppressant (e.g., mitotane, aminoglutethimide), epipodophyllotoxins (e.g., etoposide), antibiotics (e.g., daunorubicin, doxorubicin, bleomycin), enzymes (e.g., L-asparaginase), inhibitors of mitogen-activated protein kinase signaling (e.g., U0126, PD98059, PD184352, PD0325901, ARRY-142886, SB239063, SP600125, BAY 43-9006, wortmannin, or LY294002, Syk inhibitors, mTOR inhibitors, antibodies (e.g., rituxan), gossyphol, genasense, polyphenol E, Chlorofusin, all trans-retinoic acid (ATRA), bryostatin, tumor necrosis factor-related apoptosis-inducing ligand (TRAIL), 5-aza-2'-deoxycytidine, all trans retinoic acid, doxorubicin, vincristine, etoposide, gemcitabine, imatinib (Gleevec.RTM.), geldanamycin, 17-N-Allylamino-17-Demethoxygeldanamycin (17-AAG), flavopiridol, LY294002, bortezomib, trastuzumab, BAY 11-7082, PKC412, PD184352, 20-epi-l, 25 dihydroxyvitamin D3; 5-ethynyluracil; abiraterone; aclarubicin; acylfiilvene; adecypenol; adozelesin; aldesleukin; ALL-TK antagonists; altretamine; ambamustine; amidox; amifostine; aminolevulinic acid; amrubicin; amsacrine; anagrelide; anastrozole; andrographolide; angiogenesis inhibitors; antagonist D; antagonist G; antarelix; anti- dorsalizing morphogenetic protein- 1; antiandrogen, prostatic carcinoma; antiestrogen; antineoplaston; antisense oligonucleotides; aphidicolin glycinate; apoptosis gene modulators; apoptosis regulators; apurinic acid; ara-CDP-DL-PTBA; arginine deaminase; asulacrine; atamestane; atrimustine; axinastatin 1; axinastatin 2; axinastatin 3; azasetron; azatoxin; azatyrosine; baccatin III derivatives; balanol; batimastat; BCR/ABL antagonists; benzochlorins; benzoylstaurosporine; beta lactam derivatives; beta-alethine; betaclamycin B; betulinic acid; bFGF inhibitor; bicalutamide; bisantrene; bisaziridinylspermine; bisnafide; bistratene A; bizelesin; breflate; bropirimine; budotitane; buthionine sulfoximine; calcipotriol; calphostin C; camptothecin derivatives; canarypox IL-2; capecitabine; carboxamide-amino-triazole; carboxyamidotriazole; CaRest M3; CARN 700; cartilage derived inhibitor; carzelesin; casein kinase inhibitors (ICOS); castanospermine; cecropin B; cetrorelix; chlorins; chloroquinoxaline sulfonamide; cicaprost; cis-porphyrin; cladribine; clomifene analogues; clotrimazole; collismycin A; collismycin B; combretastatin A4; combretastatin analogue; conagenin; crambescidin 816; crisnatol; cryptophycin 8; cryptophycin A derivatives; curacin A; cyclopentanthraquinones; cycloplatam; cypemycin; cytarabine ocfosfate; cytolytic factor; cytostatin; dacliximab; decitabine; dehydrodidemnin B; deslorelin; dexamethasone; dexifosfamide; dexrazoxane; dexverapamil; diaziquone; didemnin B; didox; diethylnorspermine; dihydro-5-azacytidine; 9-dioxamycin; diphenyl spiromustine; docosanol; dolasetron; doxifluridine; droloxifene; dronabinol; duocarmycin SA; ebselen; ecomustine; edelfosine; edrecolomab; eflomithine; elemene; emitefiir; epirubicin; epristeride; estramustine analogue; estrogen agonists; estrogen antagonists; etanidazole; etoposide phosphate; exemestane; fadrozole; fazarabine; fenretinide; filgrastim; finasteride; flavopiridol; flezelastine; fluasterone; fludarabine; fluorodaunorunicin hydrochloride; forfenimex; formestane; fostriecin; fotemustine; gadolinium texaphyrin; gallium nitrate; galocitabine; ganirelix; gelatinase inhibitors; gemcitabine; glutathione inhibitors; hepsulfam; heregulin; hexamethylene bisacetamide; hypericin; ibandronic acid; idarubicin; idoxifene; idramantone; ilmofosine; ilomastat; imidazoacridones; imiquimod; immunostimulant peptides; insulin-like growth factor- 1 receptor inhibitor; interferon agonists; interferons; interleukins; iobenguane; iododoxorubicin; ipomeanol, 4-; iroplact; irsogladine; isobengazole; isohomohalicondrin B; itasetron; jasplakinolide; kahalalide F; lamellarin-N triacetate; lanreotide; leinamycin; lenograstim; lentinan sulfate; leptolstatin; letrozole; leukemia inhibiting factor; leukocyte alpha interferon; leuprolide+estrogen+progesterone; leuprorelin; levamisole; liarozole; linear polyamine analogue; lipophilic disaccharide peptide; lipophilic platinum compounds; lissoclinamide 7; lobaplatin; lombricine; lometrexol; lonidamine; losoxantrone; lovastatin; loxoribine; lurtotecan; lutetium texaphyrin; lysofylline; lytic peptides; maitansine; mannostatin A; marimastat; masoprocol; maspin; matrilysin inhibitors; matrix metalloproteinase inhibitors; menogaril; merbarone; meterelin; methioninase; metoclopramide; MEF inhibitor; mifepristone; miltefosine; mirimostim; mismatched double stranded RNA; mitoguazone; mitolactol; mitomycin analogues; mitonafide; mitotoxin fibroblast growth factor-saporin; mitoxantrone; mofarotene; molgramostim; monoclonal antibody, human chorionic gonadotrophin; monophosphoryl lipid A+myobacterium cell wall sk; mopidamol; multiple drug resistance gene inhibitor; multiple tumor suppressor 1 -based therapy; mustard anticancer agent; mycaperoxide B; mycobacterial cell wall extract; myriaporone; N-acetyldinaline; N- substituted benzamides; nafarelin; nagrestip; naloxone+pentazocine; napavin; naphterpin; nartograstim; nedaplatin; nemorubicin; neridronic acid; neutral endopeptidase; nilutamide; nisamycin; nitric oxide modulators; nitroxide antioxidant; nitrullyn; 06-benzylguanine; octreotide; okicenone; oligonucleotides; onapristone; ondansetron; ondansetron; oracin; oral cytokine inducer; ormaplatin; osaterone; oxaliplatin; oxaunomycin; palauamine; palmitoylrhizoxin; pamidronic acid; panaxytriol; panomifene; parabactin; pazelliptine; pegaspargase; peldesine; pentosan polysulfate sodium; pentostatin; pentrozole; perflubron; perfosfamide; perillyl alcohol; phenazinomycin; phenylacetate; phosphatase inhibitors; picibanil; pilocarpine hydrochloride; pirarubicin; piritrexim; placetin A; placetin B; plasminogen activator inhibitor; platinum complex; platinum compounds; platinum-triamine complex; porfimer sodium; porfiromycin; prednisone; propyl bis-acridone; prostaglandin J2; proteasome inhibitors; protein A-based immune modulator; protein kinase C inhibitor; protein kinase C inhibitors, microalgal; protein tyrosine phosphatase inhibitors; purine nucleoside phosphorylase inhibitors; purpurins; pyrazoloacridine; pyridoxylated hemoglobin polyoxyethylene conjugate; raf antagonists; raltitrexed; ramosetron; ras famesyl protein transferase inhibitors; ras inhibitors; ras-GAP inhibitor; retelliptine demethylated; rhenium Re 186 etidronate; rhizoxin; ribozymes; RII retinamide; rogletimide; rohitukine; romurtide; roquinimex; rubiginone Bl; ruboxyl; safmgol; saintopin; SarCNU; sarcophytol A; sargramostim; Sdi 1 mimetics; semustine; senescence derived inhibitor 1; sense oligonucleotides; signal transduction inhibitors; signal transduction modulators; single chain antigen-binding protein; sizofuran; sobuzoxane; sodium borocaptate; sodium phenylacetate; solverol; somatomedin binding protein; sonermin; sparfosic acid; spicamycin D; spiromustine; splenopentin; spongistatin 1 ; squalamine; stem cell inhibitor; stem-cell division inhibitors; stipiamide; stromelysin inhibitors; sulfmosine; superactive vasoactive intestinal peptide antagonist; suradista; suramin; swainsonine; synthetic glycosaminoglycans; tallimustine; tamoxifen methiodide; tauromustine; tazarotene; tecogalan sodium; tegafur; tellurapyrylium; telomerase inhibitors; temoporfm; temozolomide; teniposide; tetrachlorodecaoxide; tetrazomine; thaliblastine; thiocoraline; thrombopoietin; thrombopoietin mimetic; thymalfasin; thymopoietin receptor agonist; thymotrinan; thyroid stimulating hormone; tin ethyl etiopurpurin; tirapazamine; titanocene bichloride; topsentin; toremifene; totipotent stem cell factor; translation inhibitors; tretinoin; triacetyluridine; triciribine; trimetrexate; triptorelin; tropisetron; turosteride; tyrosine kinase inhibitors; tyrphostins; UBC inhibitors; ubenimex; urogenital sinus-derived growth inhibitory factor; urokinase receptor antagonists; vapreotide; variolin B; vector system, erythrocyte gene therapy; velaresol; veramine; verdins; verteporfm; vinorelbine; vinxaltine; vitaxin; vorozole; zanoterone; zeniplatin; zilascorb; zinostatin stimalamer, Adriamycin, Dactinomycin, Bleomycin, Vinblastine, Cisplatin, acivicin; aclarubicin; acodazole hydrochloride; acronine; adozelesin; aldesleukin; altretamine; ambomycin; ametantrone acetate; aminoglutethimide; amsacrine; anastrozole; anthramycin; asparaginase; asperlin; azacitidine; azetepa; azotomycin; batimastat; benzodepa; bicalutamide; bisantrene hydrochloride; bisnafide dimesylate; bizelesin; bleomycin sulfate; brequinar sodium; bropirimine; busulfan; cactinomycin; calusterone; caracemide; carbetimer; carboplatin; carmustine; carubicin hydrochloride; carzelesin; cedefingol; chlorambucil; cirolemycin; cladribine; crisnatol mesylate; cyclophosphamide; cytarabine; dacarbazine; daunorubicin hydrochloride; decitabine; dexormaplatin; dezaguanine; dezaguanine mesylate; diaziquone; doxorubicin; doxorubicin hydrochloride; droloxifene; droloxifene citrate; dromostanolone propionate; duazomycin; edatrexate; eflomithine hydrochloride; elsamitrucin; enloplatin; enpromate; epipropidine; epirubicin hydrochloride; erbulozole; esorubicin hydrochloride; estramustine; estramustine phosphate sodium; etanidazole; etoposide; etoposide phosphate; etoprine; fadrozole hydrochloride; fazarabine; fenretinide; floxuridine; fludarabine phosphate; fluorouracil; fluorocitabine; fosquidone; fostriecin sodium; gemcitabine; gemcitabine hydrochloride; hydroxyurea; idarubicin hydrochloride; ifosfamide; iimofosine; interleukin II (including recombinant interleukin II, or rlL.sub.2), interferon alfa-2a; interferon alfa-2b; interferon alfa-nl; interferon alfa-n3; interferon beta- la; interferon gamma- lb; iproplatin; irinotecan hydrochloride; lanreotide acetate; letrozole; leuprolide acetate; liarozole hydrochloride; lometrexol sodium; lomustine; losoxantrone hydrochloride; masoprocol; maytansine; mechlorethamine hydrochloride; megestrol acetate; melengestrol acetate; melphalan; menogaril; mercaptopurine; methotrexate; methotrexate sodium; metoprine; meturedepa; mitindomide; mitocarcin; mitocromin; mitogillin; mitomalcin; mitomycin; mitosper; mitotane; mitoxantrone hydrochloride; mycophenolic acid; nocodazoie; nogalamycin; ormaplatin; oxisuran; pegaspargase; peliomycin; pentamustine; peplomycin sulfate; perfosfamide; pipobroman; piposulfan; piroxantrone hydrochloride; plicamycin; plomestane; porfimer sodium; porfiromycin; prednimustine; procarbazine hydrochloride; puromycin; puromycin hydrochloride; pyrazofurin; riboprine; rogletimide; safingol; safingol hydrochloride; semustine; simtrazene; sparfosate sodium; sparsomycin; spirogermanium hydrochloride; spiromustine; spiroplatin; streptonigrin; streptozocin; sulofenur; talisomycin; tecogalan sodium; tegafur; teloxantrone hydrochloride; temoporfin; teniposide; teroxirone; testolactone; thiamiprine; thioguanine; thiotepa; tiazofurin; tirapazamine; toremifene citrate; trestolone acetate; triciribine phosphate; trimetrexate; trimetrexate glucuronate; triptorelin; tubulozole hydrochloride; uracil mustard; uredepa; vapreotide; verteporfin; vinblastine sulfate; vincristine sulfate; vindesine; vindesine sulfate; vinepidine sulfate; vinglycinate sulfate; vinleurosine sulfate; vinorelbine tartrate; vinrosidine sulfate; vinzolidine sulfate; vorozole; zeniplatin; zinostatin; zorubicin hydrochloride, agents that arrest cells in the G2-M phases and/or modulate the formation or stability of microtubules, (e.g., Taxol.TM (i.e., paclitaxel), Taxotere.TM, compounds comprising the taxane skeleton, Erbulozole (i.e., R- 55104), Dolastatin 10 (i.e., DLS-10 and NSC-376128), Mivobulin isethionate (i.e., as CI- 980), Vincristine, NSC-639829, Discodermolide (i.e., as NVP-XX-A-296), ABT-751 (Abbott, i.e., E-7010), Altorhyrtins (e.g., Altorhyrtin A and Altorhyrtin C), Spongistatins (e.g., Spongistatin 1, Spongistatin 2, Spongistatin 3, Spongistatin 4, Spongistatin 5, Spongistatin 6, Spongistatin 7, Spongistatin 8, and Spongistatin 9), Cemadotin hydrochloride (i.e., LU-103793 andNSC-D-669356), Epothilones (e.g., Epothilone A, Epothilone B, Epothilone C (i.e., desoxyepothilone A or dEpoA), Epothilone D (i.e., KOS-862, dEpoB, and desoxyepothilone B), Epothilone E, Epothilone F, Epothilone B N-oxide, Epothilone A N- oxide, 16-aza-epothilone B, 21-aminoepothilone B (i.e., BMS-310705), 21- hydroxyepothilone D (i.e., Desoxyepothilone F and dEpoF), 26-fluoroepothilone, Auristatin PE (i.e., NSC-654663), Soblidotin (i.e., TZT-1027), LS-4559-P (Pharmacia, i.e., LS-4577), LS-4578 (Pharmacia, i.e., LS-477-P), LS-4477 (Pharmacia), LS-4559 (Pharmacia), RPR- 112378 (Aventis), Vincristine sulfate, DZ-3358 (Daiichi), FR-182877 (Fujisawa, i.e., WS- 9885B), GS-164 (Takeda), GS-198 (Takeda), KAR-2 (Hungarian Academy of Sciences), BSF-223651 (BASF, i.e., ILX-651 andLU-223651), SAH-49960 (Lilly/Novartis), SDZ- 268970 (Lilly/Novartis), AM-97 (Armad/Kyowa Hakko), AM- 132 (Armad), AM-138 (Armad/Kyowa Hakko), IDN-5005 (Indena), Cryptophycin 52 (i.e., LY-355703), AC-7739 (Ajinomoto, i.e., AVE-8063A and CS-39.HC1), AC-7700 (Ajinomoto, i.e., AVE-8062, AVE- 8062A, CS-39-L-Ser.HCl, and RPR-258062A), Vitilevuamide, Tubulysin A, Canadensol, Centaureidin (i.e., NSC-106969), T-138067 (Tularik, i.e., T-67, TL-138067 and TI-138067), COBRA-1 (Parker Hughes Institute, i.e., DDE-261 and WHI-261), H10 (Kansas State University), HI 6 (Kansas State University), Oncocidin A1 (i.e., BTO-956 and DIME), DDE- 313 (Parker Hughes Institute), Fijianolide B, Laulimalide, SPA-2 (Parker Hughes Institute), SPA-1 (Parker Hughes Institute, i.e., SPIKET-P), 3-IAABU (Cytoskeleton/Mt. Sinai School of Medicine, i.e., MF-569), Narcosine (also known as NSC-5366), Nascapine, D-24851 (Asta Medica), A- 105972 (Abbott), Hemiasterlin, 3-BAABU (Cytoskeleton/Mt. Sinai School of Medicine, i.e., MF-191), TMPN (Arizona State University), Vanadocene acetylacetonate, T- 138026 (Tularik), Monsatrol, lnanocine (i.e., NSC-698666), 3-IAABE (Cytoskeleton/Mt. Sinai School of Medicine), A-204197 (Abbott), T-607 (Tuiarik, i.e., T-900607), RPR-115781 (Aventis), Eleutherobins (such as Desmethyleleutherobin, Desaetyleleutherobin, lsoeleutherobin A, and Z-Eleutherobin), Caribaeoside, Caribaeolin, Halichondrin B, D-64131 (Asta Medica), D-68144 (Asta Medica), Diazonamide A, A-293620 (Abbott), NPI-2350 (Nereus), Taccalonolide A, TUB-245 (Aventis), A-259754 (Abbott), Diozostatin, (-)- Phenylahistin (i.e., NSCL-96F037), D-68838 (Asta Medica), D-68836 (Asta Medica), Myoseverin B, D-43411 (Zentaris, i.e., D-81862), A-289099 (Abbott), A-318315 (Abbott), HTI-286 (i.e., SPA- 110, trifluoroacetate salt) (Wyeth), D-82317 (Zentaris), D-82318 (Zentaris), SC-12983 (NCI), Resverastatin phosphate sodium, BPR-OY-007 (National Health Research Institutes), and SSR-250411 (Sanofi)), steroids (e.g., dexamethasone), finasteride, aromatase inhibitors, gonadotropin-releasing hormone agonists (GriRH) such as goserelin or leuprolide, adrenocorticosteroids (e.g., prednisone), progestins (e.g., hydroxyprogesterone caproate, megestrol acetate, medroxyprogesterone acetate), estrogens (e.g., diethlystilbestrol, ethinyl estradiol), antiestrogen (e.g., tamoxifen), androgens (e.g., testosterone propionate, fluoxymesterone), antiandrogen (e.g., flutamide), immunostimulants (e.g., Bacillus Calmette- Guerin (BCG), levamisole, interleukin-2, alpha-interferon, etc.), monoclonal antibodies (e.g., anti-CD20, anti-HER2, anti-CD52, anti-HLA-DR, and anti-VEGF monoclonal antibodies), immunotoxins (e.g., anti-CD33 monoclonal antibody-calicheamicin conjugate, anti-CD22 monoclonal antibody-pseudomonas exotoxin conjugate, etc.), radioimmunotherapy (e.g., anti-CD20 monoclonal antibody conjugated to mIn, 90Y, or 131I, etc.), triptolide, homoharringtonine, dactinomycin, doxorubicin, epirubicin, topotecan, itraconazole, vindesine, cerivastatin, vincristine, deoxyadenosine, sertraline, pitavastatin, irinotecan, clofazimine, 5-nonyloxytryptamine, vemurafenib, dabrafenib, erlotinib, gefitinib, EGFR inhibitors, epidermal growth factor receptor (EGFR)-targeted therapy or therapeutic (e.g., gefitinib (Iressa™), erlotinib (Tarceva™), cetuximab (Erbitux™), lapatinib (Tykerb™), panitumumab (Vectibix™), vandetanib (Caprelsa™), afatinib/BIBW2992, CI- 1033/canertinib, neratinib/HKI-272, CP-724714, TAK-285, AST-1306, ARRY334543, ARRY-380, AG-1478, dacomitinib/PF299804, OSI-420/desmethyl erlotinib, AZD8931, AEE788, pelitinib/EKB-569, CUDC-101, WZ8040, WZ4002, WZ3146, AG-490, XL647, PD153035, BMS-599626), sorafenib, imatinib, sunitinib, dasatinib, or the like. A moiety of an anti-cancer agent is a monovalent anti-cancer agent (e.g., a monovalent form of an agent listed above). [0208] In therapeutic use for the treatment of a disease, compound utilized in the pharmaceutical compositions of the present invention may be administered at the initial dosage of about 0.001 mg/kg to about 1000 mg/kg daily. A daily dose range of about 0.01 mg/kg to about 500 mg/kg, or about 0.1 mg/kg to about 200 mg/kg, or about 1 mg/kg to about 100 mg/kg, or about 10 mg/kg to about 50 mg/kg, can be used. The dosages, however, may be varied depending upon the requirements of the patient, the severity of the condition being treated, and the compound or drug being employed. For example, dosages can be empirically determined considering the type and stage of cancer diagnosed in a particular patient. The dose administered to a patient, in the context of the present invention, should be sufficient to affect a beneficial therapeutic response in the patient over time. The size of the dose will also be determined by the existence, nature, and extent of any adverse side effects that accompany the administration of a compound in a particular patient. Determination of the proper dosage for a particular situation is within the skill of the practitioner. Generally, treatment is initiated with smaller dosages which are less than the optimum dose of the compound. Thereafter, the dosage is increased by small increments until the optimum effect under circumstances is reached. For convenience, the total daily dosage may be divided and administered in portions during the day, if desired.
[0209] The compounds described herein can be used in combination with one another, with other active agents known to be useful in treating cancer or with adjunctive agents that may not be effective alone, but may contribute to the efficacy of the active agent.
[0210] The term “associated” or “associated with” in the context of a substance or substance activity or function associated with a disease (e.g., a protein associated disease, disease associated with a cellular component) means that the disease (e.g., cancer) is caused by (in whole or in part), or a symptom of the disease is caused by (in whole or in part) the substance or substance activity or function or the disease or a symptom of the disease may be treated by modulating (e.g., inhibiting or activating) the substance (e.g., cellular component). As used herein, what is described as being associated with a disease, if a causative agent, could be a target for treatment of the disease.
[0211] Cancer model organism, as used herein, is an organism exhibiting a phenotype indicative of cancer, or the activity of cancer causing elements, within the organism. The term cancer is defined above. A wide variety of organisms may serve as cancer model organisms, and include for example, cancer cells and mammalian organisms such as rodents (e.g. mouse or rat) and primates (such as humans). Cancer cell lines are widely understood by those skilled in the art as cells exhibiting phenotypes or genotypes similar to in vivo cancers. Cancer cell lines as used herein includes cell lines from animals (e.g. mice) and from humans.
[0212] An “anticancer agent” as used herein refers to a molecule (e.g. compound, peptide, protein, nucleic acid) used to treat cancer through destruction or inhibition of cancer cells or tissues. Anticancer agents may be selective for certain cancers or certain tissues. In embodiments, anticancer agents herein may include epigenetic inhibitors and single- or multikinase inhibitors (e.g., G-protein inhibitor or Gas inhibitor).
II. Compounds
[0213] Provided herein, inter alia, are compounds. The compounds may be state-selective Gas labeling molecules, for example, based on disulfide tethering. The compounds may lable the somatic cysteine mutant selectively over all other cysteines present in the Gas protein, for example, forming a covalent irreversible bonding to the protein.
[0214] In an aspect provided is a compound having the formula:
Figure imgf000068_0001
[0215] R1 is independently halogen, -CX’a, -CUX] 2, -CH2X1, -OCX13, - OCH2X1, -OCHX^, -CN, -SO„iR1D, -SOviNR1AR1B, -NR1CNR1AR1B, -ONR1AR1b, -NHC(0)NR1CNR1AR1B, -NHC(0)NR1AR1b, -N(0)mi, -NR1AR1B, -C(0)R1c, -C(0)-ORlc, -C (0)NR1AR1b, -OR1d, -NR1AS02R1d, -NR1AC(0)R1c, -NR1AC(0)OR1c, -NR1AOR1c, -N3, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl; two adjacent R1 substituents may optionally be joined to form a substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl.
[0216] The variable zl is an integer from 0 to 6. [0217] Ring A is aryl or heteroaryl.
[0218] L1 is a bond, -NH-, -0-, -S-, -C(O)-, -C(0)NH-, -NHC(O)-, -NHC(0)NH-, -C(0)0-, -OC(O)-, substituted or unsubstituted alkylene, substituted or unsubstituted heteroalkylene, substituted or unsubstituted cycloalkylene, substituted or unsubstituted heterocycloalkylene, substituted or unsubstituted arylene, or substituted or unsubstituted heteroarylene.
[0219] L2 is a bond, -NH-, -0-, -S-, -C(O)-, -C(0)NH-, -NHC(O)-, -NHC(0)NH-, -C(0)0-, -OC(O)-, substituted or unsubstituted alkylene, substituted or unsubstituted heteroalkylene, substituted or unsubstituted cycloalkylene, substituted or unsubstituted heterocycloalkylene, substituted or unsubstituted arylene, or substituted or unsubstituted heteroarylene.
[0220] R2 is an electrophilic moiety.
[0221] R1A, R1b, R1C, and R1D are independently hydrogen, -CX3, -CHX2, -CH2X, -CN, -OH, -COOH, -CONH2, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl; R1A and R1B substituents bonded to the same nitrogen atom may optionally be joined to form a substituted or unsubstituted heterocycloalkyl or substituted or unsubstituted heteroaryl.
[0222] X and X1 are independently -F, -Cl, -Br, or -I.
[0223] nl is independently an integer from 0 to 4.
[0224] ml and vl are independently 1 or 2.
[0225] In embodiments, zl is an integer from 1 to 3. In embodiments, zl is 0. In embodiments, zl is 1. In embodiments, zl is 2. In embodiments, zl is 3.
[0226] In embodiments, Ring A is phenyl or 5 to 6-membered heteroaryl. In embodiments, Ring A is phenyl. In embodiments, Ring A is 5 to 6-membered heteroaryl. In embodiments, Ring A is 5-membered heteroaryl. In embodiments, Ring A is 6-membered heteroaryl. In embodiments, Ring A is 5-membered heteroaryl containing at least one nitrogen atom. In embodiments, Ring A is 6-membered heteroaryl containing at least one nitrogen atom.
[0227] In embodiments, the compound has the formula: [0228] Each R1 1, R1·2, R1·3, R1·4, and R1,5 is independently hydrogen, halogen, -CX^, - CHX -CH2X1, -OCX’s, -OCH2X1, -OCHX’2, -CN, -SO„IR1d, -SOVINR1AR1b, -NR1CNR1AR1B, -ONR1AR1b,
-NHC(0)NR1CNR1AR1b, -NHC(0)NR1AR1b, -N(0)mi, -NR1AR1B, -C(0)R1c,
-C(0)-0Rlc, -C(0)NR1AR1B, -OR1d, -NR1AS02R1d, -NR1AC(0)R1c, -NR1AC(0)0R1c, -NR1 AOR1c, -N3, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl.
[0229] R1A, R1b, R1C, and R1D are independently hydrogen, -CX3, -CHX2, -CH2X, -CN, -OH, -COOH, -CONH2, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl; R1A and R1B substituents bonded to the same nitrogen atom may optionally be joined to form a substituted or unsubstituted heterocycloalkyl or substituted or unsubstituted heteroaryl.
[0230] X and X1 are independently -F, -Cl, -Br, or -I.
[0231] nl is independently an integer from 0 to 4.
[0232] ml and vl are independently 1 or 2.
[0233] In embodiments, L1 is a bond, -NH-, -0-, -S-, -C(O)-, -C(0)NH-, -NHC(O)-, -NHC(0)NH-, -C(0)0-, -OC(O)-, substituted or unsubstituted alkylene, or substituted or unsubstituted heteroalkylene. In embodiments, L1 is a bond, -NH-, -0-, -S-, -C(O)-, -C(0)NH-, -NHC(O)-, -NHC(0)NH-, -C(0)0-, -OC(O)-, substituted or unsubstituted C1-C6 alkylene, or substituted or unsubstituted 2 to 6 membered heteroalkylene.
[0234] In embodiments, L1 is a bond. In embodiments, L1 is -NH-. In embodiments, L1 is -0-. In embodiments, L1 is -S-. In embodiments, L1 is -C(O)-. In embodiments, L1 is -C(0)NH-. In embodiments, L1 is -NHC(O)-. In embodiments, L1 is -NHC(0)NH-. In embodiments, L1 is -C(0)0-. In embodiments, L1 is -OC(O)-.
[0235] In embodiments, L1 is substituted or unsubstituted C1-C6 alkylene. In embodiments, L1 is substituted C1-C6 alkylene. In embodiments, L1 is unsubstituted C1-C6 alkylene. In embodiments, L1 is substituted or unsubstituted C1-C4 alkylene. In embodiments, L1 is substituted C1-C4 alkylene. In embodiments, L1 is unsubstituted C1-C4 alkylene. In embodiments, L1 is substituted or unsubstituted C1-C3 alkylene. In embodiments, L1 is substituted C1-C3 alkylene. In embodiments, L1 is unsubstituted C1-C3 alkylene. In embodiments, L1 is substituted or unsubstituted methylene. In embodiments, L1 is substituted methylene. In embodiments, L1 is unsubstituted methylene. In embodiments, L1 is substituted or unsubstituted ethylene. In embodiments, L1 is substituted ethylene. In embodiments, L1 is unsubstituted ethylene.
[0236] In embodiments, L1 is substituted or unsubstituted 2 to 6 membered heteroalkylene. In embodiments, L1 is substituted 2 to 6 membered heteroalkylene. In embodiments, L1 is unsubstituted 2 to 6 membered heteroalkylene. In embodiments, L1 is substituted or unsubstituted 2 to 5 membered heteroalkylene. In embodiments, L1 is substituted 2 to 5 membered heteroalkylene. In embodiments, L1 is unsubstituted 2 to 5 membered heteroalkylene. In embodiments, L1 is substituted or unsubstituted 2 to 4 membered heteroalkylene. In embodiments, L1 is substituted 2 to 4 membered heteroalkylene. In embodiments, L1 is unsubstituted 2 to 4 membered heteroalkylene. In embodiments, L1 is substituted or unsubstituted 2 to 3 membered heteroalkylene. In embodiments, L1 is substituted 2 to 3 membered heteroalkylene. In embodiments, L1 is unsubstituted 2 to 3 membered heteroalkylene.
[0237] In embodiments, L2 is an unsubstituted C1-C6 alkylene. In embodiments, L2 is an unsubstituted C1-C5 alkylene. In embodiments, L2 is an unsubstituted C1-C4 alkylene. In embodiments, L2 is an unsubstituted C1-C3 alkylene. In embodiments, L2 is an unsubstituted C1-C2 alkylene. In embodiments, L2 is unsubstituted methylene. In embodiments, L2 is unsubstituted ethylene. In embodiments, L2 is unsubstituted propylene. In embodiments, L2 is unsubstituted isopropylene. In embodiments, L2 is unsubstituted butylene. In embodiments, L2 is unsubstituted isobutylene. In embodiments, L2 is unsubstituted t- butylene. In embodiments, L2 is unsubstituted 2-methyl propylene. In embodiments, L2 is a bond.
[0238] In embodiments, R1.1 is hydrogen, halogen,
Figure imgf000072_0001
( ) ( ) ( ) ( )
Figure imgf000072_0002
substituted or unsubstituted C1-C6 alkyl, substituted or unsubstituted 2 to 6 membered heteroalkyl, substituted or unsubstituted C3-C6 cycloalkyl, substituted or unsubstituted 3 to 6 membered heterocycloalkyl, substituted or unsubstituted C6-C12 aryl, or substituted or unsubstituted 5 to 12 membered heteroaryl.
[0239] In embodiments, R12 is hydrogen, halogen, -
Figure imgf000072_0003
Figure imgf000072_0004
Figure imgf000072_0005
Figure imgf000072_0006
substituted or unsubstituted C1-C6 alkyl, substituted or unsubstituted 2 to 6 membered heteroalkyl, substituted or unsubstituted C3-C6 cycloalkyl, substituted or unsubstituted 3 to 6 membered heterocycloalkyl, substituted or unsubstituted C6-C12 aryl, or substituted or unsubstituted 5 to 12 membered heteroaryl.
[0240] In embodiments, R1·3 is hydrogen, halogen,
Figure imgf000072_0007
substituted or unsubstituted C1-C6 alkyl, substituted or unsubstituted 2 to 6
Figure imgf000072_0008
membered heteroalkyl, substituted or unsubstituted C3-C6 cycloalkyl, substituted or unsubstituted 3 to 6 membered heterocycloalkyl, substituted or unsubstituted C6-C12 aryl, or substituted or unsubstituted 5 to 12 membered heteroaryl.
[0241] In embodiments, R1·4 is hydrogen, halogen,
Figure imgf000072_0009
-C(0)-0Rlc, -C(0)NR1AR1B, -OR1d, -NR1AS02R1d, -NR1AC(0)R1c, -NR1AC(0)0R1c, -NR1 AOR1c, -N3, substituted or unsubstituted C1-C6 alkyl, substituted or unsubstituted 2 to 6 membered heteroalkyl, substituted or unsubstituted C3-C6 cycloalkyl, substituted or unsubstituted 3 to 6 membered heterocycloalkyl, substituted or unsubstituted C6-C12 aryl, or substituted or unsubstituted 5 to 12 membered heteroaryl.
[0242] In embodiments, R1 5 is hydrogen, halogen, -CX’s, -CHX -CH2X1, -OCX13, - OCH2X1, -OCHX’i, -CN, -SO„iR1D, -SOviNR1AR1B, -NR1CNR1AR1B, -ONR1AR1b, -NHC(0)NR1CNR1AR1b, -NHC(0)NR1AR1b, -N(0)mi, -NR1AR1B, -C(0)R1c,
-C(0)-0Rlc, -C(0)NR1AR1B, -OR1d, -NR1AS02R1d, -NR1AC(0)R1c, -NR1AC(0)0R1c, -NR1A ORlc, -N3, substituted or unsubstituted C1-C6 alkyl, substituted or unsubstituted 2 to 6 membered heteroalkyl, substituted or unsubstituted C3-C6 cycloalkyl, substituted or unsubstituted 3 to 6 membered heterocycloalkyl, substituted or unsubstituted C6-C12 aryl, or substituted or unsubstituted 5 to 12 membered heteroaryl.
[0243] In embodiments, R1A is hydrogen, or substituted or unsubstituted alkyl. In embodiments, R1A is hydrogen. In embodiments, R1A is substituted or unsubstituted alkyl. In embodiments, R1A is substituted alkyl. In embodiments, R1A is unsubstituted alkyl. In embodiments, R1A is substituted or unsubstituted C1-C6 alkyl. In embodiments, R1A is unsubstituted C1-C6 alkyl. In embodiments, R1A is substituted or unsubstituted C1-C5 alkyl.
In embodiments, R1A is unsubstituted C1-C5 alkyl. In embodiments, R1A is substituted or unsubstituted C1-C4 alkyl. In embodiments, R1A is unsubstituted C1-C4 alkyl. In embodiments, R1A is methyl. In embodiments, R1A is ethyl. In embodiments, R1A is propyl. In embodiments, R1A is isopropyl. In embodiments, R1A is butyl. In embodiments, R1A is t- butyl.
[0244] In embodiments, R1B is hydrogen, or substituted or unsubstituted alkyl. In embodiments, R1B is hydrogen. In embodiments, R1B is substituted or unsubstituted alkyl. In embodiments, R1B is substituted alkyl. In embodiments, R1B is unsubstituted alkyl. In embodiments, R1B is substituted or unsubstituted C1-C6 alkyl. In embodiments, R1B is unsubstituted C1-C6 alkyl. In embodiments, R1B is substituted or unsubstituted C1-C5 alkyl.
In embodiments, R1B is unsubstituted C1-C5 alkyl. In embodiments, R1B is substituted or unsubstituted C1-C4 alkyl. In embodiments, R1B is unsubstituted C1-C4 alkyl. In embodiments, R1B is methyl. In embodiments, R1B is ethyl. In embodiments, R1B is propyl. In embodiments, R1B is isopropyl. In embodiments, R1B is butyl. In embodiments, R1B is t- butyl.
[0245] In embodiments, R1C is hydrogen, or substituted or unsubstituted alkyl. In embodiments, R1C is hydrogen. In embodiments, R1C is substituted or unsubstituted alkyl. In embodiments, R1C is substituted alkyl. In embodiments, R1C is unsubstituted alkyl. In embodiments, R1C is substituted or unsubstituted C1-C6 alkyl. In embodiments, R1C is unsubstituted C1-C6 alkyl. In embodiments, R1C is substituted or unsubstituted C1-C5 alkyl.
In embodiments, R1C is unsubstituted C1-C5 alkyl. In embodiments, R1C is substituted or unsubstituted C1-C4 alkyl. In embodiments, R1C is unsubstituted C1-C4 alkyl. In embodiments, R1C is methyl. In embodiments, R1C is ethyl. In embodiments, R1C is propyl. In embodiments, R1C is isopropyl. In embodiments, R1C is butyl. In embodiments, R1C is t- butyl.
[0246] In embodiments, R1D is hydrogen, or substituted or unsubstituted alkyl. In embodiments, R1D is hydrogen. In embodiments, R1D is substituted or unsubstituted alkyl. In embodiments, R1D is substituted alkyl. In embodiments, R1D is unsubstituted alkyl. In embodiments, R1D is substituted or unsubstituted C1-C6 alkyl. In embodiments, R1D is unsubstituted C1-C6 alkyl. In embodiments, R1D is substituted or unsubstituted C1-C5 alkyl.
In embodiments, R1D is unsubstituted C1-C5 alkyl. In embodiments, R1D is substituted or unsubstituted C1-C4 alkyl. In embodiments, R1D is unsubstituted C1-C4 alkyl. In embodiments, R1D is methyl. In embodiments, R1D is ethyl. In embodiments, R1D is propyl. In embodiments, R1D is isopropyl. In embodiments, R1D is butyl. In embodiments, R1D is t- butyl.
[0247] In embodiments, Ru is -CN. In embodiments, R1 1 is hydrogen.
[0248] In embodiments, R1,2 is halogen (e.g., -F, -Cl, -Br, or -I) or -CN. In embodiments, In embodiments, R1,2 is -F. In embodiments, R1,2 is -Cl. In embodiments, R1,2 is -Br. In embodiments, R1,2 is -I. In embodiments, R1,2 is -CN. In embodiments, R1,2 is hydrogen.
[0249] In embodiments, R1,2 is -OR1D. In embodiments, R1D is hydrogen, or substituted or unsubstituted C1-C4 alkyl. In embodiments, R1D is hydrogen. In embodiments, R1D is substituted or unsubstituted C1-C4 alkyl. In embodiments, R1D is unsubstituted C1-C4 alkyl.
In embodiments, R1D is methyl. In embodiments, R1D is ethyl. In embodiments, R1D is propyl. In embodiments, R1D is isopropyl. In embodiments, R1D is butyl. In embodiments, R1D is t-butyl. In embodiments, R1 2 is -OH. In embodiments, R1 2 is -OCH3. In embodiments, R1 2 is -OCH2CH3.
[0250] R1,3 is halogen, -CN, substituted or unsubstituted C1-C6 alkyl, or substituted or unsubstituted 2 to 6 membered heteroalkyl. In embodiments, R1,3 is -F. In embodiments, R1,3 is -Cl. In embodiments, R1,3 is -Br. In embodiments, R1,3 is -I. In embodiments, R1,3 is -CN. In embodiments, R1,3 is hydrogen.
[0251] In embodiments, R1,3 is substituted or unsubstituted C1-C6 alkyl. In embodiments, R1·3 is substituted C1-C6 alkyl. In embodiments, R1,3 is unsubstituted C1-C6 alkyl. In embodiments, R1,3 is substituted or unsubstituted C1-C5 alkyl. In embodiments, R1,3 is substituted C1-C5 alkyl. In embodiments, R1,3 is unsubstituted C1-C5 alkyl. In embodiments, R1·3 is substituted or unsubstituted C1-C4 alkyl. In embodiments, R1,3 is substituted C1-C4 alkyl. In embodiments, R1,3 is unsubstituted C1-C4 alkyl. In embodiments, R1·3 is substituted or unsubstituted C2-C4 alkyl. In embodiments, R1·3 is substituted C2-C4 alkyl. In embodiments, R1·3 is unsubstituted C2-C4 alkyl. In embodiments, R1·3 is substituted or unsubstituted C1-C3 alkyl. In embodiments, R1·3 is substituted C1-C3 alkyl. In embodiments, R1·3 is unsubstituted C1-C3 alkyl. In embodiments, R1·3 is OH-substituted C1-C6 alkyl. In embodiments, R1·3 is OH-substituted C1-C4 alkyl. In embodiments, R1·3 is -CH2OH. In embodiments, R1 3 is -CH2CH2OH. In embodiments, R1 3 is -CH2CH2CH2OH. In embodiments, R1 3 is -CH2CH2CH2CH2OH.
[0252] In embodiments, R1·3 is substituted or unsubstituted 2 to 6 membered heteroalkyl.
In embodiments, R1·3 is substituted 2 to 6 membered heteroalkyl. In embodiments, R1·3 is unsubstituted 2 to 6 membered heteroalkyl. In embodiments, R1·3 is substituted or unsubstituted 2 to 5 membered heteroalkyl. In embodiments, R1·3 is substituted 2 to 5 membered heteroalkyl. In embodiments, R1·3 is unsubstituted 2 to 5 membered heteroalkyl.
In embodiments, R1·3 is substituted or unsubstituted 2 to 4 membered heteroalkyl. In embodiments, R1·3 is substituted 2 to 4 membered heteroalkyl. In embodiments, R1·3 is unsubstituted 2 to 4 membered heteroalkyl. In embodiments, R1·3 is substituted or unsubstituted 3 to 6 membered heteroalkyl. In embodiments, R1·3 is substituted 3 to 6 membered heteroalkyl. In embodiments, R1·3 is unsubstituted 3 to 6 membered heteroalkyl.
In embodiments, R1·3 is substituted or unsubstituted 3 to 5 membered heteroalkyl. In embodiments, R1·3 is substituted 3 to 5 membered heteroalkyl. In embodiments, R1·3 is unsubstituted 3 to 5 membered heteroalkyl. In embodiments, R1·3 is substituted or unsubstituted 3 to 4 membered heteroalkyl. In embodiments, R1 3 is substituted 3 to 4 membered heteroalkyl. In embodiments, R1,3 is unsubstituted 3 to 4 membered heteroalkyl.
In embodiments, R1,3 is -CH2OH. In embodiments, R1,3 is -CH2CH2OH. In embodiments,
R1 3 is -CH2CH2CH2OH. In embodiments, R1 3 is -CH2CH2CH2CH2OH.
[0253] In embodiments, R1,3 is -C(0)Rlc, or -C(0)-0Rlc. In embodiments, R1,3 is -C(0)Rlc. In embodiments, R1,3 is -C(0)-0Rlc. In embodiments, R1C is hydrogen, or substituted or unsubstituted C1-C4 alkyl. In embodiments, R1C is hydrogen. In embodiments, R1C is substituted or unsubstituted C1-C4 alkyl. In embodiments, R1C is unsubstituted C1-C4 alkyl. In embodiments, R1C is methyl. In embodiments, R1C is ethyl. In embodiments, R1C is propyl. In embodiments, R1C is isopropyl. In embodiments, R1C is butyl. In embodiments, R1C is t-butyl. In embodiments, R1,3 is -C(0)H. In embodiments, R1,3 is -C(0)CH3. In embodiments, R1 3 is -C(0)CH2CH3. In embodiments, R1 3 is -C(0)CH2CH2CH3. In embodiments, R1 3 is -C(0)CH2CH2CH2CH3. In embodiments, R1 3 is -C(0)0H. In embodiments, R1 3 is -C(0)0CH3. In embodiments, R1 3 is -C(0)0CH2CH3. In embodiments, R1 3 is -C(0)0CH2CH2CH3. In embodiments, R1 3 is -C(0)0CH2CH2CH2CH3.
[0254] In embodiments, R1,3 is -OR1D. In embodiments, R1D is hydrogen, or substituted or unsubstituted C1-C4 alkyl. In embodiments, R1D is hydrogen. In embodiments, R1D is substituted or unsubstituted C1-C4 alkyl. In embodiments, R1D is unsubstituted C1-C4 alkyl.
In embodiments, R1D is methyl. In embodiments, R1D is ethyl. In embodiments, R1D is propyl. In embodiments, R1D is isopropyl. In embodiments, R1D is butyl. In embodiments, R1D is phenyl. In embodiments, R1D is t-butyl. In embodiments, R1·3 is -OH. In embodiments, R1·3 is -OCH3. In embodiments, R1·3 is -OCH2CH3. In embodiments, R1·3 is -
OC5H6.
[0255] In embodiments, R1 3 is -OCX^, -OCH2X1, or -OCHX^. In embodiments, R1 3 is -OCXV In embodiments, R1·3 is -OCH2X1. In embodiments, R1·3 is -OCHX^. In embodiments, R1 3 is -OCF3, -OCCl3, -OCBr3, or -OCI3. In embodiments, R1 3 is -OCHF2, - OCHCl2,-OCHBr2, or -OCHI2. In embodiments, R1 3 is -OCH2F, -OCH2CI, -OCH2Br, or - OCH2I. In embodiments, R1 3 is -OCF3.
[0256] In embodiments, R1,4 is halogen (e.g., -F, -Cl, -Br, or -I) or -CN. In embodiments,
In embodiments, R1,4 is -F. In embodiments, R1,4 is -Cl. In embodiments, R1·4 is -Br. In embodiments, R1·4 is -I. In embodiments, R1·4 is -CN. In embodiments, R1·4 is hydrogen. [0257] In embodiments, R1 4 is -OR1D. In embodiments, R1D is hydrogen, or substituted or unsubstituted C1-C4 alkyl. In embodiments, R1D is hydrogen. In embodiments, R1D is substituted or unsubstituted C1-C4 alkyl. In embodiments, R1D is unsubstituted C1-C4 alkyl.
In embodiments, R1D is methyl. In embodiments, R1D is ethyl. In embodiments, R1D is propyl. In embodiments, R1D is isopropyl. In embodiments, R1D is butyl. In embodiments, R1D is t-butyl. In embodiments, R1,4 is -OH. In embodiments, R1,4 is -OCH3. In embodiments, R1 4 is -OCH2CH3.
[0258] In embodiments, R1,5 is -CN. In embodiments, R1,5 is hydrogen.
[0259] In embodiments, R1,2 and R1,4 are hydrogen; and R1,3 is substituted or unsubstituted 2 to 6 membered heteroalkyl. In embodiments, R1 1, R1,2, R1,4 and R1,5 are hydrogen; and R1,3 is substituted or unsubstituted 2 to 6 membered heteroalkyl. In embodiments, R1 1, R1,2, R1,4 and R1 5 is hydrogen; and R1 3 is -CH2OH, -CH2CH2OH, -CH2CH2CH2OH, or - CH2CH2CH2CH2OH. In embodiments, R1 1, R12, R1 4 and R1 5 is hydrogen; and R1 3 is - CH2CH2OH. In embodiments, R1,2 and R1,4 is hydrogen; and R1,3 is -CN. In embodiments, R1·1, 1.2^ £i.4 an(j £i.5 js hydrogen; and R1·3 is -CN.
[0260] In embodiments, R1,2 is halogen (e.g., -F, -Cl, -Br, or -I); and R1,5 is -CN. In embodiments, R1,2 is -Cl, and R1,5 is -CN. In embodiments, R1,2 is halogen (e.g., -F, -Cl, -Br, or -I); R1·3 is hydrogen, and R1·5 is -CN. In embodiments, R1,2 is -Cl; R1·3 is hydrogen; and R1·5 is -CN. In embodiments, R1 1, R1,3, and R1,4 are hydrogen; R1·2 is halogen (e.g., -F, -Cl, - Br, or -I); and R1·5 is -CN. In embodiments, R1 1, R1,3, and R1,4 are hydrogen; R1·2 is -Cl; and R1 5 is -CN.
[0261] In embodiments, R1 1 is -CN; and R1,4 is halogen (e.g., -F, -Cl, -Br, or -I). In embodiments, Ru is -CN; and R1·4 is -Cl. In embodiments, Ru is -CN; R1·3 is hydrogen; and R1,4 is halogen (e.g., -F, -Cl, -Br, or -I). In embodiments, Ru is -CN; R1·3 is hydrogen; and R1,4 is -Cl. In embodiments, Ru is -CN; R1,2, R1·3, and R1·5 are hydrogen; and R1,4 is halogen (e.g., -F, -Cl, -Br, or -I). In embodiments, Ru is -CN; R1,2, R1·3, and R1,5 are hydrogen; and R1,4 is -Cl.
[0262] In embodiments, R1,2 is -CN; and R1·3 is halogen (e.g., -F, -Cl, -Br, or -I). In embodiments, R1,2 is -CN; and R1·3 is -F. In embodiments, Ru and R1·5 are hydrogen; R1·2 is -CN; and R1,3 is halogen (e.g., -F, -Cl, -Br, or -I). In embodiments, Ru and R1·5 are hydrogen; R1·2 is -CN; and R1,3 is -F. In embodiments, R1 1, R1,4 and R1,5 are hydrogen; R1·2 is -CN; and R1 3 is halogen (e.g., -F, -Cl, -Br, or -I). In embodiments, Ru, R1 4 and R1 5 are hydrogen; R1·2 is -CN; and R1,3 is -F.
[0263] In embodiments, R1,3 is halogen (e.g., -F, -Cl, -Br, or -I); and R1,4 is -CN. In embodiments, R1,3 is -F; and R1,4 is -CN. In embodiments, Ru and R1,5 are hydrogen; R1·3 is halogen (e.g., -F, -Cl, -Br, or -I); and and R1,4 is -CN. In embodiments, Ru and R1,5 are hydrogen; R1·3 is -F; and R1,4 is -CN. In embodiments, R1 1, R1,2 and R1·5 are hydrogen; R1·3 is halogen (e.g., -F, -Cl, -Br, or -I); and R1·4 is -CN. In embodiments, R1 1, R1,2 and R1,5 are hydrogen; R1·3 is -F; and R1,4 is -CN.
[0264] In embodiments, R1 3 is -C(0)0CH3; and R1 4 is -OCH3. In embodiments, R1 1 and R1·5 are hydrogen; R1·3 is -C(0)0CH3; and R1,4 is -OCH3. In embodiments, R1 1, R1,2, and R1 5 are hydrogen; R1 3 is -C(0)0CH3; and R1 4 is -OCH3. In embodiments, R1 3 is -C(0)0CH3; and R1,2 is -OCH3. In embodiments, Ru and R1·5 are hydrogen; R1·3 is -C(0)0CH3; and R1,2 is -OCH3. In embodiments, R1 1, R1·4, and R1·5 are hydrogen; R1·2 is -C(0)0CH3; and R1 4 is -OCH3.
[0265] In embodiments, R1 3 is -C(0)0H; and R1 4 is -OCH3. In embodiments, R1 1 and R1·5 are hydrogen; R1·3 is -C(0)0H; and R1·4 is -OCH3. In embodiments, R1 1, R1,2, and R1·5 are hydrogen; R1 3 is -C(0)0H; and R1 4 is -OCH3. In embodiments, R1 3 is -C(0)0H; and R1·2 is -OCH3. In embodiments, Ru and R1·5 are hydrogen; R1·3 is -C(0)0H; and R1·2 is - OCH3. In embodiments, R1 1, R1·4, and R1·5 are hydrogen; R1·2 is -C(0)0H; and R1,4 is - OCH3.
Figure imgf000078_0001
Figure imgf000079_0002
, -OCH2X16, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl.
[0268] R17 is hydrogen, halogen, -CX17 3, -CHX17 2, -CH2X17, -CN, -SOni7R17D, -SOVI7NR17AR 17B, -NHNR R17B, -ONR17AR17B, -NHC(O)NHNR17AR17B,
-NHC(O)NR17AR17B, -N(O)mi7, -NR17AR 1177BB,, --CC((OO))RR1177CC :, -C(O)-OR17C, -C(O)NR17AR17B, -OR 17D, -NR17ASO2R17B, -NR17AC(O)R17C, -NR17AC(O)OR17C, -NR17AOR17D, -OCX17 3, -OCHX17: , -OCH2X17, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl.
[0269] R18 is hydrogen, halogen, -CX18 3, -CHX18 2, -CH2X18, -CN, -SOn18R18D, -SOV18NR18AR 18AR18B -ONR18AR18B, -NHC(O)NHNR18AR18B,
Figure imgf000079_0001
, -OCH2X18, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl. [0270] R19 is hydrogen, halogen, -CX19 3, -CHX19 2, -CH2X19, -CN, -SO„I9R19D, -SOVI9NR19AR19B, -NHNR19AR19B, -ONR19AR19B, -NHC(0)NHNR19AR19B,
-NHC(0)NR19AR19B, -N(0)mi9, -NR19AR19B, -C(0)R19C, -C(0)-0R19C, -C(0)NR19AR19B, -OR 19D, -NR19AS02R19B, -NR19AC(0)R19C, -NR19AC(0)0R19C, -NR19AOR19D, -OCX19 3, -OCHX19 2 , -OCH2X19, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl.
Figure imgf000080_0001
R19C, and R19D are independently hydrogen, -CX3, -CHX2, -CH2X, -CN, -OH, -COOH, -CONH2, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl.
[0272] R16A and R16B substituents bonded to the same nitrogen atom may optionally be joined to form a substituted or unsubstituted heterocycloalkyl or substituted or unsubstituted heteroaryl. R17A and R17B substituents bonded to the same nitrogen atom may optionally be joined to form a substituted or unsubstituted heterocycloalkyl or substituted or unsubstituted heteroaryl. R18A and R18B substituents bonded to the same nitrogen atom may optionally be joined to form a substituted or unsubstituted heterocycloalkyl or substituted or unsubstituted heteroaryl. R19A and R19B substituents bonded to the same nitrogen atom may optionally be joined to form a substituted or unsubstituted heterocycloalkyl or substituted or unsubstituted heteroaryl.
[0273] X16, X17, X18, and X19 are independently -F, -Cl, -Br, or -I.
[0274] nl 6, nl 7, nl 8, and nl 9 are independently an integer from 0 to 4.
[0275] ml 6, ml 7, ml 8, ml 9, vl6, vl7, vl8, and vl9 are independently 1 or 2.
[0276] In embodiments, R16A and R16B substituents bonded to the same nitrogen atom are joined to form a substituted or unsubstituted 5 to 6-membered heterocycloalkyl. In embodiments, R16A and R16B substituents bonded to the same nitrogen atom are joined to form a substituted or unsubstituted 5-membered heterocycloalkyl. In embodiments, R16A and R16B substituents bonded to the same nitrogen atom are joined to form a substituted 5- membered heterocycloalkyl. In embodiments, R16A and R16B substituents bonded to the same nitrogen atom are joined to form an unsubstituted 5-membered heterocycloalkyl. In embodiments, R16A and R16B substituents bonded to the same nitrogen atom are joined to form a substituted or unsubstituted 6-membered heterocycloalkyl. In embodiments, R16A and R16B substituents bonded to the same nitrogen atom are joined to form a substituted 6- membered heterocycloalkyl. In embodiments, R16A and R16B substituents bonded to the same nitrogen atom are joined to form an unsubstituted 6-membered heterocycloalkyl.
[0277] In embodiments, R17A and R17B substituents bonded to the same nitrogen atom are joined to form a substituted or unsubstituted 5 to 6-membered heterocycloalkyl. In embodiments, R17A and R17B substituents bonded to the same nitrogen atom are joined to form a substituted or unsubstituted 5-membered heterocycloalkyl. In embodiments, R17A and R17B substituents bonded to the same nitrogen atom are joined to form a substituted 5- membered heterocycloalkyl. In embodiments, R17A and R17B substituents bonded to the same nitrogen atom are joined to form an unsubstituted 5-membered heterocycloalkyl. In embodiments, R17A and R17B substituents bonded to the same nitrogen atom are joined to form a substituted or unsubstituted 6-membered heterocycloalkyl. In embodiments, R17A and R17B substituents bonded to the same nitrogen atom are joined to form a substituted 6- membered heterocycloalkyl. In embodiments, R17A and R17B substituents bonded to the same nitrogen atom are joined to form an unsubstituted 6-membered heterocycloalkyl.
[0278] In embodiments, R18A and R18B substituents bonded to the same nitrogen atom are joined to form a substituted or unsubstituted 5 to 6-membered heterocycloalkyl. In embodiments, R18A and R18B substituents bonded to the same nitrogen atom are joined to form a substituted or unsubstituted 5-membered heterocycloalkyl. In embodiments, R18A and R18B substituents bonded to the same nitrogen atom are joined to form a substituted 5- membered heterocycloalkyl. In embodiments, R18A and R18B substituents bonded to the same nitrogen atom are joined to form an unsubstituted 5-membered heterocycloalkyl. In embodiments, R18A and R18B substituents bonded to the same nitrogen atom are joined to form a substituted or unsubstituted 6-membered heterocycloalkyl. In embodiments, R18A and R18B substituents bonded to the same nitrogen atom are joined to form a substituted 6- membered heterocycloalkyl. In embodiments, R18A and R18B substituents bonded to the same nitrogen atom are joined to form an unsubstituted 6-membered heterocycloalkyl. [0279] In embodiments, R19A and R19B substituents bonded to the same nitrogen atom are joined to form a substituted or unsubstituted 5 to 6-membered heterocycloalkyl. In embodiments, R19A and R19B substituents bonded to the same nitrogen atom are joined to form a substituted or unsubstituted 5-membered heterocycloalkyl. In embodiments, R19A and R19B substituents bonded to the same nitrogen atom are joined to form a substituted 5- membered heterocycloalkyl. In embodiments, R19A and R19B substituents bonded to the same nitrogen atom are joined to form an unsubstituted 5-membered heterocycloalkyl. In embodiments, R19A and R19B substituents bonded to the same nitrogen atom are joined to form a substituted or unsubstituted 6-membered heterocycloalkyl. In embodiments, R19A and R19B substituents bonded to the same nitrogen atom are joined to form a substituted 6- membered heterocycloalkyl. In embodiments, R19A and R19B substituents bonded to the same nitrogen atom are joined to form an unsubstituted 6-membered heterocycloalkyl.
[0280] In embodiments, R2 is -CN. In embodiments, R2 is
Figure imgf000082_0001
. In embodiments, R2
Figure imgf000082_0002
is r18 . In embodiments, R2 is r18 . In embodiments, R2 is
Figure imgf000082_0003
In embodiments, R2 is
Figure imgf000082_0008
, embodiments,
Figure imgf000082_0004
embodiments,
Figure imgf000082_0005
embodiments,
Figure imgf000082_0006
embodiments, R2 is
Figure imgf000082_0007
. In embodiments, R2 , . In embodiments, R2 is
Figure imgf000083_0001
,
[0281] In embodiments, R16 is hydrogen, unsubstituted C1-C4 alkyl, or unsubstituted C3-C6 cycloalkyl. In embodiments, R16 is hydrogen. In embodiments, R16 is unsubstituted C1-C4 alkyl. In embodiments, R16 is unsubstituted C1-C3 alkyl. In embodiments, R16 is unsubstituted methyl. In embodiments, R16 is unsubstituted ethyl. In embodiments, R16 is unsubstituted propyl. In embodiments, R16 is unsubstituted isopropyl. In embodiments, R16 is unsubstituted butyl. In embodiments, R16 is unsubstituted isobutyl. In embodiments, R16 is unsubstituted 2-methyl propyl. In embodiments, R16 is unsubstituted t-butyl. In embodiments, R16 is unsubstituted C3-C6 cycloalkyl. In embodiments, R16 is unsubstituted C3-C5 cycloalkyl. In embodiments, R16 is unsubstituted C3-C4 cycloalkyl. In embodiments, R16 is unsubstituted C5-C6 cycloalkyl. In embodiments, R16 is unsubstituted cyclopropyl. In embodiments, R16 is unsubstituted cyclobutyl. In embodiments, R16 is unsubstituted cyclopentyl. In embodiments, R16 is unsubstituted cyclohexyl.
[0282] In embodiments, R17 is hydrogen, unsubstituted C1-C4 alkyl, or unsubstituted C3-C6 cycloalkyl. In embodiments, R17 is hydrogen. In embodiments, R17 is unsubstituted C1-C4 alkyl. In embodiments, R17 is unsubstituted C1-C3 alkyl. In embodiments, R17 is unsubstituted methyl. In embodiments, R17 is unsubstituted ethyl. In embodiments, R17 is unsubstituted propyl. In embodiments, R17 is unsubstituted isopropyl. In embodiments, R17 is unsubstituted butyl. In embodiments, R17 is unsubstituted isobutyl. In embodiments, R17 is unsubstituted 2-methyl propyl. In embodiments, R17 is unsubstituted t-butyl. In embodiments, R17 is unsubstituted C3-C6 cycloalkyl. In embodiments, R17 is unsubstituted C3-C5 cycloalkyl. In embodiments, R17 is unsubstituted C3-C4 cycloalkyl. In embodiments, R17 is unsubstituted C5-C6 cycloalkyl. In embodiments, R17 is unsubstituted cyclopropyl. In embodiments, R17 is unsubstituted cyclobutyl. In embodiments, R17 is unsubstituted cyclopentyl. In embodiments, R17 is unsubstituted cyclohexyl. [0283] In embodiments, R18 is hydrogen, unsubstituted C1-C4 alkyl, or unsubstituted C3-C6 cycloalkyl. In embodiments, R18 is hydrogen. In embodiments, R18 is unsubstituted C1-C4 alkyl. In embodiments, R18 is unsubstituted C1-C3 alkyl. In embodiments, R18 is unsubstituted methyl. In embodiments, R18 is unsubstituted ethyl. In embodiments, R18 is unsubstituted propyl. In embodiments, R18 is unsubstituted isopropyl. In embodiments, R18 is unsubstituted butyl. In embodiments, R18 is unsubstituted isobutyl. In embodiments, R18 is unsubstituted 2-methyl propyl. In embodiments, R18 is unsubstituted t-butyl. In embodiments, R18 is unsubstituted C3-C6 cycloalkyl. In embodiments, R18 is unsubstituted C3-C5 cycloalkyl. In embodiments, R18 is unsubstituted C3-C4 cycloalkyl. In embodiments, R18 is unsubstituted C5-C6 cycloalkyl. In embodiments, R18 is unsubstituted cyclopropyl. In embodiments, R18 is unsubstituted cyclobutyl. In embodiments, R18 is unsubstituted cyclopentyl. In embodiments, R18 is unsubstituted cyclohexyl.
[0284] In embodiments, R16 is hydrogen or unsubstituted C1-C4 alkyl; R17 is hydrogen or unsubstituted C1-C4 alkyl; and R18 is hydrogen or unsubstituted C1-C4 alkyl.
[0285] In embodiments, R16 is hydrogen; R17 is hydrogen or unsubstituted C1-C4 alkyl; and R18 is hydrogen or unsubstituted C1-C4 alkyl. In embodiments, R16 is unsubstituted C1-C4 alkyl; R17 is hydrogen or unsubstituted C1-C4 alkyl; and R18 is hydrogen or unsubstituted Ci- C4 alkyl. In embodiments, R16 is hydrogen or unsubstituted C1-C4 alkyl; R17 is hydrogen; and R18 is hydrogen or unsubstituted C1-C4 alkyl. In embodiments, R16 is hydrogen or unsubstituted C1-C4 alkyl; R17 is unsubstituted C1-C4 alkyl; and R18 is hydrogen or unsubstituted C1-C4 alkyl. In embodiments, R16 is hydrogen or unsubstituted C1-C4 alkyl; R17 is hydrogen or unsubstituted C1-C4 alkyl; and R18 is hydrogen. In embodiments, R16 is hydrogen or unsubstituted C1-C4 alkyl; R17 is hydrogen or unsubstituted C1-C4 alkyl; and R18 is unsubstituted C1-C4 alkyl.
[0286] In embodiments, R16 is hydrogen; R17 is hydrogen; and R18 is hydrogen or unsubstituted C1-C4 alkyl. In embodiments, R16 is hydrogen; R17 is unsubstituted C1-C4 alkyl; and R18 is hydrogen or unsubstituted C1-C4 alkyl. In embodiments, R16 is unsubstituted C1-C4 alkyl; R17 is hydrogen; and R18 is hydrogen or unsubstituted C1-C4 alkyl. In embodiments, R16 is unsubstituted C1-C4 alkyl; R17 is unsubstituted C1-C4 alkyl; and R18 is hydrogen or unsubstituted C1-C4 alkyl. In embodiments, R16 is hydrogen; R17 is hydrogen; and R18 is hydrogen. In embodiments, R16 is hydrogen; R17 is hydrogen; and R18 is unsubstituted C1-C4 alkyl. In embodiments, R16 is hydrogen; R17 is unsubstituted C1-C4 alkyl; and R18 is hydrogen. In embodiments, R16 is hydrogen; R17 is unsubstituted C1-C4 alkyl; and R18 is unsubstituted C1-C4 alkyl. In embodiments, R16 is unsubstituted C1-C4 alkyl; R17 is hydrogen; and R18 is hydrogen. In embodiments, R16 is unsubstituted C1-C4 alkyl; R17 is hydrogen; and R18 is unsubstituted C1-C4 alkyl. In embodiments, R16 is unsubstituted Ci- C4 alkyl; R17 is unsubstituted C1-C4 alkyl; and R18 is hydrogen. In embodiments, R16 is unsubstituted C1-C4 alkyl; R17 is unsubstituted C1-C4 alkyl; and R18 is unsubstituted C1-C4 alkyl. In embodiments, R16, R17, and R18 are hydrogen.
[0287] In embodiments is provided a compound having the formula
Figure imgf000085_0001
are described herein.
[0288] In embodiments is provided a compound having the formula
Figure imgf000085_0002
are described herein.
[0289] In embodiments, R1·3 is substituted or unsubstituted 2 to 6 membered heteroalkyl.
In embodiments, R1·3 is -CN. In embodiments, Ru and R1·5 are hydrogen; and R1·3 is -CN. In embodiments, Ru and R1·5 are hydrogen; and R1·3 is -CN. In embodiments, R1 1, R1·4 and R1·5 are hydrogen; and R1·3 is -CN. In embodiments, R1 1, R1,2 and R1·5 is hydrogen; and R1·3 is -CN.
[0290] In embodiments is provided a compound having the formula are described herein.
[0291] In embodiments is provided a compound having the formula
1.2 .0
HN-
// - N h //
/
R1·3 - ( - HN - L2 N \ R 2
R1 ·4 (IV). L1, L2, R1 2, R1 3, R1 4 and R2 are described herein.
[0292] In embodiments, R1,2 is substituted or unsubstituted alkyl. In embodiments, R1,2 is hydrogen. In embodiments, R1,2 is substituted or unsubstituted alkyl. In embodiments, R1,2 is substituted alkyl. In embodiments, R1,2 is unsubstituted alkyl. In embodiments, R1,2 is substituted or unsubstituted C1-C6 alkyl. In embodiments, R1,2 is unsubstituted C1-C6 alkyl.
In embodiments, R1,2 is substituted or unsubstituted C1-C5 alkyl. In embodiments, R1,2 is unsubstituted C1-C5 alkyl. In embodiments, R1,2 is substituted or unsubstituted C1-C4 alkyl.
In embodiments, R1,2 is unsubstituted C1-C4 alkyl. In embodiments, R1,2 is methyl. In embodiments, R1,2 is ethyl. In embodiments, R1,2 is propyl. In embodiments, R1,2 is isopropyl. In embodiments, R1,2 is butyl. In embodiments, R1,2 is t-butyl.
[0293] In embodiments, R1,2 is -OR1D. In embodiments, R1D is hydrogen, or substituted or unsubstituted C1-C4 alkyl. In embodiments, R1D is hydrogen. In embodiments, R1D is substituted or unsubstituted C1-C4 alkyl. In embodiments, R1D is unsubstituted C1-C4 alkyl.
In embodiments, R1D is methyl. In embodiments, R1D is ethyl. In embodiments, R1D is propyl. In embodiments, R1D is isopropyl. In embodiments, R1D is butyl. In embodiments, R1D is t-butyl. In embodiments, R1,2 is -OH. In embodiments, R1,2 is -OCH3. In embodiments, R1 2 is -OCH2CH3. [0294] In embodiments, R1 4 is substituted or unsubstituted alkyl. In embodiments, R1 4 is hydrogen. In embodiments, R1,4 is substituted or unsubstituted alkyl. In embodiments, R1,4 is substituted alkyl. In embodiments, R1,4 is unsubstituted alkyl. In embodiments, R1,4 is substituted or unsubstituted C1-C6 alkyl. In embodiments, R1,4 is unsubstituted C1-C6 alkyl.
In embodiments, R1,4 is substituted or unsubstituted C1-C5 alkyl. In embodiments, R1,4 is unsubstituted C1-C5 alkyl. In embodiments, R1,4 is substituted or unsubstituted C1-C4 alkyl.
In embodiments, R1,4 is unsubstituted C1-C4 alkyl. In embodiments, R1,4 is methyl. In embodiments, R1,4 is ethyl. In embodiments, R1,4 is propyl. In embodiments, R1,4 is isopropyl. In embodiments, R1,4 is butyl. In embodiments, R1,4 is t-butyl.
[0295] In embodiments, R1,4 is -OR1D. In embodiments, R1D is hydrogen, or substituted or unsubstituted C1-C4 alkyl. In embodiments, R1D is hydrogen. In embodiments, R1D is substituted or unsubstituted C1-C4 alkyl. In embodiments, R1D is unsubstituted C1-C4 alkyl.
In embodiments, R1D is methyl. In embodiments, R1D is ethyl. In embodiments, R1D is propyl. In embodiments, R1D is isopropyl. In embodiments, R1D is butyl. In embodiments, R1D is t-butyl. In embodiments, R1·4 is -OH. In embodiments, R1·4 is -OCH3. In embodiments, R1 4 is -OCH2CH3.
[0296] In embodiments, R1,2 is unsubstituted C1-C4 alkyl and R1,4 is -OR1D. In embodiments, R1,2 is methyl and R1·4 is -OH. In embodiments, R1·2 is methyl and R1·4 is - OCH3. In embodiments, R1,2 is ethyl and R1·4 is -OCH3. In embodiments, R1,2 is ethyl and R1·4 is -OCH2CH3. In embodiments, R1,2 is -OR1D and R1·4 is unsubstituted C1-C4 alkyl. In embodiments, R1,2 is -OH and R1·4 is methyl. In embodiments, R1,2 is -OCH3 and R1·4 is methyl. In embodiments, R1,2 is -OCH3 and R1·4 is ethyl. In embodiments, R1,2 is -OCH2CH3 and R1,4 is ethyl.
[0297] In embodiments is provided a compound having the formula
Figure imgf000087_0001
are described herein.
[0298] In embodiments, R1,2 is substituted or unsubstituted alkyl. In embodiments, R1,2 is hydrogen. In embodiments, R1,2 is substituted or unsubstituted alkyl. In embodiments, R1,2 is substituted alkyl. In embodiments, R1,2 is unsubstituted alkyl. In embodiments, R1,2 is substituted or unsubstituted C1-C6 alkyl. In embodiments, R1,2 is unsubstituted C1-C6 alkyl.
In embodiments, R1,2 is substituted or unsubstituted C1-C5 alkyl. In embodiments, R1,2 is unsubstituted C1-C5 alkyl. In embodiments, R1,2 is substituted or unsubstituted C1-C4 alkyl.
In embodiments, R1,2 is unsubstituted C1-C4 alkyl. In embodiments, R1,2 is methyl. In embodiments, R1,2 is ethyl. In embodiments, R1,2 is propyl. In embodiments, R1,2 is isopropyl. In embodiments, R1,2 is butyl. In embodiments, R1,2 is t-butyl.
[0299] In embodiments, R1,3 is substituted or unsubstituted alkyl. In embodiments, R1,3 is hydrogen. In embodiments, R1,3 is substituted or unsubstituted alkyl. In embodiments, R1,3 is substituted alkyl. In embodiments, R1,3 is unsubstituted alkyl. In embodiments, R1,3 is substituted or unsubstituted C1-C6 alkyl. In embodiments, R1,3 is unsubstituted C1-C6 alkyl.
In embodiments, R1,3 is substituted or unsubstituted C1-C5 alkyl. In embodiments, R1,3 is unsubstituted C1-C5 alkyl. In embodiments, R1,3 is substituted or unsubstituted C1-C4 alkyl.
In embodiments, R1,3 is unsubstituted C1-C4 alkyl. In embodiments, R1·3 is methyl. In embodiments, R1·3 is ethyl. In embodiments, R1·3 is propyl. In embodiments, R1·3 is isopropyl. In embodiments, R1·3 is butyl. In embodiments, R1·3 is t-butyl.
[0300] In embodiments, R1·4 is substituted or unsubstituted alkyl. In embodiments, R1·4 is hydrogen. In embodiments, R1·4 is substituted or unsubstituted alkyl. In embodiments, R1·4 is substituted alkyl. In embodiments, R1·4 is unsubstituted alkyl. In embodiments, R1·4 is substituted or unsubstituted C1-C6 alkyl. In embodiments, R1·4 is unsubstituted C1-C6 alkyl.
In embodiments, R1·4 is substituted or unsubstituted C1-C5 alkyl. In embodiments, R1·4 is unsubstituted C1-C5 alkyl. In embodiments, R1·4 is substituted or unsubstituted C1-C4 alkyl.
In embodiments, R1·4 is unsubstituted C1-C4 alkyl. In embodiments, R1·4 is methyl. In embodiments, R1,4 is ethyl. In embodiments, R1,4 is propyl. In embodiments, R1,4 is isopropyl. In embodiments, R1,4 is butyl. In embodiments, R1,4 is t-butyl.
[0301] In embodiments, R1,2 and R1,3 are independently hydrogen or unsubstituted C1-C4 alkyl. In embodiments, R1,2 and R1,3 are independently unsubstituted C1-C4 alkyl. In embodiments, R1,2 and R1,3 are independently methyl or ethyl. In embodiments, R1,2 and R1,3 are methyl. In embodiments, R1,3 and R1,4 are independently hydrogen or unsubstituted C1-C4 alkyl. In embodiments, R1,3 and R1,4 are independently unsubstituted C1-C4 alkyl. In embodiments, R1·3 and R1·4 are independently methyl or ethyl. In embodiments, R1·3 and R1·4 are methyl.
[0302] In embodiments is provided a compound having the formula
Figure imgf000089_0001
are described herein.
[0303] In embodiments, R1·3 is hydrogen, or substituted or unsubstituted alkyl. In embodiments, R1·3 is substituted or unsubstituted alkyl. In embodiments, R1·3 is hydrogen. In embodiments, R1·3 is substituted or unsubstituted alkyl. In embodiments, R1·3 is substituted alkyl. In embodiments, R1·3 is unsubstituted alkyl. In embodiments, R1·3 is substituted or unsubstituted C1-C6 alkyl. In embodiments, R1·3 is unsubstituted C1-C6 alkyl. In embodiments, R1·3 is substituted or unsubstituted C1-C5 alkyl. In embodiments, R1·3 is unsubstituted C1-C5 alkyl. In embodiments, R1·3 is substituted or unsubstituted C1-C4 alkyl.
In embodiments, R1·3 is unsubstituted C1-C4 alkyl. In embodiments, R1·3 is methyl. In embodiments, R1·3 is ethyl. In embodiments, R1·3 is propyl. In embodiments, R1·3 is isopropyl. In embodiments, R1·3 is butyl. In embodiments, R1·3 is t-butyl. In embodiments, R1·3 is hydrogen.
[0304] In embodiments, R1·4 is hydrogen, or substituted or unsubstituted alkyl. In embodiments, R1·4 is substituted or unsubstituted alkyl. In embodiments, R1,4 is hydrogen. In embodiments, R1,4 is substituted or unsubstituted alkyl. In embodiments, R1,4 is substituted alkyl. In embodiments, R1,4 is unsubstituted alkyl. In embodiments, R1,4 is substituted or unsubstituted C1-C6 alkyl. In embodiments, R1 4 is unsubstituted C1-C6 alkyl. In embodiments, R1,4 is substituted or unsubstituted C1-C5 alkyl. In embodiments, R1,4 is unsubstituted C1-C5 alkyl. In embodiments, R1,4 is substituted or unsubstituted C1-C4 alkyl. In embodiments, R1,4 is unsubstituted C1-C4 alkyl. In embodiments, R1,4 is methyl. In embodiments, R1,4 is ethyl. In embodiments, R1,4 is propyl. In embodiments, R1,4 is isopropyl. In embodiments, R1,4 is butyl. In embodiments, R1,4 is t-butyl. In embodiments, R1·4 is hydrogen.
[0305] In embodiments, R1,3 and R1,4 are independently hydrogen or unsubstituted C1-C4 alkyl. In embodiments, R1,3 is hydrogen and R1,4 is unsubstituted C1-C4 alkyl. In embodiments, R1·3 is unsubstituted C1-C4 alkyl and R1·4 is hydrogen. In embodiments, R1·3 is hydrogen and R1·4 is methyl or ethyl. In embodiments, R1·3 is methyl or ethyl and R1·4 is hydrogen.
[0306] In embodiments is provided a compound having the formula
Figure imgf000090_0001
are described herein.
[0307] In embodiments, R1·4 is hydrogen, or substituted or unsubstituted alkyl. In embodiments, R1·4 is substituted or unsubstituted alkyl. In embodiments, R1·4 is hydrogen. In embodiments, R1·4 is substituted or unsubstituted alkyl. In embodiments, R1·4 is substituted alkyl. In embodiments, R1·4 is unsubstituted alkyl. In embodiments, R1·4 is substituted or unsubstituted C1-C6 alkyl. In embodiments, R1·4 is unsubstituted C1-C6 alkyl. In embodiments, R1·4 is substituted or unsubstituted C1-C5 alkyl. In embodiments, R1·4 is unsubstituted C1-C5 alkyl. In embodiments, R1·4 is substituted or unsubstituted C1-C4 alkyl. In embodiments, R1·4 is unsubstituted C1-C4 alkyl. In embodiments, R1·4 is methyl. In embodiments, R1·4 is ethyl. In embodiments, R1·4 is propyl. In embodiments, R1·4 is isopropyl. In embodiments, R1·4 is butyl. In embodiments, R1·4 is t-butyl. In embodiments, R1·4 is hydrogen.
[0308] In embodiments is provided a compound having the formula [0309] In embodiments, R1,2 is hydrogen, or substituted or unsubstituted alkyl. In embodiments, R1,2 is substituted or unsubstituted alkyl. In embodiments, R1,2 is hydrogen. In embodiments, R1,2 is substituted or unsubstituted alkyl. In embodiments, R1,2 is substituted alkyl. In embodiments, R1,2 is unsubstituted alkyl. In embodiments, R1,2 is substituted or unsubstituted C1-C6 alkyl. In embodiments, R1,2 is unsubstituted C1-C6 alkyl. In embodiments, R1,2 is substituted or unsubstituted C1-C5 alkyl. In embodiments, R1,2 is unsubstituted C1-C5 alkyl. In embodiments, R1,2 is substituted or unsubstituted C1-C4 alkyl. In embodiments, R1,2 is unsubstituted C1-C4 alkyl. In embodiments, R1,2 is methyl. In embodiments, R1·2 is ethyl. In embodiments, R1·2 is propyl. In embodiments, R1·2 is isopropyl. In embodiments, R1,2 is butyl. In embodiments, R1,2 is t-butyl. In embodiments, R1·2 is hydrogen.
[0310] In embodiments, R1,3 is hydrogen, or substituted or unsubstituted alkyl. In embodiments, R1,3 is substituted or unsubstituted alkyl. In embodiments, R1,3 is hydrogen. In embodiments, R1,3 is substituted or unsubstituted alkyl. In embodiments, R1,3 is substituted alkyl. In embodiments, R1,3 is unsubstituted alkyl. In embodiments, R1,3 is substituted or unsubstituted C1-C6 alkyl. In embodiments, R1,3 is unsubstituted C1-C6 alkyl. In embodiments, R1,3 is substituted or unsubstituted C1-C5 alkyl. In embodiments, R1,3 is unsubstituted C1-C5 alkyl. In embodiments, R1,3 is substituted or unsubstituted C1-C4 alkyl. In embodiments, R1·3 is unsubstituted C1-C4 alkyl. In embodiments, R1·3 is methyl. In embodiments, R1·3 is ethyl. In embodiments, R1·3 is propyl. In embodiments, R1·3 is isopropyl. In embodiments, R1·3 is butyl. In embodiments, R1·3 is t-butyl. In embodiments, R1·3 is hydrogen.
[0311] In embodiments, R1,2 and R1·3 are independently hydrogen or unsubstituted C1-C4 alkyl. In embodiments, R1,2 is hydrogen and R1·3 is unsubstituted C1-C4 alkyl. In embodiments, R1,2 is hydrogen and R1·3 is methyl. In embodiments, R1,2 is hydrogen and R1·3 is ethyl. In embodiments, R1 2 is hydrogen and R1 3 is propyl. In embodiments, R1 2 is hydrogen and R1,3 is isopropyl. In embodiments, R1,2 is hydrogen and R1,3 is butyl. In embodiments, R1,2 is hydrogen and R1,3 is t-butyl. In embodiments, R1,2 is unsubstituted Ci- C4 alkyl and R1,3 is hydrogen. In embodiments, R1,2 is methyl and R1,3 is hydrogen. In embodiments, R1,2 is ethyl and R1,3 is hydrogen. In embodiments, R1,2 is propyl and R1,3 is hydrogen. In embodiments, R1,2 is isopropyl and R1,3 is hydrogen. In embodiments, R1,2 is butyl and R1,3 is hydrogen. In embodiments, R1,2 is t-butyl and R1,3 is hydrogen.
[0312] In embodiments, examples
Figure imgf000092_0001
moiety including following structure:
Figure imgf000092_0002
In embodiments,
Figure imgf000092_0003
moiety in Formula (I) is
Figure imgf000092_0004
In embodiments,
Figure imgf000092_0005
moiety in Formula (I) is
Figure imgf000092_0006
In embodiments, moiety in Formula
In embodiments,
Figure imgf000093_0001
moiety in Formula
Figure imgf000093_0002
In embodiments,
Figure imgf000093_0003
moiety in Formula (I) is
Figure imgf000093_0004
In embodiments,
Figure imgf000093_0005
moiety in Formula
Figure imgf000093_0006
In embodiments,
Figure imgf000093_0007
moiety in Formula
Figure imgf000093_0008
In embodiments,
Figure imgf000093_0009
moiety in Formula (
Figure imgf000093_0010
In embodiments,
Figure imgf000093_0011
moiety in Formula (
Figure imgf000093_0012
N¾ ·
In embodiments,
Figure imgf000093_0013
moiety in Formula (I) is VNH In embodiments, moiety in Formula
Figure imgf000094_0001
In embodiments, moiety in Formula
In embodiments, moiety in Formula
In embodiments, moiety in Formula
In embodiments, moiety in Formula
In embodiments,
Figure imgf000094_0002
moiety in Formula
Figure imgf000094_0004
[0313] In embodiments, R1 is independently halogen
Figure imgf000094_0003
-NHC(0)NHCH3), -N(0)mi (e.g., -NO, or-N02), -NR1AR1B (e.g., -NH2, or - NHCHs), -C(0)Rlc (e.g., -C(0)H or -C(0)CH3), -C(0)-0Rlc(e.g., -C(0)0H or - C(0)0CH3), -C(0)NR1AR1B (e.g., -C(0)NH2 or -C(O) NHCH3), -OR1D(e.g., -OH, or - OCH3), -NR1AS02R1D (e.g., -NHS02H), -NR1AC(0)Rlc (e.g., -NHCOH), -NR1AC(0)0Rlc (e.g., -NHC(O)OH), -NR1AORlc (e.g., -NHOH), -N3, substituted (e.g., substituted with a substituent group, a size-limited substituent group, or lower substituent group) or unsubstituted alkyl (e.g., Ci-Cs, C1-C6, or C1-C4 alkyl), substituted (e.g., substituted with a substituent group, a size-limited substituent group, or lower substituent group) or unsubstituted heteroalkyl (e.g., 2 to 8 membered, 2 to 6 membered, or 2 to 4 membered heteroalkyl), substituted (e.g., substituted with a substituent group, a size-limited substituent group, or lower substituent group) or unsubstituted cycloalkyl (e.g., C3-Cs, C3-C6, or C5-C6 cycloalkyl), substituted (e.g., substituted with a substituent group, a size-limited substituent group, or lower substituent group) or unsubstituted heterocycloalkyl (e.g., 3 to 8 membered, 3 to 6 membered, or 5 to 6 membered heterocycloalkyl), substituted (e.g., substituted with a substituent group, a size-limited substituent group, or lower substituent group) or unsubstituted aryl (e.g., C6-C10, C10 aryl, or phenyl), or substituted (e.g., substituted with a substituent group, a size-limited substituent group, or lower substituent group) or unsubstituted heteroaryl (e.g., 5 to 10 membered, 5 to 9 membered, or 5 to 6 membered heteroaryl).
[0314] In embodiments, a substituted R1 is substituted with at least one substituent group, size-limited substituent group, or lower substituent group; wherein if the substituted R1 is substituted with a plurality of groups selected from substituent groups, size-limited substituent groups, and lower substituent groups; each substituent group, size-limited substituent group, and/or lower substituent group may optionally be different. In embodiments, when R1 is substituted, it is substituted with at least one substituent group. In embodiments, when R1 is substituted, it is substituted with at least one size-limited substituent group. In embodiments, when R1 is substituted, it is substituted with at least one lower substituent group.
[0315] In embodiments, each R1 is independently -F, -Cl, -Br, -I, -CF3, -CHF2, -CH2F, - CC13,-CHC12, -CH2C1, -CBr3, -CHBr2, -CH2Br, -CI3, -CHI2, -CH2I, -OCF3, -OCCl3, - OCBr3, -OCI3, -OCHF2, -OCHCk, -OCHBr2, -OCHI2, -OCH2F, -OCH2Cl, -OCH2Br, - OCH2I, -N3, -CN, -SH, -SCH3, -S02H, -SC CHs, -S02NH2, -SC NHCHs, -NHC(0)NH2, -NHC(0)NHCH3, -Neb, -NH2J -NHCHS, -C(0)H, -Geo)®, -C(0)0H, - C(0)0CH3, -C(0)NH2, -C(0)NHCH3, -OH, -OCH3, -NHS02H, -NHS02CH3, -NHC(0)H, - NCH3C(0)H, -NHC(0)0H, -NCH3C(0)0H, -NHOH, -NCH3OH, -NCH3OCH3, R1e- substituted or unsubstituted alkyl (e.g., Ci-C2o, Ci-Ci2, Ci-Cs, C1-C6, C1-C4, or Ci-C2), R1E- substituted or unsubstituted heteroalkyl (e.g., 2 to 20 membered, 2 to 12 membered, 2 to 8 membered, 2 to 6 membered, 4 to 6 membered, 2 to 3 membered, or 4 to 5 membered), R1E- substituted or unsubstituted cycloalkyl (e.g., C3-Cio, C3-C8, C3-C6, C4-C6, or C5-C6), R1E- substituted or unsubstituted heterocycloalkyl (e.g., 3 to 10 membered, 3 to 8 membered, 3 to 6 membered, 4 to 6 membered, 4 to 5 membered, or 5 to 6 membered), R1E-substituted or unsubstituted aryl (e.g., C6-Ci2, C6-C10, or phenyl), or R1E-substituted or unsubstituted heteroaryl (e.g., 5 to 12 membered, 5 to 10 membered, 5 to 9 membered, or 5 to 6 membered). In embodiments, each R1 is independently -F, -Cl, -Br, -I, -CF3, -CHF2, -CH2F, -CC13,-CHC12, -CH2C1, -CBr3, CHBr2, -CH2Br, -CI3, -CHI2, -CH2I, -OCF3, -OCCl3, - OCBr3, -OCI3, -OCHF2, -OCHCk, -OCHBr2, -OCHI2, -OCH2F, -OCH2Cl, -OCH2Br, - OCH2I, -N3, -CN, -SH, -SCH3, -S02H, -S02CH3, -S02NH2, -S02NHCH3, -NHC(0)NH2, -NHC(0)NHCH3, -N02, -NH2, -NHCH3, -C(0)H, -C(0)CH3, -C(0)0H, - C(0)0CH3, -C(0)NH2, -C(0)NHCH3, -OH, -OCH3, -NHS02H, -NHS02CH3, -NHC(0)H, - NCH3C(0)H, -NHC(0)0H, -NCH3C(0)0H, -NHOH, -NCH3OH, -NCH3OCH3, R1e- substituted alkyl (e.g., Ci-C2o, Ci-Ci2, Ci-C8, C1-C6, C1-C4, or Ci-C2), R1E-substituted heteroalkyl (e.g., 2 to 20 membered, 2 to 12 membered, 2 to 8 membered, 2 to 6 membered, 4 to 6 membered, 2 to 3 membered, or 4 to 5 membered), R1E-substituted cycloalkyl (e.g., C3- C10, C3-C8, C3-C6, C4-C6, or C5-C6), R1E-substituted heterocycloalkyl (e.g., 3 to 10 membered, 3 to 8 membered, 3 to 6 membered, 4 to 6 membered, 4 to 5 membered, or 5 to 6 membered), R1E-substituted aryl (e.g., C6-Ci2, C6-C10, or phenyl), or R1E-substituted heteroaryl (e.g., 5 to 12 membered, 5 to 10 membered, 5 to 9 membered, or 5 to 6 membered). In embodiments, each R1 is independently -F, -Cl, -Br, -I, -CF3, -CHF2, -CH2F, -CC13, -CHC12, -CH2C1, - CBr3, CHBr2, -CH2Br, -CI3, -CHI2, -CH2I, -OCF3, -OCCl3, -OCBr3, -OCI3, OCHF2, - OCHCk, -OCHBr2, -OCHk, -OCH2F, -OCH2Cl, -OCH2Br, -OCH2I, -N3, -CN, -SH, - SCH3, -S02H, -S02CH3, -S02NH2, -S02NHCH3, -NHC(0)NH2,-NHC(0)NHCH3 - N02, -NH2, -NHCH3, -C(0)H, -C(0)CH3, -C(0)OH, -
C(0)0CH3, -C(0)NH2, -C(0)NHCH3, -OH, -OCH3, -NHS02H, -NHS02CH3, -NHC(0)H, - NCH3C(0)H, -NHC(0)OH, -NCH3C(0)OH, -NHOH, -NCH3OH, -NCH3OCH3, unsubstituted alkyl (e.g., C1-C20, C1-C12, Ci-Cs, C1-C6, C1-C4, or C1-C2), unsubstituted heteroalkyl (e.g., 2 to 20 membered, 2 to 12 membered, 2 to 8 membered, 2 to 6 membered, 4 to 6 membered, 2 to 3 membered, or 4 to 5 membered), unsubstituted cycloalkyl (e.g., C3-C10, C3-C8, C3-C6, C4-C6, or C5-C6), unsubstituted heterocycloalkyl (e.g., 3 to 10 membered, 3 to 8 membered, 3 to 6 membered, 4 to 6 membered, 4 to 5 membered, or 5 to 6 membered), unsubstituted aryl (e.g., C6-C12, C6-C10, or phenyl), or unsubstituted heteroaryl (e.g., 5 to 12 membered, 5 to 10 membered, 5 to 9 membered, or 5 to 6 membered).
[0316] Each Ru, R12, R1 3, R14, and R1 5 is independently hydrogen, halogen (e.g., -F, -Cl,
Figure imgf000097_0001
SO3H, or -SO4H), -SOviNR1AR1B (e.g., -SO2NH2, or -SO2NHCH3), -NR1CNR1AR1B (e.g., NHNH2 or NHNHCH3), -ONR1AR1B (e.g., -ONH2, or -ONHCH3), -NHC(0)NR1CNR1AR1B (e.g., -NHC(0)NHNH2, or -NHC(0)NHNHCH3), -NHC(0)NR1AR1B (e.g., -NHC(0)NH2, or -NHC(0)NHCH3), -N(0)mi (e.g., -NO, or -NO2), -NR1AR1B (e.g., -NH2, or - NHCH3), -C(0)Rlc (e.g., -C(0)H or -C(0)CH3), -C(0)-ORlc(e.g., -C(0)OH or - C(0)OCH3), -C(0)NR1AR1B (e.g., -C(0)NH2 or -C(O) NHCH3), -OR1D(e.g., -OH, or - OCH3), -NR1AS02R1D (e.g., -NHSO2H), -NR1AC(0)Rlc (e.g., -NHCOH), -NR1AC(0)ORlc (e.g., -NHC(O)OH), -NR1AORlc (e.g., -NHOH), -N3, substituted (e.g., substituted with a substituent group, a size-limited substituent group, or lower substituent group) or unsubstituted alkyl (e.g., Ci-Cs, C1-C6, or C1-C4 alkyl), substituted (e.g., substituted with a substituent group, a size-limited substituent group, or lower substituent group) or unsubstituted heteroalkyl (e.g., 2 to 8 membered, 2 to 6 membered, or 2 to 4 membered heteroalkyl), substituted (e.g., substituted with a substituent group, a size-limited substituent group, or lower substituent group) or unsubstituted cycloalkyl (e.g., C3-C8, C3-C6, or C5-C6 cycloalkyl), substituted (e.g., substituted with a substituent group, a size-limited substituent group, or lower substituent group) or unsubstituted heterocycloalkyl (e.g., 3 to 8 membered, 3 to 6 membered, or 5 to 6 membered heterocycloalkyl), substituted (e.g., substituted with a substituent group, a size-limited substituent group, or lower substituent group) or unsubstituted aryl (e.g., C6-C10, C10 aryl, or phenyl), or substituted (e.g., substituted with a substituent group, a size-limited substituent group, or lower substituent group) or unsubstituted heteroaryl (e.g., 5 to 10 membered, 5 to 9 membered, or 5 to 6 membered heteroaryl).
[0317] In embodiments, a substituted Ru is substituted with at least one substituent group, size-limited substituent group, or lower substituent group; wherein if the substituted Ru is substituted with a plurality of groups selected from substituent groups, size-limited substituent groups, and lower substituent groups; each substituent group, size-limited substituent group, and/or lower substituent group may optionally be different. In embodiments, when R1 1 is substituted, it is substituted with at least one substituent group. In embodiments, when R1 1 is substituted, it is substituted with at least one size-limited substituent group. In embodiments, when Ru is substituted, it is substituted with at least one lower substituent group.
[0318] In embodiments, a substituted R1,2 is substituted with at least one substituent group, size-limited substituent group, or lower substituent group; wherein if the substituted R1,2 is substituted with a plurality of groups selected from substituent groups, size-limited substituent groups, and lower substituent groups; each substituent group, size-limited substituent group, and/or lower substituent group may optionally be different. In embodiments, when R1·2 is substituted, it is substituted with at least one substituent group. In embodiments, when R1·2 is substituted, it is substituted with at least one size-limited substituent group. In embodiments, when R1·2 is substituted, it is substituted with at least one lower substituent group.
[0319] In embodiments, a substituted R1,3 is substituted with at least one substituent group, size-limited substituent group, or lower substituent group; wherein if the substituted R1,3 is substituted with a plurality of groups selected from substituent groups, size-limited substituent groups, and lower substituent groups; each substituent group, size-limited substituent group, and/or lower substituent group may optionally be different. In embodiments, when R1·3 is substituted, it is substituted with at least one substituent group. In embodiments, when R1·3 is substituted, it is substituted with at least one size-limited substituent group. In embodiments, when R1·3 is substituted, it is substituted with at least one lower substituent group.
[0320] In embodiments, a substituted R1,4 is substituted with at least one substituent group, size-limited substituent group, or lower substituent group; wherein if the substituted R1,4 is substituted with a plurality of groups selected from substituent groups, size-limited substituent groups, and lower substituent groups; each substituent group, size-limited substituent group, and/or lower substituent group may optionally be different. In embodiments, when R1 4 is substituted, it is substituted with at least one substituent group. In embodiments, when R1·4 is substituted, it is substituted with at least one size-limited substituent group. In embodiments, when R1·4 is substituted, it is substituted with at least one lower substituent group.
[0321] In embodiments, a substituted R1,5 is substituted with at least one substituent group, size-limited substituent group, or lower substituent group; wherein if the substituted R1,5 is substituted with a plurality of groups selected from substituent groups, size-limited substituent groups, and lower substituent groups; each substituent group, size-limited substituent group, and/or lower substituent group may optionally be different. In embodiments, when R1·5 is substituted, it is substituted with at least one substituent group. In embodiments, when R1·5 is substituted, it is substituted with at least one size-limited substituent group. In embodiments, when R1·5 is substituted, it is substituted with at least one lower substituent group.
[0322] In embodiments, each R1 1, R1·2, R1·3, R1·4, and R1,5 is independently hydrogen, -F, - Cl, -Br, -I, -CF3, -CHF2, -CH2F, -CC13, -CHCk, -CH2C1, -CBr3, -CHBr2, -CH2Br, -CI3, - CHI2, -CH2I, -OCF3, -OCCl3, -OCBr3, -OCI3, -OCHF2, OCHCh, -OCHBr2, -OCHI2, - OCH2F, -OCH2Cl, -OCH2Br, -OCH2I, -N3, -CN, -SH, -SCH3, -S02H, -S02CH3, -S02NH2, - S02NHCH3, -NHC(0)NH2, -NHC(0)NHCH3, -NO;!, -NH2, -NHCH3, -C(0)H, -C(0)CH3, - C(0)0H, -C(0)0CH3, -C(0)NH2, -C(0)NHCH3, -OH, -OCH3, -NHSO2H, -NHSO2CH3, - NHC(0)H, -NCH3C(0)H, -NHC(0)0H, -NCH3C(0)0H, -NHOH, -NCH3OH, -NCH3OCH3, R1E-substituted or unsubstituted alkyl (e.g., Ci-C2o, Ci-Ci2, Ci-Cs, C1-C6, C1-C4, or Ci-C2), R1E-substituted or unsubstituted heteroalkyl (e.g., 2 to 20 membered, 2 to 12 membered, 2 to 8 membered, 2 to 6 membered, 4 to 6 membered, 2 to 3 membered, or 4 to 5 membered), R1E-substituted or unsubstituted cycloalkyl (e.g., C3-Cio, C3-Cs, C3-C6, C4-C6, or C5-C6), R1E- substituted or unsubstituted heterocycloalkyl (e.g., 3 to 10 membered, 3 to 8 membered, 3 to 6 membered, 4 to 6 membered, 4 to 5 membered, or 5 to 6 membered), R1E-substituted or unsubstituted aryl (e.g., C6-Ci2, C6-C10, or phenyl), or R1E-substituted or unsubstituted heteroaryl (e.g., 5 to 12 membered, 5 to 10 membered, 5 to 9 membered, or 5 to 6 membered). In embodiments, each R1 1, R1·2, R1·3, R1·4, and R1,5 is independently hydrogen, - F, -Cl, -Br, -I, -CF3, -CHF2, -CH2F, -CCI3, -CHCk, -CH2C1, -CBr3, -CHBr2, -CH2Br, - CI3, -CHI2, -CH2I, -OCF3, -OCCl3, -OCBr3, -OCI3, -OCHF2, OCHCh, -OCHBr2, - OCHI2, -OCH2F, -OCH2Cl, -OCH2Br, -OCH2I, -N3, -CN, -SH, -SCH3, -S02H, -S02CH3, - S02NH2, -S02NHCH3, -NHC(0)NH2, -NHC(0)NHCH3, -N02, -NH2, -NHCH3, -C(0)H, - C(0)CH3, -C(0)0H, -C(0)0CH3, -C(0)NH2, -C(0)NHCH3, -OH, -OCH3, -NHSO2H, - NHS02CH3, -NHC(0)H, -NCH3C(0)H, -NHC(0)0H, -
NCH3C(0)0H, -NHOH, -NCHSOH, -NCH3OCH3, R1E-substituted alkyl (e.g., Ci-C20, Ci- Ci2, C1-C8, C1-C6, C1-C4, or Ci-C2), R1E-substituted heteroalkyl (e.g., 2 to 20 membered, 2 to 12 membered, 2 to 8 membered, 2 to 6 membered, 4 to 6 membered, 2 to 3 membered, or 4 to
5 membered), R1E-substituted cycloalkyl (e.g., C3-Cio, C3-Cs, C3-C6, C4-C6, or C5-C6), R1E- substituted heterocycloalkyl (e.g., 3 to 10 membered, 3 to 8 membered, 3 to 6 membered, 4 to
6 membered, 4 to 5 membered, or 5 to 6 membered), R1E-substituted aryl (e.g., C6-Ci2, C6- C10, or phenyl), or R1E-substituted heteroaryl (e.g., 5 to 12 membered, 5 to 10 membered, 5 to 9 membered, or 5 to 6 membered). In embodiments, each R1·1, R1·2, R1·3, R1·4, and R1 5 is independently hydrogen, -F, -Cl, -Br, -I, -CF3, -CHF2, -CH2F, -CC13,-CHC12, -CH2C1, - CBr3, CHBr2, -CH2Br, -CI3, -CHI2, -CH2I, -OCF3, -OCCl3, -OCBr3, -OCI3, OCHF2, - OCHCh, -OCHBr2, -OCHI2, -OCH2F, -OCH2Cl, -OCH2Br, -OCH2I, -N3, -CN, -SH, - SCH3, -S02H, -S02CH3, -S02NH2, -S02NHCH3, -NHC(0)NH2,-NHC(0)NHCH3 -
N02, -NH2, -NHCH3, -C(0)H, -C(0)CH3, -C(0)0H, -
C(0)0CH3, -C(0)NH2, -C(0)NHCH3, -OH, -OCH3, -NHS02H, -NHS02CH3, -NHC(0)H, - NCH3C(0)H, -NHC(0)0H, -NCH3C(0)0H, -NHOH, -NCH3OH, -NCH3OCH3, unsubstituted alkyl (e.g., Ci-C2o, Ci-Ci2, Ci-Cs, C1-C6, C1-C4, or Ci-C2), unsubstituted heteroalkyl (e.g., 2 to 20 membered, 2 to 12 membered, 2 to 8 membered, 2 to 6 membered, 4 to 6 membered, 2 to 3 membered, or 4 to 5 membered), unsubstituted cycloalkyl (e.g., C3-Cio, C3-C8, C3-C6, C4-C6, or C5-C6), unsubstituted heterocycloalkyl (e.g., 3 to 10 membered, 3 to 8 membered, 3 to 6 membered, 4 to 6 membered, 4 to 5 membered, or 5 to 6 membered), unsubstituted aryl (e.g., C6-Ci2, C6-C10, or phenyl), or unsubstituted heteroaryl (e.g., 5 to 12 membered, 5 to 10 membered, 5 to 9 membered, or 5 to 6 membered).
[0323] R1E is independently oxo, halogen, -CF3, -CCl3,-CBr3, -CI3, -CHF2, -CHCh,- CHBr2, -CHI2, -CH2F,-CH2C1, -CH2Br, -
CH2I, -CN, -OH, -NH2, -COOH, -CONH2, -N02, -SH, -SCH3, -S03H, -S04H, -S02NH2, -NHNH2, -ONH2, -NHC(0)NHNH2, -NHC(0)NH2, -NHS02H, -NHC(0)H, - NHC(0)0H, -NHOH, -OCF3, -OCCI3, -OCBr3, -OCI3, -OCHF2, -OCHCI2, OCHBr2, - OCHI2,-OCH2F, -OCH2CI, -OCH2Br, -OCH2I, R1F-substituted or unsubstituted alkyl (e.g., C1-C8, C1-C6, or C1-C4 alkyl), R1F-substituted or unsubstituted heteroalkyl (e.g., 2 to 8 membered, 2 to 6 membered, or 2 to 4 membered heteroalkyl), R1F-substituted or unsubstituted cycloalkyl (e.g., C3-C8, C3-C6, or C5-C6 cycloalkyl), R1F-substituted or unsubstituted heterocycloalkyl (e.g., 3 to 8 membered, 3 to 6 membered, or 5 to 6 membered heterocycloalkyl), R1F-substituted or unsubstituted aryl (e.g., C6-C10, C10 aryl, or phenyl), or R1F-substituted or unsubstituted heteroaryl (e.g., 5 to 10 membered, 5 to 9 membered, or 5 to 6 membered heteroaryl). In embodiments, R1E is independently oxo, halogen, -CF3, -CCI3,- CBr3, -CI3, -CHF2, -CHCl2,-CHBr2, -CHI2, -CH2F,-CH2C1, -CH2Br, - CH2I, -CN, -OH, -NH2, -COOH, -CONH2, -NO2, -SH, -SCH3, -SO3H, -SO4H, -SO2NH2, -NHNH2, -ONH2, -NHC(0)NHNH2, -NHC(0)NH2, -NHSO2H, -NHC(0)H, - NHC(0)0H, -NHOH, -OCF3, -OCCI3, -OCBr3, -OCI3, -OCHF2, -OCHCI2, OCHBr2, - 0CHI2 -0CH2F, -OCH2CI, -OCH2Br, -OCH2I, R1F-substituted alkyl (e.g., Ci-C8, Ci-C6, or C1-C4 alkyl), R1F-substituted heteroalkyl (e.g., 2 to 8 membered, 2 to 6 membered, or 2 to 4 membered heteroalkyl), R1F-substituted cycloalkyl (e.g., C3-C8, C3-C6, or C5-C6 cycloalkyl), R1F-substituted heterocycloalkyl (e.g., 3 to 8 membered, 3 to 6 membered, or 5 to 6 membered heterocycloalkyl), R1F-substituted aryl (e.g., C6-C10, C10 aryl, or phenyl), or R1F- substituted heteroaryl (e.g., 5 to 10 membered, 5 to 9 membered, or 5 to 6 membered heteroaryl). In embodiments, R1E is independently oxo, halogen, -CF3, -CCI3, -CBr3, -CI3, - CHF2, -CHCl2,-CHBr2, -CHI2, -CH2F,-CH2C1, -CH2Br, -
CH2I, -CN, -OH, -NH2, -COOH, -CONH2, -NO2, -SH, -SCH3, -SO3H, -SO4H, -SO2NH2, -NHNH2, -ONH2, -NHC(0)NHNH2, -NHC(0)NH2, -NHSO2H, -NHC(0)H, - NHC(0)OH, -NHOH, -OCF3, -OCCI3, -OCBr3, -OCI3, -OCHF2, -OCHCI2, OCHBr2, - 0CHI2 -0CH2F, -OCH2CI, -OCH2Br, -OCH2I, unsubstituted alkyl (e.g., Ci-C8, Ci-C6, or C1-C4 alkyl), unsubstituted heteroalkyl (e.g., 2 to 8 membered, 2 to 6 membered, or 2 to 4 membered heteroalkyl), unsubstituted cycloalkyl (e.g., C3-C8, C3-C6, or C5-C6 cycloalkyl), unsubstituted heterocycloalkyl (e.g., 3 to 8 membered, 3 to 6 membered, or 5 to 6 membered heterocycloalkyl), unsubstituted aryl (e.g., C6-C10, C10 aryl, or phenyl), or unsubstituted heteroaryl (e.g., 5 to 10 membered, 5 to 9 membered, or 5 to 6 membered heteroaryl).
[0324] R16 is halogen (e.g., -F, -Cl, -Br, or -I), -CX16 3 (e.g., -CF3, -CCI3, -CBr3, or -CI3), -
CHX162 (e.g., -CHF2, -CHCl2,-CHBr2, or -CHI2), -CH2X16 (e.g., -CH2F,-CH2C1, -CH2Br, or -CH2I), -OCX163 (e.g., -OCF3, -OCCI3, -OCBr3, or-OCI3), -OCH2X16 (e.g., -OCH2F, - OCH2CI, -OCH2Br, or -OCH2I), -OCHX16 2 (e.g., -OCHF2, -OCHCI2, -OCHBr2, - OCHI2), -CN, -SO„I6R16D (e.g., -SH, -SCH3, -SO2H, -SO3H, or -SO4H), -SOVI6NR16AR16B (e.g., -SO2NH2, or -SO2NHCH3), -NR16CNR16AR16B (e.g., NHNH2orNHNHCH3), -ONR16AR16B (e.g., -ONH2, or -ONHCH3), -NHC(0)NR16CNR16AR16B (e.g., -NHC(0)NHNH2, or -NHC(0)NHNHCH3), -NHC(0)NR16AR16B (e.g., -NHC(0)NH2, or -NHC(0)NHCH3), -N(0)mi6 (e.g., -NO, or -NO2), -NR16AR16B (e.g., -NH2, or - NHCH3), -C(0)R16C(e.g., -C(0)H or -C(0)CH3), -C(0)-0R16C (e.g., -C(0)0H or - C(0)0CH3), -C(0)NR16AR16B (e.g., -C(0)NH2 or -C(O) NHCH3), -OR16D (e.g., -OH, or - OCH3), -NR16AS02R16D (e.g., -NHSO2H), -NR16AC(0)R16C (e.g., - NHCOH), -NR16AC(0)0R16C (e.g., -NHC(O)OH), -NR16AOR16C (e.g., -NHOH), -N3, substituted (e.g., substituted with a substituent group, a size-limited substituent group, or lower substituent group) or unsubstituted alkyl (e.g., Ci-Cs, C1-C6, or C1-C4 alkyl), substituted (e.g., substituted with a substituent group, a size-limited substituent group, or lower substituent group) or unsubstituted heteroalkyl (e.g., 2 to 8 membered, 2 to 6 membered, or 2 to 4 membered heteroalkyl), substituted (e.g., substituted with a substituent group, a size-limited substituent group, or lower substituent group) or unsubstituted cycloalkyl (e.g., C3-C8, C3-C6, or C5-C6 cycloalkyl), substituted (e.g., substituted with a substituent group, a size-limited substituent group, or lower substituent group) or unsubstituted heterocycloalkyl (e.g., 3 to 8 membered, 3 to 6 membered, or 5 to 6 membered heterocycloalkyl), substituted (e.g., substituted with a substituent group, a size-limited substituent group, or lower substituent group) or unsubstituted aryl (e.g., C6-C10, C10 aryl, or phenyl), or substituted (e.g., substituted with a substituent group, a size-limited substituent group, or lower substituent group) or unsubstituted heteroaryl (e.g., 5 to 10 membered, 5 to 9 membered, or 5 to 6 membered heteroaryl).
[0325] In embodiments, a substituted R16 is substituted with at least one substituent group, size-limited substituent group, or lower substituent group; wherein if the substituted R16 is substituted with a plurality of groups selected from substituent groups, size-limited substituent groups, and lower substituent groups; each substituent group, size-limited substituent group, and/or lower substituent group may optionally be different. In embodiments, when R16 is substituted, it is substituted with at least one substituent group. In embodiments, when R16 is substituted, it is substituted with at least one size-limited substituent group. In embodiments, when R16 is substituted, it is substituted with at least one lower substituent group.
[0326] In embodiments, R16 is hydrogen, -F, -Cl, -Br, -I, -CF3, -CHF2, -CH2F, -CC13, - CHCk, -CH2C1, -CBr3, -CHBr2, -CH2Br, -CI3, -CHI2, -CH2I, -OCF3, -OCCl3, -OCBr3, - OCI3, -OCHF2, -OCHCk, -OCHBr2, -OCHI2, -OCH2F, -OCH2Cl, -OCH2Br, - OCH2I, -N3, -CN, -SH, -SCH3, -S02H, -S02CH3, -S02NH2, -S02NHCH3, -NHC(0)NH2, -NHC(0)NHCH3, -N02, -NH2, -NHCH3, -C(0)H, -C(0)CH3, -C(0)0H, - C(0)0CH3, -C(0)NH2, -C(0)NHCH3, -OH, -OCH3, -NHS02H, -NHS02CH3, -NHC(0)H, - NCH3C(0)H, -NHC(0)0H, -NCH3C(0)0H, -NHOH, -NCH3OH, -NCH3OCH3, R16E- substituted or unsubstituted alkyl (e.g., Ci-C2o, Ci-Ci2, Ci-Cs, C1-C6, C1-C4, or Ci-C2), R16E- substituted or unsubstituted heteroalkyl (e.g., 2 to 20 membered, 2 to 12 membered, 2 to 8 membered, 2 to 6 membered, 4 to 6 membered, 2 to 3 membered, or 4 to 5 membered), R16E- substituted or unsubstituted cycloalkyl (e.g., C3-Cio, C3-C8, C3-C6, C4-C6, or C5-C6), R16E- substituted or unsubstituted heterocycloalkyl (e.g., 3 to 10 membered, 3 to 8 membered, 3 to 6 membered, 4 to 6 membered, 4 to 5 membered, or 5 to 6 membered), R16E-substituted or unsubstituted aryl (e.g., C6-Ci2, C6-C10, or phenyl), or R16E-substituted or unsubstituted heteroaryl (e.g., 5 to 12 membered, 5 to 10 membered, 5 to 9 membered, or 5 to 6 membered). In embodiments, R16 is hydrogen, -F, -Cl, -Br, -I, -CF3, -CHF2, -CH2F, -CC13, -CHCk, -CH2C1, -CBr3, CHBr2, -CH2Br, -CI3, -CHk, -CH2I, -OCF3, -OCCl3, -OCBr3, - OCI3, -OCHF2, -OCHCk, -OCHBr2, -OCHk, -OCH2F, -OCH2Cl, -OCH2Br, - OCH2I, -N3, -CN, -SH, -SCH3, -S02H, -S02CH3, -S02NH2, -SCkNHCHs, -NHC(0)NH2, -NHC(0)NHCH3, -N02, -NH2, -NHCH3, -C(0)H, -C(0)CH3, -C(0)OH, - C(0)0CH3, -C(0)NH2, -C(0)NHCH3, -OH, -OCH3, -NHS02H, -NHS02CH3, -NHC(0)H, - NCH3C(0)H, -NHC(0)OH, -NCH3C(0)OH, -NHOH, -NCH3OH, -NCH3OCH3, R16E- substituted alkyl (e.g., Ci-C2o, Ci-Ci2, Ci-C8, C1-C6, C1-C4, or Ci-C2), R16E-substituted heteroalkyl (e.g., 2 to 20 membered, 2 to 12 membered, 2 to 8 membered, 2 to 6 membered, 4 to 6 membered, 2 to 3 membered, or 4 to 5 membered), R16E-substituted cycloalkyl (e.g., C3- C10, C3-C8, C3-C6, C4-C6, or C5-C6), R16E-substituted heterocycloalkyl (e.g., 3 to 10 membered, 3 to 8 membered, 3 to 6 membered, 4 to 6 membered, 4 to 5 membered, or 5 to 6 membered), R16E-substituted aryl (e.g., C6-Ci2, C6-C10, or phenyl), or R16E-substituted heteroaryl (e.g., 5 to 12 membered, 5 to 10 membered, 5 to 9 membered, or 5 to 6 membered). In embodiments, R16 is hydrogen, -F, -Cl, -Br, -I, -CF3, -CHF2, -CH2F, -CC13, -CHCI2, -CH2CI, -CBr3, CHBr2, -CH2Br, -CI3, -CHI2, -CH2I, -OCF3, -OCCI3, -OCBr3, - OCI3, -OCHF2, -OCHCI2, -OCHBr2, -OCHI2, -OCH2F, -OCH2CI, -OCH2Br, - OCH2I, -N3, -CN, -SH, -SCH3, -SO2H, -SO2CH3, -SO2NH2, -SO2NHCH3, -NHC(0)NH2, -NHC(0)NHCH3, -NO2, -NH2, -NHCH3, -C(0)H, -Geo)®, -C(0)0H, - C(0)0CH3, -C(0)NH2, -C(0)NHCH3, -OH, -0CH3, -NHSO2H, -NHSO2CH3, -NHC(0)H, - NCH3C(0)H, -NHC(0)0H, -NCH3C(0)0H, -NHOH, -NCH3OH, -NCH3OCH3, unsubstituted alkyl (e.g., C1-C20, C1-C12, Ci-Cs, C1-C6, C1-C4, or C1-C2), unsubstituted heteroalkyl (e.g., 2 to 20 membered, 2 to 12 membered, 2 to 8 membered, 2 to 6 membered, 4 to 6 membered, 2 to 3 membered, or 4 to 5 membered), unsubstituted cycloalkyl (e.g., C3-C10, C3-C8, C3-C6, C4-C6, or C5-C6), unsubstituted heterocycloalkyl (e.g., 3 to 10 membered, 3 to 8 membered, 3 to 6 membered, 4 to 6 membered, 4 to 5 membered, or 5 to 6 membered), unsubstituted aryl (e.g., C6-C12, C6-C10, or phenyl), or unsubstituted heteroaryl (e.g., 5 to 12 membered, 5 to 10 membered, 5 to 9 membered, or 5 to 6 membered).
[0327] R16E is independently oxo, halogen, -CF3, -CCl3,-CBr3, -CI3, -CHF2, -CHCI2,- CHBr2, -CHI2, -CH2F,-CH2C1, -CH2Br, -
CH2I, -CN, -OH, -NH2, -COOH, -CONH2, -NO2, -SH, -SCH3, -SO3H, -S04H, -SO2NH2, -NHNH2, -ONH2, -NHC(0)NHNH2, -NHC(0)NH2, -NHSO2H, -NHC(0)H, - NHC(0)OH, -NHOH, -OCF3, -OCCI3, -OCBr3, -OCI3, -OCHF2, -OCHCI2, OCHBr2, - 0CHI2 -0CH2F, -OCH2CI, -OCH2Br, -OCH2I, R16F-substituted or unsubstituted alkyl (e.g., Ci-Cs, C1-C6, or C1-C4 alkyl), R16F-substituted or unsubstituted heteroalkyl (e.g., 2 to 8 membered, 2 to 6 membered, or 2 to 4 membered heteroalkyl), R16F-substituted or unsubstituted cycloalkyl (e.g., C3-C8, C3-C6, or C5-C6 cycloalkyl), R16F-substituted or unsubstituted heterocycloalkyl (e.g., 3 to 8 membered, 3 to 6 membered, or 5 to 6 membered heterocycloalkyl), R16F-substituted or unsubstituted aryl (e.g., C6-C10, C10 aryl, or phenyl), or R16F-substituted or unsubstituted heteroaryl (e.g., 5 to 10 membered, 5 to 9 membered, or 5 to 6 membered heteroaryl). In embodiments, R16E is independently oxo, halogen, -CF3, -CCI3,- CBr3, -CI3, -CHF2, -CHCl2,-CHBr2, -CHI2, -CH2F,-CH2C1, -CH2Br, - CH2I, -CN, -OH, -NH2, -COOH, -CONH2, -NO2, -SH, -SCH3, -SO3H, -S04H, -SO2NH2, -NHNH2, -ONH2, -NHC(0)NHNH2, -NHC(0)NH2, -NHSO2H, -NHC(0)H, - NHC(0)OH, -NHOH, -OCF3, -OCCI3, -OCBr3, -OCI3, -OCHF2, -OCHCI2, OCHBr2, - 0CHI2 -0CH2F, -OCH2CI, -OCH2Br, -OCH2I, R16F-substituted alkyl (e.g., Ci-C8, Ci-C6, or C1-C4 alkyl), R16F-substituted heteroalkyl (e.g., 2 to 8 membered, 2 to 6 membered, or 2 to 4 membered heteroalkyl), R16F-substituted cycloalkyl (e.g., C3-C8, C3-C6, or C5-C6 cycloalkyl), R16F-substituted heterocycloalkyl (e.g., 3 to 8 membered, 3 to 6 membered, or 5 to 6 membered heterocycloalkyl), R16F-substituted aryl (e.g., C6-C10, C10 aryl, or phenyl), or R16F- substituted heteroaryl (e.g., 5 to 10 membered, 5 to 9 membered, or 5 to 6 membered heteroaryl). In embodiments, R16E is independently oxo, halogen, -CF3, -CCl3,-CBr3, -CI3,
Figure imgf000105_0004
( ) , , 3, 3, 3, 3, , , , , unsubstituted alkyl (e.g., Ci-C8, Ci-C6, or
Figure imgf000105_0005
C1-C4 alkyl), unsubstituted heteroalkyl (e.g., 2 to 8 membered, 2 to 6 membered, or 2 to 4 membered heteroalkyl), unsubstituted cycloalkyl (e.g., C3-C8, C3-C6, or C5-C6 cycloalkyl), unsubstituted heterocycloalkyl (e.g., 3 to 8 membered, 3 to 6 membered, or 5 to 6 membered heterocycloalkyl), unsubstituted aryl (e.g., C6-C10, C10 aryl, or phenyl), or unsubstituted heteroaryl (e.g., 5 to 10 membered, 5 to 9 membered, or 5 to 6 membered heteroaryl).
[0328] R17 is halogen
Figure imgf000105_0001
( g ) ( ) ( g
Figure imgf000105_0002
Figure imgf000105_0003
substituted (e.g., substituted with a substituent group, a size-limited substituent group, or lower substituent group) or unsubstituted alkyl (e.g., Ci-Cs, C1-C6, or C1-C4 alkyl), substituted (e.g., substituted with a substituent group, a size-limited substituent group, or lower substituent group) or unsubstituted heteroalkyl (e.g., 2 to 8 membered, 2 to 6 membered, or 2 to 4 membered heteroalkyl), substituted (e.g., substituted with a substituent group, a size-limited substituent group, or lower substituent group) or unsubstituted cycloalkyl (e.g., C3-C8, C3-C6, or C5-C6 cycloalkyl), substituted (e.g., substituted with a substituent group, a size-limited substituent group, or lower substituent group) or unsubstituted heterocycloalkyl (e.g., 3 to 8 membered, 3 to 6 membered, or 5 to 6 membered heterocycloalkyl), substituted (e.g., substituted with a substituent group, a size-limited substituent group, or lower substituent group) or unsubstituted aryl (e.g., C6-C10, C10 aryl, or phenyl), or substituted (e.g., substituted with a substituent group, a size-limited substituent group, or lower substituent group) or unsubstituted heteroaryl (e.g., 5 to 10 membered, 5 to 9 membered, or 5 to 6 membered heteroaryl).
[0329] In embodiments, a substituted R17 is substituted with at least one substituent group, size-limited substituent group, or lower substituent group; wherein if the substituted R17 is substituted with a plurality of groups selected from substituent groups, size-limited substituent groups, and lower substituent groups; each substituent group, size-limited substituent group, and/or lower substituent group may optionally be different. In embodiments, when R17 is substituted, it is substituted with at least one substituent group. In embodiments, when R17 is substituted, it is substituted with at least one size-limited substituent group. In embodiments, when R17 is substituted, it is substituted with at least one lower substituent group.
[0330] In embodiments, R17 is hydrogen, -F, -Cl, -Br, -I, -CF3, -CHF2, -CH2F, -CCI3, - CHC12, -CH2C1, -CBr3, -CHBr2, -CH2Br, -CI3, -CHI2, -CH2I, -OCF3, -OCCI3, -OCBr3, - OCI3, -OCHF2, -OCHCk, -OCHBr2, -OCHI2, -OCH2F, -OCH2Cl, -OCH2Br, - OCH2I, -N3, -CN, -SH, -SCH3, -S02H, -S02CH3, -S02NH2, -S02NHCH3, -NHC(0)NH2, -NHC(0)NHCH3, -NO;!, -NH2, -NHCH3, -C(0)H, -C(0)CH3, -C(0)OH, - C(0)0CH3, -C(0)NH2, -C(0)NHCH3, -OH, -OCH3, -NHS02H, -NHS02CH3, -NHC(0)H, - NCH3C(0)H, -NHC(0)OH, -NCH3C(0)OH, -NHOH, -NCH3OH, -NCH3OCH3, R17E- substituted or unsubstituted alkyl (e.g., Ci-C2o, Ci-Ci2, Ci-Cs, C1-C6, C1-C4, or Ci-C2), R17E- substituted or unsubstituted heteroalkyl (e.g., 2 to 20 membered, 2 to 12 membered, 2 to 8 membered, 2 to 6 membered, 4 to 6 membered, 2 to 3 membered, or 4 to 5 membered), R17E- substituted or unsubstituted cycloalkyl (e.g., C3-C10, C3-C8, C3-C6, C4-C6, or C5-C6), R17E- substituted or unsubstituted heterocycloalkyl (e.g., 3 to 10 membered, 3 to 8 membered, 3 to 6 membered, 4 to 6 membered, 4 to 5 membered, or 5 to 6 membered), R17E-substituted or unsubstituted aryl (e.g., C6-C12, C6-C10, or phenyl), or R17E-substituted or unsubstituted heteroaryl (e.g., 5 to 12 membered, 5 to 10 membered, 5 to 9 membered, or 5 to 6 membered). In embodiments, R17 is hydrogen, -F, -Cl, -Br, -I, -CF3, -CHF2, -CH2F, -CCI3, -CHCI2, -CH2CI, -CBr3, CHBr2, -CH2Br, -CI3, -CHI2, -CH2I, -OCF3, -OCCI3, -OCBr3, - OCI3, -OCHF2, -OCHCI2, -OCHBr2, -OCHI2, -OCH2F, -OCH2CI, -OCH2Br, - OCH2I, -N3, -CN, -SH, -SCH3, -SO2H, -SO2CH3, -SO2NH2, -SO2NHCH3, -NHC(0)NH2, -NHC(0)NHCH3, -NO2, -NH2, -NHCH3, -C(0)H, -C(0)CH3, -C(0)0H, - C(0)0CH3, -C(0)NH2, -C(0)NHCH3, -OH, -0CH3, -NHSO2H, -NHSO2CH3, -NHC(0)H, - NCH3C(0)H, -NHC(0)0H, -NCH3C(0)0H, -NHOH, -NCH3OH, -NCH3OCH3, R17E- substituted alkyl (e.g., C1-C20, C1-C12, Ci-Cs, C1-C6, C1-C4, or C1-C2), R17E-substituted heteroalkyl (e.g., 2 to 20 membered, 2 to 12 membered, 2 to 8 membered, 2 to 6 membered, 4 to 6 membered, 2 to 3 membered, or 4 to 5 membered), R17E-substituted cycloalkyl (e.g., C3- C10, C3-C8, C3-C6, C4-C6, or C5-C6), R17E-substituted heterocycloalkyl (e.g., 3 to 10 membered, 3 to 8 membered, 3 to 6 membered, 4 to 6 membered, 4 to 5 membered, or 5 to 6 membered), R17E-substituted aryl (e.g., C6-C12, C6-C10, or phenyl), or R17E-substituted heteroaryl (e.g., 5 to 12 membered, 5 to 10 membered, 5 to 9 membered, or 5 to 6 membered). In embodiments, R17 is hydrogen, -F, -Cl, -Br, -I, -CF3, -CHF2, -CH2F, -CCI3, -CHCI2, -CH2CI, -CBr3, CHBr2, -CH2Br, -CI3, -CHI2, -CH2I, -OCF3, -OCCI3, -OCBr3, - OCI3, -OCHF2, -OCHCI2, -OCHBr2, -OCHI2, -OCH2F, -OCH2CI, -OCH2Br, - OCH2I, -N3, -CN, -SH, -SCH3, -SO2H, -SO2CH3, -SO2NH2, -SO2NHCH3, -NHC(0)NH2, -NHC(0)NHCH3, -NO2, -NH2, -NHCH3, -C(0)H, -C(0)CH3, -C(0)OH, - GOOCHS, -C(0)NH2, -C(0)NHCH3, -OH, -OCH3, -NHSO2H, -NHSO2CH3, -NHC(0)H, - NCH3C(0)H, -NHC(0)OH, -NCH3C(0)OH, -NHOH, -NCH3OH, -NCH3OCH3, unsubstituted alkyl (e.g., C1-C20, C1-C12, Ci-Cs, C1-C6, C1-C4, or C1-C2), unsubstituted heteroalkyl (e.g., 2 to 20 membered, 2 to 12 membered, 2 to 8 membered, 2 to 6 membered, 4 to 6 membered, 2 to 3 membered, or 4 to 5 membered), unsubstituted cycloalkyl (e.g., C3-C10, C3-C8, C3-C6, C4-C6, or C5-C6), unsubstituted heterocycloalkyl (e.g., 3 to 10 membered, 3 to 8 membered, 3 to 6 membered, 4 to 6 membered, 4 to 5 membered, or 5 to 6 membered), unsubstituted aryl (e.g., C6-C12, C6-C10, or phenyl), or unsubstituted heteroaryl (e.g., 5 to 12 membered, 5 to 10 membered, 5 to 9 membered, or 5 to 6 membered).
[0331] R17E is independently oxo, halogen, -CF3, -CCl3,-CBr3, -CI3, -CHF2, -CHCI2,- CHBr2, -CHI2, -CH2F,-CH2C1, -CH2Br, - CH2I, -CN, -OH, -NH2, -COOH, -CONH2, -NO2, -SH, -SCH3, -SO3H, -SO4H, -SO2NH2, -NHNH2, -ONH2, -NHC(0)NHNH2, -NHC(0)NH2, -NHSO2H, -NHC(0)H, - NHC(0)0H, -NHOH, -OCF3, -OCCI3, -OCBr3, -OCI3, -OCHF2, -OCHCI2, OCHBr2, - OCHI2,-OCH2F, -OCH2CI, -OCH2Br, -OCH2I, R1 ^-substituted or unsubstituted alkyl (e.g., C1-C8, C1-C6, or C1-C4 alkyl), R17F-substituted or unsubstituted heteroalkyl (e.g., 2 to 8 membered, 2 to 6 membered, or 2 to 4 membered heteroalkyl), R17F-substituted or unsubstituted cycloalkyl (e.g., C3-C8, C3-C6, or C5-C6 cycloalkyl), R17F-substituted or unsubstituted heterocycloalkyl (e.g., 3 to 8 membered, 3 to 6 membered, or 5 to 6 membered heterocycloalkyl), R17F-substituted or unsubstituted aryl (e.g., C6-C10, C10 aryl, or phenyl), or R17F-substituted or unsubstituted heteroaryl (e.g., 5 to 10 membered, 5 to 9 membered, or 5 to 6 membered heteroaryl). In embodiments, R17E is independently oxo, halogen, -CF3, -CCI3,- CBr3, -CI3, -CHF2, -CHCl2,-CHBr2, -CHI2, -CH2F,-CH2C1, -CH2Br, - CH2I, -CN, -OH, -NH2, -COOH, -CONH2, -NO2, -SH, -SCH3, -SO3H, -SO4H, -SO2NH2, -NHNH2, -ONH2, -NHC(0)NHNH2, -NHC(0)NH2, -NHSO2H, -NHC(0)H, - I3, -OCHF2, -OCHCI2, OCHBr2, -
Figure imgf000108_0001
substituted alkyl (e.g., Ci-C8, Ci-C6, or C1-C4 alkyl), R17F-substituted heteroalkyl (e.g., 2 to 8 membered, 2 to 6 membered, or 2 to 4 membered heteroalkyl), R17F-substituted cycloalkyl (e.g., C3-C8, C3-C6, or C5-C6 cycloalkyl), R17F-substituted heterocycloalkyl (e.g., 3 to 8 membered, 3 to 6 membered, or 5 to 6 membered heterocycloalkyl), R17F-substituted aryl (e.g., C6-C10, C10 aryl, or phenyl), or R17F- substituted heteroaryl (e.g., 5 to 10 membered, 5 to 9 membered, or 5 to 6 membered heteroaryl). In embodiments, R17E is independently oxo, halogen, -CF3, -CCl3,-CBr3, -CI3, CHF2, -CHCl2,-CHBr2, -CHI2, -CH2F,-CH2C1, -CH2Br, -
CH2I, -CN, -OH, -NH2, -COOH, -CONH2, -NO2, -SH, -SCH3, -SO3H, -S04H, -SO2NH2, -NHNH2, -ONH2, -NHC(0)NHNH2, -NHC(0)NH2, -NHSO2H, -NHC(0)H, - NHC(0)0H, -NHOH, -OCF3, -OCCI3, -OCBr3, -OCI3, -OCHF2, -OCHCI2, OCHBr2, - 0CHI2 -0CH2F, -OCH2CI, -OCH2Br, -OCH2I, unsubstituted alkyl (e.g., Ci-C8, Ci-C6, or C1-C4 alkyl), unsubstituted heteroalkyl (e.g., 2 to 8 membered, 2 to 6 membered, or 2 to 4 membered heteroalkyl), unsubstituted cycloalkyl (e.g., C3-C8, C3-C6, or C5-C6 cycloalkyl), unsubstituted heterocycloalkyl (e.g., 3 to 8 membered, 3 to 6 membered, or 5 to 6 membered heterocycloalkyl), unsubstituted aryl (e.g., C6-C10, C10 aryl, or phenyl), or unsubstituted heteroaryl (e.g., 5 to 10 membered, 5 to 9 membered, or 5 to 6 membered heteroaryl).
Figure imgf000109_0001
substituted (e.g., substituted with a substituent group, a size-limited substituent group, or lower substituent group) or unsubstituted alkyl (e.g., Ci-C8, C1-C6, or C1-C4 alkyl), substituted (e.g., substituted with a substituent group, a size-limited substituent group, or lower substituent group) or unsubstituted heteroalkyl (e.g., 2 to 8 membered, 2 to 6 membered, or 2 to 4 membered heteroalkyl), substituted (e.g., substituted with a substituent group, a size-limited substituent group, or lower substituent group) or unsubstituted cycloalkyl (e.g., C3-C8, C3-C6, or C5-C6 cycloalkyl), substituted (e.g., substituted with a substituent group, a size-limited substituent group, or lower substituent group) or unsubstituted heterocycloalkyl (e.g., 3 to 8 membered, 3 to 6 membered, or 5 to 6 membered heterocycloalkyl), substituted (e.g., substituted with a substituent group, a size-limited substituent group, or lower substituent group) or unsubstituted aryl (e.g., C6-C10, C10 aryl, or phenyl), or substituted (e.g., substituted with a substituent group, a size-limited substituent group, or lower substituent group) or unsubstituted heteroaryl (e.g., 5 to 10 membered, 5 to 9 membered, or 5 to 6 membered heteroaryl).
[0333] In embodiments, a substituted R18 is substituted with at least one substituent group, size-limited substituent group, or lower substituent group; wherein if the substituted R18 is substituted with a plurality of groups selected from substituent groups, size-limited substituent groups, and lower substituent groups; each substituent group, size-limited substituent group, and/or lower substituent group may optionally be different. In embodiments, when R18 is substituted, it is substituted with at least one substituent group. In embodiments, when R18 is substituted, it is substituted with at least one size-limited substituent group. In embodiments, when R18 is substituted, it is substituted with at least one lower substituent group.
[0334] In embodiments, R18 is hydrogen, -F, -Cl, -Br, -I, -CF3, -CHF2, -CH2F, -CC13, - CHCk, -CH2C1, -CBr3, -CHBr2, -CH2Br, -CI3, -CHI2, -CH2I, -OCF3, -OCCl3, -OCBr3, - OCI3, -OCHF2, -OCHCk, -OCHBr2, -OCHI2, -OCH2F, -OCH2Cl, -OCH2Br, - OCH2I, -N3, -CN, -SH, -SCH3, -S02H, -S02CH3, -S02NH2, -S02NHCH3, -NHC(0)NH2, -NHC(0)NHCH3, -N02, -NH2, -NHCH3, -C(0)H, -C(0)CH3, -C(0)0H, - C(0)0CH3, -C(0)NH2, -C(0)NHCH3, -OH, -OCH3, -NHS02H, -NHS02CH3, -NHC(0)H, - NCH3C(0)H, -NHC(0)0H, -NCH3C(0)0H, -NHOH, -NCH3OH, -NCH3OCH3, R18E- substituted or unsubstituted alkyl (e.g., Ci-C2o, Ci-Ci2, Ci-Cs, C1-C6, C1-C4, or Ci-C2), R18E- substituted or unsubstituted heteroalkyl (e.g., 2 to 20 membered, 2 to 12 membered, 2 to 8 membered, 2 to 6 membered, 4 to 6 membered, 2 to 3 membered, or 4 to 5 membered), R18E- substituted or unsubstituted cycloalkyl (e.g., C3-Cio, C3-C8, C3-C6, C4-C6, or C5-C6), R18E- substituted or unsubstituted heterocycloalkyl (e.g., 3 to 10 membered, 3 to 8 membered, 3 to 6 membered, 4 to 6 membered, 4 to 5 membered, or 5 to 6 membered), R18E-substituted or unsubstituted aryl (e.g., C6-Ci2, C6-C10, or phenyl), or R18E-substituted or unsubstituted heteroaryl (e.g., 5 to 12 membered, 5 to 10 membered, 5 to 9 membered, or 5 to 6 membered). In embodiments, R18 is hydrogen, -F, -Cl, -Br, -I, -CF3, -CHF2, -CH2F, -CC13, -CHCk, -CH2C1, -CBr3, CHBr2, -CH2Br, -CI3, -CHk, -CH2I, -OCF3, -OCCl3, -OCBr3, - OCI3, -OCHF2, -OCHCk, -OCHBr2, -OCHk, -OCH2F, -OCH2Cl, -OCH2Br, - OCH2I, -N3, -CN, -SH, -SCH3, -S02H, -S02CH3, -S02NH2, -S02NHCH3, -NHC(0)NH2, -NHC(0)NHCH3, -N02, -NH2, -NHCH3, -C(0)H, -C(0)CH3, -C(0)OH, - C(0)0CH3, -C(0)NH2, -C(0)NHCH3, -OH, -OCH3, -NHS02H, -NHS02CH3, -NHC(0)H, - NCH3C(0)H, -NHC(0)OH, -NCH3C(0)OH, -NHOH, -NCH3OH, -NCH3OCH3, R18E- substituted alkyl (e.g., Ci-C2o, Ci-Ci2, Ci-C8, C1-C6, C1-C4, or Ci-C2), R18E-substituted heteroalkyl (e.g., 2 to 20 membered, 2 to 12 membered, 2 to 8 membered, 2 to 6 membered, 4 to 6 membered, 2 to 3 membered, or 4 to 5 membered), R18E-substituted cycloalkyl (e.g., C3- C10, C3-C8, C3-C6, C4-C6, or C5-C6), R18E-substituted heterocycloalkyl (e.g., 3 to 10 membered, 3 to 8 membered, 3 to 6 membered, 4 to 6 membered, 4 to 5 membered, or 5 to 6 membered), R18E-substituted aryl (e.g., C6-Ci2, C6-C10, or phenyl), or R18E-substituted heteroaryl (e.g., 5 to 12 membered, 5 to 10 membered, 5 to 9 membered, or 5 to 6 membered). In embodiments, R18 is hydrogen, -F, -Cl, -Br, -I, -CF3, -CHF2, -CH2F, -CCI3, -CHCI2, -CH2CI, -CBr3, CHBr2, -CH2Br, -CI3, -CHI2, -CH2I, -OCF3, -OCCI3, -OCBr3, - OCI3, -OCHF2, -OCHCI2, -OCHBr2, -OCHI2, -OCH2F, -OCH2CI, -OCH2Br, - OCH2I, -N3, -CN, -SH, -SCH3, -SO2H, -SO2CH3, -SO2NH2, -SO2NHCH3, -NHC(0)NH2, -NHC(0)NHCH3, -NO2, -NH2, -NHCH3, -C(0)H, -C(0)CH3, -C(0)0H, - Co als, -C(0)NH2, -C(0)NHCH3, -OH, -0CH3, -NHSO2H, -NHSO2CH3, -NHC(0)H, - NCH3C(0)H, -NHC(0)0H, -NCH3C(0)0H, -NHOH, -NCH3OH, -NCH3OCH3, unsubstituted alkyl (e.g., C1-C20, C1-C12, Ci-Cs, C1-C6, C1-C4, or C1-C2), unsubstituted heteroalkyl (e.g., 2 to 20 membered, 2 to 12 membered, 2 to 8 membered, 2 to 6 membered, 4 to 6 membered, 2 to 3 membered, or 4 to 5 membered), unsubstituted cycloalkyl (e.g., C3-C10, C3-C8, C3-C6, C4-C6, or C5-C6), unsubstituted heterocycloalkyl (e.g., 3 to 10 membered, 3 to 8 membered, 3 to 6 membered, 4 to 6 membered, 4 to 5 membered, or 5 to 6 membered), unsubstituted aryl (e.g., C6-C12, C6-C10, or phenyl), or unsubstituted heteroaryl (e.g., 5 to 12 membered, 5 to 10 membered, 5 to 9 membered, or 5 to 6 membered).
[0335] R18E is independently oxo, halogen, -CF3, -CCl3,-CBr3, -CI3, -CHF2, -CHCI2,- CHBr2, -CHI2, -CH2F,-CH2C1, -CH2Br, -
CH2I, -CN, -OH, -NH2, -COOH, -CONH2, -NO2, -SH, -SCH3, -SO3H, -S04H, -SO2NH2, -NHNH2, -ONH2, -NHC(0)NHNH2, -NHC(0)NH2, -NHSO2H, -NHC(0)H, - NHC(0)OH, -NHOH, -OCF3, -OCCI3, -OCBr3, -OCI3, -OCHF2, -OCHCI2, OCHBr2, - 0CHI2 -0CH2F, -OCH2CI, -OCH2Br, -OCH2I, R18F-substituted or unsubstituted alkyl (e.g., Ci-Cs, C1-C6, or C1-C4 alkyl), R18F-substituted or unsubstituted heteroalkyl (e.g., 2 to 8 membered, 2 to 6 membered, or 2 to 4 membered heteroalkyl), R18F-substituted or unsubstituted cycloalkyl (e.g., C3-C8, C3-C6, or C5-C6 cycloalkyl), R18F-substituted or unsubstituted heterocycloalkyl (e.g., 3 to 8 membered, 3 to 6 membered, or 5 to 6 membered heterocycloalkyl), R18F-substituted or unsubstituted aryl (e.g., C6-C10, C10 aryl, or phenyl), or R18F-substituted or unsubstituted heteroaryl (e.g., 5 to 10 membered, 5 to 9 membered, or 5 to 6 membered heteroaryl). In embodiments, R18E is independently oxo, halogen, -CF3, -CCI3,- CBr3, -CI3, -CHF2, -CHCl2,-CHBr2, -CHI2, -CH2F,-CH2C1, -CH2Br, - CH2I, -CN, -OH, -NH2, -COOH, -CONH2, -NO2, -SH, -SCH3, -SO3H, -S04H, -SO2NH2, -NHNH2, -ONH2, -NHC(0)NHNH2, -NHC(0)NH2, -NHSO2H, -NHC(0)H, - NHC(0)OH, -NHOH, -OCF3, -OCCI3, -OCBr3, -OCI3, -OCHF2, -OCHCI2, OCHBr2, - substituted alkyl (e.g., C1-C8, C1-C6, or
Figure imgf000112_0002
C1-C4 alkyl), R18F-substituted heteroalkyl (e.g., 2 to 8 membered, 2 to 6 membered, or 2 to 4 membered heteroalkyl), R18F-substituted cycloalkyl (e.g., C3-C8, C3-C6, or C5-C6 cycloalkyl), R18F-substituted heterocycloalkyl (e.g., 3 to 8 membered, 3 to 6 membered, or 5 to 6 membered heterocycloalkyl), R18F-substituted aryl (e.g., C6-C10, C10 aryl, or phenyl), or R18F- substituted heteroaryl (e.g., 5 to 10 membered, 5 to 9 membered, or 5 to 6 membered heteroaryl). In embodiments, R18E is independently oxo, halogen, -CF3, -CCl3,-CBr3, -CI3, CHF2, -CHCk,-CHBr2 -CHI2, -CH2F,-CH2C1, -CH2Br, -
CH2I, -CN, -OH, -NH2, -COOH, -CONH2, -N02, -SH, -SCH3, -SO3H, -SO4H, -SO2NH2, -NHNH2, -ONH2, -NHC(0)NHNH2, -NHC(0)NH2, -NHS02H, -NHC(0)H, - NHC(0)0H, -NHOH, -OCF3, -OCCI3, -OCBr3, -OCI3, OCHF2, OCHCb, OCHBr2, - 0CHI2 -0CH2F, -OCH2Cl, -OCH2Br, -OCH2I, unsubstituted alkyl (e.g., Ci-C8, Ci-C6, or C1-C4 alkyl), unsubstituted heteroalkyl (e.g., 2 to 8 membered, 2 to 6 membered, or 2 to 4 membered heteroalkyl), unsubstituted cycloalkyl (e.g., C3-C8, C3-C6, or C5-C6 cycloalkyl), unsubstituted heterocycloalkyl (e.g., 3 to 8 membered, 3 to 6 membered, or 5 to 6 membered heterocycloalkyl), unsubstituted aryl (e.g., C6-C10, C10 aryl, or phenyl), or unsubstituted heteroaryl (e.g., 5 to 10 membered, 5 to 9 membered, or 5 to 6 membered heteroaryl).
C - O O ( -
Figure imgf000112_0001
-NHC(0)NHNH2, or -NHC(0)NHNHCH3), -NHC(0)NR19AR19B (e.g., -NHC(0)NH2, or -NHC(0)NHCH3), -N(0)mi9 (e.g., -NO, or -N02), -NR19AR19B (e.g., -NH2, or - NHCH3), -C(0)R19C(e.g., -C(0)H or -C(0)CH3), -C(0)-0R19C (e.g., -C(0)0H or - C(0)0CH3), -C(0)NR19AR19B (e.g., -C(0)NH2 or -C(O) NHCH3), -OR19D (e.g., -OH, or - OCH3), -NR19AS02R19D (e.g., -NHS02H), -NR19AC(0)R19C(e.g., - NHCOH), -NR19AC(0)0R19C (e.g., -NHC(O)OH), -NR19AOR19C (e.g., -NHOH), -N3, substituted (e.g., substituted with a substituent group, a size-limited substituent group, or lower substituent group) or unsubstituted alkyl (e.g., Ci-Cs, C1-C6, or C1-C4 alkyl), substituted (e.g., substituted with a substituent group, a size-limited substituent group, or lower substituent group) or unsubstituted heteroalkyl (e.g., 2 to 8 membered, 2 to 6 membered, or 2 to 4 membered heteroalkyl), substituted (e.g., substituted with a substituent group, a size-limited substituent group, or lower substituent group) or unsubstituted cycloalkyl (e.g., C3-C8, C3-C6, or C5-C6 cycloalkyl), substituted (e.g., substituted with a substituent group, a size-limited substituent group, or lower substituent group) or unsubstituted heterocycloalkyl (e.g., 3 to 8 membered, 3 to 6 membered, or 5 to 6 membered heterocycloalkyl), substituted (e.g., substituted with a substituent group, a size-limited substituent group, or lower substituent group) or unsubstituted aryl (e.g., C6-C10, C10 aryl, or phenyl), or substituted (e.g., substituted with a substituent group, a size-limited substituent group, or lower substituent group) or unsubstituted heteroaryl (e.g., 5 to 10 membered, 5 to 9 membered, or 5 to 6 membered heteroaryl).
[0337] In embodiments, a substituted R19 is substituted with at least one substituent group, size-limited substituent group, or lower substituent group; wherein if the substituted R19 is substituted with a plurality of groups selected from substituent groups, size-limited substituent groups, and lower substituent groups; each substituent group, size-limited substituent group, and/or lower substituent group may optionally be different. In embodiments, when R19 is substituted, it is substituted with at least one substituent group. In embodiments, when R19 is substituted, it is substituted with at least one size-limited substituent group. In embodiments, when R19 is substituted, it is substituted with at least one lower substituent group.
[0338] In embodiments, R19 is hydrogen, -F, -Cl, -Br, -I, -CF3, -CHF2, -CH2F, -CCI3, - CHC12, -CH2C1, -CBr3, -CHBr2, -CH2Br, -CI3, -CHI2, -CH2I, -OCF3, -OCCI3, -OCBr3, - OCI3, -OCHF2, -OCHCk, -OCHBr2, -OCHI2, -OCH2F, -OCH2Cl, -OCH2Br, - OCH2I, -N3, -CN, -SH, -SCH3, -S02H, -S02CH3, -S02NH2, -S02NHCH3, -NHC(0)NH2, -NHC(0)NHCH3, -NO;!, -NH2, -NHCH3, -C(0)H, -C(0)CH3, -C(0)0H, - C(0)0CH3, -C(0)NH2, -C(0)NHCH3, -OH, -0CH3, -NHS02H, -NHS02CH3, -NHC(0)H, - NCH3C(0)H, -NHC(0)0H, -NCH3C(0)0H, -NHOH, -NCH3OH, -NCH3OCH3, R19E- substituted or unsubstituted alkyl (e.g., Ci-C2o, Ci-Ci2, Ci-Cs, C1-C6, C1-C4, or Ci-C2), R19E- substituted or unsubstituted heteroalkyl (e.g., 2 to 20 membered, 2 to 12 membered, 2 to 8 membered, 2 to 6 membered, 4 to 6 membered, 2 to 3 membered, or 4 to 5 membered), R19E- substituted or unsubstituted cycloalkyl (e.g., C3-C10, C3-C8, C3-C6, C4-C6, or C5-C6), R19E- substituted or unsubstituted heterocycloalkyl (e.g., 3 to 10 membered, 3 to 8 membered, 3 to 6 membered, 4 to 6 membered, 4 to 5 membered, or 5 to 6 membered), R19E-substituted or unsubstituted aryl (e.g., C6-C12, C6-C10, or phenyl), or R19E-substituted or unsubstituted heteroaryl (e.g., 5 to 12 membered, 5 to 10 membered, 5 to 9 membered, or 5 to 6 membered). In embodiments, R19 is hydrogen, -F, -Cl, -Br, -I, -CF3, -CHF2, -CH2F, -CCI3, -CHCI2, -CH2CI, -CBr3, CHBr2, -CH2Br, -CI3, -CHI2, -CH2I, -OCF3, -OCCI3, -OCBr3, - OCI3, -OCHF2, -OCHCI2, -OCHBr2, -OCHI2, -OCH2F, -OCH2CI, -OCH2Br, - OCH2I, -N3, -CN, -SH, -SCH3, -SO2H, -SO2CH3, -SO2NH2, -SO2NHCH3, -NHC(0)NH2, -NHC(0)NHCH3, -NO2, -NH2, -NHCH3, -C(0)H, -cecils, -C(0)0H, - C(0)0CH3, -C(0)NH2, -C(0)NHCH3, -OH, -0CH3, -NHSO2H, -NHSO2CH3, -NHC(0)H, - NCH3C(0)H, -NHC(0)0H, -NCH3C(0)0H, -NHOH, -NCH3OH, -NCH3OCH3, R19E- substituted alkyl (e.g., C1-C20, C1-C12, Ci-Cs, C1-C6, C1-C4, or C1-C2), R19E-substituted heteroalkyl (e.g., 2 to 20 membered, 2 to 12 membered, 2 to 8 membered, 2 to 6 membered, 4 to 6 membered, 2 to 3 membered, or 4 to 5 membered), R19E-substituted cycloalkyl (e.g., C3- C10, C3-C8, C3-C6, C4-C6, or C5-C6), R19E-substituted heterocycloalkyl (e.g., 3 to 10 membered, 3 to 8 membered, 3 to 6 membered, 4 to 6 membered, 4 to 5 membered, or 5 to 6 membered), R19E-substituted aryl (e.g., C6-C12, C6-C10, or phenyl), or R19E-substituted heteroaryl (e.g., 5 to 12 membered, 5 to 10 membered, 5 to 9 membered, or 5 to 6 membered). In embodiments, R19 is hydrogen, -F, -Cl, -Br, -I, -CF3, -CHF2, -CH2F, -CCI3, -CHCI2, -CH2CI, -CBr3, CHBr2, -CH2Br, -CI3, -CHI2, -CH2I, -OCF3, -OCCI3, -OCBr3, - OCI3, -OCHF2, -OCHCI2, -OCHBr2, -OCHI2, -OCH2F, -OCH2CI, -OCH2Br, - OCH2I, -N3, -CN, -SH, -SCH3, -SO2H, -SO2CH3, -SO2NH2, -SO2NHCH3, -NHC(0)NH2, -NHC(0)NHCH3, -NO2, -NH2, -NHCH3, -C(0)H, -C(0)CH3, -C(0)OH, - C(0)0CH3, -C(0)NH2, -C(0)NHCH3, -OH, -OCH3, -NHSO2H, -NHSO2CH3, -NHC(0)H, - NCH3C(0)H, -NHC(0)OH, -NCH3C(0)OH, -NHOH, -NCH3OH, -NCH3OCH3, unsubstituted alkyl (e.g., C1-C20, C1-C12, Ci-Cs, C1-C6, C1-C4, or C1-C2), unsubstituted heteroalkyl (e.g., 2 to 20 membered, 2 to 12 membered, 2 to 8 membered, 2 to 6 membered, 4 to 6 membered, 2 to 3 membered, or 4 to 5 membered), unsubstituted cycloalkyl (e.g., C3-C10, C3-C8, C3-C6, C4-C6, or C5-C6), unsubstituted heterocycloalkyl (e.g., 3 to 10 membered, 3 to 8 membered, 3 to 6 membered, 4 to 6 membered, 4 to 5 membered, or 5 to 6 membered), unsubstituted aryl (e.g., C6-C12, C6-C10, or phenyl), or unsubstituted heteroaryl (e.g., 5 to 12 membered, 5 to 10 membered, 5 to 9 membered, or 5 to 6 membered). [0339] R19E is independently oxo, halogen, -CF3, -CCl3,-CBr3, -CI3, -CHF2, CHCb, CHBr2, -CHI2, -CH2F,-CH2C1, -CH2Br, -
CH2I, -CN, -OH, -NH2, -COOH, -CONH2, -NO2, -SH, -SCH3, -SO3H, -SO4H, -SO2NH2,
-NHNH2, -ONH2, -NHC(0)NHNH2, -NHC(0)NH2, -NHS02H, -NHC(0)H, - NHC(0)0H, -NHOH, -OCF3, -OCCl3, -OCBr3, -OCI3, OCHF2, OCHCb, OCHBr2, - 0CHI2 -0CH2F, -OCH2Cl, -OCH2Br, -OCH2I, R1 ^-substituted or unsubstituted alkyl (e.g., Ci-Cs, Ci-C6, or C1-C4 alkyl), R19F-substituted or unsubstituted heteroalkyl (e.g., 2 to 8 membered, 2 to 6 membered, or 2 to 4 membered heteroalkyl), R19F-substituted or unsubstituted cycloalkyl (e.g., C3-Cs, C3-C6, or C5-C6 cycloalkyl), R19F-substituted or unsubstituted heterocycloalkyl (e.g., 3 to 8 membered, 3 to 6 membered, or 5 to 6 membered heterocycloalkyl), R19F-substituted or unsubstituted aryl (e.g., C6-C10, C10 aryl, or phenyl), or R19F-substituted or unsubstituted heteroaryl (e.g., 5 to 10 membered, 5 to 9 membered, or 5 to 6 membered heteroaryl). In embodiments, R19E is independently oxo, halogen, -CF3, -CC13,- CBr3, -CI3, -CHF2, -CHCb,-CHBr2 -CHI2, -CH2F, CH2C1, -CH2Br, - CH2I, -CN, -OH, -NH2, -COOH, -CONH2, -N02, -SH, -SCH3, -S03H, -SO4H, -SO2NH2, -NHNH2, -ONH2, -NHC(0)NHNH2, -NHC(0)NH2, -NHS02H, -NHC(0)H, - I3, OCHF2, OCHCb, OCHBr2, -
Figure imgf000115_0001
substituted alkyl (e.g., Ci-C8, Ci-C6, or C1-C4 alkyl), R19F-substituted heteroalkyl (e.g., 2 to 8 membered, 2 to 6 membered, or 2 to 4 membered heteroalkyl), R19F-substituted cycloalkyl (e.g., C3-Cs, C3-C6, or C5-C6 cycloalkyl), R19F-substituted heterocycloalkyl (e.g., 3 to 8 membered, 3 to 6 membered, or 5 to 6 membered heterocycloalkyl), R19F-substituted aryl (e.g., C6-C10, C10 aryl, or phenyl), or R19F- substituted heteroaryl (e.g., 5 to 10 membered, 5 to 9 membered, or 5 to 6 membered heteroaryl). In embodiments, R19E is independently oxo, halogen, -CF3, -CCl3,-CBr3, -CI3, CHF2, -CHCb,-CHBr2 -CHI2, -CH2F,-CH2C1, -CH2Br, -
CH2I, -CN, -OH, -NH2, -COOH, -CONH2, -N02, -SH, -SCH3, -S03H, -SO4H, -SO2NH2, -NHNH2, -ONH2, -NHC(0)NHNH2, -NHC(0)NH2, -NHS02H, -NHC(0)H, - NHC(0)0H, -NHOH, -OCF3, -OCCl3, -OCBr3, -OCI3, OCHF2, -OCHCb, OCHBr2, - OCHb, -OCH2F, -OCH2Cl, -OCH2Br, -OCH2I, unsubstituted alkyl (e.g., Ci-C8, Ci-C6, or C1-C4 alkyl), unsubstituted heteroalkyl (e.g., 2 to 8 membered, 2 to 6 membered, or 2 to 4 membered heteroalkyl), unsubstituted cycloalkyl (e.g., C3-Cs, C3-C6, or C5-C6 cycloalkyl), unsubstituted heterocycloalkyl (e.g., 3 to 8 membered, 3 to 6 membered, or 5 to 6 membered heterocycloalkyl), unsubstituted aryl (e.g., C6-C10, C10 aryl, or phenyl), or unsubstituted heteroaryl (e.g., 5 to 10 membered, 5 to 9 membered, or 5 to 6 membered heteroaryl).
[0340] L1 is a bond, -NH-, -0-, -S-, -C(O)-, -C(0)NH-, -NHC(O)-, -NHC(0)NH-, -C(0)0-, -OC(O)-, substituted (e.g., substituted with a substituent group, a size-limited substituent group, or lower substituent group) or unsubstituted alkylene (e.g., Ci-Cs, C1-C6, or C1-C4 alkylene), substituted (e.g., substituted with a substituent group, a size-limited substituent group, or lower substituent group) or unsubstituted heteroalkylene (e.g., 2 to 8 membered, 2 to 6 membered, or 2 to 4 membered heteroalkylene), substituted (e.g., substituted with a substituent group, a size-limited substituent group, or lower substituent group) or unsubstituted cycloalkylene (e.g., C3-C8, C3-C6, or C5-C6 cycloalkylene), substituted (e.g., substituted with a substituent group, a size-limited substituent group, or lower substituent group) or unsubstituted heterocycloalkylene (e.g., 3 to 8 membered, 3 to 6 membered, or 5 to 6 membered heterocycloalkylene), substituted (e.g., substituted with a substituent group, a size-limited substituent group, or lower substituent group) or unsubstituted arylene (e.g., C6- C10, C10 aryl, or phenylene), or substituted (e.g., substituted with a substituent group, a size- limited substituent group, or lower substituent group) or unsubstituted heteroarylene (e.g., 5 to 10 membered, 5 to 9 membered, or 5 to 6 membered heteroarylene).
[0341] In embodiments, a substituted L1 is substituted with at least one substituent group, size-limited substituent group, or lower substituent group; wherein if the substituted L1 is substituted with a plurality of groups selected from substituent groups, size-limited substituent groups, and lower substituent groups; each substituent group, size-limited substituent group, and/or lower substituent group may optionally be different. In embodiments, when L1 is substituted, it is substituted with at least one substituent group. In embodiments, when L1 is substituted, it is substituted with at least one size-limited substituent group. In embodiments, when L1 is substituted, it is substituted with at least one lower substituent group.
[0342] In embodiments, L1 is a bond, -NH-, -0-, -S-, -C(O)-, -C(0)NH-, -NHC(O)-, -NHC(0)NH-, -C(0)0-, -OC(O)-, R20- substituted or unsubstituted alkylene (e.g., Ci-Cs, C1-C6, or C1-C4 alkylene), R20-substituted or unsubstituted heteroalkylene (e.g., 2 to 8 membered, 2 to 6 membered, or 2 to 4 membered heteroalkylene), R20-substituted or unsubstituted cycloalkylene (e.g., C3-C8, C3-C6, or C5-C6 cycloalkylene), R20-substituted or unsubstituted heterocycloalkylene (e.g., 3 to 8 membered,
3 to 6 membered, or 5 to 6 membered heterocycloalkylene), R20-substituted or unsubstituted arylene (e.g., C6-C10, C10 aryl, or phenylene), or R20-substituted or unsubstituted heteroarylene (e.g., 5 to 10 membered, 5 to 9 membered, or 5 to 6 membered heteroarylene). In embodiments, L1 is a bond, -NH-, -0-, -S-, -C(O)-, -C(0)NH-, -NHC(O)-, -NHC(0)NH-, -C(0)0-, -OC(O)-, R20- substituted alkylene (e.g., Ci-Cs, C1-C6, or C1-C4 alkylene), R20-substituted heteroalkylene (e.g., 2 to 8 membered, 2 to 6 membered, or 2 to 4 membered heteroalkylene), R20-substituted cycloalkylene (e.g., C3-C8, C3-C6, or C5-C6 cycloalkylene), R20-substituted heterocycloalkylene (e.g., 3 to 8 membered, 3 to 6 membered, or 5 to 6 membered heterocycloalkylene), R20-substituted arylene (e.g., C6-C10, C10 aryl, or phenylene), or R20- substituted heteroarylene (e.g., 5 to 10 membered, 5 to 9 membered, or 5 to 6 membered heteroarylene). In embodiments, L1 is a bond, -NH-, -0-, -S-, -C(O)-, -C(0)NH-, -NHC(O)-, -NHC(0)NH-, -C(0)0-, -OC(O)-, unsubstituted alkylene (e.g., Ci-Cs, C1-C6, or C1-C4 alkylene), unsubstituted heteroalkylene (e.g., 2 to 8 membered, 2 to 6 membered, or 2 to 4 membered heteroalkylene), unsubstituted cycloalkylene (e.g., C3-C8, C3-C6, or C5-C6 cycloalkylene), unsubstituted heterocycloalkylene (e.g., 3 to 8 membered, 3 to 6 membered, or 5 to 6 membered heterocycloalkylene), unsubstituted arylene (e.g., C6-C10, C10 aryl, or phenylene), or unsubstituted heteroarylene (e.g., 5 to 10 membered, 5 to 9 membered, or 5 to 6 membered heteroarylene).
[0343] R20 is oxo, halogen, -CF3, -CCl3,-CBr3, -CI3, -CHF2, -CHCl2,-CHBr2 -CHI2, - CH2F,-CH2C1, -CH2Br, -CH2I, -CN, -OH, -NH2, -COOH, -CONH2, -N02, -SH, -SCH3, - SO3H, -SO4H, -S02NH2, -NHNH2, -ONH2, -NHC(0)NHNH2, -NHC(0)NH2, -NHSO2H, - NHC(0)H, -NHC(0)OH, -NHOH, -OCF3, -OCCI3, -OCBr3, -OCI3, -OCHF2, OCHCb, - OCHBr2, -0CHI2 -0CH2F, -OCH2Cl, -OCH2Br, -OCH2I, R21 -substituted or unsubstituted alkyl (e.g., Ci-Cs, C1-C6, or C1-C4 alkyl), R21 -substituted or unsubstituted heteroalkyl (e.g., 2 to 8 membered, 2 to 6 membered, or 2 to 4 membered heteroalkyl), R21 -substituted or unsubstituted cycloalkyl (e.g., C3-C8, C3-C6, or C5-C6 cycloalkyl), R21 -substituted or unsubstituted heterocycloalkyl (e.g., 3 to 8 membered, 3 to 6 membered, or 5 to 6 membered heterocycloalkyl), R21 -substituted or unsubstituted aryl (e.g., C6-C10, C10 aryl, or phenyl), or R21 -substituted or unsubstituted heteroaryl (e.g., 5 to 10 membered, 5 to 9 membered, or 5 to 6 membered heteroaryl). In embodiments, R20 is oxo, halogen, -CF3, -CCI3, -CBr3, -CI3, - CHF2, -CHCl2,-CHBr2, -CHI2, -CH2F,-CH2C1, -CH2Br, -
CH2I, -CN, -OH, -NH2, -COOH, -CONH2, -N02, -SH, -SCH3, -SO3H, -SO4H, -SO2NH2, -NHNH2, -ONH2, -NHC(0)NHNH2, -NHC(0)NH2, -NHS02H, -NHC(0)H, - NHC(0)0H, -NHOH, -OCF3, -OCCl3, -OCBr3, -OCI3, OCHF2, OCHCb, OCHBr2, - 0CHI2 -0CH2F, -OCH2Cl, -OCH2Br, -OCH2I, R21 -substituted alkyl (e.g., Ci-C8, Ci-C6, or C1-C4 alkyl), R21 -substituted heteroalkyl (e.g., 2 to 8 membered, 2 to 6 membered, or 2 to 4 membered heteroalkyl), R21 -substituted cycloalkyl (e.g., C3-C8, C3-C6, or C5-C6 cycloalkyl), R21 -substituted heterocycloalkyl (e.g., 3 to 8 membered, 3 to 6 membered, or 5 to 6 membered heterocycloalkyl), R21 -substituted aryl (e.g., C6-C10, C10 aryl, or phenyl), or R21- substituted heteroaryl (e.g., 5 to 10 membered, 5 to 9 membered, or 5 to 6 membered heteroaryl). In embodiments, R20 is oxo, halogen, -CF3, -CC13, -CBr3, -CI3, -CHF2, - CHCk,-CHBr2 -CHI2, -CH2F,-CH2C1, -CH2Br, -
CH2I, -CN, -OH, -NH2, -COOH, -CONH2, -N02, -SH, -SCH3, -S03H, -S04H, -S02NH2, -NHNH2, -ONH2, -NHC(0)NHNH2, -NHC(0)NH2, -NHS02H, -NHC(0)H, - NHC(0)0H, -NHOH, -OCF3, -OCCl3, -OCBr3, -OCI3, OCHF2, OCHCb, OCHBr2, - 0CHI2,-0CH2F, -OCH2Cl, -OCH2Br, -OCH2I, unsubstituted alkyl (e.g., Ci-C8, Ci-C6, or C1-C4 alkyl), unsubstituted heteroalkyl (e.g., 2 to 8 membered, 2 to 6 membered, or 2 to 4 membered heteroalkyl), unsubstituted cycloalkyl (e.g., C3-C8, C3-C6, or C5-C6 cycloalkyl), unsubstituted heterocycloalkyl (e.g., 3 to 8 membered, 3 to 6 membered, or 5 to 6 membered heterocycloalkyl), unsubstituted aryl (e.g., C6-C10, C10 aryl, or phenyl), or unsubstituted heteroaryl (e.g., 5 to 10 membered, 5 to 9 membered, or 5 to 6 membered heteroaryl).
[0344] L2 is a bond, -NH-, -0-, -S-, -C(O)-, -C(0)NH-, -NHC(O)-, -NHC(0)NH-, -C(0)0-, -OC(O)-, substituted (e.g., substituted with a substituent group, a size-limited substituent group, or lower substituent group) or unsubstituted alkylene (e.g., Ci-C8, C1-C6, or C1-C4 alkylene), substituted (e.g., substituted with a substituent group, a size-limited substituent group, or lower substituent group) or unsubstituted heteroalkylene (e.g., 2 to 8 membered, 2 to 6 membered, or 2 to 4 membered heteroalkylene), substituted (e.g., substituted with a substituent group, a size-limited substituent group, or lower substituent group) or unsubstituted cycloalkylene (e.g., C3-C8, C3-C6, or C5-C6 cycloalkylene), substituted (e.g., substituted with a substituent group, a size-limited substituent group, or lower substituent group) or unsubstituted heterocycloalkylene (e.g., 3 to 8 membered, 3 to 6 membered, or 5 to 6 membered heterocycloalkylene), substituted (e.g., substituted with a substituent group, a size-limited substituent group, or lower substituent group) or unsubstituted arylene (e.g., C6- Cio, Cio aryl, or phenylene), or substituted (e.g., substituted with a substituent group, a size- limited substituent group, or lower substituent group) or unsubstituted heteroarylene (e.g., 5 to 10 membered, 5 to 9 membered, or 5 to 6 membered heteroarylene).
[0345] In embodiments, a substituted L2 is substituted with at least one substituent group, size-limited substituent group, or lower substituent group; wherein if the substituted L2 is substituted with a plurality of groups selected from substituent groups, size-limited substituent groups, and lower substituent groups; each substituent group, size-limited substituent group, and/or lower substituent group may optionally be different. In embodiments, when L2 is substituted, it is substituted with at least one substituent group. In embodiments, when L2 is substituted, it is substituted with at least one size-limited substituent group. In embodiments, when L2 is substituted, it is substituted with at least one lower substituent group.
[0346] In embodiments, L2 is a bond, -NH-, -0-, -S-, -C(O)-, -C(0)NH-, -NHC(O)-, -NHC(0)NH-, -C(0)0-, -OC(O)-, R22- substituted or unsubstituted alkylene (e.g., Ci-Cs, C1-C6, or C1-C4 alkylene), R22-substituted or unsubstituted heteroalkylene (e.g., 2 to 8 membered, 2 to 6 membered, or 2 to 4 membered heteroalkylene), R22-substituted or unsubstituted cycloalkylene (e.g., C3-C8, C3-C6, or C5-C6 cycloalkylene), R22-substituted or unsubstituted heterocycloalkylene (e.g., 3 to 8 membered,
3 to 6 membered, or 5 to 6 membered heterocycloalkylene), R22-substituted or unsubstituted arylene (e.g., C6-C10, Cio aryl, or phenylene), or R22-substituted or unsubstituted heteroarylene (e.g., 5 to 10 membered, 5 to 9 membered, or 5 to 6 membered heteroarylene). In embodiments, L2 is a bond, -NH-, -0-, -S-, -C(O)-, -C(0)NH-, -NHC(O)-, -NHC(0)NH-, -C(0)0-, -OC(O)-, R22- substituted alkylene (e.g., Ci-Cs, C1-C6, or C1-C4 alkylene), R22-substituted heteroalkylene (e.g., 2 to 8 membered, 2 to 6 membered, or 2 to 4 membered heteroalkylene), R22-substituted cycloalkylene (e.g., C3-C8, C3-C6, or C5-C6 cycloalkylene), R22-substituted heterocycloalkylene (e.g., 3 to 8 membered, 3 to 6 membered, or 5 to 6 membered heterocycloalkylene), R22-substituted arylene (e.g., C6-C10, Cio aryl, or phenylene), or R22- substituted heteroarylene (e.g., 5 to 10 membered, 5 to 9 membered, or 5 to 6 membered heteroarylene). In embodiments, L2 is a bond, -NH-, -0-, -S-, -C(O)-, -C(0)NH-, -NHC(O)-, -NHC(0)NH-, -C(0)0-, -OC(O)-, unsubstituted alkylene (e.g., Ci-Cs, C1-C6, or C1-C4 alkylene), unsubstituted heteroalkylene (e.g., 2 to 8 membered, 2 to 6 membered, or 2 to 4 membered heteroalkylene), unsubstituted cycloalkylene (e.g., C3-C8, C3-C6, or C5-C6 cycloalkylene), unsubstituted heterocycloalkylene (e.g., 3 to 8 membered, 3 to 6 membered, or 5 to 6 membered heterocycloalkylene), unsubstituted arylene (e.g., C6-C10, C10 aryl, or phenylene), or unsubstituted heteroarylene (e.g., 5 to 10 membered, 5 to 9 membered, or 5 to 6 membered heteroarylene).
[0347] R22 is independently oxo, halogen, -CF3, -CCl3,-CBr3, -CI3, -CHF2, -CHCI2,- CHBr2, -CHI2, -CH2F,-CH2C1, -CH2Br, -
CH2I, -CN, -OH, -NH2, -COOH, -CONH2, -N02, -SH, -SCH3, -SO3H, -SO4H, -SO2NH2, -NHNH2, -ONH2, -NHC(0)NHNH2, -NHC(0)NH2, -NHS02H, -NHC(0)H, - NHC(0)0H, -NHOH, -OCF3, -OCCI3, -OCBr3, -OCI3, OCHF2, OCHCb, OCHBr2, - 0CHI2 -0CH2F, -OCH2Cl, -OCH2Br, -OCH2I, R23 -substituted or unsubstituted alkyl (e.g., Ci-Cs, C1-C6, or C1-C4 alkyl), R23-substituted or unsubstituted heteroalkyl (e.g., 2 to 8 membered, 2 to 6 membered, or 2 to 4 membered heteroalkyl), R23-substituted or unsubstituted cycloalkyl (e.g., C3-C8, C3-C6, or C5-C6 cycloalkyl), R23 -substituted or unsubstituted heterocycloalkyl (e.g., 3 to 8 membered, 3 to 6 membered, or 5 to 6 membered heterocycloalkyl), R23 -substituted or unsubstituted aryl (e.g., C6-C10, C10 aryl, or phenyl), or R23 -substituted or unsubstituted heteroaryl (e.g., 5 to 10 membered, 5 to 9 membered, or 5 to 6 membered heteroaryl). In embodiments, R22 is independently oxo, halogen, -CF3, -CCI3, - CBr3, -CI3, -CHF2, -CHCb,-CHBr2 -CHI2, -CH2F,-CH2C1, -CH2Br, - CH2I, -CN, -OH, -NH2, -COOH, -CONH2, -N02, -SH, -SCH3, -SO3H, -SO4H, -S02NH2, -NHNH2, -ONH2, -NHC(0)NHNH2, -NHC(0)NH2, -NHS02H, -NHC(0)H, - NHC(0)0H, -NHOH, -OCF3, -OCCI3, -OCBr3, -OCI3, OCHF2, OCHCb, OCHBr2, - 0CHI2,-0CH2F, -OCH2Cl, -OCH2Br, -OCH2I, R23 -substituted alkyl (e.g., Ci-C8, Ci-C6, or C1-C4 alkyl), R23 -substituted heteroalkyl (e.g., 2 to 8 membered, 2 to 6 membered, or 2 to 4 membered heteroalkyl), R23 -substituted cycloalkyl (e.g., C3-C8, C3-C6, or C5-C6 cycloalkyl), R23 -substituted heterocycloalkyl (e.g., 3 to 8 membered, 3 to 6 membered, or 5 to 6 membered heterocycloalkyl), R23-substituted aryl (e.g., C6-C10, C10 aryl, or phenyl), or R23- substituted heteroaryl (e.g., 5 to 10 membered, 5 to 9 membered, or 5 to 6 membered heteroaryl). In embodiments, R22 is independently oxo, halogen, -CF3, -CC ,-CBr3, -CI3, - CHF2, -CHCb,-CHBr2 -CHI2, -CH2F,-CH2C1, -CH2Br, - CH2I, -CN, -OH, -NH2, -COOH, -CONH2, -NO2, -SH, -SCH3, -SO3H, -SO4H, -SO2NH2, -NHNH2, -ONH2, -NHC(0)NHNH2, -NHC(0)NH2, -NHSO2H, -NHC(0)H, - NHC(0)0H, -NHOH, -OCF3, -OCCI3, -OCBr3, -OCI3, -OCHF2, -OCHCI2, OCHBr2, - 0CHI2 -0CH2F, -OCH2CI, -OCH2Br, -OCH2I, unsubstituted alkyl (e.g., Ci-C8, Ci-C6, or C1-C4 alkyl), unsubstituted heteroalkyl (e.g., 2 to 8 membered, 2 to 6 membered, or 2 to 4 membered heteroalkyl), unsubstituted cycloalkyl (e.g., C3-C8, C3-C6, or C5-C6 cycloalkyl), unsubstituted heterocycloalkyl (e.g., 3 to 8 membered, 3 to 6 membered, or 5 to 6 membered heterocycloalkyl), unsubstituted aryl (e.g., C6-C10, C10 aryl, or phenyl), or unsubstituted heteroaryl (e.g., 5 to 10 membered, 5 to 9 membered, or 5 to 6 membered heteroaryl).
[0348] Each R1A, R1B, R1C, R1D, R16A, R16B, R16C, R16D, R17A, R17B, R17C, R17D, R18A, R18B, R18C, R18D, R19A, R19B, R19C, and R19D are independently hydrogen, -CX3, -CHX2, -CH2X (e.g., -CF3, CHF2, -CH2F, -CCI3, -CHCI2, -CH2CI, -CBr3, CHBr2, -CH2Br, -CI3, -CHI2, -CH2I), -CN, -OH, -COOH, -CONH2, substituted (e.g., substituted with a substituent group, a size-limited substituent group, or lower substituent group) or unsubstituted alkyl (e.g., C1-C20, C1-C12, C1-C8, C1-C6, C1-C4, or C1-C2), substituted (e.g., substituted with a substituent group, a size-limited substituent group, or lower substituent group) or unsubstituted heteroalkyl (e.g., 2 to 20 membered, 2 to 12 membered, 2 to 8 membered, 2 to 6 membered, 4 to 6 membered, 2 to 3 membered, or 4 to 5 membered), substituted (e.g., substituted with a substituent group, a size-limited substituent group, or lower substituent group) or unsubstituted cycloalkyl (e.g., C3-C10, C3-C8, C3-C6, C4-C6, or C5-C6), substituted (e.g., substituted with a substituent group, a size-limited substituent group, or lower substituent group) or unsubstituted heterocycloalkyl (e.g., 3 to 10 membered, 3 to 8 membered, 3 to 6 membered, 4 to 6 membered, 4 to 5 membered, or 5 to 6 membered), substituted (e.g., substituted with a substituent group, a size-limited substituent group, or lower substituent group) or unsubstituted aryl (e.g., C6-C12, C6-C10, or phenyl), or substituted (e.g., substituted with a substituent group, a size-limited substituent group, or lower substituent group) or unsubstituted heteroaryl (e.g., 5 to 12 membered, 5 to 10 membered, 5 to 9 membered, or 5 to 6 membered). X is independently -F, -Cl, -Br, or -I. In embodiments, each R1A, R1B, R1C, p iv ID5 pivl6A , p ivl6B 5 pivl6C , p ivl6D 5 pivl7A , p iv 17B 5 piv 17C , p ivl7D 5 pivl8A , p ivl8B 5 pivl8C , p ivl8D 5 pivl9A , p ivl9B 5 pivl9C and R19D are independently hydrogen, -CF3, -CHF2, -CH2F, -CCI3, -CHCI2, -CH2CI, -CBr3, -CHBr2, -CH2Br, -CI3, -CHI2, -CH2I, -CN, -OH, -COOH, -CONH2, R24-substituted or unsubstituted alkyl (e.g., C1-C20, C1-C12, Ci-Cs, C1-C6, C1-C4, or C1-C2), R24-substituted or unsubstituted heteroalkyl (e.g., 2 to 20 membered, 2 to 12 membered, 2 to 8 membered, 2 to 6 membered, 4 to 6 membered, 2 to 3 membered, or 4 to 5 membered), R24-substituted or unsubstituted cycloalkyl (e.g., C3-C10, C3-C8, C3-C6, C4-C6, or C5-C6), R24-substituted or unsubstituted heterocycloalkyl (e.g., 3 to 10 membered, 3 to 8 membered, 3 to 6 membered, 4 to 6 membered, 4 to 5 membered, or 5 to 6 membered), R24-substituted or unsubstituted aryl (e.g., C6-C12, C6-C10, or phenyl), or R24-substituted or unsubstituted heteroaryl (e.g., 5 to 12 membered, 5 to 10 membered, 5 to 9 membered, or 5 to 6 membered). In embodiments, each are independently hydrogen, -CF3, -CHF2, -CH2F, -CCI3, -CHC12, -
Figure imgf000122_0001
CH2C1, -CBr3, -CHBr2, -CH2Br, -CI3, -CHI2, -CH2I, -CN, -OH, -COOH, -CONH2, R24- substituted alkyl (e.g., Ci-C2o, Ci-Ci2, Ci-Cs, C1-C6, C1-C4, or Ci-C2), R24-substituted heteroalkyl (e.g., 2 to 20 membered, 2 to 12 membered, 2 to 8 membered, 2 to 6 membered, 4 to 6 membered, 2 to 3 membered, or 4 to 5 membered), R24-substituted cycloalkyl (e.g., C3- C10, C3-C8, C3-C6, C4-C6, or C5-C6), R^-substituted heterocycloalkyl (e.g., 3 to 10 membered, 3 to 8 membered, 3 to 6 membered, 4 to 6 membered, 4 to 5 membered, or 5 to 6 membered), R24-substituted aryl (e.g., C6-Ci2, C6-C10, or phenyl), or R24-substituted heteroaryl (e.g., 5 to 12 membered, 5 to 10 membered, 5 to 9 membered, or 5 to 6 membered). In embodiments, each R1A R1B R1C R1D R16A R16B R16C R16D R17A R17B R17C R17D R18A R18B R18C R18D R19A, R19B, R19C, and R19D are independently hydrogen, -CF3, -CHF2, -CH2F, -CCI3, - CHC12, -CH2C1, -CBr3, -CHBr2, -CH2Br, -CI3, -CHI2, -CH2I, -CN, - OH, -COOH, -CONH2, unsubstituted alkyl (e.g., Ci-C20, Ci-Ci¾ Ci-C8, Ci-C6, C1-C4, or Ci- C2), unsubstituted heteroalkyl (e.g., 2 to 20 membered, 2 to 12 membered, 2 to 8 membered,
2 to 6 membered, 4 to 6 membered, 2 to 3 membered, or 4 to 5 membered), unsubstituted cycloalkyl (e.g., C3-C10, C3-C8, C3-C6, C4-C6, or C5-C6), unsubstituted heterocycloalkyl (e.g.,
3 to 10 membered, 3 to 8 membered, 3 to 6 membered, 4 to 6 membered, 4 to 5 membered, or 5 to 6 membered), unsubstituted aryl (e.g., C6-Ci2, C6-C10, or phenyl), or unsubstituted heteroaryl (e.g., 5 to 12 membered, 5 to 10 membered, 5 to 9 membered, or 5 to 6 membered). In embodiments, each R1A, R1B, R1C, R1D, R16A, R16B, R16C, R16D, R17A, R17B,
R17C, R17D, R18A, R18B, R18C, R18D, R19A, R19B, R19C, and R19D are independently hydrogen.
[0349] Each R1A and R1B, R16A and R16B, R17A and R17B, R18A and R18B, and R19A and R19B together with nitrogen attached thereto may be joined to form R24-substituted or unsubstituted heterocycloalkyl (e.g., 3 to 10 membered, 3 to 8 membered, 3 to 6 membered, 4 to 6 membered, 4 to 5 membered, or 5 to 6 membered), or R24-substituted or unsubstituted heteroaryl (e.g., 5 to 12 membered, 5 to 10 membered, 5 to 9 membered, or 5 to 6 membered). Each R1A and R1B, R16A and R16B, R17A and R17B, R18A and R18B, and R19A and R19B together with nitrogen attached thereto may be joined to form R24-substituted heterocycloalkyl (e.g., 3 to 10 membered, 3 to 8 membered, 3 to 6 membered, 4 to 6 membered, 4 to 5 membered, or 5 to 6 membered), or R24-substituted heteroaryl (e.g., 5 to 12 membered, 5 to 10 membered, 5 to 9 membered, or 5 to 6 membered). Each R1A and R1B, R16A and R16B, R17A and R17B, R18A and R18B, and R19A and R19B together with nitrogen attached thereto may be joined to form unsubstituted heterocycloalkyl (e.g., 3 to 10 membered, 3 to 8 membered, 3 to 6 membered, 4 to 6 membered, 4 to 5 membered, or 5 to 6 membered), or unsubstituted heteroaryl (e.g., 5 to 12 membered, 5 to 10 membered, 5 to 9 membered, or 5 to 6 membered). In embodiments, each R1A and R1B, R16Aand R16B, R17A and R17B, R18A and R18B, and R19A and R19B together with nitrogen attached thereto may be joined to form R24-substituted or unsubstituted pyridyl. In embodiments, each R1A and R1B, R16A and R16B, R17A and R17B, R18A and R18B, and R19A and R19B together with nitrogen attached thereto may be joined to form R24-substituted or unsubstituted piperidinyl. In embodiments, each R1A and R1B, R16A and R16B, R17A and R17B, R18A and R18B, and R19A and R19B together with nitrogen attached thereto may be joined to form R24-substituted or unsubstituted morpholinyl. In embodiments, each R1A and R1B, R16A and R16B, R17A and R17B, R18A and R18B, and R19A and R19B joined to form R24-substituted or unsubstituted pyrrolyl. In embodiments, each R1A and R1B, R16Aand R16B, R17A and R17B, R18A and R18B, and R19A and R19B together with nitrogen attached thereto may be joined to form R24-substituted or unsubstituted pyrimidinyl.
[0350] In embodiments, a substituted R1A (e.g., substituted alkyl, substituted heteroalkyl, substituted cycloalkyl, substituted heterocycloalkyl, substituted aryl, and/or substituted heteroaryl) is substituted with at least one substituent group, size-limited substituent group, or lower substituent group; wherein if the substituted R1A is substituted with a plurality of groups selected from substituent groups, size-limited substituent groups, and lower substituent groups; each substituent group, size-limited substituent group, and/or lower substituent group may optionally be different. In embodiments, when R1A is substituted, it is substituted with at least one substituent group. In embodiments, when R1A is substituted, it is substituted with at least one size-limited substituent group. In embodiments, when R1A is substituted, it is substituted with at least one lower substituent group.
[0351] In embodiments, a substituted R1B (e.g., substituted alkyl, substituted heteroalkyl, substituted cycloalkyl, substituted heterocycloalkyl, substituted aryl, and/or substituted heteroaryl) is substituted with at least one substituent group, size-limited substituent group, or lower substituent group; wherein if the substituted R1B is substituted with a plurality of groups selected from substituent groups, size-limited substituent groups, and lower substituent groups; each substituent group, size-limited substituent group, and/or lower substituent group may optionally be different. In embodiments, when R1B is substituted, it is substituted with at least one substituent group. In embodiments, when R1B is substituted, it is substituted with at least one size-limited substituent group. In embodiments, when R1B is substituted, it is substituted with at least one lower substituent group.
[0352] In embodiments, a substituted ring formed when R1A and R1B substituents bonded to the same nitrogen atom are joined (e.g., substituted heterocycloalkyl and/or substituted heteroaryl) is substituted with at least one substituent group, size-limited substituent group, or lower substituent group; wherein if the substituted ring formed when R1A and R1B substituents bonded to the same nitrogen atom are joined is substituted with a plurality of groups selected from substituent groups, size-limited substituent groups, and lower substituent groups; each substituent group, size-limited substituent group, and/or lower substituent group may optionally be different. In embodiments, when the ring formed when R1A and R1B substituents bonded to the same nitrogen atom are joined is substituted, it is substituted with at least one substituent group. In embodiments, when the ring formed when R1A and R1B substituents bonded to the same nitrogen atom are joined is substituted, it is substituted with at least one size-limited substituent group. In embodiments, when the ring formed when R1A and R1B substituents bonded to the same nitrogen atom are joined is substituted, it is substituted with at least one lower substituent group.
[0353] In embodiments, a substituted R1C (e.g., substituted alkyl, substituted heteroalkyl, substituted cycloalkyl, substituted heterocycloalkyl, substituted aryl, and/or substituted heteroaryl) is substituted with at least one substituent group, size-limited substituent group, or lower substituent group; wherein if the substituted R1C is substituted with a plurality of groups selected from substituent groups, size-limited substituent groups, and lower substituent groups; each substituent group, size-limited substituent group, and/or lower substituent group may optionally be different. In embodiments, when R1C is substituted, it is substituted with at least one substituent group. In embodiments, when R1C is substituted, it is substituted with at least one size-limited substituent group. In embodiments, when R1C is substituted, it is substituted with at least one lower substituent group.
[0354] In embodiments, a substituted R1D (e.g., substituted alkyl, substituted heteroalkyl, substituted cycloalkyl, substituted heterocycloalkyl, substituted aryl, and/or substituted heteroaryl) is substituted with at least one substituent group, size-limited substituent group, or lower substituent group; wherein if the substituted R1D is substituted with a plurality of groups selected from substituent groups, size-limited substituent groups, and lower substituent groups; each substituent group, size-limited substituent group, and/or lower substituent group may optionally be different. In embodiments, when R1D is substituted, it is substituted with at least one substituent group. In embodiments, when R1D is substituted, it is substituted with at least one size-limited substituent group. In embodiments, when R1D is substituted, it is substituted with at least one lower substituent group.
[0355] In embodiments, a substituted R16A (e.g., substituted alkyl, substituted heteroalkyl, substituted cycloalkyl, substituted heterocycloalkyl, substituted aryl, and/or substituted heteroaryl) is substituted with at least one substituent group, size-limited substituent group, or lower substituent group; wherein if the substituted R16A is substituted with a plurality of groups selected from substituent groups, size-limited substituent groups, and lower substituent groups; each substituent group, size-limited substituent group, and/or lower substituent group may optionally be different. In embodiments, when R16A is substituted, it is substituted with at least one substituent group. In embodiments, when R16A is substituted, it is substituted with at least one size-limited substituent group. In embodiments, when R16A is substituted, it is substituted with at least one lower substituent group.
[0356] In embodiments, a substituted R16B (e.g., substituted alkyl, substituted heteroalkyl, substituted cycloalkyl, substituted heterocycloalkyl, substituted aryl, and/or substituted heteroaryl) is substituted with at least one substituent group, size-limited substituent group, or lower substituent group; wherein if the substituted R16B is substituted with a plurality of groups selected from substituent groups, size-limited substituent groups, and lower substituent groups; each substituent group, size-limited substituent group, and/or lower substituent group may optionally be different. In embodiments, when R16B is substituted, it is substituted with at least one substituent group. In embodiments, when R16B is substituted, it is substituted with at least one size-limited substituent group. In embodiments, when R16B is substituted, it is substituted with at least one lower substituent group.
[0357] In embodiments, a substituted ring formed when R16A and R16B substituents bonded to the same nitrogen atom are joined (e.g., substituted heterocycloalkyl and/or substituted heteroaryl) is substituted with at least one substituent group, size-limited substituent group, or lower substituent group; wherein if the substituted ring formed when R16A and R16B substituents bonded to the same nitrogen atom are joined is substituted with a plurality of groups selected from substituent groups, size-limited substituent groups, and lower substituent groups; each substituent group, size-limited substituent group, and/or lower substituent group may optionally be different. In embodiments, when the ring formed when R16A and R16B substituents bonded to the same nitrogen atom are joined is substituted, it is substituted with at least one substituent group. In embodiments, when the ring formed when R16A and R16B substituents bonded to the same nitrogen atom are joined is substituted, it is substituted with at least one size-limited substituent group. In embodiments, when the ring formed when R16A and R16B substituents bonded to the same nitrogen atom are joined is substituted, it is substituted with at least one lower substituent group.
[0358] In embodiments, a substituted R16C (e.g., substituted alkyl, substituted heteroalkyl, substituted cycloalkyl, substituted heterocycloalkyl, substituted aryl, and/or substituted heteroaryl) is substituted with at least one substituent group, size-limited substituent group, or lower substituent group; wherein if the substituted R16C is substituted with a plurality of groups selected from substituent groups, size-limited substituent groups, and lower substituent groups; each substituent group, size-limited substituent group, and/or lower substituent group may optionally be different. In embodiments, when R16C is substituted, it is substituted with at least one substituent group. In embodiments, when R16C is substituted, it is substituted with at least one size-limited substituent group. In embodiments, when R16C is substituted, it is substituted with at least one lower substituent group.
[0359] In embodiments, a substituted R16D (e.g., substituted alkyl, substituted heteroalkyl, substituted cycloalkyl, substituted heterocycloalkyl, substituted aryl, and/or substituted heteroaryl) is substituted with at least one substituent group, size-limited substituent group, or lower substituent group; wherein if the substituted R16D is substituted with a plurality of groups selected from substituent groups, size-limited substituent groups, and lower substituent groups; each substituent group, size-limited substituent group, and/or lower substituent group may optionally be different. In embodiments, when R16D is substituted, it is substituted with at least one substituent group. In embodiments, when R16D is substituted, it is substituted with at least one size-limited substituent group. In embodiments, when R16D is substituted, it is substituted with at least one lower substituent group.
[0360] In embodiments, a substituted R17A (e.g., substituted alkyl, substituted heteroalkyl, substituted cycloalkyl, substituted heterocycloalkyl, substituted aryl, and/or substituted heteroaryl) is substituted with at least one substituent group, size-limited substituent group, or lower substituent group; wherein if the substituted R17A is substituted with a plurality of groups selected from substituent groups, size-limited substituent groups, and lower substituent groups; each substituent group, size-limited substituent group, and/or lower substituent group may optionally be different. In embodiments, when R17A is substituted, it is substituted with at least one substituent group. In embodiments, when R17A is substituted, it is substituted with at least one size-limited substituent group. In embodiments, when R17A is substituted, it is substituted with at least one lower substituent group.
[0361] In embodiments, a substituted R17B (e.g., substituted alkyl, substituted heteroalkyl, substituted cycloalkyl, substituted heterocycloalkyl, substituted aryl, and/or substituted heteroaryl) is substituted with at least one substituent group, size-limited substituent group, or lower substituent group; wherein if the substituted R17B is substituted with a plurality of groups selected from substituent groups, size-limited substituent groups, and lower substituent groups; each substituent group, size-limited substituent group, and/or lower substituent group may optionally be different. In embodiments, when R17B is substituted, it is substituted with at least one substituent group. In embodiments, when R17B is substituted, it is substituted with at least one size-limited substituent group. In embodiments, when R17B is substituted, it is substituted with at least one lower substituent group.
[0362] In embodiments, a substituted ring formed when R17A and R17B substituents bonded to the same nitrogen atom are joined (e.g., substituted heterocycloalkyl and/or substituted heteroaryl) is substituted with at least one substituent group, size-limited substituent group, or lower substituent group; wherein if the substituted ring formed when R17A and R17B substituents bonded to the same nitrogen atom are joined is substituted with a plurality of groups selected from substituent groups, size-limited substituent groups, and lower substituent groups; each substituent group, size-limited substituent group, and/or lower substituent group may optionally be different. In embodiments, when the ring formed when R17A and R17B substituents bonded to the same nitrogen atom are joined is substituted, it is substituted with at least one substituent group. In embodiments, when the ring formed when R17A and R17B substituents bonded to the same nitrogen atom are joined is substituted, it is substituted with at least one size-limited substituent group. In embodiments, when the ring formed when R17A and R17B substituents bonded to the same nitrogen atom are joined is substituted, it is substituted with at least one lower substituent group.
[0363] In embodiments, a substituted R17C (e.g., substituted alkyl, substituted heteroalkyl, substituted cycloalkyl, substituted heterocycloalkyl, substituted aryl, and/or substituted heteroaryl) is substituted with at least one substituent group, size-limited substituent group, or lower substituent group; wherein if the substituted R17C is substituted with a plurality of groups selected from substituent groups, size-limited substituent groups, and lower substituent groups; each substituent group, size-limited substituent group, and/or lower substituent group may optionally be different. In embodiments, when R17C is substituted, it is substituted with at least one substituent group. In embodiments, when R17C is substituted, it is substituted with at least one size-limited substituent group. In embodiments, when R17C is substituted, it is substituted with at least one lower substituent group.
[0364] In embodiments, a substituted R17D (e.g., substituted alkyl, substituted heteroalkyl, substituted cycloalkyl, substituted heterocycloalkyl, substituted aryl, and/or substituted heteroaryl) is substituted with at least one substituent group, size-limited substituent group, or lower substituent group; wherein if the substituted R17D is substituted with a plurality of groups selected from substituent groups, size-limited substituent groups, and lower substituent groups; each substituent group, size-limited substituent group, and/or lower substituent group may optionally be different. In embodiments, when R17D is substituted, it is substituted with at least one substituent group. In embodiments, when R17D is substituted, it is substituted with at least one size-limited substituent group. In embodiments, when R17D is substituted, it is substituted with at least one lower substituent group.
[0365] In embodiments, a substituted R18A (e.g., substituted alkyl, substituted heteroalkyl, substituted cycloalkyl, substituted heterocycloalkyl, substituted aryl, and/or substituted heteroaryl) is substituted with at least one substituent group, size-limited substituent group, or lower substituent group; wherein if the substituted R18A is substituted with a plurality of groups selected from substituent groups, size-limited substituent groups, and lower substituent groups; each substituent group, size-limited substituent group, and/or lower substituent group may optionally be different. In embodiments, when R18A is substituted, it is substituted with at least one substituent group. In embodiments, when R18A is substituted, it is substituted with at least one size-limited substituent group. In embodiments, when R18A is substituted, it is substituted with at least one lower substituent group.
[0366] In embodiments, a substituted R18B (e.g., substituted alkyl, substituted heteroalkyl, substituted cycloalkyl, substituted heterocycloalkyl, substituted aryl, and/or substituted heteroaryl) is substituted with at least one substituent group, size-limited substituent group, or lower substituent group; wherein if the substituted R18B is substituted with a plurality of groups selected from substituent groups, size-limited substituent groups, and lower substituent groups; each substituent group, size-limited substituent group, and/or lower substituent group may optionally be different. In embodiments, when R18B is substituted, it is substituted with at least one substituent group. In embodiments, when R18B is substituted, it is substituted with at least one size-limited substituent group. In embodiments, when R18B is substituted, it is substituted with at least one lower substituent group.
[0367] In embodiments, a substituted ring formed when R18A and R18B substituents bonded to the same nitrogen atom are joined (e.g., substituted heterocycloalkyl and/or substituted heteroaryl) is substituted with at least one substituent group, size-limited substituent group, or lower substituent group; wherein if the substituted ring formed when R18A and R18B substituents bonded to the same nitrogen atom are joined is substituted with a plurality of groups selected from substituent groups, size-limited substituent groups, and lower substituent groups; each substituent group, size-limited substituent group, and/or lower substituent group may optionally be different. In embodiments, when the ring formed when R18A and R18B substituents bonded to the same nitrogen atom are joined is substituted, it is substituted with at least one substituent group. In embodiments, when the ring formed when R18A and R18B substituents bonded to the same nitrogen atom are joined is substituted, it is substituted with at least one size-limited substituent group. In embodiments, when the ring formed when R18A and R18B substituents bonded to the same nitrogen atom are joined is substituted, it is substituted with at least one lower substituent group.
[0368] In embodiments, a substituted R18C (e.g., substituted alkyl, substituted heteroalkyl, substituted cycloalkyl, substituted heterocycloalkyl, substituted aryl, and/or substituted heteroaryl) is substituted with at least one substituent group, size-limited substituent group, or lower substituent group; wherein if the substituted R18C is substituted with a plurality of groups selected from substituent groups, size-limited substituent groups, and lower substituent groups; each substituent group, size-limited substituent group, and/or lower substituent group may optionally be different. In embodiments, when R18C is substituted, it is substituted with at least one substituent group. In embodiments, when R18C is substituted, it is substituted with at least one size-limited substituent group. In embodiments, when R18C is substituted, it is substituted with at least one lower substituent group.
[0369] In embodiments, a substituted R18D (e.g., substituted alkyl, substituted heteroalkyl, substituted cycloalkyl, substituted heterocycloalkyl, substituted aryl, and/or substituted heteroaryl) is substituted with at least one substituent group, size-limited substituent group, or lower substituent group; wherein if the substituted R18D is substituted with a plurality of groups selected from substituent groups, size-limited substituent groups, and lower substituent groups; each substituent group, size-limited substituent group, and/or lower substituent group may optionally be different. In embodiments, when R18D is substituted, it is substituted with at least one substituent group. In embodiments, when R18D is substituted, it is substituted with at least one size-limited substituent group. In embodiments, when R18D is substituted, it is substituted with at least one lower substituent group.
[0370] In embodiments, a substituted R19A (e.g., substituted alkyl, substituted heteroalkyl, substituted cycloalkyl, substituted heterocycloalkyl, substituted aryl, and/or substituted heteroaryl) is substituted with at least one substituent group, size-limited substituent group, or lower substituent group; wherein if the substituted R19A is substituted with a plurality of groups selected from substituent groups, size-limited substituent groups, and lower substituent groups; each substituent group, size-limited substituent group, and/or lower substituent group may optionally be different. In embodiments, when R19A is substituted, it is substituted with at least one substituent group. In embodiments, when R19A is substituted, it is substituted with at least one size-limited substituent group. In embodiments, when R19A is substituted, it is substituted with at least one lower substituent group.
[0371] In embodiments, a substituted R19B (e.g., substituted alkyl, substituted heteroalkyl, substituted cycloalkyl, substituted heterocycloalkyl, substituted aryl, and/or substituted heteroaryl) is substituted with at least one substituent group, size-limited substituent group, or lower substituent group; wherein if the substituted R19B is substituted with a plurality of groups selected from substituent groups, size-limited substituent groups, and lower substituent groups; each substituent group, size-limited substituent group, and/or lower substituent group may optionally be different. In embodiments, when R19B is substituted, it is substituted with at least one substituent group. In embodiments, when R19B is substituted, it is substituted with at least one size-limited substituent group. In embodiments, when R19B is substituted, it is substituted with at least one lower substituent group.
[0372] In embodiments, a substituted ring formed when R19A and R19B substituents bonded to the same nitrogen atom are joined (e.g., substituted heterocycloalkyl and/or substituted heteroaryl) is substituted with at least one substituent group, size-limited substituent group, or lower substituent group; wherein if the substituted ring formed when R19A and R19B substituents bonded to the same nitrogen atom are joined is substituted with a plurality of groups selected from substituent groups, size-limited substituent groups, and lower substituent groups; each substituent group, size-limited substituent group, and/or lower substituent group may optionally be different. In embodiments, when the ring formed when R19A and R19B substituents bonded to the same nitrogen atom are joined is substituted, it is substituted with at least one substituent group. In embodiments, when the ring formed when R19A and R19B substituents bonded to the same nitrogen atom are joined is substituted, it is substituted with at least one size-limited substituent group. In embodiments, when the ring formed when R19A and R19B substituents bonded to the same nitrogen atom are joined is substituted, it is substituted with at least one lower substituent group.
[0373] In embodiments, a substituted R19C (e.g., substituted alkyl, substituted heteroalkyl, substituted cycloalkyl, substituted heterocycloalkyl, substituted aryl, and/or substituted heteroaryl) is substituted with at least one substituent group, size-limited substituent group, or lower substituent group; wherein if the substituted R19C is substituted with a plurality of groups selected from substituent groups, size-limited substituent groups, and lower substituent groups; each substituent group, size-limited substituent group, and/or lower substituent group may optionally be different. In embodiments, when R19C is substituted, it is substituted with at least one substituent group. In embodiments, when R19C is substituted, it is substituted with at least one size-limited substituent group. In embodiments, when R19C is substituted, it is substituted with at least one lower substituent group.
[0374] In embodiments, a substituted R19D (e.g., substituted alkyl, substituted heteroalkyl, substituted cycloalkyl, substituted heterocycloalkyl, substituted aryl, and/or substituted heteroaryl) is substituted with at least one substituent group, size-limited substituent group, or lower substituent group; wherein if the substituted R19D is substituted with a plurality of groups selected from substituent groups, size-limited substituent groups, and lower substituent groups; each substituent group, size-limited substituent group, and/or lower substituent group may optionally be different. In embodiments, when R19D is substituted, it is substituted with at least one substituent group. In embodiments, when R19D is substituted, it is substituted with at least one size-limited substituent group. In embodiments, when R19D is substituted, it is substituted with at least one lower substituent group.
[0375] R1F, R16F, R17F, R18F, R19F, R21, R23, and R24 are independently oxo, halogen, -CF3, - CCl3,-CBr3, -CI3, -CHF2, -CHCl2,-CHBr2 -CHI2, -CH2F,-CH2C1, -CH2Br, - CH2I, -CN, -OH, -NH2, -COOH, -CONH2, -N02, -SH, -SCH3, -S03H, -SO4H, -SO2NH2, -NHNH2, -ONH2, -NHC(0)NHNH2, -NHC(0)NH2, -NHS02H, -NHC(0)H, - NHC(0)0H, -NHOH, -OCF3, -OCCl3, -OCBr3, -OCI3, OCHF2, OCHCb, OCHBr2, - 0CHI2 -0CH2F, -OCH2Cl, -OCH2Br, -OCH2I, unsubstituted alkyl (e.g., Ci-C8, Ci-C6, or C1-C4 alkyl), unsubstituted heteroalkyl (e.g., 2 to 8 membered, 2 to 6 membered, or 2 to 4 membered heteroalkyl), unsubstituted cycloalkyl (e.g., C3-Cs, C3-C6, or C5-C6 cycloalkyl), unsubstituted heterocycloalkyl (e.g., 3 to 8 membered, 3 to 6 membered, or 5 to 6 membered heterocycloalkyl), unsubstituted aryl (e.g., C6-C10 aryl, C10 aryl or phenyl), or unsubstituted heteroaryl (e.g., 5 to 10 membered, 5 to 9 membered, or 5 to 6 membered heteroaryl).
[0376] X, X1, X16, X17, X18, are X19 are independently -F, -Cl, -Br, or -I. In embodiments,
X is -F. In embodiments, X is -Cl. In embodiments, X is -Br. In embodiments, X is -I. In embodiments, X1 is -F. In embodiments, X1 is -Cl. In embodiments, X1 is -Br. In embodiments, X1 is -I. In embodiments, X16 is -F. In embodiments, X16 is -Cl. In embodiments, X16 is -Br. In embodiments, X16 is -I. In embodiments, X17 is -F. In embodiments, X17 is -Cl. In embodiments, X17 is -Br. In embodiments, X17 is -I. In embodiments, X18 is -F. In embodiments, X18 is -Cl. In embodiments, X18 is -Br. In embodiments, X18 is -I. In embodiments, X19 is -F. In embodiments, X19 is -Cl. In embodiments, X19 is -Br. In embodiments, X19 is -I.
[0377] nl, nl6, nl7, nl8, and nl9 are independently an integer from 0 to 4 (e.g. 0). In embodiments, nl is 0. In embodiments, nl is 1. In embodiments, nl is 2. In embodiments, nl is 3. In embodiments, nl is 4. In embodiments, nl6 is 0. In embodiments, nl 6 is 1. In embodiments, nl6 is 2. In embodiments, nl 6 is 3. In embodiments, nl6 is 4. In embodiments, nl7 is 0. In embodiments, nl 7 is 1. In embodiments, nl7 is 2. In embodiments, nl 7 is 3. In embodiments, nl7 is 4. In embodiments, nl8 is 0. In embodiments, nl 8 is 1. In embodiments, nl8 is 2. In embodiments, nl 8 is 3. In embodiments, nl8 is 4. In embodiments, nl9 is 0. In embodiments, nl 9 is 1. In embodiments, nl9 is 2. In embodiments, nl 9 is 3. In embodiments, nl9 is 4.
[0378] ml, ml 6, ml 7, ml 8, and ml 9 are independently an integer from 1 to 2. In embodiments, ml is 1. In embodiments, ml is 2. In embodiments, m2 is 1. In embodiments, ml 6 is 1. In embodiments, ml 6 is 2. In embodiments, ml 7 is 1. In embodiments, ml 7 is 2.
In embodiments, ml 8 is 1. In embodiments, ml 8 is 2. In embodiments, ml 9 is 1. In embodiments, ml 9 is 2.
[0379] vl, vl6, vl7, vl8, and vl9 are independently an integer from 1 to 2. In embodiments, vl is 1. In embodiments, vl is 2. In embodiments, vl 6 is 1. In embodiments, vl 6 is 2. In embodiments, vl 7 is 1. In embodiments, vl7 is 2. In embodiments, vl 8 is 1. In embodiments, vl8 is 2. In embodiments, vl 9 is 1. In embodiments, vl9 is 2.
[0380] In embodiments, the compound is useful as a comparator compound. In embodiments, the comparator compound can be used to assess the activity of a test compound as set forth in an assay described herein (e.g., in the examples section, figures, or tables).
[0381] In embodiments, the compound is a compound as described herein, including in embodiments. In embodiments the compound is a compound described herein (e.g., in the examples section, figures, tables, or claims).
III. Proteins
[0382] A compound as described herein may form a covalent bond with an amino acid moiety of a Gas protein (e.g., human Gas). Thus, in an aspect is provided a Gas protein covalently bonded to a compound as described herein. In embodiments, the Gas is in the GTP state. In embodiments, the Gas is in the GDP state.
[0383] In embodiments, the compound is bonded to a cysteine residue of the protein. In embodiments, the Gas protein as being covalently bonded to the compound has the structure:
Figure imgf000134_0001
[0384] W together with the -CH2S- to which it is attached form said Gas protein covalently bonded to a compound; and L3 is substituted or unsubstituted alkylene or substituted or unsubstituted heteroalkylene. L1, L2, R1, and zl are as described above.
Figure imgf000134_0002
R19 are as described above.
[0386] In embodiments, L3 is
Figure imgf000134_0004
In embodiments, L3 is
Figure imgf000134_0003
. In embodiments, L3 is
Figure imgf000134_0008
In embodiments, L3 is
Figure imgf000134_0005
embo
Figure imgf000134_0007
embodiments
Figure imgf000134_0006
embodiments, embodiments, L3 is
Figure imgf000135_0001
. In embodiments, L3 is
Figure imgf000135_0003
, , embodiments, L3 is
Figure imgf000135_0004
, embodiments,
Figure imgf000135_0002
[0387] In embodiments, L3 is a substituted (e.g., substituted with a substituent group, a size-limited substituent group, or lower substituent group) or unsubstituted alkylene (e.g., Ci- C8, Ci-C6, or C1-C4 alkylene), substituted (e.g., substituted with a substituent group, a size- limited substituent group, or lower substituent group) or unsubstituted heteroalkylene (e.g., 2 to 8 membered, 2 to 6 membered, or 2 to 4 membered heteroalkylene). In embodiments, L3 is a substituted (e.g., substituted with a substituent group, a size-limited substituent group, or lower substituent group) or unsubstituted alkylene (e.g., Ci-Cs, C1-C6, or C1-C4 alkylene). In embodiments, L3 is a substituted (e.g., substituted with a substituent group, a size-limited substituent group, or lower substituent group) or unsubstituted heteroalkylene (e.g., 2 to 8 membered, 2 to 6 membered, or 2 to 4 membered heteroalkylene). [0388] In embodiments, a substituted L3 is substituted with at least one substituent group, size-limited substituent group, or lower substituent group; wherein if the substituted L3 is substituted with a plurality of groups selected from substituent groups, size-limited substituent groups, and lower substituent groups; each substituent group, size-limited substituent group, and/or lower substituent group may optionally be different. In embodiments, when L3 is substituted, it is substituted with at least one substituent group. In embodiments, when L3 is substituted, it is substituted with at least one size-limited substituent group. In embodiments, when L3 is substituted, it is substituted with at least one lower substituent group.
[0389] In embodiments, L3 is a substituted (e.g., substituted with a substituent group, a size-limited substituent group, or lower substituent group) or unsubstituted Ci-Cs alkylene.
In embodiments, L3 is a substituted (e.g., substituted with a substituent group, a size-limited substituent group, or lower substituent group) Ci-Cs alkylene. In embodiments, L3 is an unsubstituted Ci-Cs alkylene. In embodiments, L3 is a substituted (e.g., substituted with a substituent group, a size-limited substituent group, or lower substituent group) or unsubstituted C1-C6 alkylene. In embodiments, L3 is a substituted (e.g., substituted with a substituent group, a size-limited substituent group, or lower substituent group) C1-C6 alkylene. In embodiments, L3 is an unsubstituted C1-C6 alkylene. In embodiments, L3 is a substituted (e.g., substituted with a substituent group, a size-limited substituent group, or lower substituent group) or unsubstituted C1-C4 alkylene. In embodiments, L3 is a substituted (e.g., substituted with a substituent group, a size-limited substituent group, or lower substituent group) C1-C4 alkylene. In embodiments, L3 is an unsubstituted C1-C4 alkylene.
[0390] In embodiments, L3 is a substituted (e.g., substituted with a substituent group, a size-limited substituent group, or lower substituent group) or unsubstituted 2 to 8 membered heteroalkylene. In embodiments, L3 is a substituted (e.g., substituted with a substituent group, a size-limited substituent group, or lower substituent group) 2 to 8 membered heteroalkylene. In embodiments, L3 is an unsubstituted 2 to 8 membered heteroalkylene. In embodiments, L3 is a substituted (e.g., substituted with a substituent group, a size-limited substituent group, or lower substituent group) or unsubstituted 2 to 6 membered heteroalkylene. In embodiments, L3 is a substituted (e.g., substituted with a substituent group, a size-limited substituent group, or lower substituent group) 2 to 6 membered heteroalkylene. In embodiments, L3 is an unsubstituted 2 to 6 membered heteroalkylene. In embodiments, L3 is a substituted (e.g., substituted with a substituent group, a size-limited substituent group, or lower substituent group) or unsubstituted 2 to 4 membered heteroalkylene. In embodiments, L3 is a substituted (e.g., substituted with a substituent group, a size-limited substituent group, or lower substituent group) 2 to 4 membered heteroalkylene. In embodiments, L3 is an unsubstituted 2 to 4 membered heteroalkylene.
[0391] In embodiments, L3 is a R25-substituted or unsubstituted Ci-Cs alkylene. In embodiments, L3 is a R25-substituted Ci-Cs alkylene. In embodiments, L3 is an unsubstituted Ci-Cs alkylene. In embodiments, L3 is a R25-substituted or unsubstituted C1-C6 alkylene. In embodiments, L3 is a R25-substituted C1-C6 alkylene. In embodiments, L3 is an unsubstituted Ci-Ce alkylene. In embodiments, L3 is a R25-substituted or unsubstituted C1-C4 alkylene. In embodiments, L3 is a R25-substituted C1-C4 alkylene. In embodiments, L3 is an unsubstituted C1-C4 alkylene.
[0392] In embodiments, L3 is a R25-substituted or unsubstituted 2 to 8 membered heteroalkylene. In embodiments, L3 is a R25-substituted 2 to 8 membered heteroalkylene. In embodiments, L3 is an unsubstituted 2 to 8 membered heteroalkylene. In embodiments, L3 is a R25-substituted or unsubstituted 2 to 6 membered heteroalkylene. In embodiments, L3 is a R25-substituted 2 to 6 membered heteroalkylene. In embodiments, L3 is an unsubstituted 2 to 6 membered heteroalkylene. In embodiments, L3 is a R25-substituted or unsubstituted 2 to 4 membered heteroalkylene. In embodiments, L3 is a R25-substituted 2 to 4 membered heteroalkylene. In embodiments, L3 is an unsubstituted 2 to 4 membered heteroalkylene.
[0393] R25 is independently oxo, halogen, -CF3, -CCl3,-CBr3, -CI3, -CHF2, -CHCI2,- CHBr2, -CHI2, -CH2F,-CH2C1, -CH2Br, -
CH2I, -CN, -OH, -NH2, -COOH, -CONH2, -N02, -SH, -SCH3, -S03H, -SO4H, -SO2NH2, -NHNH2, -ONH2, -NHC(0)NHNH2, -NHC(0)NH2, -NHS02H, -NHC(0)H, - NHC(0)0H, -NHOH, -OCF3, -OCCl3, -OCBr3, -OCI3, OCHF2, OCHCb, OCHBr2, - 0CHI2 -0CH2F, -OCH2Cl, -OCH2Br, -OCH2I, R26-substituted or unsubstituted alkyl (e.g., Ci-Cs, C1-C6, or C1-C4 alkyl), R26-substituted or unsubstituted heteroalkyl (e.g., 2 to 8 membered, 2 to 6 membered, or 2 to 4 membered heteroalkyl), R26-substituted or unsubstituted cycloalkyl (e.g., C3-Cs, C3-C6, or C5-C6 cycloalkyl), R26-substituted or unsubstituted heterocycloalkyl (e.g., 3 to 8 membered, 3 to 6 membered, or 5 to 6 membered heterocycloalkyl), R26-substituted or unsubstituted aryl (e.g., C6-C10, C10 aryl, or phenyl), or R26-substituted or unsubstituted heteroaryl (e.g., 5 to 10 membered, 5 to 9 membered, or 5 to 6 membered heteroaryl). In embodiments, R25 is independently oxo, halogen, -CF3, -CCI3, - CBr3, -CI3, -CHF2, -CHCl2,-CHBr2, -CHI2, -CH2F, CH2C1, -CH2Br, - CH2I, -CN, -OH, -NH2, -COOH, -CONH2, -N02, -SH, -SCH3, -SO3H, -SO4H, -SO2NH2, -NHNH2, -ONH2, -NHC(0)NHNH2, -NHC(0)NH2, -NHS02H, -NHC(0)H, - NHC(0)0H, -NHOH, -OCF3, -OCCI3, -OCBr3, -OCI3, OCHF2, OCHCb, OCHBr2, - 0CHI2 -0CH2F, -OCH2Cl, -OCH2Br, -OCH2I, R26-substituted alkyl (e.g., Ci-C8, Ci-C6, or C1-C4 alkyl), R26-substituted heteroalkyl (e.g., 2 to 8 membered, 2 to 6 membered, or 2 to 4 membered heteroalkyl), R26-substituted cycloalkyl (e.g., C3-C8, C3-C6, or C5-C6 cycloalkyl), R26-substituted heterocycloalkyl (e.g., 3 to 8 membered, 3 to 6 membered, or 5 to 6 membered heterocycloalkyl), R26-substituted aryl (e.g., C6-C10, C10 aryl, or phenyl), or R26- substituted heteroaryl (e.g., 5 to 10 membered, 5 to 9 membered, or 5 to 6 membered heteroaryl). In embodiments, R25 is independently oxo, halogen, -CF3, -CCl3,-CBr3, -CI3, - CHF2, -CHCb,-CHBr2 -CHI2, -CH2F,-CH2C1, -CH2Br, -
CH2I, -CN, -OH, -NH2, -COOH, -CONH2, -N02, -SH, -SCH3, -SO3H, -S04H, -S02NH2, -NHNH2, -ONH2, -NHC(0)NHNH2, -NHC(0)NH2, -NHS02H, -NHC(0)H, - NHC(0)0H, -NHOH, -OCF3, -OCCI3, -OCBr3, -OCI3, OCHF2, OCHCb, OCHBr2, - 0CHI2,-0CH2F, -OCH2Cl, -OCH2Br, -OCH2I, unsubstituted alkyl (e.g., Ci-C8, Ci-C6, or C1-C4 alkyl), unsubstituted heteroalkyl (e.g., 2 to 8 membered, 2 to 6 membered, or 2 to 4 membered heteroalkyl), unsubstituted cycloalkyl (e.g., C3-C8, C3-C6, or C5-C6 cycloalkyl), unsubstituted heterocycloalkyl (e.g., 3 to 8 membered, 3 to 6 membered, or 5 to 6 membered heterocycloalkyl), unsubstituted aryl (e.g., C6-C10, C10 aryl, or phenyl), or unsubstituted heteroaryl (e.g., 5 to 10 membered, 5 to 9 membered, or 5 to 6 membered heteroaryl).
[0394] R26 is independently oxo, halogen, -CF3, -CCl3,-CBr3, -CI3, -CHF2, -CHCb,- CHBr2, -CHb, -CH2F,-CH2C1, -CH2Br, -
CH2I, -CN, -OH, -NH2, -COOH, -CONH2, -N02, -SH, -SCH3, -SO3H, -S04H, -S02NH2, -NHNH2, -ONH2, -NHC(0)NHNH2, -NHC(0)NH2, -NHS02H, -NHC(0)H, - NHC(0)0H, -NHOH, -OCF3, -OCCI3, -OCBr3, -OCI3, OCHF2, -OCHCb, OCHBr2, - OCHb, -OCH2F, -OCH2Cl, -OCH2Br, -OCH2I, unsubstituted alkyl (e.g., Ci-C8, Ci-C6, or C1-C4 alkyl), unsubstituted heteroalkyl (e.g., 2 to 8 membered, 2 to 6 membered, or 2 to 4 membered heteroalkyl), unsubstituted cycloalkyl (e.g., C3-C8, C3-C6, or C5-C6 cycloalkyl), unsubstituted heterocycloalkyl (e.g., 3 to 8 membered, 3 to 6 membered, or 5 to 6 membered heterocycloalkyl), unsubstituted aryl (e.g., C6-C10 aryl, C10 aryl or phenyl), or unsubstituted heteroaryl (e.g., 5 to 10 membered, 5 to 9 membered, or 5 to 6 membered heteroaryl).
[0395] In embodiments, the Gas protein has the amino acid sequence of SEQ ID NO: 1 including the sequence below with one or more mutations (e.g., R201C and C237S). The amino acids, R201 and C237, in the SEQ ID NO: 1 may be where the mutations (e.g., R201C and C237S) can occur.
[0396] In embodiments, the Gas protein includes R201C mutation in SEQ ID NO: 1. In embodiments, the Gas protein includes Cys201. In embodiments, the Gas protein does not include Cys237.
[0397] In embodiments, the compound is bonded to Cys201 of the mutant human Gas (e.g., R201C mutation in SEQ ID NO: 1) or a selected residue in a selected protein corresponding to Cys201. In embodiments, the compound is bonded to cysteine 201 of the mutant human Gas (e.g., R201C mutation in SEQ ID NO: 1). In embodiments, the compound is bonded to an amin acid residue corresponding to Cys201 in the selected Gas.
[0398] In embodiments, the compound is bonded to Cys237 of the mutant human Gas (e.g., C237 in SEQ ID NO: 1) or a selected residue in a selected protein corresponding to Cys237. In embodiments, the compound is bonded to cysteine 237 of the human Gas (e.g., C237 in SEQ ID NO: 1). In embodiments, the compound is bonded to an amin acid residue corresponding to cystein237 in the selected Gas.
[0399] In embodiments, the Gas protein has the amino acid sequence of SEQ ID NO:2 including the sequence below with one or more mutations (e.g., R187C and C223S). The amino acids, R187 and C223, in the SEQ ID NO: 1 may be where the mutations (e.g., R187C and C223S) can occur.
[0400] In embodiments, the Gas protein includes R187C mutation in SEQ ID NO: 2. In embodiments, the Gas protein includes Cysl87. In embodiments, the Gas protein does not include Cys223.
[0401] In embodiments, the compound is bonded to Cysl 87 of the mutant human Gas (e.g., R187C mutation in SEQ ID NO: 2) or a selected residue in a selected protein corresponding to Cysl 87. In embodiments, the compound is bonded to Cysl 87 of the mutant human Gas (e.g., R187C mutation in SEQ ID NO: 2). In embodiments, the compound is bonded to an amin acid residue corresponding to Cysl87 in the selected Gas.
[0402] In embodiments, the compound is bonded to Cys223 of the human Gas (e.g., C223 in SEQ ID NO: 2) or a selected residue in a selected protein corresponding to Cys223. In embodiments, the compound is bonded to Cys223 of the human Gas (e.g., C223 in SEQ ID NO: 2). In embodiments, the compound is bonded to an amin acid residue corresponding to Cys223 in the selected Gas.
[0403] In an aspect is provided a Gas protein that is covalently bonded to a portion of a compound as described herein.
[0404] In embodiments, the Gas protein is covalently bonded to a Gas small molecule inhibitor **not defined** at R201C. In embodiments, the Gas protein is a GTP-bound Gas protein. In embodiments, the Gas protein is a GDP-bound Gas protein.
[0405] In embodiments, the Gas protein is covalently bonded to a human Gas small molecule inhibitor at R201C. In embodiments, the Gas protein is a GTP-bound human Gas protein. In embodiments, the Gas protein is a GDP-bound human Gas protein.
[0406] In embodiments, the Gas protein is covalently bonded to a human Gas small molecule inhibitor at a corresponding residue of R201C in SEQ ID NO: 1. In embodiments, the Gas protein is a GTP-bound human Gas protein. In embodiments, the Gas protein is a GDP-bound human Gas protein.
[0407] In embodiments, the Gas protein covalently bonded to a Gas small molecule inhibitor at C237. In embodiments, the Gas protein is a GTP-bound Gas protein. In embodiments, the Gas protein is a GDP-bound Gas protein.
[0408] In embodiments, the Gas protein covalently bonded to a human Gas small molecule inhibitor at C237. In embodiments, the Gas protein is a GTP-bound human Gas protein. In embodiments, the Gas protein is a GDP-bound human Gas protein.
[0409] In embodiments, the Gas protein covalently bonded to a human Gas small molecule inhibitor at a corresponding residue of C237 in SEQ ID NO: 1. In embodiments, the Gas protein is a GTP-bound human Gas protein. In embodiments, the Gas protein is a GDP- bound human Gas protein. [0410] In embodiments, the Gas protein is covalently bonded to a human Gas small molecule inhibitor at a corresponding residue of R187C in SEQ ID NO: 2. In embodiments, the Gas protein is a GTP -bound human Gas protein. In embodiments, the Gas protein is a GDP-bound human Gas protein.
[0411] In embodiments, the Gas protein covalently bonded to a human Gas small molecule inhibitor at a corresponding residue of C223 in SEQ ID NO: 2. In embodiments, the Gas protein is a GTP-bound human Gas protein. In embodiments, the Gas protein is a GDP- bound human Gas protein.
IV. Pharmaceutical compositions
[0412] In embodiments, the compound described herein (e.g., Formula (I), (II), (IH-a), (III- b), (III-c), (IV), (V-a), (V-b), (VI), (VII), or (VIII)) is administered as a pure chemical. In embodiments, the compound as described herein (e.g., Formula (I), (II), (Ill-a), (Ill-b), (III- c), (IV), (V-a), (V-b), (VI), (VII), or (VIII)) is combined with a pharmaceutically suitable or acceptable carrier (also referred to herein as a pharmaceutically suitable (or acceptable) excipient, physiologically suitable (or acceptable) excipient, or physiologically suitable (or acceptable) carrier) selected on the basis of a chosen route of administration and standard pharmaceutical practice as described, for example, in Gennaro, A. R., “Remington: The Science and Practice of Pharmacy,” 21st ed., Easton: Lippincott Williams & Wilkins, 2005.
[0413] In certain embodiments, the compound of Formula (I), (II), (Ill-a), (Ill-b), (III-c), (IV), (V-a), (V-b), (VI), (VII), or (VIII) as described herein is administered as a pure chemical. In some embodiments, the compound of Formula (I), (II), (Ill-a), (Ill-b), (III-c), (IV), (V-a), (V-b), (VI), (VII), or (VIII) described herein is combined with a pharmaceutically suitable or acceptable carrier (also referred to herein as a pharmaceutically suitable (or acceptable) excipient, physiologically suitable (or acceptable) excipient, or physiologically suitable (or acceptable) carrier) selected on the basis of a chosen route of administration and standard pharmaceutical practice as described, for example, in Gennaro,
A. R., “Remington: The Science and Practice of Pharmacy,” 21st ed., Easton: Lippincott Williams & Wilkins, 2005.
[0414] Accordingly, provided herein is a pharmaceutical composition including at least one compound of Formula (I), (II), (Ill-a), (Ill-b), (III-c), (IV), (V-a), (V-b), (VI), (VII), or (Vlll)described herein, or a pharmaceutically acceptable salt or solvate thereof, together with one or more pharmaceutically acceptable carriers. The carrier(s) (or excipient(s)) is acceptable or suitable if the carrier is compatible with the other ingredients of the composition and not deleterious to the recipient (i.e., the subject) of the composition.
[0415] Accordingly, provided herein is a pharmaceutical composition including at least one compound of Formula (I), (II), (Ill-a), (Ill-b), (III-c), (IV), (V-a), (V-b), (VI), (VII), or (VIII) described herein, or a pharmaceutically acceptable salt or solvate thereof, together with one or more pharmaceutically acceptable carriers. The carrier(s) (or excipient(s)) is acceptable or suitable if the carrier is compatible with the other ingredients of the composition and not deleterious to the recipient (i.e., the subject) of the composition.
[0416] In embodiments, the compound described herein (e.g., of Formula (I), (II), (Ill-a), (Ill-b), (III-c), (IV), (V-a), (V-b), (VI), (VII), or (VIII)) is substantially pure, in that it contains less than about 5%, or less than about 1%, or less than about 0.1%, of other organic small molecules, such as contaminating intermediates or by-products that are created, for example, in one or more of the steps of a synthesis method.
[0417] In certain embodiments, the compound of Formula (I), (II), (Ill-a), (Ill-b), (III-c), (IV), (V-a), (V-b), (VI), (VII), or (VIII) as described herein is substantially pure, in that it contains less than about 5%, or less than about 1%, or less than about 0.1%, of other organic small molecules, such as contaminating intermediates or by-products that are created, for example, in one or more of the steps of a synthesis method.
[0418] These pharmaceutical compositions include those suitable for oral, rectal, topical, buccal, parenteral (e.g., subcutaneous, intramuscular, intradermal, or intravenous), vaginal, ophthalmic, or aerosol administration.
[0419] Exemplary pharmaceutical compositions are used in the form of a pharmaceutical preparation, for example, in solid, semisolid or liquid form, which includes one or more of a disclosed compound, as an active ingredient, in a mixture with an organic or inorganic carrier or excipient suitable for external, enteral or parenteral applications. In some embodiments, the active ingredient is compounded, for example, with the usual non-toxic, pharmaceutically acceptable carriers for tablets, pellets, capsules, suppositories, solutions, emulsions, suspensions, and any other form suitable for use. The active compound is included in the pharmaceutical composition in an amount sufficient to produce the desired effect upon the process or condition of the disease. [0420] The dose of the composition including at least one compound described herein (e.g., of Formula (I), (II), (Ill-a), (Ill-b), (III-c), (IV), (V-a), (V-b), (VI), (VII), or (VIII)) differs, depending upon the patient’s (e.g., human) condition, that is, stage of the disease, general health status, age, and other factors.
[0421] The dose of the composition including at least one compound of Formula (I), (II), (Ill-a), (Ill-b), (III-c), (IV), (V-a), (V-b), (VI), (VII), or (VIII) as described herein differs, depending upon the patient’s (e.g., human) condition, that is, stage of the disease, general health status, age, and other factors.
[0422] Pharmaceutical compositions are administered in a manner appropriate to the disease to be treated (or prevented). An appropriate dose and a suitable duration and frequency of administration will be determined by such factors as the condition of the patient, the type and severity of the patient’s disease, the particular form of the active ingredient, and the method of administration. In general, an appropriate dose and treatment regimen provides the composition(s) in an amount sufficient to provide therapeutic and/or prophylactic benefit (e.g., an improved clinical outcome, such as more frequent complete or partial remissions, or longer disease-free and/or overall survival, or a lessening of symptom severity. Optimal doses are generally determined using experimental models and/or clinical trials. In some embodiments, the optimal dose depends upon the body mass, weight, or blood volume of the patient.
[0423] Oral doses typically range from about 1.0 mg to about 1000 mg, one to four times, or more, per day.
[0424] Disclosed compounds are administered to subjects or patients (animals and humans) in need of such treatment in dosages that will provide optimal pharmaceutical efficacy. It will be appreciated that the dose required for use in any particular application will vary from patient to patient, not only with the particular compound or composition selected, but also with the route of administration, the nature of the condition being treated, the age and condition of the patient, concurrent medication or special diets then being followed by the patient, and other factors, with the appropriate dosage ultimately being at the discretion of the attendant physician. For treating clinical conditions and diseases noted above, a contemplated compound disclosed herein is administered orally, subcutaneously, topically, parenterally, by inhalation spray or rectally in dosage unit formulations containing conventional non-toxic pharmaceutically acceptable carriers, adjuvants and vehicles. Parenteral administration include subcutaneous injections, intravenous or intramuscular injections or infusion techniques.
Effective Dosages
[0425] The pharmaceutical composition may include compositions wherein the active ingredient is contained in a therapeutically effective amount, i.e., in an amount effective to achieve its intended purpose. The actual amount effective for a particular application will depend, inter alia, on the condition being treated.
[0426] The dosage and frequency (single or multiple doses) of compounds administered can vary depending upon a variety of factors, including route of administration; size, age, sex, health, body weight, body mass index, and diet of the recipient; nature and extent of symptoms of the disease being treated; presence of other diseases or other health-related problems; kind of concurrent treatment; and complications from any disease or treatment regimen. Other therapeutic regimens or agents can be used in conjunction with the methods and compounds disclosed herein.
[0427] As is well known in the art, therapeutically effective amounts for use in humans can also be determined from animal models. For example, a dose for humans can be formulated to achieve a concentration that has been found to be effective in animals. The dosage in humans can be adjusted by monitoring compounds effectiveness and adjusting the dosage upwards or downwards, as described above. Adjusting the dose to achieve maximal efficacy in humans based on the methods described above and other methods is well within the capabilities of the ordinarily skilled artisan.
[0428] Dosages may be varied depending upon the requirements of the subject and the compound being employed. The dose administered to a subject, in the context of the pharmaceutical compositions presented herein, should be sufficient to effect a beneficial therapeutic response in the subject over time. The size of the dose also will be determined by the existence, nature, and extent of any adverse side effects. Generally, treatment is initiated with smaller dosages, which are less than the optimum dose of the compound. Thereafter, the dosage is increased by small increments until the optimum effect under circumstances is reached.
[0429] Dosage amounts and intervals can be adjusted individually to provide levels of the administered compounds effective for the particular clinical indication being treated. This will provide a therapeutic regimen that is commensurate with the severity of the individual's disease state.
[0430] Utilizing the teachings provided herein, an effective prophylactic or therapeutic treatment regimen can be planned that does not cause substantial toxicity and yet is entirely effective to treat the clinical symptoms demonstrated by the particular patient. This planning should involve the careful choice of active compound by considering factors such as compound potency, relative bioavailability, patient body weight, presence and severity of adverse side effects, preferred mode of administration, and the toxicity profile of the selected agent.
V. Methods of Use
[0431] In an aspect is provided a method of treating cancer. The method includes administering to a subject in need thereof an effective amount of a compound as described herein.
[0432] In embodiments, the subject is a human. In embodiments, the cancer is selected from human cancers and carcinomas, sarcomas, adenocarcinomas, lymphomas, leukemias, and the like. In embodiments, the cancer is a solid cancer or tumor. In embodiments, the cancer is pancreatic cancer. In embodiments, the cancer is a pituitary tumor. In embodiments, the cancer is a bone tumor.
[0433] In embodiments, the cancer or cancer cell is sensitive to Gas inhibition.
[0434] In an aspect is provided a method of treating a bone condition. The method includes administering to a subject in need thereof an effective amount of a compound as described herein.
[0435] In embodiments, the bone condition is fibrous dysplasia. Im embodiments, the fibrous dysplasia is monostotic fibrous dysplasia or polystotic fibrous dysplasia. Im embodiments, the fibrous dysplasia is monostotic fibrous dysplasia. In embodiments, the fibrous dysplasia is polystotic fibrous dysplasia.
[0436] In an aspect is provided a method of treating McCune-Albright Syndrome. The method includes administering to a subject in need thereof an effective amount of a compound as described herein. [0437] In an aspect is provided a method of treating cancer. The method include administering a Gas cysteine 201 covalent inhibitor. In embodiments, the Gas cysteine 201 covalent inhibitor is a compound as described herein.
[0438] In an aspect is provided a method of treating cancer. The method include administering a Gas cysteine 237 covalent inhibitor. In embodiments, the Gas cysteine 237 covalent inhibitor is a compound as described herein.
VI. Embodiments P
[0439] Embodiment PI. A compound having the formula:
Figure imgf000146_0001
wherein,
R1 is independently halogen, -CX’s, -CRX -CH2X1, -OCX’s, - OCH2X1, -OCHX’2, -CN, -SO„IR1d, -SOviNR1AR1B, -NR1CNR1AR1B, -ONR1AR1b, -NHC(0)NR1CNR1AR1B, -NHC(0)NR1AR1b, -N(0)mi, -NR1AR1B, -C(0)R1c, -C(0)-0R1c, -C (0)NR1AR1b, -OR1d, -NR1AS02R1d, -NR1AC(0)R1c, -NR1AC(0)0R1c, -NR1AOR1c, -N3, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl; two adjacent R1 substituents may optionally be joined to form a substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl; zl is an integer from 0 to 6;
Ring A is aryl or heteroaryl;
L1 is a bond, -NH-, -0-, -S-, -C(O)-, -C(0)NH-, -NHC(O)-, -NHC(0)NH-, -C(0)0-, -OC(O)-, substituted or unsubstituted alkylene, substituted or unsubstituted heteroalkylene, substituted or unsubstituted cycloalkylene, substituted or unsubstituted heterocycloalkylene, substituted or unsubstituted arylene, or substituted or unsubstituted heteroarylene; L2 is a bond, -NH-, -0-, -S-, -C(O)-, -C(0)NH-, -NHC(O)-, -NHC(0)NH-, -C(0)0-, -OC(O)-, substituted or unsubstituted alkylene, substituted or unsubstituted heteroalkylene, substituted or unsubstituted cycloalkylene, substituted or unsubstituted heterocycloalkylene, substituted or unsubstituted arylene, or substituted or unsubstituted heteroarylene;
R2 is an electrophilic moiety;
R1A, R1b, R1C, and R1D are independently hydrogen, -CX3, -CHX2, -CH2X, -CN, -OH, -COOH, -CONH2, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl; R1A and R1B substituents bonded to the same nitrogen atom may optionally be joined to form a substituted or unsubstituted heterocycloalkyl or substituted or unsubstituted heteroaryl;
X and X1 are independently -F, -Cl, -Br, or -I; nl is independently an integer from 0 to 4; and ml and vl are independently 1 or 2.
[0440] Embodiment P2. The compound of Embodiment 1, wherein zl is an integer from 1 to 3.
[0441] Embodiment P3. The compound of Embodiment 1, wherein zl is 0.
[0442] Embodiment P4. The compound of one of Embodiments 1 to 3, wherein Ring A is phenyl or 5 to 6-membered heteroaryl.
[0443] Embodiments P5. The compound of one of Embodiments 1 to 4, having the formula:
Figure imgf000147_0001
wherein;
Each R1·1, R1·2, R1 3, R1 4, and R1 5 is independently hydrogen, halogen, -CX^, -
CHX^, -CH2X1, -OCX’s, -OCH2X1, -OCHX^, -CN, -SO„iR1D, -SOviNR1AR1B,
-NR1CNR1AR1B, -ONR1AR1b,
-NHC(0)NRlcNR1AR1B, -NHC(0)NR1AR1b, -N(0)mi, -NR1AR1B, -C(0)R1c, -C(0)-ORlc, -C (0)NR1AR1B, -OR1d, -NR1AS02R1d, -NR1AC(0)R1c, -NR1AC(0)0R1c, -NR1AOR1c, -N3, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl;
R1A, R1b, R1C, and R1D are independently hydrogen, -CX3, -CHX2, -CH2X, -CN, -OH, -COOH, -CONH2, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl; R1A and R1B substituents bonded to the same nitrogen atom may optionally be joined to form a substituted or unsubstituted heterocycloalkyl or substituted or unsubstituted heteroaryl;
X and X1 are independently -F, -Cl, -Br, or -I; nl is independently an integer from 0 to 4; and ml and vl are independently 1 or 2.
[0444] Embodiment P6. The compound of one of Embodiments 1 to 5, wherein L1 is a bond, -NH-, -0-, -S-, -C(O)-, -C(0)NH-, -NHC(O)-, -NHC(0)NH-, -C(0)0-, -OC(O)-, substituted or unsubstituted alkylene, or substituted or unsubstituted heteroalkylene.
[0445] Embodiment P7. The compound of one of Embodiments 1 to 5, wherein L1 is a bond, -NH-, -0-, -S-, -C(O)-, -C(0)NH-, -NHC(O)-, -NHC(0)NH-, -C(0)0-, -OC(O)-, substituted or unsubstituted C1-C6 alkylene, or substituted or unsubstituted 2 to 6 membered heteroalkylene.
[0446] Embodiment P8. The compound of one of Embodiments 1 to 5, wherein L1 is a bond.
[0447] Embodiment P9. The compound of one of Embodiments 1 to 8, wherein L2 is a bond, -NH-, -0-, -S-, -C(O)-, -C(0)NH-, -NHC(O)-, -NHC(0)NH-, -C(0)0-, -OC(O)-, substituted or unsubstituted alkylene, or substituted or unsubstituted heteroalkylene.
[0448] Embodiment P10. The compound of one of Embodiments 1 to 8, wherein L2 is a bond, -NH-, -0-, -S-, -C(O)-, -C(0)NH-, -NHC(O)-, -NHC(0)NH-, -C(0)0-, -OC(O)-, substituted or unsubstituted C1-C6 alkylene, or substituted or unsubstituted 2 to 6 membered heteroalkylene.
[0449] Embodiment Pll. The compound of one of Embodiments 1 to 8, wherein L2 is an unsubstituted C1-C6 alkylene. [0450] Embodiment P12. The compound of one of Embodiments 1 to 8, wherein L2 is a bond.
[0451] Embodiment P13. The compound of one of Embodiments 1 to 12, wherein R2 is
Figure imgf000149_0001
R16 is hydrogen, halogen, -CX16 3, -CHX16 2, -CH2X16, -CN, -SOni6R16D, -SOVI6NR16AR16B, -NHNR16AR16B, -ONR16AR16B, -NHC(0)NHNR16AR16B,
-NHC(0)NR16AR16B, -N(0)mi6, -NR16AR16B, -C(0)R16C, -C(0)-0R16C, -C(0)NR16AR16B, -OR 16D, -NR16AS02R16B, -NR16AC(0)R16C, -NR16AC(0)0R16C, -NR16AOR16D, -OCX163, -OCHX16 2 , -OCH2X16, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl;
R17 is hydrogen, halogen, -CX17 3, -CHX17 2, -CH2X17, -CN, -SO„I7R17D, -SOv17NR17AR17B, -NHNR17AR17B, -ONR17AR17B, -NHC(0)NHNR17AR17B,
-NHC(0)NR17AR17B, -N(0)mi7, -NR17AR17B, -C(0)R17C, -C(0)-0R17C, -C(0)NR17AR17B, -OR 17D, -NR17AS02R17B, -NR17AC(0)R17C, -NR17AC(0)0R17C, -NR17AOR17D, -OCX17 3, -OCHX17 2 , -OCH2X17, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl;
R18 is hydrogen, halogen,
Figure imgf000150_0002
-ONR18AR18B, -NHC(0)NHNR18AR18B, -OR
Figure imgf000150_0003
, -OCH2X18, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl;
R19 is hydrogen, halogen, -CX19 3, -CHX19 2, -CH2X19, -CN, -SO„I9R19D, -SOVI9NR19AR19B, -NHNR19AR19B, -ONR19AR19B, -NHC(0)NHNR19AR19B,
Figure imgf000150_0004
, -OCH2X19, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl;
Figure imgf000150_0001
and R19D are independently hydrogen, -CX3, -CHX2, -CH2X, -CN, -OH, -COOH, -CONH2, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl; R16A and R16B substituents bonded to the same nitrogen atom may optionally be joined to form a substituted or unsubstituted heterocycloalkyl or substituted or unsubstituted heteroaryl; R17A and R17B substituents bonded to the same nitrogen atom may optionally be joined to form a substituted or unsubstituted heterocycloalkyl or substituted or unsubstituted heteroaryl; R18A and R18B substituents bonded to the same nitrogen atom may optionally be joined to form a substituted or unsubstituted heterocycloalkyl or substituted or unsubstituted heteroaryl; R19A and R19B substituents bonded to the same nitrogen atom may optionally be joined to form a substituted or unsubstituted heterocycloalkyl or substituted or unsubstituted heteroaryl;
X16, X17, X18, and X19 are independently -F, -Cl, -Br, or -I; nl6, nl7, nl8, and nl9 are independently an integer from 0 to 4; and ml6, ml7, ml8, ml9, vl6, vl7, vl8, and vl9 are independently 1 or 2.
[0452] Embodiment P14. The compound of one of Embodiments 1 to 12, wherein R2 is
Figure imgf000151_0001
[0453] Embodiment P15. The compound of one of Embodiments 1 to 14, wherein:
R16 is hydrogen, unsubstituted C1-C4 alkyl, or unsubstituted C3-C6 cycloalkyl;
R17 is hydrogen, unsubstituted C1-C4 alkyl, or unsubstituted C3-C6 cycloalkyl; and R18 is hydrogen, unsubstituted C1-C4 alkyl, or unsubstituted C3-C6 cycloalkyl.
[0454] Embodiment P16. The compound of one of Embodiments 1 to 14, wherein:
R16 is hydrogen or unsubstituted C1-C4 alkyl;
R17 is hydrogen or unsubstituted C1-C4 alkyl; and R18 is hydrogen or unsubstituted C1-C4 alky.
[0455] Embodiment P17. The compound of one of Embodiments 1 to 14, wherein R16, R17, and R18 are hydrogen.
[0456] Embodiment P18. A pharmaceutical composition comprising the compound of any one of Embodiments 1 to 17 and a pharmaceutically acceptable excipient.
[0457] Embodiment P19. A method of inhibiting Gas protein activity, said method comprising: contacting the Gas protein with a compound of one of Embodiments 1 to 17.
[0458] Embodiment P20. A method of treating cancer, said method comprising administering to a subject in need thereof an effective amount of a compound of one of Embodiments 1 to 17.
[0459] Embodiment P21. The method of Embodiment 20, wherein the cancer is pancreatic cancer, a pituitary tumor, or a bone tumor.
[0460] Embodiment P22. The method of Embodiment 20, wherein the cancer is sensitive to Gas inhibition.
[0461] Embodiment P23. A method of treating a bone condition, said method comprising administering to a subject in need thereof an effective amount of a compound of one of Embodiments 1 to 17. [0462] Embodiment P24. The method of Embodiment 23, wherein the bone condition is fibrous dysplasia.
[0463] Embodiment P25. The method of Embodiment 24, wherein the fibrous dysplasia is monostotic fibrous dysplasia or polystotic fibrous dysplasia.
[0464] Embodiment P26. A method of treating McCune-Albright Syndrome, said method comprising administering to a subject in need thereof an effective amount of a compound of one of Embodiments 1 to 17.
[0465] Embodiment P27. A Gas protein covalently bonded to a compound of one of Embodiments 1 to 17.
[0466] Embodiment P28. The Gas protein of Embodiment 27, wherein Gas is in the GTP state.
[0467] Embodiment P29. The Gas protein of Embodiment 27, wherein Gas is in the GDP state.
[0468] Embodiment P30. The Gas protein of Embodiment 27, wherein the compound is bonded to a cysteine residue of the protein.
[0469] Embodiment P31. The Gas protein of Embodiment 27, having the structure:
Figure imgf000152_0001
W together with the -CH2S- to which it is attached form said Gas protein covalently bonded to a compound; and
L3 is substituted or unsubstituted alkylene or substituted or unsubstituted heteroalkylene. [0470] Embodiment P32. The Gas protein of Embodiment 31, wherein L3 is f- NH
Figure imgf000153_0001
[0471] Embodiment P33. The Gas protein of Embodiment 30, wherein the compound is bonded to cysteine 201.
[0472] Embodiment P34. The Gas protein of Embodiment 30, wherein the compound is bonded to cysteine 237.
[0473] Embodiment P35. A Gas protein covalently bonded to a portion of a compound of one of Embodiments 1 to 17.
[0474] Embodiment P36. A Gas protein covalently bonded to a Gas small molecule inhibitor at R201C.
[0475] Embodiment P37. The Gas protein of Embodiment 36, wherein the Gas protein is a GTP-bound Gas protein.
[0476] Embodiment P38. The Gas protein of Embodiment 36, wherein the Gas protein is a GDP-bound Gas protein.
[0477] Embodiment P39. A Gas protein covalently bonded to a Gas small molecule inhibitor at C237. [0478] Embodiment P40. The Gas protein of Embodiment 39, wherein the Gas protein is a GTP-bound Gas protein.
[0479] Embodiment P41. The Gas protein of Embodiment 39, wherein the Gas protein is a GDP-bound Gas protein.
[0480] Embodiment P42. A method of treating cancer comprising administering a Gas cysteine 201 covalent inhibitor.
[0481] Embodiment P43. The method of Embodiment 42, wherein the Gas cysteine 201 covalent inhibitor is a compound of one of Embodiments 1 to 17.
[0482] Embodiment P44. A method of treating cancer comprising administering a Gas cysteine 237 covalent inhibitor.
[0483] Embodiment P45. The method of Embodiment 44, wherein the Gas cysteine 237 covalent inhibitor is a compound of one of Embodiments 1 to 17.
EXAMPLES
[0484] State-selective Gas labeling molecules based on disulfide tethering are demonstrated. The leading compounds can lable the somatic cysteine mutant selectively over all other cysteines present in the protein. Based on (i) the structure activity relationships and (ii)GDP orGTP state dependent labelling, the leading compounds are excellent starting points for discovery of covalent irreversible (likely acrylamide) based drug candidates, which can yield enhanced drug candidate for Gas associated cancer or disease. In particular, the leading compounds may be used to treat a cancer caused by mutations (e.g., R201C) in the GNAS gene.
Example 1. Design of Inhibitors of Cancer-associated Mutant GNAS
[0485] Deep sequencing reveals that G-protein mutations occur in several kinds of cancers [1]. Some of the remarkable mutations were observed in GNAS, which encodes the a-subunit of the stimulatory G protein (Gas). GNAS was first proved to be a putative oncogene that was abnormally activated in human growth hormone (GH) -secreting pituitary tumors in 1987 [2, 3]; activating mutations were identified in about 43% of 42 GH-secreting pituitary tumors, and they were responsible for the high secretory activity of such tumors [4]. Since then, activating mutations of GNAS have been revealed to contribute to progression and metastasis of several other kinds of cancers. For example, to understand the pathogenesis of intraductal papillary mucinous neoplasm (IPMN, a precursor to invasive adenocarcinoma), Jian Wu et al. searched the mutations in IPMN patients, and found that 66% of 132 patients carried activating mutations at codon 201 of GNAS[5 According to the catalogue of somatic mutations in cancer (COSMIC) v62, approximately 4.2% of all cancer types harbor activating mutations in GNAS[] About 64% of such GNAS mutations result in R201C [1]. Arg201 can stabilize the pentavalent phosphate intermediate thus facilitates GTP hydrolysis; therefore mutation of this residue disrupts the GTPase activity of Gas, keeping Gas in a constitutively active state [6, 7].
Using small molecules to specifically inhibit the cancer-associated mutant Gas(R201C), would be a promising strategy for the therapy of cancers in which GNAS mutations occur. However, only a few small molecules have been reported to be Gas inhibitors, and their selectivity between different subtypes of G-proteins is poor. No inhibitor that selectively targets Gas(R201C) has been reported. In this proposal, I will take advantage of the similarity of Gas(R201C) with K-Ras(G12C) and Gaq to design Gas(R201C) -specific inhibitors. Such a design is based on the structure of Gaq with a non-covalent inhibitor [8], and the crystal structures of K-Ras(G12C) with inhibitors that’s covalently linked with Cysl2 [9 11]. Activity assays are also proposed to evaluate the potency of the designed inhibitors.
[0486] The G-proteins are composed of Ga, ΰb and Gy subunits. Among them, Ga can form a heterotrimer with ΰbg when one molecule of GDP is located in the nucleotide-binding pocket of Ga. The GDP-bound Ga is inactive, and can be activated by the corresponding GPCR. As for Gas, it can be activated by b2 adrenergic receptor ^2AR). Association of an agonist to the extracellular side of b2AR induces a conformational change of the intracellular side of the b2AR; then b2AR recruits the Gas-Obg heterotrimer, and induces a rearrangement of the “P-loop” of the nucleotide-binding pocket of Gas, leading to GDP release and GTP binding [12]· The nucleotide exchange results in the dissociation of Gas from both b2AR and the ΰbg dimer [6]. After dissociation, the GTP-bound Gas binds with and activates adenylyl cyclase (AC), which can catalyze the conversion of ATP to cAMP [i3]. Gas has relatively slow GTPase activity. The hydrolysis of the GTP molecule in the nucleotide-binding pocket of Gas to GDP induces the release of AC from Gas. Then the GDP -bound Gas associates with ΰbg, waiting for P2AR to activate it again.
[0487] The above cycle maintains the activity of Gas at a proper level. But the cancer- associated mutation R201C breaks this cycle by locking Gas in its GTP-bound state. The constitutive activation of Gas can promote hyperplasia of cells in several kinds of cancers [1]. So using small molecules to inhibit the abnormally activated Gas would be a promising strategy for the therapy of cancer with a R201C mutation in GNAS. Because of the mosaic nature of GNAS in cancer patients [14]’ the inhibitors should specifically target the mutant Gas but not the wild-type Gas to avoid side effects.
[0488] So far, only a few types of G-protein inhibitors have been reported. They targeted different steps of G-protein activation. Some of them could disrupt the interaction between G- proteins and their receptors. For example, A small peptide, pGlu-Gln-D-Trp-Phe-D-Trp-D- Trp-Met-NIL·, was reported to competitively inhibit the binding of Gi (or Go) to M2 muscarinic cholinergic receptor or the binding of Gs to P2AR [15]· Another compound, BIM- 46187, was first reported to bind to the Ga subunit and block the receptor-G protein interaction with a poor selectivity [16]’ but in a recent study, BIM-46187 preferentially inhibited Gaq by blocking GTP entry [17]· Some other compounds were used to inhibit replacement of GDP with GTP, such as compound YM-254890, which was reported to selectively block GDP-GTP exchange of Gaq/n [18] Suramin and its analogues are another class of G-protein inhibitors, but the molecular mechanism of inhibition is controversial [19 21]· None of these inhibitors was reported to selectively target Gas, let alone specific inhibitors of the cancer-associated mutant Gas(R201C).
[0489] It is aimed to develop small molecule inhibitors to specifically inhibit the cancer- associated mutant Gas(R201C). To this end, the specific aims include 1) design of leading compounds that bind Gas; 2) modification of the compounds to covalently bond Cys201 of Gas(R201C); 3) structural analysis of the binding of these compounds with Gas(R201C); 4) evaluation of the potency of these compounds in cellular models.
Methods
[0490] Within G-protein family, Gaq shares a sequence identity of 42.5% with Gas.
Crystal structure of Gaq in complex with a specific inhibitor named YM254890 has been reported, giving us the only example of small molecule inhibitor-G-protein binding [8]. In addition, G-proteins show similar features to other GTPase, such as the Ras family proteins. Their GDP-bound state is inactive, while the GTP-bound state is active in signal transduction. Structural analysis of Ras proteins revealed that two regions largely switched during the replacement of GDP with GTP [22]· The two regions, named switch I and II, are also involved in nucleotide-exchange in G-proteins [7, i3].
Design of leading compounds that can bind Cys201 of Gas(R201C)
[0491] A crystal structure of Gaq-YM254890 complexed with Gaq has been reported because Gaq is closely related to Gas. YM254890, a cyclic depsipeptide produced by Chromobacterium sp. QS3666, was first identified as a platelet aggregation inhibitor [23], then it turned out to be a novel Gaq/11 -selective inhibitor [18]. The cyclic scaffold of YM254890 is linked by ester bonds and amide bonds, and the nitrogen atoms of the amides are highly methylated. The moiety around the cyclic scaffold consists of aliphatic and aromatic residues, indicating that hydrophobic interactions involve in YM254890- Gaq binding [24].
[0492] In the crystal structure of Gaq-GDP-YM254890 complex, YM254890 located in a pocket between the Ras-like domain and helical domain (FIG. IB, PDB code 1 AZT). The a- helix and b-sheet that linked by switch I, as well as switch I, surround YM254890, playing an important role for binding. Binding of YM254890 locks Gaq in a GDP -bound state, thus inhibits Gaq activation [8]. Crystal structure of Gas-GTPyS complex can be superimposed with that of Gaq-GDP-YM254890 complex with a root mean squared deviation (r.m.s.d.) of 2.3 A (FIG. 1C). A similar pocket surrounded by switch I in Gas provides potential inhibitor-binding sites.
[0493] To design leading compounds that can bind Gas, I carefully analyzed the interactions between YM254890 and Gaq (FIG. ID). The phenyl group of YM254890 inserts into a hydrophobic pocket of the Ras-like domain of Gaq. It was reported that replacement of the hydrophobic residues of switch I with hydrophilic residues severely weakened the inhibition effect [8]. Switch I was thus supposed to determine the sensitivity of G-proteins to YM254890 [8]. Besides, there are three hydrogen bonds between YM254890 and Arg60 of Gaq, signifying the importance of Arg60. Comparison reveals that most of the key residues are conserved in Gas. But there are also some obvious differences between Gas and Gaq that may explain the inability of YM254890 to inhibit Gas. These differences include K91 vs. F75, D94 vs. L78, F206 vs. 1190, T210 vs. Y192 andK211 vs. P193. Such differences result a less hydrophobic pocket, and also change the shape of the pocket. [0494] Leading compounds that can bind Gas could obtained by modification of YM254890. Residue (2S,3R)-N,0-Me2Thr of YM254890 is adjacent to F75 and L78 of Gaq. To change the specificity from Gaq to Gas, (2S,3R)-N,0-Me2Thr could be replaced with hydrophilic residues to bind K91 and D94 in Gas. The isopropyl group of (2 S , 3 R) - b-HyLeu- 2 interact with 1190 in Gaq, but replacement of 1190 with F206 in Gas narrows the pocket.
So the isopropyl group could be changed to a smaller group, such as methyl group, to be accommodated by F206. 1 think such a rational design could help us obtain the leading compounds.
Modification of the leading compounds to covalently bond Cys201 of Gas(R201C) [0495] The aim of this proposal is to develop small molecules to specifically inhibit the cancer-associated mutant Gas(R201C) but not wild-type Gas, so the leading compounds should be further modified. Design of specific inhibitors of cancer-associated mutant K- Ras(G12C) provides good examples of using cysteine-reactive small molecules in drug design.
[0496] K-Ras, an important member in the Ras family, also has cancer-associated mutants. One of these mutants, G12C, disrupts the GTPase activity of K-Ras, keeping K-Ras in a GTP-bound state. Small molecule inhibitors specifically target the mutant but not wild-type K-Ras have been reported by two groups [9 11]· These inhibitors harbor electrophilic groups that can be covalently linked with Cysl2 of the mutant K-Ras. Such electrophilic groups guarantee the specificity of the inhibitors.
[0497] Noting that R201C mutation of Gas is just located in switch I, and is adjacent to the YM254890-binding pocket, I propose to introduce a cysteine-reactive group in the leading compounds to bond Cys201 of the mutant Gas. Residue (2S,3R)-N,0-Me2Thr of YM254890 may be a proper position to introduce cysteine-reactive groups. Comparing to other positions on YM254890, (2S,3R)-N,0-Me2Thr is more close to R183 (corresponding to R201 in Gas). In addition, a surface grove lays between the helical domain and Ras-like domain; R183 and (2S,3R)-N,0-Me2Thr can be connected by a linker across this grove (FIG. IE). Therefore, a linker would be added to the side chain or main chain of (2S,3R)-N,0-Me2Thr; the other head of the linker would be linked with various cysteine-reactive groups. The length and composition of the linker would be varied to acquire a better inhibitor. [0498] Specifically, a long linker is needed because the distance between the a-carbon of R183 and the main chain of (2S,3R)-N,0-Me2Thr is nearly 10 A (FIG. IF). Considering that there are several hydrophilic residues in the grove between the helical domain and Ras-like domain in Gas (FIG. 1G), a linker with certain hydrophilicity would be used. Such a linker might also increase the binding affinity of the inhibitor, and fix switch I in an inactive conformation.
[0499] As for the cysteine-reactive groups, because cysteine has long been an ideal residue for selective modification of proteins, several classes of reactive groups have been developed to chemically modify cysteine residues, such as a-halocarbonyls (e.g., iodoacetamides), maleimides, vinyl sulfones, etc. [25, 26]. Besides, a series of cysteine proteases inhibitors that can covalently modify the cysteine residue have been reported, such as epoxysuccinyl derivatives and O-acyl hydroxamates [27]. These reactive groups can be employed to link the leading compounds with Cys201.
Structural analysis of the binding of these compounds with Gas(R201C);
[0500] Gas can be easily over-expressed in E. coli [28] and in insect cells [29]. Crystal structures of Gas -GTPyS complex, Gas-adenylyl cyclase complex, and the ternary complex of Gas-G y- 2AR, have been reported [7, 13, 29]. So the crystal structure of Gas or Gas(R201C) in complex with its inhibitor may be obtained.
Evaluation of the potency of these inhibitors
[0501] An in vitro assay system can be used to evaluate the inhibition effects of the designed compounds on the activities of Gas and the cancer-associated mutant Gas(R201C). Covalent modification of Gas(R201C) can be detected by mass spectrometry as described in the study of K-Ras(G12C) inhibitors that carried by Kevan Shokat’s laboratory in 2013 [11]· After modification, nucleotide exchange rates on Gas can be determined by a fluorescence- based assay[30, 31] .
Potential Problems and alternatives
[0502] It might be possible that simple modifications of YM254890 cannot give us the desired Gas-specific leading compounds, and even if we get the leading compounds, we might fail to introduce a proper linker with a cysteine-reactive group. If so, other strategies would be considered. As I mentioned above, specific inhibitors of K-Ras(G12C) have been reported by two groups. One is Kevan Shokat’s group. They have developed a series of compounds with cysteine-reactive groups to covalently modify Cysl2 of K-Ras(G12C), while the aryl groups of these compounds bound into a pocket around switch II (not shown, PDB code: 4NMM) [11]· This binding disturbed switch II, and thus convert the nucleotide preference of K- Ras(G12C) to favour GDP over GTP[11]. There is also a similar pocket around switch II in Gas that has the potential to bind with inhibitors; besides, the location of Cys201 gives it the similar advantage to Cysl2 in K-Ras for inhibitor design (not shown, PDB code: 4NMM). The other is Nathanael S. Gray’s group. They used GDP analogues to occupy the nucleotide binding pocket, thus block the entry of GTP; these GDP analogues also contain a cysteine - reactive group to form covalent bond with Cysl2 (not shown, PDB code: 4NMM) [9, 10]. So we could employ similar strategies to design Gas(R201C)-specific inhibitors.
[0503] Somatic mutations of GNAS (encoding Gas) occur in approximately 4.2% of all cancer types [1]. For example, statistics show that 11.8% of 473 pancreas cancer samples and 27.9% of 816 pituitary cancer samples harbor GNAS mutations [1]; 66% of 132 intraductal papillary mucinous neoplasm (IPMN) patients carried a GNAS mutation [5]. These mutations lead to constitutive activation of Gas, and promote tumourigenesis. About 64% of the cancer- associated mutations of GNAS change Arg201 of Gas to a cysteine residue (R201C). Therefore, specific inhibitors of the R201C mutant of Gas would be effective tools for cancer therapies. Development of such inhibitors is just the aim of the proposed research.
Significance
[0504] Somatic mutations of GNAS (encoding Gas) occur in approximately 4.2% of all cancer types [1]. For example, statistics show that 11.8% of 473 pancreas cancer samples and 27.9% of 816 pituitary cancer samples harbor GNAS mutations [1]; 66% of 132 intraductal papillary mucinous neoplasm (IPMN) patients carried a GNAS mutation [5]. These mutations lead to constitutive activation of Gas, and promote tumourigenesis. About 64% of the cancer- associated mutations of GNAS change Arg201 of Gas to a cysteine residue (R201C). Therefore, specific inhibitors of the R201C mutant of Gas would be effective tools for cancer therapies. Development of such inhibitors is just the aim of the proposed research.
References in Example 1
[1] O'Hayre M, Vazquez-Prado J, Kufareva I, et al. The emerging mutational landscape of G proteins and G-protein-coupled receptors in cancer. Nat Rev Cancer, 2013,13(6):412-424. [2] Landis C A, Masters S B, Spada A, et al. GTPase inhibiting mutations activate the alpha chain of Gs and stimulate adenylyl cyclase in human pituitary tumours. Nature, 1989,340(6236):692-696.
[3] Vallar L, Spada A, Giannattasio G. Altered Gs and adenylate cyclase activity in human GH-secreting pituitary adenomas. Nature, 1987,330(6148):566-568.
[4] Lyons J, Landis C A, Harsh G, et al. Two G protein oncogenes in human endocrine tumors. Science, 1990,249(4969):655-659.
[5] Wu J, Matthaei H, Maitra A, et al. Recurrent GNAS mutations define an unexpected pathway for pancreatic cyst development. Sci Transl Med, 201 l,3(92):66r-92r.
[6] Coleman D E, Berghuis A M, Lee E, et al. Structures of active conformations of Gi alpha 1 and the mechanism of GTP hydrolysis. Science, 1994,265(5177):1405-1412.
[7] Sunahara R K, Tesmer J J, Gilman A G, et al. Crystal structure of the adenylyl cyclase activator Gsalpha. Science, 1997,278(5345): 1943-1947.
[8] Nishimura A, Kitano K, Takasaki J, et al. Structural basis for the specific inhibition of heterotrimeric Gq protein by a small molecule. Proc Natl Acad Sci U S A, 2010, 107(31): 13666-13671.
[9] Hunter J C, Gurbani D, Ficarro S B, et al. In situ selectivity profiling and crystal structure of SML-8-73-1, an active site inhibitor of oncogenic K-Ras G12C. Proc Natl Acad Sci U S A, 2014,1 ll(24):8895-8900.
[10] Lim S M, Westover K D, Ficarro S B, et al. Therapeutic targeting of oncogenic K-Ras by a covalent catalytic site inhibitor. Angew Chem Int Ed Engl, 2014,53(l):199-204.
[11] Ostrem J M, Peters U, Sos M L, et al. K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions. Nature, 2013,503(7477):548-551.
[12] Chung K Y, Rasmussen S G, Liu T, et al. Conformational changes in the G protein Gs induced by the beta2 adrenergic receptor. Nature, 2011,477(7366):611-615.
[13] Tesmer J J, Sunahara R K, Gilman A G, et al. Crystal structure of the catalytic domains of adenylyl cyclase in a complex with Gsalpha. GTPgammaS. Science, 1997,278(5345): 1907- 1916.
[14] Weinstein L S, Shenker A, Gejman P V, et al. Activating mutations of the stimulatory G protein in the McCune-Albright syndrome. N Engl J Med, 1991,325(24):1688-1695.
[15] Mukai H, Munekata E, Higashijima T. G protein antagonists. A novel hydrophobic peptide competes with receptor for G protein binding. J Biol Chem, 1992,267(23):16237- 16243.
[16] Ayoub M A, Damian M, Gespach C, et al. Inhibition of heterotrimeric G protein signaling by a small molecule acting on Galpha subunit. J Biol Chem, 2009,284(42):29136- 29145.
[17] Schmitz A L, Schrage R, Gaffal E, et al. A cell-permeable inhibitor to trap Galphaq proteins in the empty pocket conformation. Chem Biol, 2014,21(7):890-902.
[18] Takasaki J, Saito T, Taniguchi M, et al. A novel Galphaq/11 -selective inhibitor. J Biol Chem, 2004,279(46):47438-47445.
[19] Freissmuth M, Boehm S, Beindl W, et al. Suramin analogues as subtype-selective G protein inhibitors. Mol Pharmacol, 1996,49(4):602-611. [20] Hohenegger M, Waldhoer M, Beindl W, et al. Gsalpha-selective G protein antagonists. Proc Natl Acad Sci U S A, 1998,95(1):346-351.
[21] Chung W C, Kermode J C. Suramin disrupts receptor-G protein coupling by blocking association of G protein alpha and betagamma subunits. J Pharmacol Exp Ther, 2005,313(1): 191-198.
[22] Milbum M V, Tong L, Devos A M, et al. Molecular switch for signal transduction: structural differences between active and inactive forms of protooncogenic ras proteins. Science, 1990,247(4945):939-945.
[23] Taniguchi M, Nagai K, Arao N, et al. YM-254890, a novel platelet aggregation inhibitor produced by Chromobacterium sp. QS3666. J Antibiot (Tokyo), 2003,56(4):358- 363.
[24] Taniguchi M, Suzumura K, Nagai K, et al. Structure of YM-254890, a novel G q/11 inhibitor from Chromobacterium sp. QS3666. Tetrahedron, 2003,59(25):4533-4538.
[25] Chalker J M, Bemardes G J, Lin Y A, et al. Chemical modification of proteins at cysteine: opportunities in chemistry and biology. Chem Asian J, 2009,4(5):630-640.
[26] Spicer C D, Davis B G. Selective chemical protein modification. Nat Commun, 2014,5:4740.
[27] Otto H H, Schirmeister T. Cysteine Proteases and Their Inhibitors. Chem Rev, 1997,97(1):133-172.
[28] Lee E, Linder M E, Gilman A G. Expression of G-protein alpha subunits in Escherichia coli. Methods Enzymol, 1994,237:146-164.
[29] Rasmussen S G, Devree B T, Zou Y, et al. Crystal structure of the beta2 adrenergic receptor-Gs protein complex. Nature, 2011,477(7366):549-555.
[30] Kimple R J, Jones M B, Shutes A, et al. Established and emerging fluorescence -based assays for G-protein function: heterotrimeric G-protein alpha subunits and regulator of G- protein signaling (RGS) proteins. Comb Chem High Throughput Screen, 2003,6(4):399-407.
[31] Mcewen D P, Gee K R, Kang H C, et al. Fluorescent BODIPY-GTP analogs: real-time measurement of nucleotide binding to G proteins. Anal Biochem, 2001,291(1):109-117.
Example 2. In Vitro Assays
Mesuaring The GDP dissociation rate of Gas R201C is slower than its GTP hydrolysis rate
[0505] The R201C mutant Gas can bypass the need for GTP binding by directly activating GDP-bound Gas through stabilization of an intramolecular hydrogen bond network between the P-loop, switch III and switch II of Gas. In order to check whether the R201C mutant in cells would be mostly in the GTP-bound form thus rendering our biochemical findings about the active GDP-bound not physiologically relevant, the single turnover GTP hydrolysis rate (feat) and the GDP dissociation rate (kos) of R201C and wild-type Gas were measured and compared. The ratio of Gas in the GTP-bound state should be less than koif/(koif+ feat) when the GTP binding and hydrolysis cycle reaches a steady state. In the presence of excess GOy subunits and millimolar Mg2+, only 11% of the R201C mutant was in the GTP state without stimulation by GPCRs.
[0506] The calculation using a [y-32P]GTP binding assay is shown in FIG. 2. The R201C mutant was pre-incubated in a low Mg2+ buffer (1 mM EDTA + 0.1 mM MgCh) with 400 mM GTP that is close to the physiological concentration of GTP; 20 nM [y-32P]GTP was added as an internal standard. After the binding of [y-32P]GTP to the R201C mutant reached a maximum, the concentration of free Mg2+ was increased to about 1.1 mM (1 mM EDTA +
2.5 mM MgCh) and the changes of bound [y-32P]GTP with time were measured. The bound [y-32P]GTP decreased to about 30% of the maximum after 4 hours, which can be explained by the faster GTP hydrolysis than GDP dissociation. When GOy subunits were added together with MgCh (GOy:Gas = 1.5:1, molar ratio), the bound [y-32P]GTP further decreased to below 10% of the maximum after 4 hours, which supports the finding that GOy subunits decrease the rate of GDP dissociation. In contrast, when the free Mg2+ concentration was kept at 0.1 mM (1 mM EDTA + 0.1 mM MgCh), the bound [y-32P]GTP only slowly decreased to about 80% of the maximum, which may be due to the instability of the R201C mutant in the low Mg2+ buffer.
[0507] The two pieces of evidence demonstrate that the R201C mutant is not locked in the GTP state, instead, without GPCR stimulation it would be mainly in the GDP state in cells considering that the presence of GOy subunits and millimolar Mg2+ dramatically decrease the rate of GDP dissociation.
Correction of the misactivation of Gas(R201Q by an arginine mimic
[0508] A crystal structure of the R201C/C237S mutant was solved and shown in FIG. 1A. Structure analysis indicates the importance of the interactions between E50 and ammonium hΐ and t|2 of R201 in maintaining GDP-bound Gas in an inactive state. The R201C mutation results in the loss of ammonium hΐ and t|2 of R201 thus freeing E50 to interact with R258 and R265 to indirectly stabilize switch II in an active-like conformation. Based on this finding, replacing the side chain of R201C with a close mimic of native arginine which contains N(h1) and N(h2) may correct the misactivation of the R201C mutant. For example, acrylamidine (Acr) can modify Cys237 and Cys201 in the R201C mutant. In the R201C/C237S double mutant, only Cys201 can be modified by Acr. This modification converts cysteine to an arginine mimic (FIG. 3A). [0509] Also effect of modifying C201 with Acr on the adenylyl cyclase-activating activity of GDP-bound Gas(R201C/C237S) was calculated. In the presence of GDP and Gpi/Gy2(C68S), the unmodified Gas(R201C/C237S) showed significantly higher activity than Gas(C237S) (FIG. 3B), consistent with our finding that Gas(R201C) has a higher activity than WT Gas. After Gas(R201C/C237S) was modified by Acr (free Acr was removed by gel filtration), its ability to activate adenylyl cyclase was lowered to the same level as that of Gas(C237S) (FIG. 3B). Particularly, site specific modification of C201 with Acr can effectively restore the canonical role of GDP to Gas disrupted by the R201C mutation, supporting the role of N(h1) and N(h2) in restraining the GDP-bound form in a state that does not activate adenylyl cyclase in the presence of ΰbg subunits. It is also demonstrated that this modification can partly restore the GTPase activity of Gas(R201 C/C237 S) . The ¾* of Gas(C237S) is 1.539 ± 0.153 min 1 (measured at 0 °C), slightly higher than that of WT Gas (FIG. 3C). The unmodified R201C/C237S mutant showed a slow feat (0.022 ± 0.002 min 1) even at 20 °C, similar to that of Gas(R201C). Following Acr modification of the R201C/C237S mutant its feat increased to 0.471 ± 0.043 min 1 (measured at 0 °C), about 30% of that of Gas(C237S). These results show the possibility of correction of the misactivation of Gas(R201C) through covalently modifying C201 with compounds that can mimic the function of arginine.
Identification of lead compounds that covalently modify C201 in Gas (112010
[0510] A tethering screening was used to identify compounds that can covalently modify C201. Untagged recombinant Gas(R201C) at 2 mM was reacted with 200 mM fragment and 200 pM bME in 20 mM HEPES, pH 8.0, 150 mM NaCl, 30 pM MgC12, 50 pM GDP for 2 h at ambient temperature. The extent of modification was assessed by electrospray mass spectrometry using a Waters LCT-Premier LC/ESI-MS.
[0511] In the related studies, a native cysteine, C237, can be more reactive than C201 so that all the compounds that efficiently modified Gas(R201C) were finally proved to target C237 but not C201. Therefore, instead of GDP -bound Gas(R201C) the double mutant Gas(R201C/C237S) was used this time. After screening about 1600 disulphide fragments, a class of compounds that modified Gas(R201C/C237S) but not Gas(C237S) was identified. These compounds are distinguished by containing a urea moiety (FIG. 4A) that likely mimics the guanidine group in arginine. Among them, compound 1H11 gave the highest modification ratio. [0512] The reactivity of C201 and C237 against compound 1H11 were compared. Not surprisingly, when the concentration of the compound was lowered from 200 mM to 50 mM, compound 1H11 only modified about 20% of the GDP-bound Gas(R201C/C237S) even when BME (beta mercaptoethanol) concentration was 0 while modified nearly 100% of GDP-bound wild-type Gas in the same condition (FIG. 4B, circle and triangle curves), indicating that in the GDP -bound state C237 is more reactive than C201 against this compound. But when GDP in Gas was replaced with GNP (5'-Guanylyl imidodiphosphate, a non-hydrolyzable GTP analog), the reactivity of C201 was dramatically increased, with a modification ratio over 50% even at a BME concentration of 1000 mM (FIG. 4B, reverse triangle curve); in contrast, the reactivity of C237 was much lower (FIG. 4B, square curve). These results demonstrate that compound 1H11 prefers C201 in the GNP-bound Gas. Such a preference makes 1H11 a good lead compound for the development of inhibitors that selectively target the active GTP-bound Gas. One possibility is that the g-phosphate in GNP directly binds to the urea moiety in compound 1H11. To get information to optimize 1H11 , the crystal structure of the GNP-bound Gas(R201C/C237S) in complex with 1H11 and effects of 1 HI 1 on the GTPase activity and adenylyl cyclase-activating activity of Gas would be obtained.
[0513] Chemotherapy is one of the mainstays of cancer treatment. However, this approach is often troubled by severe side effects mainly because anti -cancer drugs target both cancer cells and healthy cells. Cancer is caused by mutations in genes that accelerate (oncogenes) or suppress (tumor suppressors) tumor growth. Specifically targeting the mutant genes or the mutant proteins encoded by these genes is theoretically an ideal strategy to decrease the side effects of anti-cancer drugs but usually cannot be achieved. In the cases that the cancer- causing mutations result in a cysteine residue in the mutation site, inhibitors that covalently modify the cysteine residue have shown great selectivity of the mutant proteins over the normal proteins. Indeed, activating mutations in an oncogene called GNAS that encodes the protein Gas were identified in 27.9% of 816 pituitary cancer samples and 66% of a type of pancreatic cancer patients. More than half of these mutations result in the substitution of Arg201 of Gas by a cysteine residue. In recent research, a small molecule named acrylamidine can correct the misactivation of Gas(R201C) by converting Cys201 to an arginine mimic. Also identified is a disulphide fragment that preferentially modifies Cys201 in the active GTP-bound form of Gas. Both small molecules are not drug-like molecules, however, they are good starting point for development of drug-like molecules.
Method and Material
[0514] Compounds shown in FIG. 5A selected from the tethering library were tested for their ability to label different Gas mutants. Modification rate by these compounds are shown in FIG. 5B.
[0515] Proteins were diluted in 20 mM HEPES 8.0, 150 mM NaCl, 5 mM MgCh, 1 mM EDTA as indicated in Table 1.
Table 1
Figure imgf000166_0001
[0516] The compounds of covalent bond mimic from the tethering library are shown in FIG. 5A. These compounds were diluted to 2 mM using 20 mM HEPES 7.5, 150 mM NaCl,
5 mM MgCh and solutions of final sample volume of 700 pL were obtained. For each sample, 50 pL was used as control, 50 pL was mixed with 100 pM compound HQ-96 (5 mM stock in H2O), 600 pL was mixed with 0.5 mM BME (100 mM stock in H2O). Then, 50 pL of each sample that mixed with BME was incubated with 100 pM compound 5B06, 17C03, 17C05, 17D05, 17E11, 18C06, 4B06, 1H11, DMSO, or HQ-30 (5 mM stock in DMSO). The samples were incubated at room temperature for 2 hours and the modification rate of the proteins by these small molecules was checked by LC/MS.
[0517] In addition, compounds of covalent bond mimic in FIG. 6A containing an aryl urea moiety were tested for their BME50 values (FIG. 6B). Proteins (GNASSd6 R201C/C237S) in a buffer solution (8.5 mg/mL in 150 mM NaCl, 20 mM HEPES 8.0, 5 mM MgCh, 1 mM EDTA-Na (pH 8.0) were diculted ) to 2 mM using an EDTA containing buffer (150 mM NaCl, 20 mM HEPES 7.5, 1 mM EDTA). The diluted protein solutions were incubated with 0.5 mM GMPPNP at room temperature for 1 hour, then MgCh was added to a final concentration of 5 mM. BME was added to a final concentration of 0, 500, 1000, 1500 or 2000 pM. Compounds QH2018-4, QH2018-6, , QH2018-8 or QH2018-10 (5 mM in DMSO) was added to each sample to a final concentration of 50 mM. After incubation at room temperature for 2 hours, labeling ratio of the proteins by these compounds was determined by LC/MS. The measured BME50 are shown in FIG. 6B.
Example 3. Synthesis of Compounds
Figure imgf000167_0001
Scheme 1
[0518] Reactive aryl isocyate with the R1 substitution as described herein on para position and aliphatic amine with the R2 substituents as described herein may form an aryl urea upon reaction illustrated in Scheme 1.
[0519] It is understood that the examples and embodiments described herein are for illustrative purposes only and that various modifications or changes in light thereof will be suggested to persons skilled in the art and are to be included within the spirit and purview of this application and scope of the appended claims. All publications, patents, and patent applications cited herein are hereby incorporated by reference in their entirety for all purposes.

Claims

WHAT IS CLAIMED IS:
1. A compound having the formula:
Figure imgf000168_0001
wherein,
R1 is independently halogen, -CX’s, -CHX -CH2X1, -OCX’s, - OCH2X1, -OCHX’2, -CN, -SO„IR1d, -SOviNR1AR1B, -NR1CNR1AR1B, -ONR1AR1b, -NHC(0)NR1CNR1AR1B, -NHC(0)NR1AR1b, -N(0)mi, -NR1AR1B, -C(0)R1c, -C(0)-0R1c, -C (0)NR1AR1b, -OR1d, -NR1AS02R1d, -NR1AC(0)R1c, -NR1AC(0)0R1c, -NR1AOR1c, -N3, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl; two adjacent R1 substituents may optionally be joined to form a substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl; zl is an integer from 0 to 6;
Ring A is aryl or heteroaryl;
L1 is a bond, -NH-, -O-, -S-, -C(O)-, -C(0)NH-, -NHC(O)-, -NHC(0)NH-, -C(0)0-, -OC(O)-, substituted or unsubstituted alkylene, substituted or unsubstituted heteroalkylene, substituted or unsubstituted cycloalkylene, substituted or unsubstituted heterocycloalkylene, substituted or unsubstituted arylene, or substituted or unsubstituted heteroarylene;
L2 is a bond, -NH-, -O-, -S-, -C(O)-, -C(0)NH-, -NHC(O)-, -NHC(0)NH-, -C(0)0-, -OC(O)-, substituted or unsubstituted alkylene, substituted or unsubstituted heteroalkylene, substituted or unsubstituted cycloalkylene, substituted or unsubstituted heterocycloalkylene, substituted or unsubstituted arylene, or substituted or unsubstituted heteroarylene; R2 is an electrophilic moiety;
R1A, R1b, R1C, and R1D are independently hydrogen, -CX3, -CHX2, -CH2X, -CN, -OH, -COOH, -CONH2, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl; R1A and R1B substituents bonded to the same nitrogen atom may optionally be joined to form a substituted or unsubstituted heterocycloalkyl or substituted or unsubstituted heteroaryl;
X and X1 are independently -F, -Cl, -Br, or -I; nl is independently an integer from 0 to 4; and ml and vl are independently 1 or 2.
2. The compound of claim 1, wherein zl is an integer from 1 to 3.
3. The compound of claim 1, wherein zl is 0.
4. The compound of claim 1 , wherein Ring A is phenyl or 5 to 6- membered heteroaryl.
5. The compound of claim 1, having the formula:
Figure imgf000169_0001
wherein;
Each R1 1, R1·2, R1·3, R1·4, and R1,5 is independently hydrogen, halogen, -CX^, -CHX -CH2X1, -OCX1:!, -OCH2X1, -OCHX’i, -CN, -SO„iR1D, -SOviNR1AR1B, -NR1CNR1AR1B, -ONR1AR1b,
-NHC(0)NRlcNR1AR1B, -NHC(0)NR1AR1b, -N(0)mi, -NR1AR1B, -C(0)R1c, -C(0)-0R1c, -C (0)NR1AR1B, -OR1D, -NR1AS02R1D, -NR1AC(0)Rlc, -NR1AC(0)0R1c, -NR1AOR1c, -N3, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl; R1A, R1b, R1C, and R1D are independently hydrogen, -CX3, -CHX2, -CH2X, -CN, -OH, -COOH, -CONH2, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl; R1A and R1B substituents bonded to the same nitrogen atom may optionally be joined to form a substituted or unsubstituted heterocycloalkyl or substituted or unsubstituted heteroaryl;
X and X1 are independently -F, -Cl, -Br, or -I; nl is independently an integer from 0 to 4; and ml and vl are independently 1 or 2.
6. The compound of claim 1, wherein L1 is a bond, -NH-, -0-, -S-, -C(O)-, -C(0)NH-, -NHC(O)-, -NHC(0)NH-, -C(0)0-, -OC(O)-, substituted or unsubstituted alkylene, or substituted or unsubstituted heteroalkylene.
7. The compound of claim 1, wherein L1 is a bond, -NH-, -0-, -S-, -C(O)-, -C(0)NH-, -NHC(O)-, -NHC(0)NH-, -C(0)0-, -OC(O)-, substituted or unsubstituted C1-C6 alkylene, or substituted or unsubstituted 2 to 6 membered heteroalkylene.
8. The compound of claim 1, wherein L1 is a bond.
9. The compound of claim 1, wherein L2 is a bond, -NH-, -0-, -S-, -C(O)-, -C(0)NH-, -NHC(O)-, -NHC(0)NH-, -C(0)0-, -OC(O)-, substituted or unsubstituted alkylene, or substituted or unsubstituted heteroalkylene.
10. The compound of claim 1, wherein L2 is a bond, -NH-, -0-, -S-, -C(O)-, -C(0)NH-, -NHC(O)-, -NHC(0)NH-, -C(0)0-, -OC(O)-, substituted or unsubstituted C1-C6 alkylene, or substituted or unsubstituted 2 to 6 membered heteroalkylene.
11. The compound of claim 1 , wherein L2 is an unsubstituted C1-C6 alkylene.
12. The compound of claim 1, wherein L2 is a bond.
13. The compound of claim 1 , wherein R2 is
Figure imgf000171_0002
Figure imgf000171_0001
R16 is hydrogen, halogen, -CX16 3, -CHX16 2, -CH2X16, -CN, -SOni6R16D, -SOVI6NR16AR16B, -NHNR16AR16B, -ONR16AR16B, -NHC(0)NHNR16AR16B,
-NHC(0)NR16AR16B, -N(0)mi6, -NR16AR16B, -C(0)R16C, -C(0)-0R16C, -C(0)NR16AR16B, -OR 16D, -NR16AS02R16B, -NR16AC(0)R16C, -NR16AC(0)0R16C, -NR16AOR16D, -OCX163, -OCHX16 2 , -OCH2X16, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl;
R17 is hydrogen, halogen, -CX17 3, -CHX17 2, -CH2X17, -CN, -SO„17R17D, -SOvi7NR17AR17B, -NHNR17AR17B, -ONR17AR17B, -NHC(0)NHNR17AR17B,
-NHC(0)NR17AR17B, -N(0)m17, -NR17AR17B, -C(0)R17C, -C(0)-0R17C, -C(0)NR17AR17B, -OR 17D, -NR17AS02R17B, -NR17AC(0)R17C, -NR17AC(0)0R17C, -NR17AOR17D, -OCX17 3, -OCHX17 2 , -OCH2X17, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl;
R18 is hydrogen, halogen, -CX18 3, -CHX18 2, -CH2X18, -CN, -SO„18R18D, -SOVI8NR18AR18B, -NHNR18AR18B,
Figure imgf000172_0003
substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl;
R19 is hydrogen, halogen, -
Figure imgf000172_0002
, -OCH2X19, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl;
Figure imgf000172_0001
R19B, R19C, and R19D are independently hydrogen, -CX3, -CHX2, -CH2X, -CN, -OH, -COOH, -CONH2, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl; R16A and R16B substituents bonded to the same nitrogen atom may optionally be joined to form a substituted or unsubstituted heterocycloalkyl or substituted or unsubstituted heteroaryl; R17A and R17B substituents bonded to the same nitrogen atom may optionally be joined to form a substituted or unsubstituted heterocycloalkyl or substituted or unsubstituted heteroaryl; R18A and R18B substituents bonded to the same nitrogen atom may optionally be joined to form a substituted or unsubstituted heterocycloalkyl or substituted or unsubstituted heteroaryl; R19A and R19B substituents bonded to the same nitrogen atom may optionally be joined to form a substituted or unsubstituted heterocycloalkyl or substituted or unsubstituted heteroaryl;
X16, X17, X18, andX19 are independently -F, -Cl, -Br, or -I; nl6, nl7, nl8, and nl9 are independently an integer from 0 to 4; and ml6, ml7, ml 8, ml9, vl6, vl7, vl8, and vl9 are independently 1 or 2. 14. The compound of claim 1, wherein
15. The compound of claim 1 , wherein
R16 is hydrogen, unsubstituted C1-C4 alkyl, or unsubstituted C3-C6 cycloalkyl;
R17 is hydrogen, unsubstituted C1-C4 alkyl, or unsubstituted C3-C6 cycloalkyl; and
R18 is hydrogen, unsubstituted C1-C4 alkyl, or unsubstituted C3-C6 cycloalkyl.
16. The compound of claim 1 , wherein R16 is hydrogen or unsubstituted C1-C4 alkyl;
R17 is hydrogen or unsubstituted C1-C4 alkyl; and R18 is hydrogen or unsubstituted C1-C4 alky.
17. The compound of claim 1, wherein R16, R17, and R18 are hydrogen.
18. A pharmaceutical composition comprising the compound of claim 1 and a pharmaceutically acceptable excipient.
19. A method of inhibiting Gas protein activity, said method comprising: contacting the Gas protein with a compound of claim 1.
20. A method of treating cancer, said method comprising administering to a subject in need thereof an effective amount of a compound of claim 1.
21. The method of claim 20, wherein the cancer is pancreatic cancer, a pituitary tumor, or a bone tumor.
22. The method of claim 20, wherein the cancer is sensitive to Gas inhibition.
23. A method of treating a bone condition, said method comprising administering to a subject in need thereof an effective amount of a compound of claim 1.
24. The method of claim 23, wherein the bone condition is fibrous dysplasia.
25. The method of claim 24, wherein the fibrous dysplasia is monostotic fibrous dysplasia or polystotic fibrous dysplasia.
26. A method of treating McCune-Albright Syndrome, said method comprising administering to a subject in need thereof an effective amount of a compound of claim 1.
27. A Gas protein covalently bonded to a compound of claim 1.
28. The Gas protein of claim 27, wherein Gas is in the GTP state.
29. The Gas protein of claim 27, wherein Gas is in the GDP state.
30. The Gas protein of claim 27, wherein the compound is bonded to a cysteine residue of the protein.
31. The Gas protein of claim 27, having the structure:
Figure imgf000175_0001
wherein,
W together with the -CH2S- to which it is attached form said Gas protein covalently bonded to a compound; and
L3 is substituted or unsubstituted alkylene or substituted or unsubstituted heteroalkylene.
Figure imgf000175_0002
33. The Gas protein of claim 30, wherein the compound is bonded to cysteine 201.
34. The Gas protein of claim 30, wherein the compound is bonded to cysteine 237.
35. A Gas protein covalently bonded to a portion of a compound of claim
1.
36. A Gas protein covalently bonded to a Gas small molecule inhibitor at
R201C.
37. The Gas protein of claim 36, wherein the Gas protein is a GTP-bound
Gas protein.
38. The Gas protein of claim 36, wherein the Gas protein is a GDP-bound
Gas protein.
39. A Gas protein covalently bonded to a Gas small molecule inhibitor at
C237.
40. The Gas protein of claim 39, wherein the Gas protein is a GTP-bound
Gas protein.
41. The Gas protein of claim 39, wherein the Gas protein is a GDP-bound
Gas protein.
42. A method of treating cancer comprising administering a Gas cysteine 201 covalent inhibitor.
43. The method of claim 42, wherein the Gas cysteine 201 covalent inhibitor is a compound of claim 1.
44. A method of treating cancer comprising administering a Gas cysteine 237 covalent inhibitor.
45. The method of claim 44, wherein the Gas cysteine 237 covalent inhibitors a compound of claim 1.
PCT/US2022/026345 2021-04-26 2022-04-26 G-alpha-s inhibitors and uses thereof WO2022232142A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP22796551.4A EP4330228A1 (en) 2021-04-26 2022-04-26 G-alpha-s inhibitors and uses thereof

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163179969P 2021-04-26 2021-04-26
US63/179,969 2021-04-26

Publications (1)

Publication Number Publication Date
WO2022232142A1 true WO2022232142A1 (en) 2022-11-03

Family

ID=83848785

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2022/026345 WO2022232142A1 (en) 2021-04-26 2022-04-26 G-alpha-s inhibitors and uses thereof

Country Status (2)

Country Link
EP (1) EP4330228A1 (en)
WO (1) WO2022232142A1 (en)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4304935A (en) * 1980-04-09 1981-12-08 Rexolin Chemicals Ab Production of 1-phenyl-3-cyanoureas
US4332821A (en) * 1978-02-06 1982-06-01 Abbott Laboratories 1-Acryloyl-3-(substituted)phenyl ureas
US4727077A (en) * 1985-02-20 1988-02-23 Ishihara Sangyo Kaisha Ltd. Benzoyl urea compounds, process for their production, and antitumorous compositions containing them
US20170174678A1 (en) * 2014-03-31 2017-06-22 Rhe Trustees of The University of Pennsylvania Novel antiviral compounds and methods using same

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4332821A (en) * 1978-02-06 1982-06-01 Abbott Laboratories 1-Acryloyl-3-(substituted)phenyl ureas
US4304935A (en) * 1980-04-09 1981-12-08 Rexolin Chemicals Ab Production of 1-phenyl-3-cyanoureas
US4727077A (en) * 1985-02-20 1988-02-23 Ishihara Sangyo Kaisha Ltd. Benzoyl urea compounds, process for their production, and antitumorous compositions containing them
US20170174678A1 (en) * 2014-03-31 2017-06-22 Rhe Trustees of The University of Pennsylvania Novel antiviral compounds and methods using same

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
CHOI YUN HEE, KANG HATAN, LEE WON KYU, KIM TAEHYUN, RHIM HYEWHON, YU YEON GYU: "An inhibitory compound against the interaction between Gα(s) and the third intracellular loop region of serotonin receptor subtype 6 (5-HT(6)) disrupts the signaling pathway of 5-HT(6)", EXPERIMENTAL AND MOLECULAR MEDICINE, vol. 39, no. 3, 1 June 2007 (2007-06-01), pages 335 - 342, XP093003489 *

Also Published As

Publication number Publication date
EP4330228A1 (en) 2024-03-06

Similar Documents

Publication Publication Date Title
US11964941B2 (en) 5-Bromo-indirubins
EP2751112B1 (en) Substituted pyrazolo[3,4-d]pyrimidines and uses thereof
US20230242586A1 (en) Ras inhibitors and uses thereof
US11306072B2 (en) 5-bromo-indirubins
US20220193242A1 (en) Immunophilin-dependent inhibitors and uses thereof
US20210023238A1 (en) Triptolide antibody conjugates
US10570124B2 (en) Deoxycytidine kinase binding compounds
US20230135758A1 (en) Elongation factor 1-alpha inhibitors and uses thereof
US11739121B2 (en) EPHA2 agonists and uses thereof
WO2022232142A1 (en) G-alpha-s inhibitors and uses thereof
WO2020146779A1 (en) mTORC1 INHIBITORS FOR ACTIVATING AUTOPHAGY
US20230127630A1 (en) Igf2bp2 inhibitors and uses thereof
US20230255934A1 (en) Nurr1 receptor modulators and uses thereof
WO2022055940A1 (en) Vista inhibitors
WO2022232143A2 (en) G-alpha-s peptide inhibitors and uses thereof
WO2021237111A1 (en) Notch inhibitors and uses thereof
US20230203003A1 (en) Notch Inhibitors and Uses Thereof

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 22796551

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 2022796551

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2022796551

Country of ref document: EP

Effective date: 20231127